[
  {
    "text": "School-informed risk calculator tool for reducing the spread of respiratory",
    "entities": []
  },
  {
    "text": "viral infection among school-aged children.",
    "entities": []
  },
  {
    "text": "Wilson AM(1), Lowe AA(2)(3), Amoh-Asante NAA(1), Zhan Y(1), Ashraf A(1), Gerald",
    "entities": [
      {
        "text": "Wilson",
        "label": "ORG"
      },
      {
        "text": "Lowe AA(2)(3",
        "label": "ORG"
      },
      {
        "text": "Amoh-Asante NAA(1",
        "label": "ORG"
      },
      {
        "text": "Zhan",
        "label": "PERSON"
      },
      {
        "text": "Gerald\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Author information:",
    "entities": []
  },
  {
    "text": "(1)Department of Community, Environment & Policy, Mel and Enid Zuckerman College",
    "entities": [
      {
        "text": "Community, Environment & Policy",
        "label": "ORG"
      },
      {
        "text": "Mel",
        "label": "PERSON"
      },
      {
        "text": "Enid Zuckerman College",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "of Public Health, University of Arizona, Tucson, AZ, USA.",
    "entities": [
      {
        "text": "Public Health",
        "label": "ORG"
      },
      {
        "text": "University of Arizona",
        "label": "ORG"
      },
      {
        "text": "Tucson",
        "label": "GPE"
      },
      {
        "text": "AZ",
        "label": "ORG"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Nursing & Health Sciences Division, College of Nursing, University of",
    "entities": [
      {
        "text": "2)Nursing & Health Sciences Division",
        "label": "ORG"
      },
      {
        "text": "University of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(3)Asthma & Airway Disease Research Center, Tucson, AZ, USA.",
    "entities": [
      {
        "text": "3)Asthma & Airway Disease Research Center",
        "label": "ORG"
      },
      {
        "text": "Tucson",
        "label": "GPE"
      },
      {
        "text": "AZ",
        "label": "ORG"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Office of Population Health Sciences, Office of the Vice Chancellor for",
    "entities": [
      {
        "text": "Population Health Sciences",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Health Affairs, University of Illinois Chicago, Chicago, IL, USA.",
    "entities": [
      {
        "text": "Health Affairs",
        "label": "ORG"
      },
      {
        "text": "University of Illinois Chicago",
        "label": "ORG"
      },
      {
        "text": "Chicago",
        "label": "GPE"
      },
      {
        "text": "IL",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Breathe Chicago Center, University of Illinois Chicago, Chicago, IL, USA.",
    "entities": [
      {
        "text": "5)Breathe Chicago Center, University of Illinois Chicago",
        "label": "ORG"
      },
      {
        "text": "Chicago",
        "label": "GPE"
      },
      {
        "text": "IL",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "School health staff need decision support for responding to respiratory viral",
    "entities": []
  },
  {
    "text": "outbreaks. Quantitative microbial risk assessment (QMRA) tools are an",
    "entities": []
  },
  {
    "text": "inexpensive and fast resource. Our objectives were to engage school districts to",
    "entities": []
  },
  {
    "text": "inform the development of a risk-based calculator tool, test the tool across",
    "entities": []
  },
  {
    "text": "hypothetical cases, and elicit feedback among school health staff. We",
    "entities": []
  },
  {
    "text": "administered an online survey for Kindergarten (K) - Grade 5 teachers, school",
    "entities": [
      {
        "text": "Kindergarten",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "health professionals, and other school staff to gather data about respiratory",
    "entities": []
  },
  {
    "text": "viral disease interventions and model parameters. A risk calculator tool was",
    "entities": []
  },
  {
    "text": "developed in which users choose hypothetical scenarios to estimate infection",
    "entities": []
  },
  {
    "text": "risk per individual and compare interventions. Three case studies (CS) were",
    "entities": [
      {
        "text": "Three",
        "label": "CARDINAL"
      },
      {
        "text": "CS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "explored: CS1 - Rhinovirus transmission in a general education classroom with",
    "entities": []
  },
  {
    "text": "\"poor\" vs. \"great\" air quality, CS2 - Influenza A virus transmission in a music",
    "entities": []
  },
  {
    "text": "classroom with vs. without a portable air purifier, CS3 - SARS-CoV-2",
    "entities": []
  },
  {
    "text": "transmission in a special education classroom with vs. without open",
    "entities": []
  },
  {
    "text": "doors/windows. The prototype tool was presented at a national school nursing",
    "entities": []
  },
  {
    "text": "meeting, and attendees were surveyed on (dis)likes and anticipated tool uses.",
    "entities": [
      {
        "text": "dis)likes",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "For the initial survey of Arizona school personnel (n = 132), the top",
    "entities": [
      {
        "text": "Arizona",
        "label": "GPE"
      },
      {
        "text": "132",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "respiratory viral outbreak strategies reported by teachers were hand (94 %) and",
    "entities": [
      {
        "text": "94 %",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "surface hygiene (85.1 %). For all case studies, infection risks were above",
    "entities": [
      {
        "text": "85.1 %",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "thresholds used in other contexts but were comparable to published student",
    "entities": []
  },
  {
    "text": "respiratory illness incidence data. At the national meeting, school nurses (n =",
    "entities": []
  },
  {
    "text": "12) identified potential uses including advocating for interventions to",
    "entities": [
      {
        "text": "12",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "administrators. This work reflects a unique application of community partnership",
    "entities": []
  },
  {
    "text": "and QMRA to address school health decision support.",
    "entities": []
  },
  {
    "text": "gestational age prediction and acceleration.",
    "entities": []
  },
  {
    "text": "Eapen AA, Loveless IM, Pan M, Liang X, Urquhart A, Straughen J, Cassidy-Bushrow",
    "entities": [
      {
        "text": "Loveless IM",
        "label": "PERSON"
      },
      {
        "text": "Pan M",
        "label": "ORG"
      },
      {
        "text": "Liang X",
        "label": "PERSON"
      },
      {
        "text": "Straughen J",
        "label": "PERSON"
      },
      {
        "text": "Cassidy-Bushrow",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "AE, Sitarik AR, Simmerman N, Thompson EE, Kottyan L, Ober C, Johnson CC, Zoratti",
    "entities": [
      {
        "text": "AE",
        "label": "ORG"
      },
      {
        "text": "Sitarik AR",
        "label": "PERSON"
      },
      {
        "text": "Simmerman N",
        "label": "PERSON"
      },
      {
        "text": "Thompson EE",
        "label": "ORG"
      },
      {
        "text": "Kottyan L",
        "label": "ORG"
      },
      {
        "text": "Johnson CC",
        "label": "PERSON"
      },
      {
        "text": "Zoratti",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "E, Levin AM.",
    "entities": [
      {
        "text": "Levin AM",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "DNA methylation (DNAm), capturing biological gestational age (GA) and epigenetic",
    "entities": []
  },
  {
    "text": "gestational age acceleration (EGAA), can be modified by environmental exposures.",
    "entities": []
  },
  {
    "text": "The Asthma&Allergy array is a new DNAm array developed with content focused on",
    "entities": []
  },
  {
    "text": "asthma and allergy loci. The association between content on the Asthma&Allergy",
    "entities": []
  },
  {
    "text": "array and chronological GA and EGAA has not been evaluated alone or in the",
    "entities": [
      {
        "text": "EGAA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "context of perinatal exposures. We performed an epigenome wide association",
    "entities": []
  },
  {
    "text": "study(EWAS) based on chronological GA at single CpG sites and regions. We",
    "entities": [
      {
        "text": "CpG",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "further constructed a multi-CpG site methylation model to predict chronological",
    "entities": []
  },
  {
    "text": "GA in cord blood from 391 newborn children from a Detroit-based birth cohort.",
    "entities": [
      {
        "text": "391",
        "label": "CARDINAL"
      },
      {
        "text": "Detroit",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Associations between perinatal environmental factors with GA, epigenetic",
    "entities": [
      {
        "text": "GA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "gestational age (EGA), and EGAA were assessed. We identified 2,435 CpG sites",
    "entities": [
      {
        "text": "EGA",
        "label": "ORG"
      },
      {
        "text": "2,435",
        "label": "CARDINAL"
      },
      {
        "text": "CpG",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "associated with chronological GA. HLA class II ( HLA-DRB1,HLA-DQB1,HLA-DRB6 )",
    "entities": []
  },
  {
    "text": "were the most significantly associated with chronological GA. Our multi-CpG site",
    "entities": []
  },
  {
    "text": "model attained predictive accuracy (cross-validated Pearson's correlation=0.75)",
    "entities": [
      {
        "text": "Pearson",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "comparable to other EGA methods. Using genes implicated in region-based analyses",
    "entities": [
      {
        "text": "EGA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(n=395 regions), the pathways most significantly enriched with chronological",
    "entities": []
  },
  {
    "text": "GA-associated CpGs included T helper 1(Th1) and 2(Th2) activation, macrophage",
    "entities": [
      {
        "text": "CpGs",
        "label": "ORG"
      },
      {
        "text": "2(Th2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "classical activation, and IL10 signaling, which were also enriched in at least",
    "entities": []
  },
  {
    "text": "one of the other published epigenetic clocks. In multi-exposure models, prenatal",
    "entities": [
      {
        "text": "one",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "indoor pet exposure and unplanned C-section were associated with EGA",
    "entities": [
      {
        "text": "EGA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "deceleration, while infant's first-born status was associated with EGAA. Our",
    "entities": [
      {
        "text": "first",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "findings highlight enrichment for T cell modulated pathways and antigen",
    "entities": []
  },
  {
    "text": "presentation as biological processes enriched in chronological GA, as well as",
    "entities": []
  },
  {
    "text": "novel perinatal factors that may impact EGAA.",
    "entities": []
  },
  {
    "text": "3. J Transl Med. 2025 Jul 15;23(1):796. doi: 10.1186/s12967-025-06646-5.",
    "entities": [
      {
        "text": "3",
        "label": "CARDINAL"
      },
      {
        "text": "15;23(1):796",
        "label": "CARDINAL"
      },
      {
        "text": "10.1186",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Meta-analysis of microarray data to identify potential signature genes and",
    "entities": []
  },
  {
    "text": "MiRNAs associated with the pathogenesis of asthma.",
    "entities": []
  },
  {
    "text": "(1)Student Research Committee, Shiraz University of Medical Sciences, Shiraz,",
    "entities": [
      {
        "text": "Research Committee",
        "label": "ORG"
      },
      {
        "text": "Shiraz University of Medical Sciences",
        "label": "ORG"
      },
      {
        "text": "Shiraz",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(2)Department of Medical Biotechnology, School of Advanced Medical Sciences and",
    "entities": [
      {
        "text": "Medical Biotechnology, School of Advanced Medical Sciences",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Technologies, Shiraz University of Medical Sciences, Shiraz, Iran.",
    "entities": [
      {
        "text": "Shiraz University of Medical Sciences",
        "label": "ORG"
      },
      {
        "text": "Shiraz",
        "label": "GPE"
      },
      {
        "text": "Iran",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Epilepsy Research Center, Shiraz University of Medical Sciences, Shiraz,",
    "entities": [
      {
        "text": "Shiraz University of Medical Sciences",
        "label": "ORG"
      },
      {
        "text": "Shiraz",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(4)Department of Research and Technology, Kermanshah University of Medical",
    "entities": [
      {
        "text": "Research and Technology",
        "label": "ORG"
      },
      {
        "text": "Kermanshah University of Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Sciences, Kermanshah, Iran.",
    "entities": [
      {
        "text": "Kermanshah",
        "label": "GPE"
      },
      {
        "text": "Iran",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Department of Medical Biotechnology, School of Advanced Medical Sciences and",
    "entities": [
      {
        "text": "Medical Biotechnology, School of Advanced Medical Sciences",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(6)Infertility Research Center, Shiraz University of Medical Sciences, Shiraz,",
    "entities": [
      {
        "text": "Research Center",
        "label": "FAC"
      },
      {
        "text": "Shiraz University of Medical Sciences",
        "label": "ORG"
      },
      {
        "text": "Shiraz",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(7)Pharmaceutical Sciences Research Center, Shiraz University of Medical",
    "entities": [
      {
        "text": "Sciences Research Center",
        "label": "ORG"
      },
      {
        "text": "Shiraz University of Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Sciences, Shiraz, Iran. manica.negahdaripour@gmail.com.",
    "entities": [
      {
        "text": "Shiraz",
        "label": "GPE"
      },
      {
        "text": "Iran",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(8)Department of Pharmaceutical Biotechnology, School of Pharmacy, Shiraz",
    "entities": [
      {
        "text": "Pharmaceutical Biotechnology",
        "label": "ORG"
      },
      {
        "text": "School of Pharmacy",
        "label": "ORG"
      },
      {
        "text": "Shiraz",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "University of Medical Sciences, Shiraz, Iran. manica.negahdaripour@gmail.com.",
    "entities": [
      {
        "text": "University of Medical Sciences",
        "label": "ORG"
      },
      {
        "text": "Shiraz",
        "label": "GPE"
      },
      {
        "text": "Iran",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(9)Department of Artificial Intelligence, School of Medicine, Shiraz University",
    "entities": [
      {
        "text": "Artificial Intelligence, School of Medicine",
        "label": "ORG"
      },
      {
        "text": "Shiraz University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of Medical Sciences, Shiraz, Iran. manica.negahdaripour@gmail.com.",
    "entities": [
      {
        "text": "Medical Sciences",
        "label": "ORG"
      },
      {
        "text": "Shiraz",
        "label": "GPE"
      },
      {
        "text": "Iran",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Declarations. Ethics approval and consent to",
    "entities": []
  },
  {
    "text": "participate: Not applicable. Consent for publication: Not applicable. Competing",
    "entities": []
  },
  {
    "text": "interests: None declared.",
    "entities": []
  },
  {
    "text": "Burden level and quality of life of caregivers of hemodialysis patient's in",
    "entities": []
  },
  {
    "text": "central India: a mixed-method cross-sectional study.",
    "entities": [
      {
        "text": "India",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(1)School of Public Health (at time of study), All India Institute of Medical",
    "entities": [
      {
        "text": "1)School of Public Health",
        "label": "ORG"
      },
      {
        "text": "All India Institute of Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Sciences, Raipur, Chhattisgarh, India.",
    "entities": [
      {
        "text": "Raipur",
        "label": "GPE"
      },
      {
        "text": "Chhattisgarh",
        "label": "GPE"
      },
      {
        "text": "India",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Vedanta Medical Research Foundation (BALCO Medical Centre), Raipur,",
    "entities": [
      {
        "text": "2)Vedanta Medical Research Foundation",
        "label": "ORG"
      },
      {
        "text": "BALCO Medical Centre",
        "label": "ORG"
      },
      {
        "text": "Raipur",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(3)Department of Nephrology, All India Institute of Medical Sciences, Raipur,",
    "entities": [
      {
        "text": "Nephrology",
        "label": "ORG"
      },
      {
        "text": "All India Institute of Medical Sciences",
        "label": "ORG"
      },
      {
        "text": "Raipur",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(4)Department of Nephrology, Dau Kalyan Singh Post Graduate Institute and",
    "entities": [
      {
        "text": "Nephrology",
        "label": "ORG"
      },
      {
        "text": "Dau Kalyan Singh Post Graduate Institute",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Research center, Raipur, Chhattisgarh, India.",
    "entities": [
      {
        "text": "Raipur",
        "label": "PERSON"
      },
      {
        "text": "Chhattisgarh",
        "label": "GPE"
      },
      {
        "text": "India",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Department of Community & Family Medicine, All India Institute of Medical",
    "entities": [
      {
        "text": "Community & Family Medicine",
        "label": "ORG"
      },
      {
        "text": "All India Institute of Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Sciences, Raipur, Chhattisgarh, India. abhiruchigalhotra@aiimsraipur.edu.in.",
    "entities": [
      {
        "text": "Raipur",
        "label": "GPE"
      },
      {
        "text": "Chhattisgarh",
        "label": "GPE"
      },
      {
        "text": "India",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "PURPOSE: Caregivers of hemodialysis patients are at high risk of developing",
    "entities": [
      {
        "text": "PURPOSE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "reduced quality of life (QoL) and increased caregiver burden.",
    "entities": [
      {
        "text": "QoL",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "AIM: This study aims to explore the level of caregiver burden and quality of",
    "entities": [
      {
        "text": "AIM",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "life in caregivers of hemodialysis patients in central India.",
    "entities": [
      {
        "text": "India",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "METHODS: This cross-sectional mixed-method study was undertaken among caregivers",
    "entities": []
  },
  {
    "text": "of stable hemodialysis patients attending a tertiary care hospital in central",
    "entities": [
      {
        "text": "tertiary",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "India. The Zarit Burden Interview (ZBI) and WHOQoL BREF questionnaire measured",
    "entities": [
      {
        "text": "India",
        "label": "GPE"
      },
      {
        "text": "The Zarit Burden Interview",
        "label": "ORG"
      },
      {
        "text": "BREF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "caregiver burden and QoL. The qualitative data was gathered through in-depth",
    "entities": []
  },
  {
    "text": "interviews using a semi-structured open-ended questionnaire that delved into",
    "entities": []
  },
  {
    "text": "their personal experiences with caregiving. The transcripts of these interviews",
    "entities": []
  },
  {
    "text": "were analysed using applied thematic analysis, allowing for the identification",
    "entities": []
  },
  {
    "text": "and exploration of recurring themes and patterns within the data.",
    "entities": []
  },
  {
    "text": "RESULTS: A total of 105 caregivers took part in this study, with a mean age of",
    "entities": [
      {
        "text": "105",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "40.04 \u00b1 12.96 years. 56 (53.3%) caregivers were female. Most (48.6%, n = 51)",
    "entities": [
      {
        "text": "40.04",
        "label": "CARDINAL"
      },
      {
        "text": "12.96 years",
        "label": "DATE"
      },
      {
        "text": "56",
        "label": "CARDINAL"
      },
      {
        "text": "53.3%",
        "label": "PERCENT"
      },
      {
        "text": "48.6%",
        "label": "PERCENT"
      },
      {
        "text": "51",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "were spouses/partners. Ten caregivers (9.5%) had to change their occupations due",
    "entities": [
      {
        "text": "Ten",
        "label": "CARDINAL"
      },
      {
        "text": "9.5%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "hypertension, asthma, and arthritis) themselves. The mean caregiver burden level",
    "entities": []
  },
  {
    "text": "(ZBI) was 18.55 \u00b1 7.58. Most (59.0%) experienced mild to moderate burden, while",
    "entities": [
      {
        "text": "ZBI",
        "label": "ORG"
      },
      {
        "text": "18.55",
        "label": "CARDINAL"
      },
      {
        "text": "59.0%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "28.6% reported a high burden. The WHOQoL BREF mean score of various domains of",
    "entities": [
      {
        "text": "28.6%",
        "label": "PERCENT"
      },
      {
        "text": "BREF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "physical health, psychological, social relationship and environmental was",
    "entities": []
  },
  {
    "text": "35.70 \u00b1 12.14, 44.20 \u00b1 13.28, 44.28 \u00b1 15.10 and 40.07 \u00b1 13.36 respectively. The",
    "entities": [
      {
        "text": "35.70",
        "label": "CARDINAL"
      },
      {
        "text": "12.14",
        "label": "DATE"
      },
      {
        "text": "44.20",
        "label": "CARDINAL"
      },
      {
        "text": "13.28",
        "label": "CARDINAL"
      },
      {
        "text": "44.28",
        "label": "CARDINAL"
      },
      {
        "text": "15.10",
        "label": "CARDINAL"
      },
      {
        "text": "40.07",
        "label": "CARDINAL"
      },
      {
        "text": "13.36",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "thematic analysis revealed, difficulty in continuing education and employment,",
    "entities": []
  },
  {
    "text": "changing jobs, the need to travel long distances to reach dialysis facilities",
    "entities": []
  },
  {
    "text": "and hardship due to COVID-19 pandemic as recurring challenges among caregivers.",
    "entities": [
      {
        "text": "COVID-19",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "CONCLUSION: Caregivers of Hemodialysis patients had significant caregiver burden",
    "entities": []
  },
  {
    "text": "and poor QoL. Regular assessment and special attention are needed for these",
    "entities": []
  },
  {
    "text": "\u00a9 2025. The Author(s).",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "PMID: 40665407 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40665407",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Declarations. Ethical approval and consent to",
    "entities": []
  },
  {
    "text": "participate: This study was approved by the Institutional Ethical Committee with",
    "entities": [
      {
        "text": "the Institutional Ethical Committee",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "IEC Proposal No: AIIMSRPR/IEC/2021/1041 from the All India Institute of Medical",
    "entities": [
      {
        "text": "the All India Institute of Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Sciences, Raipur, Chhattisgarh, India. All participants signed an informed",
    "entities": [
      {
        "text": "Raipur",
        "label": "GPE"
      },
      {
        "text": "Chhattisgarh",
        "label": "GPE"
      },
      {
        "text": "India",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "written consent before participation and informed consent was obtained from",
    "entities": []
  },
  {
    "text": "parents and/or legal guardians of minor/illiterate study participants. The study",
    "entities": []
  },
  {
    "text": "was conducted under the principles of the Helsinki Declaration. Consent for",
    "entities": [
      {
        "text": "the Helsinki Declaration",
        "label": "LAW"
      }
    ]
  },
  {
    "text": "publication: Not applicable. Competing interests: The authors declare no",
    "entities": []
  },
  {
    "text": "competing interests.",
    "entities": []
  },
  {
    "text": "Utility of patient-reported outcomes for pulmonary symptoms and sleep",
    "entities": []
  },
  {
    "text": "disturbance and impairment in children with systemic juvenile idiopathic",
    "entities": []
  },
  {
    "text": "arthritis.",
    "entities": []
  },
  {
    "text": "(1)Division of Rheumatology, TriHealth Hospital System, Cincinnati, OH, USA.",
    "entities": [
      {
        "text": "TriHealth Hospital System",
        "label": "ORG"
      },
      {
        "text": "Cincinnati",
        "label": "GPE"
      },
      {
        "text": "OH",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Division of Rheumatology, 3333 Burnet Ave, MLC 4010, Cincinnati, OH, 45208,",
    "entities": [
      {
        "text": "Burnet Ave",
        "label": "PERSON"
      },
      {
        "text": "4010",
        "label": "DATE"
      },
      {
        "text": "Cincinnati",
        "label": "GPE"
      },
      {
        "text": "OH",
        "label": "GPE"
      },
      {
        "text": "45208",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "(3)Department of Pediatrics, University of Cincinnati College of Medicine,",
    "entities": [
      {
        "text": "Pediatrics, University of Cincinnati College of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, 3333",
    "entities": [
      {
        "text": "4)Pulmonary Medicine",
        "label": "ORG"
      },
      {
        "text": "Cincinnati Children's",
        "label": "ORG"
      },
      {
        "text": "Hospital Medical Center",
        "label": "ORG"
      },
      {
        "text": "3333",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Burnet Ave, MLC 4010, Cincinnati, OH, 45208, USA. Christopher.towe@cchmc.org.",
    "entities": [
      {
        "text": "4010",
        "label": "DATE"
      },
      {
        "text": "Cincinnati",
        "label": "GPE"
      },
      {
        "text": "OH",
        "label": "GPE"
      },
      {
        "text": "45208",
        "label": "DATE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Department of Pediatrics, University of Cincinnati College of Medicine,",
    "entities": [
      {
        "text": "Pediatrics, University of Cincinnati College of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(6)Division of Rheumatology, 3333 Burnet Ave, MLC 4010, Cincinnati, OH, 45208,",
    "entities": [
      {
        "text": "Burnet Ave",
        "label": "PERSON"
      },
      {
        "text": "4010",
        "label": "DATE"
      },
      {
        "text": "Cincinnati",
        "label": "GPE"
      },
      {
        "text": "OH",
        "label": "GPE"
      },
      {
        "text": "45208",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "(7)Department of Pediatrics, University of Cincinnati College of Medicine,",
    "entities": [
      {
        "text": "Pediatrics, University of Cincinnati College of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "BACKGROUND: Patient-reported outcomes (PROs) are critical assessment tools for",
    "entities": []
  },
  {
    "text": "clinical practice, observational studies, and interventional trials. While",
    "entities": []
  },
  {
    "text": "families of children with systemic juvenile idiopathic arthritis (SJIA) and",
    "entities": [
      {
        "text": "SJIA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "SJIA-associated lung disease (SJIA-LD) report significant limitations in their",
    "entities": []
  },
  {
    "text": "quality of life, existing PROs for juvenile idiopathic arthritis may not",
    "entities": []
  },
  {
    "text": "properly measure the full impact of these disorders. Our objective was to",
    "entities": []
  },
  {
    "text": "utilize a newly developed lung symptom survey as well as existing, validated",
    "entities": []
  },
  {
    "text": "Patient-Reported Outcomes Measurement Information System (PROMIS) measures in",
    "entities": []
  },
  {
    "text": "children with SJIA with and without LD.",
    "entities": [
      {
        "text": "SJIA",
        "label": "ORG"
      },
      {
        "text": "LD",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "METHODS: Participants were parents/guardians of SJIA patients \u2264 18 years and",
    "entities": [
      {
        "text": "SJIA",
        "label": "ORG"
      },
      {
        "text": "\u2264 18 years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "were invited to participate using the Cincinnati Children's Hospital Medical",
    "entities": [
      {
        "text": "the Cincinnati Children's Hospital Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Center (CCHMC) JIA Registry, and memberships in the Systemic JIA Foundation, and",
    "entities": [
      {
        "text": "JIA Registry",
        "label": "ORG"
      },
      {
        "text": "the Systemic JIA Foundation",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "SJIA Facebook Group. Participants provided proxy-reports for their child using",
    "entities": [
      {
        "text": "SJIA Facebook Group",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "several PRO questionnaires [CCHMC Lung Symptom Survey; PROMIS Asthma Impact,",
    "entities": [
      {
        "text": "PRO",
        "label": "ORG"
      },
      {
        "text": "Lung Symptom Survey",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Sleep Disturbance, Sleep Impairment Forms] and selected demographic and SJIA",
    "entities": [
      {
        "text": "SJIA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "specific information.",
    "entities": []
  },
  {
    "text": "RESULTS: There were 139 responses, of which 40.3% (n = 57) reported some lung",
    "entities": [
      {
        "text": "139",
        "label": "CARDINAL"
      },
      {
        "text": "40.3%",
        "label": "PERCENT"
      },
      {
        "text": "57",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "disease including 12.9% (n = 20) with interstitial lung disease (ILD), pulmonary",
    "entities": [
      {
        "text": "12.9%",
        "label": "PERCENT"
      },
      {
        "text": "20",
        "label": "CARDINAL"
      },
      {
        "text": "ILD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "alveolar proteinosis (PAP) and/or pulmonary artery hypertension (PAH). All SJIA",
    "entities": [
      {
        "text": "PAH",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "patients with any lung disease and those with ILD/PAP/PAH had significantly",
    "entities": [
      {
        "text": "ILD/PAP/PAH",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "higher total questionnaire scores than patients without lung disease on the",
    "entities": []
  },
  {
    "text": "CCHMC Lung Symptoms Survey. Both the full survey and individual questions showed",
    "entities": [
      {
        "text": "CCHMC Lung Symptoms Survey",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "good ability to distinguish patients with ILD/PAP/PAH from those without (area",
    "entities": [
      {
        "text": "ILD/PAP/PAH",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "under the curve (AUC) > 0.7). The majority of patients reported some level of",
    "entities": [
      {
        "text": "0.7",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "regardless of presence or absence of lung disease, including moderate to severe",
    "entities": []
  },
  {
    "text": "sleep impairment and/or disturbance in 48% of SJIA patients.",
    "entities": [
      {
        "text": "48%",
        "label": "PERCENT"
      },
      {
        "text": "SJIA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "CONCLUSIONS: Children with SJIA and lung problems had higher scores on the CCHMC",
    "entities": [
      {
        "text": "SJIA",
        "label": "ORG"
      },
      {
        "text": "CCHMC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Lung Symptom Survey; however, these measures did not discriminate between",
    "entities": [
      {
        "text": "Lung Symptom Survey",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "SJIA-LD and other pulmonary conditions such as asthma. Based on PROMIS measures,",
    "entities": [
      {
        "text": "SJIA-LD",
        "label": "ORG"
      },
      {
        "text": "PROMIS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "a majority of children with SJIA had sleep disturbance and impairment,",
    "entities": [
      {
        "text": "SJIA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "regardless of steroid use or presence of lung disease.",
    "entities": []
  },
  {
    "text": "PMID: 40665383 [Indexed for MEDLINE]",
    "entities": []
  },
  {
    "text": "participate: This study was reviewed and approved by the Cincinnati Children\u2019s",
    "entities": [
      {
        "text": "the Cincinnati Children\u2019s",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Hospital Medical Center Institutional Review Board (2019 \u2212 0888) with a waiver",
    "entities": [
      {
        "text": "Hospital Medical Center Institutional Review Board",
        "label": "ORG"
      },
      {
        "text": "2019 \u2212",
        "label": "DATE"
      },
      {
        "text": "0888",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "of consent. Competing interests: Dr. Schulert has received consulting fees from",
    "entities": [
      {
        "text": "Schulert",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Novartis and Boehringer Ingelheim and research support from IpiNovyx. Dr. Grom",
    "entities": [
      {
        "text": "Boehringer Ingelheim",
        "label": "ORG"
      },
      {
        "text": "IpiNovyx",
        "label": "ORG"
      },
      {
        "text": "Grom\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "has received consulting fees from Novartis and SOBI. All author authors report",
    "entities": [
      {
        "text": "Novartis",
        "label": "ORG"
      },
      {
        "text": "SOBI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "no competing interests.",
    "entities": []
  },
  {
    "text": "6. J Med Case Rep. 2025 Jul 15;19(1):344. doi: 10.1186/s13256-025-05067-8.",
    "entities": [
      {
        "text": "6",
        "label": "CARDINAL"
      },
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "15;19(1):344",
        "label": "CARDINAL"
      },
      {
        "text": "10.1186",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "A mixed immediate and delayed allergy to oral vitamin D supplementation: a case",
    "entities": []
  },
  {
    "text": "Ridge A(1)(2), Cooling N(3), Seidel B(4)(3).",
    "entities": [
      {
        "text": "Ridge",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)School of Pharmacy and Pharmacology, College of Health and Medicine,",
    "entities": [
      {
        "text": "1)School of Pharmacy and Pharmacology, College of Health and Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University of Tasmania, Hobart, TAS, 7000, Australia. a.ridge@utas.edu.au.",
    "entities": [
      {
        "text": "University of Tasmania",
        "label": "ORG"
      },
      {
        "text": "Hobart",
        "label": "GPE"
      },
      {
        "text": "TAS",
        "label": "GPE"
      },
      {
        "text": "7000",
        "label": "DATE"
      },
      {
        "text": "Australia",
        "label": "GPE"
      },
      {
        "text": "a.ridge@utas.edu.au",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Ochre Health Research Network, c/- 85 Main Road, Huonville, TAS, 7109,",
    "entities": [
      {
        "text": "2)Ochre",
        "label": "CARDINAL"
      },
      {
        "text": "Health Research Network",
        "label": "ORG"
      },
      {
        "text": "85",
        "label": "CARDINAL"
      },
      {
        "text": "Main Road, Huonville",
        "label": "FAC"
      },
      {
        "text": "TAS",
        "label": "GPE"
      },
      {
        "text": "7109",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "(3)School of Medicine, College of Health and Medicine, University of Tasmania,",
    "entities": [
      {
        "text": "Medicine, College of Health and Medicine, University of Tasmania",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Hobart, TAS, 7000, Australia.",
    "entities": [
      {
        "text": "Hobart",
        "label": "PERSON"
      },
      {
        "text": "TAS",
        "label": "GPE"
      },
      {
        "text": "7000",
        "label": "DATE"
      },
      {
        "text": "Australia",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Ochre Health Research Network, c/- 85 Main Road, Huonville, TAS, 7109,",
    "entities": [
      {
        "text": "Health Research Network",
        "label": "ORG"
      },
      {
        "text": "85",
        "label": "CARDINAL"
      },
      {
        "text": "Main Road, Huonville",
        "label": "FAC"
      },
      {
        "text": "TAS",
        "label": "GPE"
      },
      {
        "text": "7109",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "BACKGROUND: Vitamin D deficiency is common worldwide and of particular concern",
    "entities": [
      {
        "text": "Vitamin",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "for populations at higher latitudes, including those in developed areas such as",
    "entities": []
  },
  {
    "text": "Australia. The role of vitamin D in modulating bone health and the immune system",
    "entities": [
      {
        "text": "Australia",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "is well recognized. Patients frequently have vitamin D deficiency identified and",
    "entities": []
  },
  {
    "text": "managed in the primary healthcare setting. Despite the high prevalence of use in",
    "entities": []
  },
  {
    "text": "CASE PRESENTATION: The case presented here is a 53-year-old Caucasian female of",
    "entities": [
      {
        "text": "53-year-old",
        "label": "DATE"
      },
      {
        "text": "Caucasian",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "Northern European ancestry, with a history of asthma and irritable bowel",
    "entities": [
      {
        "text": "Northern European ancestry",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "syndrome who was prescribed supplemental vitamin D. She experienced dyspepsia",
    "entities": [
      {
        "text": "D.",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "and stomach cramps within minutes of ingesting a vitamin D supplement. An",
    "entities": [
      {
        "text": "minutes",
        "label": "TIME"
      }
    ]
  },
  {
    "text": "alternative formulation of vitamin D produced similar gastrointestinal effects,",
    "entities": []
  },
  {
    "text": "worsening asthma and a rash. The results of the investigations were unremarkable",
    "entities": []
  },
  {
    "text": "except for mildly elevated total immunoglobulin levels. The patient was referred",
    "entities": []
  },
  {
    "text": "to an allergy clinic where a diagnosis of vitamin D hypersensitivity, with",
    "entities": []
  },
  {
    "text": "features of both immunoglobulin-E-mediated (type 1) and T-cell (type 4)-mediated",
    "entities": [
      {
        "text": "1",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "pathways, was made. A desensitization program was commenced using a modified",
    "entities": []
  },
  {
    "text": "Australian protocol. During the 18-week course, the patient was exposed to",
    "entities": [
      {
        "text": "Australian",
        "label": "NORP"
      },
      {
        "text": "18-week",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "increasing doses of vitamin D, and after 6 months, a daily dose of 1000 IU was",
    "entities": [
      {
        "text": "6 months",
        "label": "DATE"
      },
      {
        "text": "daily",
        "label": "DATE"
      },
      {
        "text": "1000",
        "label": "CARDINAL"
      },
      {
        "text": "IU",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "tolerated. She continues to use daily antihistamines and avoids foods rich in",
    "entities": [
      {
        "text": "daily",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "CONCLUSION: This case report highlights a rare likely allergic reaction to",
    "entities": []
  },
  {
    "text": "supplemental vitamin D. The patient was never known to have supratherapeutic",
    "entities": [
      {
        "text": "D.",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "levels of vitamin D, but her history of atopy may increase the likelihood of an",
    "entities": []
  },
  {
    "text": "immune-mediated response to the supplement. While skin sensitivity testing was",
    "entities": []
  },
  {
    "text": "negative, a provocation test and the Naranjo scoring system indicated that a",
    "entities": [
      {
        "text": "Naranjo",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "\"probable\" allergy occurred. Vitamin D deficiency is easily detected in primary",
    "entities": [
      {
        "text": "Vitamin",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "healthcare, and oral supplementation is usually a safe and effective means to",
    "entities": [
      {
        "text": "healthcare",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "restore blood levels. While reactions to vitamin D supplementation in normal",
    "entities": []
  },
  {
    "text": "doses are rare, an allergic cause should be considered when there are no other",
    "entities": []
  },
  {
    "text": "likely precipitants. Personalized, carefully supervised, desensitization to",
    "entities": []
  },
  {
    "text": "vitamin D may enable the resumption of supplementation and help prevent",
    "entities": []
  },
  {
    "text": "unnecessary morbidity and mortality from vitamin D deficiency.",
    "entities": []
  },
  {
    "text": "PMID: 40665361 [Indexed for MEDLINE]",
    "entities": []
  },
  {
    "text": "participate: An exemption from ethical review was granted by the University of",
    "entities": [
      {
        "text": "the University of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Tasmania Human Research Ethics Committee (Project ID: 30944). Consent for",
    "entities": [
      {
        "text": "Tasmania Human Research Ethics Committee",
        "label": "ORG"
      },
      {
        "text": "30944",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "publication: Written informed consent was obtained from the patient for",
    "entities": []
  },
  {
    "text": "publication of this case report and any accompanying images. A copy of the",
    "entities": []
  },
  {
    "text": "written consent is available for review by the Editor-in-Chief of this journal.",
    "entities": []
  },
  {
    "text": "Competing interests: The authors declare that there are no conflicts of",
    "entities": []
  },
  {
    "text": "Association between neighborhood deprivation and type 2 diabetes risks among",
    "entities": [
      {
        "text": "2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "asthma patients: a nationwide population-based cohort study.",
    "entities": []
  },
  {
    "text": "(1)School of Public Health, Ningxia Medical University, Yinchuan, China.",
    "entities": [
      {
        "text": "1)School of Public Health",
        "label": "ORG"
      },
      {
        "text": "Ningxia Medical University",
        "label": "ORG"
      },
      {
        "text": "Yinchuan",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Key Laboratory of Environmental Factors and Chronic Disease Control, Ningxia",
    "entities": [
      {
        "text": "2)Key Laboratory of Environmental Factors",
        "label": "ORG"
      },
      {
        "text": "Ningxia",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Medical University, Yinchuan, China.",
    "entities": [
      {
        "text": "Medical University",
        "label": "ORG"
      },
      {
        "text": "Yinchuan",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Center for Primary Health Care Research, Department of Clinical Sciences,",
    "entities": [
      {
        "text": "Primary Health Care Research",
        "label": "ORG"
      },
      {
        "text": "Department of Clinical Sciences",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)University Clinic Primary Care, Sk\u00e5ne University Hospital, Region Sk\u00e5ne,",
    "entities": [
      {
        "text": "Clinic Primary Care",
        "label": "ORG"
      },
      {
        "text": "Sk\u00e5ne University Hospital",
        "label": "ORG"
      },
      {
        "text": "Sk\u00e5ne",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(5)Departments of Family and Community Medicine and of Epidemiology, The",
    "entities": [
      {
        "text": "Family and Community Medicine",
        "label": "ORG"
      },
      {
        "text": "Epidemiology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University of Texas Health Science Center, Houston, TX, USA.",
    "entities": [
      {
        "text": "University of Texas Health Science Center",
        "label": "ORG"
      },
      {
        "text": "Houston",
        "label": "GPE"
      },
      {
        "text": "TX",
        "label": "ORG"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)Center for Community-based Healthcare Research and Education (CoHRE),",
    "entities": [
      {
        "text": "6)Center",
        "label": "CARDINAL"
      },
      {
        "text": "Community",
        "label": "ORG"
      },
      {
        "text": "Healthcare Research and Education",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Department of Functional Pathology, School of Medicine, Matsue, Shimane",
    "entities": [
      {
        "text": "Department of Functional Pathology",
        "label": "ORG"
      },
      {
        "text": "School of Medicine",
        "label": "ORG"
      },
      {
        "text": "Matsue",
        "label": "GPE"
      },
      {
        "text": "Shimane\n",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "University, Matsue, Japan.",
    "entities": [
      {
        "text": "Matsue",
        "label": "PERSON"
      },
      {
        "text": "Japan",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(7)Center for Primary Health Care Research, Department of Clinical Sciences,",
    "entities": [
      {
        "text": "Primary Health Care Research",
        "label": "ORG"
      },
      {
        "text": "Department of Clinical Sciences",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(8)University Clinic Primary Care, Sk\u00e5ne University Hospital, Region Sk\u00e5ne,",
    "entities": [
      {
        "text": "8)University Clinic Primary Care",
        "label": "ORG"
      },
      {
        "text": "Sk\u00e5ne University Hospital",
        "label": "ORG"
      },
      {
        "text": "Sk\u00e5ne",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "This study aimed to investigate the potential impact of neighborhood deprivation",
    "entities": []
  },
  {
    "text": "on the incidence of type 2 diabetes mellitus (T2DM) among individuals with",
    "entities": [
      {
        "text": "2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "asthma. This nationwide, open cohort study conducted in Sweden from 1997 to 2018",
    "entities": [
      {
        "text": "Sweden",
        "label": "GPE"
      },
      {
        "text": "1997",
        "label": "DATE"
      },
      {
        "text": "2018",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "included asthma patients of all ages (n = 1,051,240) to assess their subsequent",
    "entities": [
      {
        "text": "1,051,240",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "risk of developing T2DM. The study compared asthma patients residing in highly",
    "entities": []
  },
  {
    "text": "deprived neighborhoods with those living in moderately or less deprived areas",
    "entities": []
  },
  {
    "text": "(reference group). Cox proportional hazards regression models were employed to",
    "entities": []
  },
  {
    "text": "analyze the association between neighborhood deprivation and T2DM incidence,",
    "entities": []
  },
  {
    "text": "with results expressed as hazard ratios (HRs) and 95% confidence intervals (95%",
    "entities": [
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "CIs). Analyses were stratified by sex and adjusted for potential confounders. A",
    "entities": [
      {
        "text": "CIs",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "significant association between neighborhood deprivation and T2DM risk in asthma",
    "entities": []
  },
  {
    "text": "patients was shown. These associations remained statistically significant after",
    "entities": []
  },
  {
    "text": "adjusting for confounders, with adjusted HRs of 1.44 (95% CI 1.38-1.50) for men",
    "entities": [
      {
        "text": "1.44",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "1.38-1.50",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "and 1.51 (95% CI 1.46-1.57) for women. Furthermore, a graded relationship was",
    "entities": [
      {
        "text": "1.51",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "1.46-1.57",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "observed, with higher levels of neighborhood deprivation associated with an",
    "entities": []
  },
  {
    "text": "increased incidence of T2DM among asthma patients. These findings underscore",
    "entities": []
  },
  {
    "text": "critical clinical and public health concerns. The results of this study provide",
    "entities": []
  },
  {
    "text": "valuable insights for policymakers, highlighting the need to consider",
    "entities": []
  },
  {
    "text": "neighborhood deprivation when allocating resources in primary healthcare",
    "entities": []
  },
  {
    "text": "settings. They also offer guidance for optimizing clinical care strategies for",
    "entities": []
  },
  {
    "text": "patients in socioeconomically disadvantaged communities.",
    "entities": []
  },
  {
    "text": "DOI: 10.1038/s41598-025-09150-4",
    "entities": [
      {
        "text": "10.1038",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "PMID: 40665105 [Indexed for MEDLINE]",
    "entities": []
  },
  {
    "text": "Conflict of interest statement: Declarations. Competing interests: The authors",
    "entities": []
  },
  {
    "text": "declare no competing interests. Ethics approval: This study was approved by the",
    "entities": []
  },
  {
    "text": "regional ethical review board in Lund, Sweden on Feb. 6th, 2013 (registration No",
    "entities": [
      {
        "text": "Lund",
        "label": "GPE"
      },
      {
        "text": "Sweden",
        "label": "GPE"
      },
      {
        "text": "Feb. 6th, 2013",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "2012/795) and later amendments. Guidelines of the Helsinki Declaration were",
    "entities": [
      {
        "text": "2012/795",
        "label": "CARDINAL"
      },
      {
        "text": "the Helsinki Declaration",
        "label": "LAW"
      }
    ]
  },
  {
    "text": "followed. Data were obtained from the national registers collected by various",
    "entities": []
  },
  {
    "text": "Swedish health and social agencies. The agency Statistics Sweden linked the",
    "entities": [
      {
        "text": "Swedish",
        "label": "NORP"
      },
      {
        "text": "Statistics Sweden",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(pseudonymised) unique personal identification number assigned to all Swedish",
    "entities": [
      {
        "text": "Swedish",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "residents at birth or migration. Informed consent: Informed consent was not",
    "entities": []
  },
  {
    "text": "applicable, as the study was based on secondary pseudonymized data from",
    "entities": []
  },
  {
    "text": "8. Nat Med. 2025 Jul 15. doi: 10.1038/s41591-025-03790-9. Online ahead of print.",
    "entities": [
      {
        "text": "8",
        "label": "CARDINAL"
      },
      {
        "text": "Nat Med",
        "label": "PERSON"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "15",
        "label": "CARDINAL"
      },
      {
        "text": "10.1038",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Deep phenotyping of health-disease continuum in the Human Phenotype Project.",
    "entities": [
      {
        "text": "the Human Phenotype Project",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Y(12), Stossel C(12), Raitses-Gurevich M(12), Golan T(4)(12), Dhir R(13),",
    "entities": [
      {
        "text": "Stossel C(12",
        "label": "ORG"
      },
      {
        "text": "Raitses-Gurevich M(12",
        "label": "PERSON"
      },
      {
        "text": "Golan T(4)(12",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "(1)Department of Computer Science and Applied Mathematics, Weizmann Institute of",
    "entities": [
      {
        "text": "Computer Science",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Science, Rehovot, Israel.",
    "entities": [
      {
        "text": "Rehovot",
        "label": "GPE"
      },
      {
        "text": "Israel",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot,",
    "entities": [
      {
        "text": "Molecular Cell Biology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(3)Lis Maternity and Women's Hospital, Tel Aviv Sourasky Medical Center, Tel",
    "entities": [
      {
        "text": "Tel Aviv Sourasky Medical Center",
        "label": "ORG"
      },
      {
        "text": "Tel\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(4)Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv,",
    "entities": [
      {
        "text": "4)Faculty of Medical and Health Sciences",
        "label": "ORG"
      },
      {
        "text": "Tel Aviv University",
        "label": "ORG"
      },
      {
        "text": "Tel Aviv",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)The Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes,",
    "entities": [
      {
        "text": "Jesse Z",
        "label": "WORK_OF_ART"
      },
      {
        "text": "Sara Lea Shafer Institute for Endocrinology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "National Center for Childhood Diabetes, Schneider Children's Medical Center of",
    "entities": [
      {
        "text": "National Center for Childhood Diabetes",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(6)Department of Internal Medicine A, Shamir Medical Center (Assaf Harofeh),",
    "entities": [
      {
        "text": "Internal Medicine A",
        "label": "ORG"
      },
      {
        "text": "Shamir Medical Center",
        "label": "ORG"
      },
      {
        "text": "Assaf Harofeh",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(7)Department of Cardiology, Rabin Medical Center, Petah-Tikva, Israel.",
    "entities": [
      {
        "text": "Cardiology",
        "label": "GPE"
      },
      {
        "text": "Rabin Medical Center",
        "label": "ORG"
      },
      {
        "text": "Israel",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(8)Cancer Research Center, Sheba Medical Center, Ramat-Gan, Israel.",
    "entities": [
      {
        "text": "Research Center",
        "label": "ORG"
      },
      {
        "text": "Sheba Medical Center",
        "label": "ORG"
      },
      {
        "text": "Ramat-Gan",
        "label": "ORG"
      },
      {
        "text": "Israel",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(9)Institute of Breast Oncology, the Jusidman Cancer Center, Sheba Medical",
    "entities": [
      {
        "text": "Breast Oncology",
        "label": "ORG"
      },
      {
        "text": "the Jusidman Cancer Center",
        "label": "ORG"
      },
      {
        "text": "Sheba Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(10)The Department of Gastroenterology and Liver Disease, Tel Aviv Medical",
    "entities": [
      {
        "text": "10)The Department of Gastroenterology and Liver Disease",
        "label": "ORG"
      },
      {
        "text": "Tel Aviv Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Center, affiliated to the Grey Faculty of Medicine and Health Sciences, Tel Aviv",
    "entities": [
      {
        "text": "the Grey Faculty of Medicine and Health Sciences",
        "label": "ORG"
      },
      {
        "text": "Tel Aviv",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "University, Tel Aviv, Israel.",
    "entities": [
      {
        "text": "Tel Aviv",
        "label": "GPE"
      },
      {
        "text": "Israel",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(11)Department of Internal Medicine, SBS Shizuoka Health Promotion Center,",
    "entities": [
      {
        "text": "11)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Internal Medicine",
        "label": "ORG"
      },
      {
        "text": "SBS Shizuoka Health Promotion Center",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(12)The Jusidman Cancer Center, Sheba Medical Center, Tel Hashomer, Israel.",
    "entities": [
      {
        "text": "Jusidman Cancer Center",
        "label": "ORG"
      },
      {
        "text": "Sheba Medical Center",
        "label": "ORG"
      },
      {
        "text": "Tel Hashomer",
        "label": "PERSON"
      },
      {
        "text": "Israel",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(13)Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich,",
    "entities": [
      {
        "text": "13)Swiss Institute of Allergy and Asthma Research",
        "label": "ORG"
      },
      {
        "text": "University of Zurich",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(15)Mohamed bin Zayed University of Artificial Intelligence, Abu Dhabi, UAE.",
    "entities": [
      {
        "text": "15)Mohamed",
        "label": "CARDINAL"
      },
      {
        "text": "bin Zayed University of Artificial Intelligence",
        "label": "ORG"
      },
      {
        "text": "Abu Dhabi",
        "label": "GPE"
      },
      {
        "text": "UAE",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(17)Mohamed bin Zayed University of Artificial Intelligence, Abu Dhabi, UAE.",
    "entities": [
      {
        "text": "bin Zayed University of Artificial Intelligence",
        "label": "ORG"
      },
      {
        "text": "Abu Dhabi",
        "label": "GPE"
      },
      {
        "text": "UAE",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(18)Carnegie Mellon University Pittsburgh, Pittsburgh, PA, USA.",
    "entities": [
      {
        "text": "18)Carnegie",
        "label": "CARDINAL"
      },
      {
        "text": "Mellon University",
        "label": "ORG"
      },
      {
        "text": "Pittsburgh",
        "label": "GPE"
      },
      {
        "text": "Pittsburgh",
        "label": "GPE"
      },
      {
        "text": "PA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(19)Department of Computer Science and Applied Mathematics, Weizmann Institute",
    "entities": []
  },
  {
    "text": "of Science, Rehovot, Israel. eran.segal@weizmann.ac.il.",
    "entities": [
      {
        "text": "Science, Rehovot",
        "label": "GPE"
      },
      {
        "text": "Israel",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(20)Mohamed bin Zayed University of Artificial Intelligence, Abu Dhabi, UAE.",
    "entities": [
      {
        "text": "20)Mohamed",
        "label": "CARDINAL"
      },
      {
        "text": "University of Artificial Intelligence",
        "label": "ORG"
      },
      {
        "text": "Abu Dhabi",
        "label": "GPE"
      },
      {
        "text": "UAE",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(#)Contributed equally",
    "entities": []
  },
  {
    "text": "The Human Phenotype Project (HPP) is a large-scale deep-phenotype prospective",
    "entities": [
      {
        "text": "The Human Phenotype Project",
        "label": "ORG"
      },
      {
        "text": "HPP",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "cohort. To date, approximately 28,000 participants have enrolled, with more than",
    "entities": [
      {
        "text": "approximately 28,000",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "13,000 completing their initial visit. The project is aimed at identifying novel",
    "entities": [
      {
        "text": "13,000",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "molecular signatures with diagnostic, prognostic and therapeutic value, and at",
    "entities": []
  },
  {
    "text": "developing artificial intelligence (AI)-based predictive models for disease",
    "entities": []
  },
  {
    "text": "onset and progression. The HPP includes longitudinal profiling encompassing",
    "entities": [
      {
        "text": "HPP",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "medical history, lifestyle and nutrition, anthropometrics, blood tests,",
    "entities": []
  },
  {
    "text": "immune profiling. Analysis of these data highlights the variation of phenotypes",
    "entities": []
  },
  {
    "text": "with age and ethnicity and unravels molecular signatures of disease by",
    "entities": []
  },
  {
    "text": "comparison with matched healthy controls. Leveraging extensive dietary and",
    "entities": []
  },
  {
    "text": "lifestyle data, we identify associations between lifestyle factors and health",
    "entities": [
      {
        "text": "lifestyle data",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "outcomes. Finally, we present a multi-modal foundation AI model, trained using",
    "entities": [
      {
        "text": "AI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "self-supervised learning on diet and continuous-glucose-monitoring data, that",
    "entities": []
  },
  {
    "text": "outperforms existing methods in predicting disease onset. This framework can be",
    "entities": []
  },
  {
    "text": "extended to integrate other modalities and act as a personalized digital twin.",
    "entities": []
  },
  {
    "text": "In summary, we present a deeply phenotyped cohort that serves as a platform for",
    "entities": []
  },
  {
    "text": "advancing biomarker discovery, enabling the development of multi-modal AI models",
    "entities": [
      {
        "text": "AI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and personalized medicine approaches.",
    "entities": []
  },
  {
    "text": "\u00a9 2025. The Author(s), under exclusive licence to Springer Nature America, Inc.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Springer Nature America, Inc.",
        "label": "WORK_OF_ART"
      }
    ]
  },
  {
    "text": "DOI: 10.1038/s41591-025-03790-9",
    "entities": [
      {
        "text": "10.1038",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Competing interests: Y.R., H.R. and Y.T.B are",
    "entities": [
      {
        "text": "Y.R.",
        "label": "GPE"
      },
      {
        "text": "H.R.",
        "label": "GPE"
      },
      {
        "text": "Y.T.B",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "employees at Pheno.AI. A.K., A.W. and E.S. are paid consultants of Pheno.AI.",
    "entities": [
      {
        "text": "Pheno",
        "label": "GPE"
      },
      {
        "text": "AI",
        "label": "ORG"
      },
      {
        "text": "A.K.",
        "label": "GPE"
      },
      {
        "text": "A.W.",
        "label": "GPE"
      },
      {
        "text": "E.S.",
        "label": "GPE"
      },
      {
        "text": "Pheno",
        "label": "GPE"
      },
      {
        "text": "AI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "N.M. has received speaking and consulting fees from Pfizer, Abbvie, Lilly,",
    "entities": [
      {
        "text": "N.M.",
        "label": "GPE"
      },
      {
        "text": "Pfizer, Abbvie, Lilly",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Takeda, Janssen, Ferring, BiomX, BMS, Nestle and Teva and grant support from",
    "entities": [
      {
        "text": "Ferring",
        "label": "GPE"
      },
      {
        "text": "BMS",
        "label": "ORG"
      },
      {
        "text": "Nestle",
        "label": "ORG"
      },
      {
        "text": "Teva",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "the Helmsely Charitable Trust. The other authors declare no competing interests.",
    "entities": [
      {
        "text": "the Helmsely Charitable Trust",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Mental health risks in children with food allergies: a population-based",
    "entities": []
  },
  {
    "text": "comparison of food allergies with other chronic conditions.",
    "entities": []
  },
  {
    "text": "Flaks-Manov N(#)(1), Goldshtein I(#)(1), Yanover C(1), Lachover-Roth I(2)(3).",
    "entities": [
      {
        "text": "Flaks-Manov",
        "label": "ORG"
      },
      {
        "text": "Goldshtein",
        "label": "PERSON"
      },
      {
        "text": "Yanover",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(1)KI Research Institute, Kfar Malal, Israel.",
    "entities": [
      {
        "text": "1)KI Research Institute",
        "label": "ORG"
      },
      {
        "text": "Kfar Malal",
        "label": "PERSON"
      },
      {
        "text": "Israel",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Allergy and Clinical Immunology Unit, Meir Medical Center, Kfar Saba, Israel.",
    "entities": [
      {
        "text": "Clinical Immunology Unit",
        "label": "ORG"
      },
      {
        "text": "Meir Medical Center",
        "label": "ORG"
      },
      {
        "text": "Kfar Saba",
        "label": "PERSON"
      },
      {
        "text": "Israel",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv",
    "entities": [
      {
        "text": "Medicine, Faculty of Medical and Health Sciences",
        "label": "ORG"
      },
      {
        "text": "Tel Aviv",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "University, Tel Aviv, Israel. idit.lachover@gmail.com.",
    "entities": [
      {
        "text": "Tel Aviv",
        "label": "GPE"
      },
      {
        "text": "Israel",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Children with chronic diseases face a higher risk of mental health disorders.",
    "entities": []
  },
  {
    "text": "However, the cognitive consequences of food allergies (FA), which are not",
    "entities": []
  },
  {
    "text": "classified as a chronic disease, remain insufficiently researched. The objective",
    "entities": []
  },
  {
    "text": "of this study is to examine the association between FA and mental health in",
    "entities": []
  },
  {
    "text": "children and adolescents, compared to children and adolescents without FA",
    "entities": []
  },
  {
    "text": "(controls) and those with other chronic conditions but no history of FA. This is",
    "entities": []
  },
  {
    "text": "a retrospective cohort study using IQVIA Medical Research Data from UK primary",
    "entities": [
      {
        "text": "IQVIA Medical Research Data",
        "label": "ORG"
      },
      {
        "text": "UK",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "care practices. Five cohorts of children aged 0-18 between 2000 and 2021 were",
    "entities": [
      {
        "text": "Five",
        "label": "CARDINAL"
      },
      {
        "text": "0-18 between 2000",
        "label": "DATE"
      },
      {
        "text": "2021",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "defined: FA, control, asthma, atopic dermatitis (AD), and type 1 diabetes (T1D).",
    "entities": [
      {
        "text": "1",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "The study included 1,130,721 children without FA (control), 23,263 with FA,",
    "entities": [
      {
        "text": "1,130,721",
        "label": "CARDINAL"
      },
      {
        "text": "23,263",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "136,453 with asthma, 207,575 with AD, and 4835 with T1D. Compared to control, FA",
    "entities": [
      {
        "text": "136,453",
        "label": "CARDINAL"
      },
      {
        "text": "207,575",
        "label": "CARDINAL"
      },
      {
        "text": "4835",
        "label": "DATE"
      },
      {
        "text": "T1D.",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "patients had higher risks of eating disorders (hazard ratio (HR) 1.85, 95% CI",
    "entities": [
      {
        "text": "1.85",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "1.42-2.41), anxiety (HR 1.35, 95% CI 1.25-1.45), and depression (HR 1.24, 95% CI",
    "entities": [
      {
        "text": "1.42",
        "label": "CARDINAL"
      },
      {
        "text": "1.35",
        "label": "DATE"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "1.25-1.45",
        "label": "CARDINAL"
      },
      {
        "text": "1.24",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "1.11-1.39). FA patients had lower depression risk than asthma and T1D patients",
    "entities": [
      {
        "text": "1.11-1.39",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "(HR 0.77, 95% CI 0.68-0.87, 0.64, 95% CI 0.54-0.76, respectively) and lower",
    "entities": [
      {
        "text": "0.77",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "GPE"
      },
      {
        "text": "0.68-0.87",
        "label": "CARDINAL"
      },
      {
        "text": "0.64",
        "label": "DATE"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "0.54-0.76",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "anxiety risk than asthma patients (HR 0.86, 95% CI 0.79-0.91). FA patients' risk",
    "entities": [
      {
        "text": "0.86",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "0.79-0.91",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "of eating disorders was not significantly different from asthma and T1D patients",
    "entities": []
  },
  {
    "text": "(HR 1.17, 95% CI 0.88-1.55, 1.58, 95% CI 0.81-3.10, respectively) but was",
    "entities": [
      {
        "text": "1.17",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "0.88-1.55",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "0.81-3.10",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "significantly higher than in the AD group (HR 1.43, 95% CI 1.07-1.90).",
    "entities": [
      {
        "text": "1.43",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "1.07-1.90",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "CONCLUSION: This study indicates that children with FA face elevated risks of",
    "entities": []
  },
  {
    "text": "anxiety, depression, and eating disorders compared to children without FA, and",
    "entities": []
  },
  {
    "text": "that these risks vary when compared to children with other chronic conditions.",
    "entities": []
  },
  {
    "text": "These findings highlight the need for integrated mental health support in FA",
    "entities": []
  },
  {
    "text": "management and greater awareness of FA's psychological impact among healthcare",
    "entities": []
  },
  {
    "text": "WHAT IS KNOWN: \u2022 Children with chronic illnesses such as asthma and diabetes are",
    "entities": []
  },
  {
    "text": "known to have an elevated risk of mental health disorders. However, research on",
    "entities": []
  },
  {
    "text": "the mental health impact of food allergies remains limited.",
    "entities": []
  },
  {
    "text": "WHAT IS NEW: \u2022 This study reveals that children with FA have significantly",
    "entities": []
  },
  {
    "text": "increased risks of anxiety, depression, and eating disorders compared to",
    "entities": []
  },
  {
    "text": "children without FA and provides comparative insights into the mental health",
    "entities": []
  },
  {
    "text": "risks of FA relative to other chronic conditions like asthma, atopic dermatitis,",
    "entities": []
  },
  {
    "text": "type 1 diabetes, and healthy controls.",
    "entities": [
      {
        "text": "1",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "\u00a9 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany,",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Springer-Verlag GmbH",
        "label": "ORG"
      },
      {
        "text": "Germany",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "part of Springer Nature.",
    "entities": [
      {
        "text": "Springer Nature",
        "label": "WORK_OF_ART"
      }
    ]
  },
  {
    "text": "PMID: 40664887 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40664887",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Declarations. Ethical approval: This study was",
    "entities": []
  },
  {
    "text": "performed in line with the principles of the Declaration of Helsinki. Approval",
    "entities": [
      {
        "text": "the Declaration of Helsinki",
        "label": "WORK_OF_ART"
      }
    ]
  },
  {
    "text": "was granted by the Ethics Committee of IQVIA Scientific Review Committee (SRC",
    "entities": [
      {
        "text": "the Ethics Committee of IQVIA Scientific Review Committee",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Reference Number: 23SRC014). Competing interest: The authors declare no",
    "entities": [
      {
        "text": "23SRC014",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Conducting the National Health and Morbidity Survey 2023 in Malaysia with focus",
    "entities": [
      {
        "text": "the National Health and Morbidity Survey 2023",
        "label": "ORG"
      },
      {
        "text": "Malaysia",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "on methodology and main findings on non-communicable diseases.",
    "entities": []
  },
  {
    "text": "Mat Rifin H(1), Mohd Yusoff MF(2), Abd Hamid HA(2).",
    "entities": [
      {
        "text": "Mohd Yusoff MF(2",
        "label": "PERSON"
      },
      {
        "text": "Abd Hamid HA(2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)Institute for Public Health, National Institutes of Health, Ministry of",
    "entities": [
      {
        "text": "National Institutes of Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)Institute for Public Health, National Institutes of Health, Ministry of",
    "entities": [
      {
        "text": "National Institutes of Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "The National Health and Morbidity Survey (NHMS), which focuses on",
    "entities": [
      {
        "text": "The National Health and Morbidity Survey (NHMS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "non-communicable diseases (NCDs), their risk factors and healthcare demand, is a",
    "entities": []
  },
  {
    "text": "cross-sectional, nationwide, population-based survey conducted every four-year",
    "entities": [
      {
        "text": "four-year",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "cycle since 2011. NHMS 2023 was the 7th cycle of NCDs, their risk factors and",
    "entities": [
      {
        "text": "2011",
        "label": "DATE"
      },
      {
        "text": "NHMS 2023",
        "label": "DATE"
      },
      {
        "text": "7th",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "healthcare demand, which aimed to monitor trends in diseases and healthcare",
    "entities": [
      {
        "text": "healthcare",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "utilisation. This article outlines the methodology, sociodemographic",
    "entities": []
  },
  {
    "text": "characteristics, and overall findings from the population surveyed in 2023",
    "entities": [
      {
        "text": "2023",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "regarding NCDs, their risk factors, and various health-related topics. This",
    "entities": []
  },
  {
    "text": "survey utilised a two-stage stratified random sampling design and encompassed",
    "entities": [
      {
        "text": "two",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "fifteen main scopes, with sample sizes calculated to meet the specific",
    "entities": [
      {
        "text": "fifteen",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "requirements of each scope. Conducted from July to September 2023, it involved",
    "entities": [
      {
        "text": "July to September 2023",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "the random selection of 499 enumeration blocks(EBs) by the Department of",
    "entities": [
      {
        "text": "499",
        "label": "CARDINAL"
      },
      {
        "text": "the Department of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Statistics Malaysia (DOSM) across all states and federal territories in",
    "entities": [
      {
        "text": "DOSM",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Malaysia. The step resulted in the selection of 5,988 living quarters (LQs).",
    "entities": [
      {
        "text": "Malaysia",
        "label": "GPE"
      },
      {
        "text": "5,988",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Data collection methods included validated questionnaires administered through",
    "entities": []
  },
  {
    "text": "face-to-face interviews and self-administered questionnaires, alongside clinical",
    "entities": []
  },
  {
    "text": "assessments and blood investigations using calibrated devices. To ensure the",
    "entities": []
  },
  {
    "text": "high quality of the collected data, we implemented stringent quality control",
    "entities": []
  },
  {
    "text": "measures. Furthermore, we applied complex sampling analyses to ensure that the",
    "entities": []
  },
  {
    "text": "findings accurately represented the population in Malaysia. The survey received",
    "entities": [
      {
        "text": "Malaysia",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "responses from 13,616 individuals out of the 5,006 LQs that were successfully",
    "entities": [
      {
        "text": "13,616",
        "label": "CARDINAL"
      },
      {
        "text": "5,006",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "visited, resulting in an overall response rate of the survey of 83.2%, which",
    "entities": [
      {
        "text": "83.2%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "includes individuals aged 5 years and above. A substantial segment of the",
    "entities": [
      {
        "text": "5 years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "population lived in urban regions, comprising 77.6% of the total. About half of",
    "entities": [
      {
        "text": "77.6%",
        "label": "PERCENT"
      },
      {
        "text": "About half",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "the population consisted of males (51.9%), Malay (54.6%), and individuals who",
    "entities": [
      {
        "text": "51.9%",
        "label": "PERCENT"
      },
      {
        "text": "Malay",
        "label": "PERSON"
      },
      {
        "text": "54.6%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "had attained secondary education (54.2%). Additionally, 20.0% of the population",
    "entities": [
      {
        "text": "54.2%",
        "label": "PERCENT"
      },
      {
        "text": "20.0%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "were within the age range of 30 to 39 years. The weighted prevalence of diabetes",
    "entities": [
      {
        "text": "30 to 39 years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "was 15.6%, hypertension 29.2%, hypercholesterolaemia 33.3%, overweight and",
    "entities": [
      {
        "text": "15.6%",
        "label": "PERCENT"
      },
      {
        "text": "29.2%",
        "label": "PERCENT"
      },
      {
        "text": "33.3%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "obesity 54.4%. Depression among adults was 4.6%, while mental health problems",
    "entities": [
      {
        "text": "54.4%",
        "label": "PERCENT"
      },
      {
        "text": "4.6%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "among children were reported at 16.5%. The current tobacco smokers prevalence",
    "entities": [
      {
        "text": "16.5%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "was 19.0%, and 29.9% of adults in Malaysia were physically inactive. The known",
    "entities": [
      {
        "text": "19.0%",
        "label": "PERCENT"
      },
      {
        "text": "29.9%",
        "label": "PERCENT"
      },
      {
        "text": "Malaysia",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "asthma prevalence among adults was 6.2%, while the current asthma among children",
    "entities": [
      {
        "text": "6.2%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "was 3.4%. Additionally, 37.7% of adults experienced sleep insufficiency. The",
    "entities": [
      {
        "text": "3.4%",
        "label": "PERCENT"
      },
      {
        "text": "37.7%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "results indicate that the higher proportion of diabetes, hypertension, and",
    "entities": []
  },
  {
    "text": "hypercholesterolaemia, particularly among the young age group, and the high",
    "entities": []
  },
  {
    "text": "prevalence of overweight and obesity, as well as mental health problems, are",
    "entities": []
  },
  {
    "text": "making the healthcare system deal with more non-communicable diseases,",
    "entities": []
  },
  {
    "text": "complications, and problems. The methodology of this survey is robust for a",
    "entities": []
  },
  {
    "text": "population-based study. We took comprehensive steps to ensure the validity and",
    "entities": []
  },
  {
    "text": "reliability of the findings. The findings indicate an urgent need for targeted",
    "entities": []
  },
  {
    "text": "public health interventions to address the escalating health issues. By focusing",
    "entities": []
  },
  {
    "text": "on prevention and early intervention strategies, we can mitigate the impact of",
    "entities": []
  },
  {
    "text": "NCDs on the healthcare system and improve overall population health.",
    "entities": []
  },
  {
    "text": "DOI: 10.1038/s41598-025-08311-9",
    "entities": [
      {
        "text": "10.1038",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "PMID: 40664716 [Indexed for MEDLINE]",
    "entities": []
  },
  {
    "text": "participate: All respondents provided written informed consent prior to",
    "entities": []
  },
  {
    "text": "interviews. The survey protocol was approved by the Medical Research and Ethics",
    "entities": [
      {
        "text": "the Medical Research and Ethics",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Committee (MREC), Ministry of Health Malaysia (22-00545-XAC (2)). All methods",
    "entities": [
      {
        "text": "Ministry of Health Malaysia",
        "label": "ORG"
      },
      {
        "text": "22-00545-XAC",
        "label": "DATE"
      },
      {
        "text": "2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "adhered to the principles of the Declaration of Helsinki and the Malaysian Good",
    "entities": [
      {
        "text": "the Declaration of Helsinki",
        "label": "WORK_OF_ART"
      },
      {
        "text": "Malaysian",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "Clinical Practice Guidelines. Competing interests: The authors declare no",
    "entities": [
      {
        "text": "Clinical Practice Guidelines",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Disinfection of medical devices with a steam machine that operates at",
    "entities": []
  },
  {
    "text": "atmospheric pressure and is suitable for home usage.",
    "entities": []
  },
  {
    "text": "(1)Department of Medical Microbiology, University of Groningen, University",
    "entities": [
      {
        "text": "Medical Microbiology",
        "label": "ORG"
      },
      {
        "text": "University of Groningen",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)Department of Medical Microbiology, University of Groningen, University",
    "entities": [
      {
        "text": "Medical Microbiology",
        "label": "ORG"
      },
      {
        "text": "University of Groningen",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Medical devices that come in direct contact with human skin or the oral cavity",
    "entities": []
  },
  {
    "text": "will inevitably be contaminated with microorganisms, including potential",
    "entities": []
  },
  {
    "text": "pathogens. Ensuring the microbiological safety of such devices is therefore",
    "entities": []
  },
  {
    "text": "crucial to prevent infections. Healthcare institutions usually have the",
    "entities": [
      {
        "text": "Healthcare",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "facilities needed for effective sterilization of reusable medical devices.",
    "entities": []
  },
  {
    "text": "However, effective sterilization or disinfection of medical devices for usage at",
    "entities": []
  },
  {
    "text": "home has remained challenging both in terms of pathogen elimination and user",
    "entities": []
  },
  {
    "text": "safety. Preferably, this involves easy-to-operate equipment that works at",
    "entities": []
  },
  {
    "text": "relatively low temperatures and atmospheric pressure. In principle this need can",
    "entities": []
  },
  {
    "text": "be met by disinfection with steam. Therefore, the objective of the present study",
    "entities": []
  },
  {
    "text": "was to examine the efficacy of a simple electronic steam machine designed for",
    "entities": []
  },
  {
    "text": "home usage. Our results show that exposure to steam at 100 \u00b0C for 60 s resulted",
    "entities": [
      {
        "text": "100",
        "label": "CARDINAL"
      },
      {
        "text": "60",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "in complete eradication (100% reduction) of bacterial contaminants, including",
    "entities": [
      {
        "text": "100%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "methicillin-resistant Staphylococcus aureus (MRSA). Significant bacterial",
    "entities": [
      {
        "text": "methicillin",
        "label": "PERSON"
      },
      {
        "text": "Staphylococcus aureus",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "reductions (ranging from ~ 90-100%) were also observed within shorter exposure",
    "entities": [
      {
        "text": "90-100%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "times (10-30 s), depending on the strain. Importantly, the applied steam",
    "entities": [
      {
        "text": "10-30",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "disinfection approach is effective even against biofilm-embedded bacteria, or",
    "entities": []
  },
  {
    "text": "bacteria applied to a medical device for home usage, as exemplified with a",
    "entities": []
  },
  {
    "text": "nebulizer that is used by patients with asthma or chronic obstructive pulmonary",
    "entities": []
  },
  {
    "text": "disease (COPD). In conclusion, our results provide quantitative proof-of-concept",
    "entities": []
  },
  {
    "text": "evidence that portable steam-generating devices that operate at atmospheric",
    "entities": []
  },
  {
    "text": "pressure can be used for effective disinfection of reusable medical devices in",
    "entities": []
  },
  {
    "text": "DOI: 10.1038/s41598-025-11509-6",
    "entities": [
      {
        "text": "10.1038",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "PMID: 40664706 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40664706",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Screening tools for work-related asthma and their diagnostic accuracy: a",
    "entities": []
  },
  {
    "text": "systematic review.",
    "entities": []
  },
  {
    "text": "(1)Department of Applied Health Sciences, University of Birmingham, Birmingham,",
    "entities": [
      {
        "text": "Applied Health Sciences",
        "label": "ORG"
      },
      {
        "text": "University of Birmingham",
        "label": "ORG"
      },
      {
        "text": "Birmingham",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Community Medicine and Family Medicine, Thammasat University",
    "entities": [
      {
        "text": "Community Medicine",
        "label": "ORG"
      },
      {
        "text": "Family Medicine",
        "label": "ORG"
      },
      {
        "text": "Thammasat University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Faculty of Medicine, Khlong Nueng, Pathum Thani, Thailand.",
    "entities": [
      {
        "text": "Khlong Nueng",
        "label": "PERSON"
      },
      {
        "text": "Pathum Thani",
        "label": "PERSON"
      },
      {
        "text": "Thailand",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Occupational and Interstitial Lung Disease Services, University Hospitals",
    "entities": [
      {
        "text": "Interstitial Lung Disease Services",
        "label": "ORG"
      },
      {
        "text": "University Hospitals",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Birmingham NHS Foundation Trust, Birmingham, UK.",
    "entities": [
      {
        "text": "Birmingham NHS Foundation Trust",
        "label": "ORG"
      },
      {
        "text": "Birmingham",
        "label": "GPE"
      },
      {
        "text": "UK",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Department of Epidemiology and Biostatistics, Khon Kaen University, Nai",
    "entities": [
      {
        "text": "Epidemiology and Biostatistics",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(5)Department of Applied Health Sciences, University of Birmingham, Birmingham,",
    "entities": [
      {
        "text": "5)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Applied Health Sciences",
        "label": "ORG"
      },
      {
        "text": "University of Birmingham",
        "label": "ORG"
      },
      {
        "text": "Birmingham",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "INTRODUCTION: One in four cases of asthma in adults is caused or worsened by",
    "entities": [
      {
        "text": "One",
        "label": "CARDINAL"
      },
      {
        "text": "four",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "work (work-related asthma: WRA). Early detection of WRA could prevent poor",
    "entities": [
      {
        "text": "WRA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "health and employment outcomes, but clinical diagnosis is often missed or",
    "entities": []
  },
  {
    "text": "delayed. The standardisation and effectiveness of screening tools have not been",
    "entities": []
  },
  {
    "text": "well established. We aimed to summarise and compare the performance of screening",
    "entities": []
  },
  {
    "text": "tools for identifying WRA in both clinical settings and workplaces.",
    "entities": [
      {
        "text": "WRA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "METHODS: We searched for studies that used structured questionnaires or",
    "entities": []
  },
  {
    "text": "prediction models (with/without physiological tests) to identify WRA in clinical",
    "entities": []
  },
  {
    "text": "settings or workplaces with individuals aged\u226516 years in MEDLINE, Embase, other",
    "entities": [
      {
        "text": "years",
        "label": "DATE"
      },
      {
        "text": "MEDLINE",
        "label": "GPE"
      },
      {
        "text": "Embase",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "bibliographic databases and grey literature between 1975 and 2024. Two reviewers",
    "entities": [
      {
        "text": "between 1975 and 2024",
        "label": "DATE"
      },
      {
        "text": "Two",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "independently screened titles, abstracts and full texts for inclusion, extracted",
    "entities": []
  },
  {
    "text": "data and assessed risk of bias using QUADAS-2 tool (Quality Assessment of",
    "entities": [
      {
        "text": "QUADAS-2 tool (Quality Assessment of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Diagnostic Test Accuracy 2) or PROBAST (Prediction Model Risk of Bias Assessment",
    "entities": [
      {
        "text": "2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Tool). Screening tools and their indices of accuracy were summarised with paired",
    "entities": []
  },
  {
    "text": "forest plots of sensitivities and specificities.",
    "entities": []
  },
  {
    "text": "RESULTS: Of 17 504 identified studies, 7 were included. All were implemented in",
    "entities": [
      {
        "text": "17 504",
        "label": "CARDINAL"
      },
      {
        "text": "7",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "tertiary hospitals (n=5) and specialist centres (n=2). The screening tools",
    "entities": [
      {
        "text": "tertiary",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "n=2), questionnaire with methacholine challenge test (n=1) and diagnostic models",
    "entities": []
  },
  {
    "text": "(n=4). The question 'improvement off work' had sensitivity=74-87% and",
    "entities": [
      {
        "text": "sensitivity=74-87%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "specificity=15-58% for identifying WRA. Multiple questions had",
    "entities": [
      {
        "text": "specificity=15-58%",
        "label": "PERCENT"
      },
      {
        "text": "WRA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "sensitivity=80-100% and specificity=8-55%. Addition of the methacholine",
    "entities": [
      {
        "text": "sensitivity=80-100%",
        "label": "PERCENT"
      },
      {
        "text": "55%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "challenge test to one questionnaire improved specificity to 75% with",
    "entities": [
      {
        "text": "one",
        "label": "CARDINAL"
      },
      {
        "text": "75%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "sensitivity=65%. Diagnostic models reported area under the curve (AUC) between",
    "entities": [
      {
        "text": "sensitivity=65%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "0.69 and 0.89, and AUC was improved when adding demographic variables or",
    "entities": [
      {
        "text": "0.69",
        "label": "CARDINAL"
      },
      {
        "text": "0.89",
        "label": "CARDINAL"
      },
      {
        "text": "AUC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "objective tests.",
    "entities": []
  },
  {
    "text": "DISCUSSION: A single item 'improvement off work' and multiple questions have",
    "entities": []
  },
  {
    "text": "high sensitivity but low specificity for WRA, which are sufficient for screening",
    "entities": [
      {
        "text": "WRA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "purposes to enhance WRA diagnosis. Adding demographic variables and objective",
    "entities": []
  },
  {
    "text": "tests can improve specificity or AUC. However, studies on screening tools for",
    "entities": []
  },
  {
    "text": "WRA are limited and inadequately reported; further evaluations of performance",
    "entities": []
  },
  {
    "text": "are needed in primary care populations and workplaces.",
    "entities": []
  },
  {
    "text": "PROSPERO REGISTRATION NUMBER: CRD42021246031.",
    "entities": []
  },
  {
    "text": "\u00a9 Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "CC BY-NC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "commercial re-use. See rights and permissions. Published by BMJ Group.",
    "entities": [
      {
        "text": "BMJ Group",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "PMID: 40664435 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40664435",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Competing interests: None declared.",
    "entities": []
  },
  {
    "text": "13. Ann Allergy Asthma Immunol. 2025 Jul 13:S1081-1206(25)00349-7. doi:",
    "entities": [
      {
        "text": "13",
        "label": "CARDINAL"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "10.1016/j.anai.2025.07.009. Online ahead of print.",
    "entities": [
      {
        "text": "10.1016/j.anai.2025.07.009",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "A Case of Ichthyosis Prematurity Syndrome Mimicking Hyper-IgE Syndrome.",
    "entities": []
  },
  {
    "text": "(1)Department of Pediatric Immunology and Allergy, Selcuk University Faculty of",
    "entities": [
      {
        "text": "Pediatric Immunology and Allergy",
        "label": "ORG"
      },
      {
        "text": "Selcuk University Faculty",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Medicine, Konya, Turkey. Electronic address: drsaniyeyaseminyilmaz@gmail.com.",
    "entities": [
      {
        "text": "Konya",
        "label": "GPE"
      },
      {
        "text": "Turkey",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Pediatric Immunology and Allergy, Selcuk University Faculty of",
    "entities": [
      {
        "text": "Pediatric Immunology and Allergy",
        "label": "ORG"
      },
      {
        "text": "Selcuk University Faculty",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Medicine, Konya, Turkey. Electronic address: celikilknur46@gmail.com.",
    "entities": [
      {
        "text": "Konya",
        "label": "GPE"
      },
      {
        "text": "Turkey",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Department of Pediatric Immunology and Allergy, Selcuk University Faculty of",
    "entities": [
      {
        "text": "Pediatric Immunology and Allergy",
        "label": "ORG"
      },
      {
        "text": "Selcuk University Faculty",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Medicine, Konya, Turkey. Electronic address: artachasibe@gmail.com.",
    "entities": [
      {
        "text": "Konya",
        "label": "GPE"
      },
      {
        "text": "Turkey",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Declaration of competing interest None",
    "entities": []
  },
  {
    "text": "14. Ann Allergy Asthma Immunol. 2025 Jul 13:S1081-1206(25)00348-5. doi:",
    "entities": [
      {
        "text": "14",
        "label": "CARDINAL"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "13",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "10.1016/j.anai.2025.07.008. Online ahead of print.",
    "entities": [
      {
        "text": "10.1016/j.anai.2025.07.008",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Albuterol-budesonide rescue inhaler for asthma: patterns of use and safety in",
    "entities": [
      {
        "text": "Albuterol",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "the MANDALA trial.",
    "entities": [
      {
        "text": "MANDALA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(1)Capital Allergy & Respiratory Disease Center, Sacramento, CA, USA.",
    "entities": [
      {
        "text": "Allergy & Respiratory Disease Center",
        "label": "ORG"
      },
      {
        "text": "Sacramento",
        "label": "GPE"
      },
      {
        "text": "CA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Rutgers Institute for Translational Medicine and Science, The State",
    "entities": [
      {
        "text": "Institute for Translational Medicine and Science",
        "label": "ORG"
      },
      {
        "text": "The State",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University of New Jersey, New Brunswick, NJ, USA; Child Health Institute of New",
    "entities": [
      {
        "text": "University of New Jersey",
        "label": "ORG"
      },
      {
        "text": "New Brunswick",
        "label": "GPE"
      },
      {
        "text": "NJ",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      },
      {
        "text": "Child Health Institute of New\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA.",
    "entities": [
      {
        "text": "The State University of New Jersey",
        "label": "ORG"
      },
      {
        "text": "New Brunswick",
        "label": "GPE"
      },
      {
        "text": "NJ",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Abington Family Medicine, Jenkintown, PA, USA; Department of Family and",
    "entities": [
      {
        "text": "Family Medicine",
        "label": "ORG"
      },
      {
        "text": "Jenkintown",
        "label": "GPE"
      },
      {
        "text": "PA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      },
      {
        "text": "Department of Family",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University,",
    "entities": [
      {
        "text": "Community Medicine",
        "label": "ORG"
      },
      {
        "text": "Sidney Kimmel Medical College",
        "label": "ORG"
      },
      {
        "text": "Thomas Jefferson University",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(4)BioPharmaceuticals R&D, AstraZeneca, Durham, NC, USA.",
    "entities": [
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "Durham",
        "label": "GPE"
      },
      {
        "text": "NC",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.",
    "entities": [
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "Gaithersburg",
        "label": "GPE"
      },
      {
        "text": "MD",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)BioPharmaceuticals, US Medical, AstraZeneca, Wilmington, DE, USA. Electronic",
    "entities": [
      {
        "text": "US Medical",
        "label": "ORG"
      },
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "Wilmington",
        "label": "GPE"
      },
      {
        "text": "DE",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(7)Department of Respiratory Medicine, University of Ferrara Medical School,",
    "entities": [
      {
        "text": "Respiratory Medicine",
        "label": "ORG"
      },
      {
        "text": "University of Ferrara Medical School",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Ferrara, Italy.",
    "entities": [
      {
        "text": "Ferrara",
        "label": "GPE"
      },
      {
        "text": "Italy",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "BACKGROUND: The MANDALA study (NCT03769090) in moderate-to-severe asthma served",
    "entities": [
      {
        "text": "MANDALA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "as the basis of the Food and Drug Administration's 2023 approval of",
    "entities": [
      {
        "text": "the Food and Drug Administration's",
        "label": "ORG"
      },
      {
        "text": "2023",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "albuterol-budesonide 180/160 \u00b5g pressurized metered-dose inhaler for the",
    "entities": [
      {
        "text": "albuterol-budesonide",
        "label": "ORG"
      },
      {
        "text": "180/160",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "as-needed treatment or prevention of bronchoconstriction and to reduce",
    "entities": []
  },
  {
    "text": "exacerbation risk in patients with asthma \u226518 years of age. Clinicians would",
    "entities": [
      {
        "text": "years of age",
        "label": "DATE"
      },
      {
        "text": "Clinicians",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "benefit from an understanding of the patterns of use of albuterol-budesonide",
    "entities": []
  },
  {
    "text": "versus albuterol and overall inhaled corticosteroid (ICS) exposure when",
    "entities": [
      {
        "text": "ICS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "ICS-containing rescue therapies are utilized alongside ICS-based maintenance",
    "entities": [
      {
        "text": "ICS",
        "label": "ORG"
      },
      {
        "text": "ICS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "therapies.",
    "entities": []
  },
  {
    "text": "OBJECTIVE: To evaluate patterns of as-needed use and safety profiles of",
    "entities": []
  },
  {
    "text": "albuterol-budesonide 180/160 \u00b5g versus albuterol 180 \u00b5g, using data from",
    "entities": [
      {
        "text": "albuterol-budesonide",
        "label": "ORG"
      },
      {
        "text": "180/160",
        "label": "CARDINAL"
      },
      {
        "text": "180",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "METHODS: Study medication use was patient-documented via electronic diary.",
    "entities": []
  },
  {
    "text": "Safety was assessed as adverse events (AEs). Patterns of study medication use (2",
    "entities": [
      {
        "text": "2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "inhalations = 1 dose) were summarized as mean percentages of days where",
    "entities": [
      {
        "text": "1",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "inhalations/day fell within pre-defined categories (0, 1-2, 3-4, 5-6, 7-8, 9-10,",
    "entities": [
      {
        "text": "1",
        "label": "CARDINAL"
      },
      {
        "text": "3",
        "label": "CARDINAL"
      },
      {
        "text": "5",
        "label": "CARDINAL"
      },
      {
        "text": "7",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "RESULTS: The safety population included 981 patients randomized to as-needed",
    "entities": [
      {
        "text": "981",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "albuterol-budesonide and 981 to as-needed albuterol. Patients adhered to",
    "entities": [
      {
        "text": "albuterol-budesonide",
        "label": "ORG"
      },
      {
        "text": "981",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "maintenance therapy regimens on a mean of \u226575% of days. Use of as-needed study",
    "entities": []
  },
  {
    "text": "drug was similar in both groups (mean of 2.6 and 2.8 inhalations/day of",
    "entities": [
      {
        "text": "2.6",
        "label": "CARDINAL"
      },
      {
        "text": "2.8 inhalations",
        "label": "QUANTITY"
      }
    ]
  },
  {
    "text": "albuterol-budesonide and albuterol, respectively). High daily use (\u22658",
    "entities": [
      {
        "text": "albuterol-budesonide",
        "label": "ORG"
      },
      {
        "text": "daily",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "inhalations/day) or long-term high-daily use (\u22657 consecutive days) was rare. AE",
    "entities": []
  },
  {
    "text": "frequencies (ICS-associated and not) were low and comparable between groups,",
    "entities": [
      {
        "text": "ICS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "regardless of mean daily as-needed use.",
    "entities": [
      {
        "text": "daily",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "CONCLUSION: Patterns of use and safety profiles were similar between as-needed",
    "entities": []
  },
  {
    "text": "albuterol-budesonide and albuterol.",
    "entities": [
      {
        "text": "albuterol-budesonide",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Copyright \u00a9 2025. Published by Elsevier Inc.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Elsevier Inc.",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Conflicts of Interest Dr Chipps is an advisor",
    "entities": [
      {
        "text": "Chipps",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "for, has received consultancy fees from, and is on the speakers\u2019 bureau for",
    "entities": []
  },
  {
    "text": "Sanofi Genzyme. Dr Panettieri Jr reports grants and advisory board support from",
    "entities": [
      {
        "text": "Sanofi Genzyme",
        "label": "ORG"
      },
      {
        "text": "Panettieri Jr",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Institute for Fragrance Material, National Institutes of Health, Regeneron, and",
    "entities": [
      {
        "text": "Institute for Fragrance Material",
        "label": "ORG"
      },
      {
        "text": "National Institutes of Health",
        "label": "ORG"
      },
      {
        "text": "Regeneron",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Novartis. Dr Skolnik served on advisory boards and as consultant for",
    "entities": [
      {
        "text": "Dr Skolnik",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Bayer, Genentech, Abbott, Idorsia, Merck, and Novartis. He is also a speaker for",
    "entities": [
      {
        "text": "Bayer",
        "label": "ORG"
      },
      {
        "text": "Genentech",
        "label": "ORG"
      },
      {
        "text": "Abbott",
        "label": "GPE"
      },
      {
        "text": "Idorsia",
        "label": "GPE"
      },
      {
        "text": "Merck",
        "label": "ORG"
      },
      {
        "text": "Novartis",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "AstraZeneca, Boehringer Ingelheim, Lilly, GSK, Bayer, and Heartland. He has",
    "entities": [
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "Boehringer Ingelheim",
        "label": "ORG"
      },
      {
        "text": "Lilly",
        "label": "ORG"
      },
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "Bayer",
        "label": "ORG"
      },
      {
        "text": "Heartland",
        "label": "LOC"
      }
    ]
  },
  {
    "text": "received research support from Sanofi, AstraZeneca, GSK, Bayer, and Novo",
    "entities": [
      {
        "text": "Sanofi",
        "label": "GPE"
      },
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "Bayer",
        "label": "ORG"
      },
      {
        "text": "Novo",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Nordisk. Dr Cappelletti is a former employee of, and holds stock in,",
    "entities": [
      {
        "text": "Cappelletti",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "AstraZeneca. Dr Daoud, Ms Dunsire, and Dr Gilbert are employees of, and hold",
    "entities": [
      {
        "text": "Dr Daoud",
        "label": "PERSON"
      },
      {
        "text": "Ms Dunsire",
        "label": "PERSON"
      },
      {
        "text": "Dr Gilbert",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "stock in, AstraZeneca. Prof Papi reports grants from Chiesi, AstraZeneca,",
    "entities": [
      {
        "text": "AstraZeneca",
        "label": "PRODUCT"
      },
      {
        "text": "Prof Papi",
        "label": "PERSON"
      },
      {
        "text": "Chiesi",
        "label": "GPE"
      },
      {
        "text": "AstraZeneca",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "GlaxoSmithKline, Boehringer Ingelheim, TEVA, and Sanofi, and consulting fees and",
    "entities": [
      {
        "text": "GlaxoSmithKline",
        "label": "PERSON"
      },
      {
        "text": "Boehringer Ingelheim",
        "label": "ORG"
      },
      {
        "text": "TEVA",
        "label": "ORG"
      },
      {
        "text": "Sanofi",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "honoraria for lectures or advisory boards from Chiesi, AstraZeneca,",
    "entities": [
      {
        "text": "Chiesi",
        "label": "GPE"
      },
      {
        "text": "AstraZeneca",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Online ahead of print.",
    "entities": []
  },
  {
    "text": "A small molecular fluorescence probe capable of real-time monitoring the open",
    "entities": []
  },
  {
    "text": "and closed states of TRPA1 channel.",
    "entities": [
      {
        "text": "TRPA1",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(1)Departments of Pharmacology, School of Pharmacy, Qingdao University Medical",
    "entities": [
      {
        "text": "Pharmacology, School of Pharmacy",
        "label": "ORG"
      },
      {
        "text": "Qingdao University Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "College, 1 Ningde Road, Qingdao 266073, China.",
    "entities": [
      {
        "text": "1 Ningde Road",
        "label": "TIME"
      },
      {
        "text": "266073",
        "label": "DATE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Departments of Pharmaceutical Analysis, School of Pharmacy, Qingdao",
    "entities": [
      {
        "text": "Pharmaceutical Analysis",
        "label": "ORG"
      },
      {
        "text": "School of Pharmacy",
        "label": "ORG"
      },
      {
        "text": "Qingdao",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "University Medical College, 1 Ningde Road, Qingdao 266073, China.",
    "entities": [
      {
        "text": "University Medical College",
        "label": "ORG"
      },
      {
        "text": "1 Ningde Road",
        "label": "TIME"
      },
      {
        "text": "266073",
        "label": "DATE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Shandong Key Laboratory of Neurorehabilitation, School of Life Sciences and",
    "entities": [
      {
        "text": "Key Laboratory of Neurorehabilitation, School of Life Sciences",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Health, University of Health and Rehabilitation Sciences, Qingdao 266113, China.",
    "entities": [
      {
        "text": "Health, University of Health and Rehabilitation Sciences",
        "label": "ORG"
      },
      {
        "text": "266113",
        "label": "DATE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Departments of Pharmacology, School of Pharmacy, Qingdao University Medical",
    "entities": [
      {
        "text": "Pharmacology, School of Pharmacy",
        "label": "ORG"
      },
      {
        "text": "Qingdao University Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "College, 1 Ningde Road, Qingdao 266073, China. Electronic address:",
    "entities": [
      {
        "text": "1 Ningde Road",
        "label": "TIME"
      },
      {
        "text": "266073",
        "label": "DATE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Departments of Pharmaceutical Analysis, School of Pharmacy, Qingdao",
    "entities": [
      {
        "text": "Pharmaceutical Analysis",
        "label": "ORG"
      },
      {
        "text": "School of Pharmacy",
        "label": "ORG"
      },
      {
        "text": "Qingdao",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "University Medical College, 1 Ningde Road, Qingdao 266073, China. Electronic",
    "entities": [
      {
        "text": "University Medical College",
        "label": "ORG"
      },
      {
        "text": "1 Ningde Road",
        "label": "TIME"
      },
      {
        "text": "266073",
        "label": "DATE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Transient receptor potential ankyrin 1 (TRPA1) channel serves as a critical",
    "entities": [
      {
        "text": "1",
        "label": "CARDINAL"
      },
      {
        "text": "TRPA1",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "mediator of nociceptive signaling across neural circuits, modulating",
    "entities": []
  },
  {
    "text": "pathophysiological processes from asthma to neurogenic inflammation through its",
    "entities": []
  },
  {
    "text": "unique ability to integrate chemical, thermal, and mechanical stimuli. Real-time",
    "entities": []
  },
  {
    "text": "monitoring conformational dynamics of TRPA1 is of significance for dissecting",
    "entities": [
      {
        "text": "TRPA1",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "the roles of TRPA1 channel. Here, we present a small molecular fluorescence",
    "entities": [
      {
        "text": "TRPA1",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "probe FPTRP-1 featuring a state-dependent fluorescence signature that directly",
    "entities": [
      {
        "text": "FPTRP-1",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "correlates with TRPA1 gating status. Confocal imaging verifies that the probe",
    "entities": [
      {
        "text": "TRPA1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "FPTRP-1 has high selectivity for TRPA1 channel, and can monitor the on-off",
    "entities": [
      {
        "text": "FPTRP-1",
        "label": "ORG"
      },
      {
        "text": "TRPA1 channel",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "states of TRPA1 in real time, providing a potential pharmacological tool to",
    "entities": [
      {
        "text": "TRPA1",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "further elucidate the physiological and pathological roles of TRPA1 channel in",
    "entities": [
      {
        "text": "TRPA1",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "biological systems.",
    "entities": []
  },
  {
    "text": "Copyright \u00a9 2025 Elsevier Inc. All rights reserved.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Declaration of competing interest The authors",
    "entities": []
  },
  {
    "text": "declare that they have no known competing financial interests or personal",
    "entities": []
  },
  {
    "text": "relationships that could have appeared to influence the work reported in this",
    "entities": []
  },
  {
    "text": "ahead of print.",
    "entities": []
  },
  {
    "text": "Postictal Psychosis, a Case Report.",
    "entities": [
      {
        "text": "Postictal Psychosis",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(1)Department of Psychiatry and Behavioral Sciences, Eastern Virginia Medical",
    "entities": [
      {
        "text": "Psychiatry",
        "label": "ORG"
      },
      {
        "text": "Behavioral Sciences",
        "label": "ORG"
      },
      {
        "text": "Eastern Virginia Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "School at Old Dominion University, Norfolk, VA.",
    "entities": [
      {
        "text": "Norfolk",
        "label": "GPE"
      },
      {
        "text": "VA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "OBJECTIVE: Postictal psychosis (PIP) is one of the most common psychoses for",
    "entities": [
      {
        "text": "PIP",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "patients with epilepsy and is defined as psychotic symptoms presenting at least",
    "entities": []
  },
  {
    "text": "1 week after a cluster of seizures. This case report illustrates an important",
    "entities": [
      {
        "text": "1 week",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "example of a clinical presentation of PIP.",
    "entities": [
      {
        "text": "PIP",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "METHODS: This case report identifies a 29-year-old Black man with a medical",
    "entities": [
      {
        "text": "29-year-old",
        "label": "DATE"
      },
      {
        "text": "Black",
        "label": "LOC"
      }
    ]
  },
  {
    "text": "history of asthma and epilepsy who presented with multiple seizures and",
    "entities": []
  },
  {
    "text": "visits over the past 1-2 years for recurrent seizure-like activity suggestive of",
    "entities": [
      {
        "text": "the past 1-2 years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "psychogenic nonepileptic seizures. On previous admissions for seizure-like",
    "entities": []
  },
  {
    "text": "activity, he has been intubated because of uncooperativeness. On this admission",
    "entities": []
  },
  {
    "text": "he presented to the ED after multiple at home seizures. In the ED, he became",
    "entities": []
  },
  {
    "text": "increasingly delirious with no return to baseline mental status between",
    "entities": []
  },
  {
    "text": "seizures. He was then intubated with bilateral wrist restraints for nonsensical",
    "entities": []
  },
  {
    "text": "speech and agitation.",
    "entities": []
  },
  {
    "text": "RESULTS: On day 4 in the intensive care unit, he returned to baseline mental",
    "entities": [
      {
        "text": "day 4",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "status. The patient was cooperative with medical treatment, alert, aware and",
    "entities": []
  },
  {
    "text": "attentive, and no longer agitated. The patient was able to remember the previous",
    "entities": []
  },
  {
    "text": "episode of seizure that led him to the ED. He was discharged on laxosamide 200",
    "entities": [
      {
        "text": "200",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "mg twice daily.",
    "entities": [
      {
        "text": "daily",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "CONCLUSIONS: It is important to consider as a diagnosis in a patient with",
    "entities": []
  },
  {
    "text": "epilepsy and changes in affect, mood, or the presence of delusions with no clear",
    "entities": []
  },
  {
    "text": "lucid interval to ensure timely and effective treatment and limiting potential",
    "entities": []
  },
  {
    "text": "Copyright \u00a9 2025 Wolters Kluwer Health, Inc. All rights reserved.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Wolters Kluwer Health, Inc.",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Conflicts of Interest and Source of Funding: The",
    "entities": []
  },
  {
    "text": "authors have no conflicts of interest to declare.",
    "entities": []
  },
  {
    "text": "10.1007/s00210-025-04276-8. Online ahead of print.",
    "entities": [
      {
        "text": "10.1007",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "The therapeutic effects of Plantago major and its main constituents on",
    "entities": []
  },
  {
    "text": "respiratory diseases: a narrative review.",
    "entities": []
  },
  {
    "text": "(1)Applied Biomedical Research Center, Mashhad University of Medical Sciences,",
    "entities": [
      {
        "text": "Biomedical Research Center",
        "label": "ORG"
      },
      {
        "text": "Mashhad University of Medical Sciences",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)Department of Clinical Pharmacy, Faculty of Pharmacy, Mazandaran University",
    "entities": [
      {
        "text": "Clinical Pharmacy, Faculty of Pharmacy",
        "label": "ORG"
      },
      {
        "text": "Mazandaran University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of Medical Sciences, Sari, Iran.",
    "entities": [
      {
        "text": "Medical Sciences",
        "label": "ORG"
      },
      {
        "text": "Sari",
        "label": "GPE"
      },
      {
        "text": "Iran",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Applied Biomedical Research Center, Mashhad University of Medical Sciences,",
    "entities": [
      {
        "text": "Biomedical Research Center",
        "label": "ORG"
      },
      {
        "text": "Mashhad University of Medical Sciences",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)Department of Physiology, Neurogenic Inflammation Research Center, Faculty of",
    "entities": [
      {
        "text": "Physiology, Neurogenic Inflammation Research Center, Faculty of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Medicine, Mashhad University of Medical Sciences, Mashhad, 9177948564, Iran.",
    "entities": [
      {
        "text": "Medicine, Mashhad University of Medical Sciences",
        "label": "ORG"
      },
      {
        "text": "Mashhad",
        "label": "GPE"
      },
      {
        "text": "9177948564",
        "label": "DATE"
      },
      {
        "text": "Iran",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Herbal medicines have been proposed as adjuvant treatment for respiratory",
    "entities": [
      {
        "text": "Herbal",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "diseases. One such agent is Plantago major (P. major). Therefore, this review",
    "entities": [
      {
        "text": "One",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "aims to gather the most recent experimental and clinical evidence on P. major's",
    "entities": [
      {
        "text": "P.",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "therapeutic effects on respiratory diseases. This review search was performed",
    "entities": []
  },
  {
    "text": "through Web of Science, PubMed, Google Scholar, and Scopus from the 1990s to",
    "entities": [
      {
        "text": "PubMed",
        "label": "ORG"
      },
      {
        "text": "Google Scholar",
        "label": "ORG"
      },
      {
        "text": "the 1990s",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "March 2024. In experimental studies, the effects of P. major on inflammation,",
    "entities": [
      {
        "text": "March 2024",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "infection, asthma, and COPD models were established. In clinical studies, a",
    "entities": []
  },
  {
    "text": "significant reduction in cough and wheezing, increases in FEV1 and FVC in",
    "entities": [
      {
        "text": "FEV1",
        "label": "GPE"
      },
      {
        "text": "FVC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "asthmatic patients, a rapid effect on signs and symptoms of bronchitis, and",
    "entities": []
  },
  {
    "text": "antiviral effects were observed. Despite in vitro and animal studies, there are",
    "entities": []
  },
  {
    "text": "limited clinical studies on the respiratory effects of P. major on humans.",
    "entities": []
  },
  {
    "text": "Therefore, designing more clinical studies to identify the respiratory effects",
    "entities": []
  },
  {
    "text": "of the plant and its derivatives should be considered.",
    "entities": []
  },
  {
    "text": "Conflict of interest statement: Declarations. Ethics approval: Not applicable.",
    "entities": []
  },
  {
    "text": "Conflict of interest: The authors declare no competing interests.",
    "entities": []
  },
  {
    "text": "10.1016/j.jaci.2025.06.004. Online ahead of print.",
    "entities": [
      {
        "text": "10.1016",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Comparative efficacy and safety of biologics and systemic immunomodulatory",
    "entities": []
  },
  {
    "text": "treatments for chronic urticaria: Systematic review and network meta-analysis.",
    "entities": []
  },
  {
    "text": "SK(12), Waserman S(13), Thabane L(14), Asiniwasis RN(15), Runyon L(16), Moellman",
    "entities": [
      {
        "text": "Runyon L(16",
        "label": "PERSON"
      },
      {
        "text": "Moellman",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "J(17), Oliver ET(18), Chan J(19), Cole EF(20), Baker DR(21), Khan DA(16),",
    "entities": [
      {
        "text": "J(17",
        "label": "NORP"
      },
      {
        "text": "Oliver ET(18",
        "label": "PERSON"
      },
      {
        "text": "Chan J(19",
        "label": "PERSON"
      },
      {
        "text": "Cole",
        "label": "PRODUCT"
      },
      {
        "text": "Baker",
        "label": "PERSON"
      },
      {
        "text": "Khan",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)Department of Medicine, McMaster University, Hamilton, Ontario, Canada;",
    "entities": [
      {
        "text": "Medicine, McMaster University",
        "label": "ORG"
      },
      {
        "text": "Hamilton",
        "label": "PERSON"
      },
      {
        "text": "Ontario",
        "label": "GPE"
      },
      {
        "text": "Canada",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Evidence in Allergy Group, McMaster University, Hamilton, Ontario, Canada.",
    "entities": [
      {
        "text": "Allergy Group",
        "label": "ORG"
      },
      {
        "text": "McMaster University",
        "label": "ORG"
      },
      {
        "text": "Hamilton",
        "label": "PERSON"
      },
      {
        "text": "Ontario",
        "label": "GPE"
      },
      {
        "text": "Canada",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Evidence in Allergy Group, McMaster University, Hamilton, Ontario, Canada;",
    "entities": [
      {
        "text": "Allergy Group",
        "label": "ORG"
      },
      {
        "text": "McMaster University",
        "label": "ORG"
      },
      {
        "text": "Hamilton",
        "label": "PERSON"
      },
      {
        "text": "Ontario",
        "label": "GPE"
      },
      {
        "text": "Canada",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Department of Health Research Methods, Evidence, and Impact, McMaster",
    "entities": [
      {
        "text": "Department of Health Research Methods, Evidence",
        "label": "ORG"
      },
      {
        "text": "McMaster",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "University, Hamilton, Ontario, Canada; Evidence-Based Medicine Center, School of",
    "entities": [
      {
        "text": "Hamilton",
        "label": "PERSON"
      },
      {
        "text": "Ontario",
        "label": "GPE"
      },
      {
        "text": "Canada",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Basic Medical Sciences, Lanzhou University, Lanzhou, China.",
    "entities": [
      {
        "text": "Basic Medical Sciences",
        "label": "ORG"
      },
      {
        "text": "Lanzhou University",
        "label": "ORG"
      },
      {
        "text": "Lanzhou",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Evidence in Allergy Group, McMaster University, Hamilton, Ontario, Canada;",
    "entities": [
      {
        "text": "Allergy Group",
        "label": "ORG"
      },
      {
        "text": "McMaster University",
        "label": "ORG"
      },
      {
        "text": "Hamilton",
        "label": "PERSON"
      },
      {
        "text": "Ontario",
        "label": "GPE"
      },
      {
        "text": "Canada",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Schulich School of Medicine and Dentistry, Western University, London, Ontario,",
    "entities": [
      {
        "text": "Schulich School of Medicine and Dentistry",
        "label": "ORG"
      },
      {
        "text": "Western University",
        "label": "ORG"
      },
      {
        "text": "London",
        "label": "GPE"
      },
      {
        "text": "Ontario",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Michael G. DeGroote School of Medicine, McMaster University, Hamilton,",
    "entities": [
      {
        "text": "G. DeGroote School of Medicine",
        "label": "ORG"
      },
      {
        "text": "McMaster University",
        "label": "ORG"
      },
      {
        "text": "Hamilton",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(5)Faculty of Health Sciences, Queen's University, Kingston, Ontario, Canada.",
    "entities": [
      {
        "text": "Health Sciences",
        "label": "ORG"
      },
      {
        "text": "Queen's University",
        "label": "ORG"
      },
      {
        "text": "Kingston",
        "label": "GPE"
      },
      {
        "text": "Ontario",
        "label": "GPE"
      },
      {
        "text": "Canada",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.",
    "entities": [
      {
        "text": "Faculty of Medicine, University of Toronto",
        "label": "ORG"
      },
      {
        "text": "Toronto",
        "label": "GPE"
      },
      {
        "text": "Ontario",
        "label": "GPE"
      },
      {
        "text": "Canada",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(7)Department of Clinical Immunology and Allergy, Southern California Permanente",
    "entities": [
      {
        "text": "Clinical Immunology and",
        "label": "ORG"
      },
      {
        "text": "Allergy",
        "label": "GPE"
      },
      {
        "text": "Southern California Permanente",
        "label": "LOC"
      }
    ]
  },
  {
    "text": "Medical Group, Los Angeles, Calif.",
    "entities": [
      {
        "text": "Medical Group",
        "label": "ORG"
      },
      {
        "text": "Los Angeles",
        "label": "GPE"
      },
      {
        "text": "Calif.",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(8)Department of Family and Community Medicine, Thomas Jefferson University",
    "entities": [
      {
        "text": "Family and Community Medicine",
        "label": "ORG"
      },
      {
        "text": "Thomas Jefferson University",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(9)Department of Family Medicine, University of Pittsburgh School of Medicine,",
    "entities": [
      {
        "text": "Family Medicine, University of Pittsburgh School of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(10)Department of Allergy and Clinical Immunology, Cleveland Clinic, Cleveland,",
    "entities": [
      {
        "text": "10)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Allergy and Clinical Immunology",
        "label": "ORG"
      },
      {
        "text": "Cleveland Clinic",
        "label": "ORG"
      },
      {
        "text": "Cleveland",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(11)Department of Dermatology, University of Rochester Medical Center,",
    "entities": [
      {
        "text": "11)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Dermatology, University of Rochester Medical Center",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(12)Department of Medicine, Division of Allergy, Pulmonary, and Critical Care,",
    "entities": [
      {
        "text": "12)Department of Medicine",
        "label": "MONEY"
      },
      {
        "text": "Division of Allergy",
        "label": "ORG"
      },
      {
        "text": "Pulmonary",
        "label": "PERSON"
      },
      {
        "text": "Critical Care",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University of Wisconsin School of Medicine and Public Health, Madison, Wis.",
    "entities": [
      {
        "text": "University of Wisconsin School of Medicine and Public Health",
        "label": "ORG"
      },
      {
        "text": "Madison",
        "label": "GPE"
      },
      {
        "text": "Wis.",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(13)Department of Medicine, McMaster University, Hamilton, Ontario, Canada.",
    "entities": [
      {
        "text": "13)Department",
        "label": "CARDINAL"
      },
      {
        "text": "McMaster University",
        "label": "ORG"
      },
      {
        "text": "Hamilton",
        "label": "PERSON"
      },
      {
        "text": "Ontario",
        "label": "GPE"
      },
      {
        "text": "Canada",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(14)Department of Health Research Methods, Evidence, and Impact, McMaster",
    "entities": [
      {
        "text": "14)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Health Research Methods",
        "label": "ORG"
      },
      {
        "text": "McMaster",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "University, Hamilton, Ontario, Canada.",
    "entities": [
      {
        "text": "Hamilton",
        "label": "PERSON"
      },
      {
        "text": "Ontario",
        "label": "GPE"
      },
      {
        "text": "Canada",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(15)Department of Medicine, Division of Dermatology, University of Saskatchewan,",
    "entities": [
      {
        "text": "15)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Medicine, Division of Dermatology, University of Saskatchewan",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(16)Department of Internal Medicine, Division of Allergy and Immunology, The",
    "entities": [
      {
        "text": "16)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Internal Medicine,",
        "label": "ORG"
      },
      {
        "text": "Division of Allergy and Immunology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University of Texas Southwestern Medical Center, Dallas, Tex.",
    "entities": [
      {
        "text": "University of Texas Southwestern Medical Center",
        "label": "ORG"
      },
      {
        "text": "Dallas",
        "label": "GPE"
      },
      {
        "text": "Tex.",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(17)Department of Emergency Medicine, University of Cincinnati College of",
    "entities": [
      {
        "text": "17)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Emergency Medicine, University of Cincinnati College",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(18)Department of Medicine, Division of Allergy and Clinical Immunology, Johns",
    "entities": [
      {
        "text": "Medicine, Division of Allergy and Clinical Immunology",
        "label": "ORG"
      },
      {
        "text": "Johns",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Hopkins University School of Medicine, Baltimore, Md.",
    "entities": [
      {
        "text": "Hopkins University School of Medicine",
        "label": "ORG"
      },
      {
        "text": "Baltimore",
        "label": "GPE"
      },
      {
        "text": "Md.",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(19)Emergency Medicine, Southlake Regional Health Centre, Newmarket, Ontario,",
    "entities": [
      {
        "text": "Southlake Regional Health Centre",
        "label": "ORG"
      },
      {
        "text": "Newmarket",
        "label": "GPE"
      },
      {
        "text": "Ontario",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(20)Department of Medicine, Division of Dermatology, Washington University",
    "entities": [
      {
        "text": "20)Department of Medicine,",
        "label": "MONEY"
      },
      {
        "text": "Division of Dermatology",
        "label": "ORG"
      },
      {
        "text": "Washington University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "School of Medicine, St Louis, Mo.",
    "entities": [
      {
        "text": "School of Medicine",
        "label": "ORG"
      },
      {
        "text": "St Louis",
        "label": "GPE"
      },
      {
        "text": "Mo.",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(21)Department of Dermatology, Oregon Health and Sciences University, Portland,",
    "entities": [
      {
        "text": "21)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Oregon Health and Sciences University",
        "label": "ORG"
      },
      {
        "text": "Portland",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(22)Department of Pediatrics, Division of Allergy, Immunology, and Dermatology,",
    "entities": [
      {
        "text": "22)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Division of Allergy",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "McGill University, Montreal, Quebec, Canada.",
    "entities": [
      {
        "text": "McGill University",
        "label": "ORG"
      },
      {
        "text": "Montreal",
        "label": "GPE"
      },
      {
        "text": "Quebec",
        "label": "GPE"
      },
      {
        "text": "Canada",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(23)Department of Pediatrics, University of Florida, Gainesville, Fla.",
    "entities": [
      {
        "text": "23)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Pediatrics, University of Florida",
        "label": "ORG"
      },
      {
        "text": "Gainesville",
        "label": "GPE"
      },
      {
        "text": "Fla.",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(24)Asthma and Allergy Foundation of America, Arlington, Va.",
    "entities": [
      {
        "text": "24)Asthma",
        "label": "CARDINAL"
      },
      {
        "text": "Allergy Foundation of America",
        "label": "ORG"
      },
      {
        "text": "Arlington",
        "label": "GPE"
      },
      {
        "text": "Va.",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(25)Allergy and Asthma Network, Fairfax, Va.",
    "entities": [
      {
        "text": "25)Allergy",
        "label": "CARDINAL"
      },
      {
        "text": "Asthma Network",
        "label": "ORG"
      },
      {
        "text": "Fairfax",
        "label": "GPE"
      },
      {
        "text": "Va.",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(26)Global Allergy and Airways Patient Platform, Vienna, Austria.",
    "entities": [
      {
        "text": "Allergy and Airways Patient",
        "label": "ORG"
      },
      {
        "text": "Vienna",
        "label": "GPE"
      },
      {
        "text": "Austria",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(28)Department of Internal Medicine, Division of Rheumatology, Allergy, and",
    "entities": [
      {
        "text": "28)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Internal Medicine,",
        "label": "ORG"
      },
      {
        "text": "Division of Rheumatology, Allergy",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Immunology, University of Cincinnati, Cincinnati, Ohio.",
    "entities": [
      {
        "text": "University of Cincinnati",
        "label": "ORG"
      },
      {
        "text": "Cincinnati",
        "label": "GPE"
      },
      {
        "text": "Ohio",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(29)Department of Medicine, McMaster University, Hamilton, Ontario, Canada;",
    "entities": [
      {
        "text": "29)Department",
        "label": "CARDINAL"
      },
      {
        "text": "McMaster University",
        "label": "ORG"
      },
      {
        "text": "Hamilton",
        "label": "PERSON"
      },
      {
        "text": "Ontario",
        "label": "GPE"
      },
      {
        "text": "Canada",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Evidence in Allergy Group, McMaster University, Hamilton, Ontario, Canada;",
    "entities": [
      {
        "text": "Allergy Group",
        "label": "ORG"
      },
      {
        "text": "McMaster University",
        "label": "ORG"
      },
      {
        "text": "Hamilton",
        "label": "PERSON"
      },
      {
        "text": "Ontario",
        "label": "GPE"
      },
      {
        "text": "Canada",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "University, Hamilton, Ontario, Canada; The Research Institute of St Joe's",
    "entities": [
      {
        "text": "Hamilton",
        "label": "PERSON"
      },
      {
        "text": "Ontario",
        "label": "GPE"
      },
      {
        "text": "Canada",
        "label": "GPE"
      },
      {
        "text": "The Research Institute of St Joe's",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Hamilton, St Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada. Electronic",
    "entities": [
      {
        "text": "Hamilton",
        "label": "PERSON"
      },
      {
        "text": "St Joseph's",
        "label": "PERSON"
      },
      {
        "text": "Healthcare Hamilton",
        "label": "PERSON"
      },
      {
        "text": "Hamilton",
        "label": "PERSON"
      },
      {
        "text": "Ontario",
        "label": "GPE"
      },
      {
        "text": "Canada",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "BACKGROUND: Chronic urticaria is a common skin condition characterized by itchy",
    "entities": []
  },
  {
    "text": "wheals (hives), angioedema, or both, lasting for 6 weeks or more. Beyond",
    "entities": [
      {
        "text": "6 weeks",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "antihistamines, multiple systemic treatments are available, but there is",
    "entities": []
  },
  {
    "text": "uncertainty regarding their comparative effects on chronic urticaria outcomes.",
    "entities": []
  },
  {
    "text": "OBJECTIVE: We systematically synthesized the comparative benefits and harms of",
    "entities": []
  },
  {
    "text": "systemic treatments for chronic urticaria.",
    "entities": []
  },
  {
    "text": "METHODS: As part of updating the AAAAI/ACAAI JTFPP chronic urticaria guidelines,",
    "entities": []
  },
  {
    "text": "we searched Medline, Embase, Central, Chinese Biomedical Databases (CBM), China",
    "entities": [
      {
        "text": "Medline",
        "label": "GPE"
      },
      {
        "text": "Central",
        "label": "ORG"
      },
      {
        "text": "CBM",
        "label": "ORG"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "National Knowledge Infrastructure (CNKI), Chinese Scientific Journal Database",
    "entities": [
      {
        "text": "National Knowledge Infrastructure (CNKI",
        "label": "ORG"
      },
      {
        "text": "Chinese Scientific Journal Database",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(VIP), and Wanfang from inception to February 4, 2025, for randomized trials",
    "entities": [
      {
        "text": "Wanfang",
        "label": "GPE"
      },
      {
        "text": "February 4, 2025",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "addressing systemic immunomodulatory treatments, including phototherapy, for",
    "entities": []
  },
  {
    "text": "chronic urticaria. Paired reviewers screened records, extracted data, and",
    "entities": []
  },
  {
    "text": "assessed risk of bias. Random effects Bayesian network meta-analyses addressed",
    "entities": [
      {
        "text": "Bayesian",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "urticaria activity (comprising itch and wheal scores), angioedema activity,",
    "entities": []
  },
  {
    "text": "health-related quality of life, and adverse events. The GRADE approach informed",
    "entities": [
      {
        "text": "GRADE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "certainty-of-evidence ratings (PROSPERO: CRD42023429819).",
    "entities": []
  },
  {
    "text": "RESULTS: We included 93 studies (n = 11,398; mostly adult and adolescent",
    "entities": [
      {
        "text": "93",
        "label": "CARDINAL"
      },
      {
        "text": "11,398",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "participants across 83 randomized trials and 10 nonrandomized studies) that",
    "entities": [
      {
        "text": "83",
        "label": "CARDINAL"
      },
      {
        "text": "10",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "evaluated 42 interventions. With high certainty, standard-dose omalizumab (300",
    "entities": [
      {
        "text": "42",
        "label": "CARDINAL"
      },
      {
        "text": "300",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "mg every 4 weeks) and remibrutinib are among the most effective for improving",
    "entities": [
      {
        "text": "every 4 weeks",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "multiple patient-important outcomes. The safety profile of remibrutinib,",
    "entities": []
  },
  {
    "text": "however, is less certain. Dupilumab improved urticaria activity, but its impact",
    "entities": []
  },
  {
    "text": "on quality of life is uncertain, and no dupilumab trials addressed angioedema",
    "entities": []
  },
  {
    "text": "activity. Cyclosporine may be among the most effective for improving urticaria",
    "entities": []
  },
  {
    "text": "activity but may be among the most harmful in increasing the frequency of any",
    "entities": []
  },
  {
    "text": "adverse events. Azathioprine, dapsone, hydroxychloroquine, mycophenolate,",
    "entities": []
  },
  {
    "text": "sulfasalazine, and vitamin D may improve outcomes, while benralizumab,",
    "entities": [
      {
        "text": "benralizumab",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "quilizumab, and tezepelumab may not differ from placebo, though the evidence is",
    "entities": []
  },
  {
    "text": "uncertain. Findings were consistent across age groups and baseline severity, and",
    "entities": []
  },
  {
    "text": "were robust to subgroup analyses.",
    "entities": []
  },
  {
    "text": "CONCLUSIONS: Among individuals with chronic urticaria refractory to",
    "entities": []
  },
  {
    "text": "antihistamines, standard-dose omalizumab and remibrutinib are among the most",
    "entities": []
  },
  {
    "text": "effective drugs across multiple patient-important outcomes with a favorable",
    "entities": []
  },
  {
    "text": "safety profile across the studied duration. Cyclosporine may be effective but",
    "entities": []
  },
  {
    "text": "may be among the most harmful. Dupilumab improves itch and wheals, but it is",
    "entities": []
  },
  {
    "text": "uncertain whether it improves angioedema or quality of life. Lower doses of",
    "entities": []
  },
  {
    "text": "omalizumab are of intermediate effectiveness and favorable safety. The net",
    "entities": []
  },
  {
    "text": "benefit of conventional immunosuppressants is uncertain.",
    "entities": []
  },
  {
    "text": "Copyright \u00a9 2025 The Authors. Published by Elsevier Inc. All rights reserved.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Elsevier Inc.",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Disclosure statement This study was commissioned",
    "entities": []
  },
  {
    "text": "by the American Academy of Allergy, Asthma & Immunology and the American College",
    "entities": [
      {
        "text": "the American Academy of Allergy, Asthma & Immunology",
        "label": "ORG"
      },
      {
        "text": "American College",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of Allergy, Asthma & Immunology through the Joint Task Force on Practice",
    "entities": [
      {
        "text": "Allergy, Asthma & Immunology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Parameters for Chronic Urticaria. The funder contributed to defining the scope",
    "entities": []
  },
  {
    "text": "of the review but otherwise had no role in the study design, data collection,",
    "entities": []
  },
  {
    "text": "data synthesis, or data interpretation. The review team had the opportunity, but",
    "entities": []
  },
  {
    "text": "not obligation, to incorporate Joint Task Force feedback. The first and",
    "entities": [
      {
        "text": "Joint Task Force",
        "label": "ORG"
      },
      {
        "text": "first",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "corresponding authors had full access to all the data in the study and had full",
    "entities": []
  },
  {
    "text": "responsibility for the decision to submit the report for publication. Disclosure",
    "entities": []
  },
  {
    "text": "of potential conflict of interest: D. M. Lang reports having carried out",
    "entities": [
      {
        "text": "D. M. Lang",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "clinical research with or received honoraria from and/or serving as a consultant",
    "entities": []
  },
  {
    "text": "for AstraZeneca, Blueprint, Celldex, Genentech, Novartis, and Sanofi-Regeneron.",
    "entities": [
      {
        "text": "AstraZeneca, Blueprint",
        "label": "ORG"
      },
      {
        "text": "Genentech",
        "label": "ORG"
      },
      {
        "text": "Novartis",
        "label": "ORG"
      },
      {
        "text": "Sanofi-Regeneron",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "L. A. Beck reports serving as a consultant for AbbVie, Allakos, Amgen, Arcutis,",
    "entities": [
      {
        "text": "L. A. Beck",
        "label": "PERSON"
      },
      {
        "text": "AbbVie",
        "label": "LAW"
      },
      {
        "text": "Allakos",
        "label": "GPE"
      },
      {
        "text": "Amgen",
        "label": "ORG"
      },
      {
        "text": "Arcutis",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Arena Pharmaceuticals, AstraZeneca, Astria Therapeutics, Belharra Therapeutics,",
    "entities": [
      {
        "text": "Arena Pharmaceuticals",
        "label": "ORG"
      },
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "Astria Therapeutics",
        "label": "PERSON"
      },
      {
        "text": "Belharra Therapeutics",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Celldex Therapeutics, Dermavent, Eli Lilly and Company, Escient Pharma,",
    "entities": [
      {
        "text": "Eli Lilly and Company, Escient Pharma",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Galderma, GlaxoSmithKline, Invea Therapeutics, Janssen, LEO Pharma, Merck,",
    "entities": [
      {
        "text": "Galderma",
        "label": "NORP"
      },
      {
        "text": "GlaxoSmithKline",
        "label": "PERSON"
      },
      {
        "text": "Invea Therapeutics",
        "label": "ORG"
      },
      {
        "text": "Janssen",
        "label": "GPE"
      },
      {
        "text": "LEO Pharma",
        "label": "ORG"
      },
      {
        "text": "Merck",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Nektar Therapeutics, Novartis, Numab Therapeutics, Pfizer, Rapt Therapeutics,",
    "entities": [
      {
        "text": "Nektar Therapeutics",
        "label": "PERSON"
      },
      {
        "text": "Novartis",
        "label": "GPE"
      },
      {
        "text": "Numab Therapeutics",
        "label": "PERSON"
      },
      {
        "text": "Pfizer",
        "label": "ORG"
      },
      {
        "text": "Rapt Therapeutics",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Regeneron Pharmaceuticals, ResVitaBio, Ribon Therapeutics,",
    "entities": [
      {
        "text": "Regeneron Pharmaceuticals",
        "label": "ORG"
      },
      {
        "text": "Ribon Therapeutics",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Sanofi-Aventis/Genzyme, Sitryx Therapeutics, Stealth BioTherapeutics, TRex Bio,",
    "entities": [
      {
        "text": "Sanofi-Aventis/Genzyme",
        "label": "ORG"
      },
      {
        "text": "TRex Bio",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Triveni Bio, UCB Pharma, Union Therapeutics, and Xencor; and as an investigator",
    "entities": [
      {
        "text": "Triveni Bio",
        "label": "PERSON"
      },
      {
        "text": "UCB Pharma, Union Therapeutics",
        "label": "ORG"
      },
      {
        "text": "Xencor",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Waserman reports contracts with Medexus, Mivaro Health, Novartis, and Sanofi. J.",
    "entities": [
      {
        "text": "Medexus",
        "label": "ORG"
      },
      {
        "text": "Mivaro Health",
        "label": "ORG"
      },
      {
        "text": "Novartis",
        "label": "PERSON"
      },
      {
        "text": "Sanofi",
        "label": "ORG"
      },
      {
        "text": "J.\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Moellman reports educational grants from RealCME/AstraZeneca; clinical research",
    "entities": [
      {
        "text": "Moellman",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "grants from Pharmin. E. T. Oliver reports consulting fees from Novartis and",
    "entities": [
      {
        "text": "Pharmin",
        "label": "PERSON"
      },
      {
        "text": "E. T. Oliver",
        "label": "PERSON"
      },
      {
        "text": "Novartis",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Sanofi/Regeneron. M. Ben-Shoshan reports contracts from Novartis and Sanofi; and",
    "entities": [
      {
        "text": "Sanofi/Regeneron",
        "label": "ORG"
      },
      {
        "text": "M. Ben-Shoshan",
        "label": "PERSON"
      },
      {
        "text": "Novartis",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "consulting and board participation with ALK, Novartis, and Sanofi. J. A.",
    "entities": [
      {
        "text": "ALK",
        "label": "ORG"
      },
      {
        "text": "Novartis",
        "label": "PERSON"
      },
      {
        "text": "Sanofi",
        "label": "ORG"
      },
      {
        "text": "J. A.\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Novartis, Pharvaris, Springer, TLL, and Yuhan; royalties from Amgen, Cogent",
    "entities": [
      {
        "text": "Novartis",
        "label": "ORG"
      },
      {
        "text": "Pharvaris, Springer",
        "label": "ORG"
      },
      {
        "text": "TLL",
        "label": "ORG"
      },
      {
        "text": "Yuhan",
        "label": "GPE"
      },
      {
        "text": "Amgen",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Pharmaceuticals, CRC Press, and UpToDate; consulting fees from Advanced Medical,",
    "entities": [
      {
        "text": "CRC Press",
        "label": "ORG"
      },
      {
        "text": "UpToDate",
        "label": "ORG"
      },
      {
        "text": "Advanced Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Incyte/Escient, INEOS, Intellia, IONIS, Jasper, Kenvue, Novartis, Pharvaris,",
    "entities": [
      {
        "text": "Incyte/Escient",
        "label": "ORG"
      },
      {
        "text": "INEOS",
        "label": "ORG"
      },
      {
        "text": "Intellia",
        "label": "GPE"
      },
      {
        "text": "IONIS",
        "label": "ORG"
      },
      {
        "text": "Jasper",
        "label": "GPE"
      },
      {
        "text": "Kenvue",
        "label": "GPE"
      },
      {
        "text": "Novartis",
        "label": "PERSON"
      },
      {
        "text": "Pharvaris",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "Telios, TEVA, and Yuhan; and speaking fees from Jasper. The rest of the authors",
    "entities": [
      {
        "text": "TEVA",
        "label": "ORG"
      },
      {
        "text": "Yuhan",
        "label": "GPE"
      },
      {
        "text": "Jasper",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "declare that they have no relevant conflicts of interest.",
    "entities": []
  },
  {
    "text": "Comparative Efficacy of Two Inhalational Techniques when Using a Pressurized",
    "entities": [
      {
        "text": "Two Inhalational Techniques",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Meter Dose Inhaler with Valved Holding Chamber in Children with Asthma: A",
    "entities": [
      {
        "text": "Meter Dose Inhaler",
        "label": "PERSON"
      },
      {
        "text": "Valved Holding Chamber",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Randomized Controlled Trial.",
    "entities": []
  },
  {
    "text": "(1)Department of Pediatrics, AIIMS, Bhubaneswar, India.",
    "entities": [
      {
        "text": "Pediatrics",
        "label": "ORG"
      },
      {
        "text": "Bhubaneswar",
        "label": "GPE"
      },
      {
        "text": "India",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Pulmonary Medicine and Critical Care, AIIMS, Bhubaneswar,",
    "entities": [
      {
        "text": "Pulmonary Medicine and Critical Care",
        "label": "ORG"
      },
      {
        "text": "Bhubaneswar",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Introduction: Inhaled medication delivered through a pressurized metered dose",
    "entities": []
  },
  {
    "text": "inhaler (pMDI) with a valved holding chamber (VHC) is the optimal treatment for",
    "entities": [
      {
        "text": "VHC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "asthma. The best technique is the breath-holding (BH) technique. Tidal breathing",
    "entities": [
      {
        "text": "BH",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(TB) technique is also recommended by Global Initiative for Asthma (GINA) as an",
    "entities": [
      {
        "text": "TB",
        "label": "ORG"
      },
      {
        "text": "Global Initiative for Asthma (GINA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "alternative. Clinical studies have shown variable results, but the scintigraphy",
    "entities": []
  },
  {
    "text": "study shows better lung deposition with the BH technique. The present study was",
    "entities": [
      {
        "text": "BH",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "designed to address the shortcomings in previous studies and to confirm the",
    "entities": []
  },
  {
    "text": "scintigraphy study findings by comparing the two techniques. Methods: This",
    "entities": [
      {
        "text": "two",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "randomized controlled trial included children aged 5-14 years with nonsevere",
    "entities": [
      {
        "text": "5-14 years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "asthma not taking inhaled medications on entry to the study, but during the",
    "entities": []
  },
  {
    "text": "study, they were given inhaled medications by pMDI + VHC (according to GINA",
    "entities": []
  },
  {
    "text": "guidelines) over an 8-week period. Demography, clinical details, spirometry",
    "entities": [
      {
        "text": "8-week",
        "label": "DATE"
      },
      {
        "text": "Demography",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "parameters, and asthma control were recorded/assessed. The primary outcome was",
    "entities": []
  },
  {
    "text": "change in spirometry parameters at 2 and 8 weeks. Results: Eighty-two children",
    "entities": [
      {
        "text": "2 and 8 weeks",
        "label": "DATE"
      },
      {
        "text": "Eighty-two",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "(mean age: 8.64 years, 46 boys) were included. There was no intergroup",
    "entities": [
      {
        "text": "8.64 years",
        "label": "DATE"
      },
      {
        "text": "46",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "difference in the spirometry parameters and asthma control scores at any point",
    "entities": []
  },
  {
    "text": "in time (p > 0.05). A significant intragroup improvement was noted only for",
    "entities": [
      {
        "text": "0.05",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "forced expiratory volume in the first second at 8 weeks (p < 0.05). Similarly, a",
    "entities": [
      {
        "text": "the first second",
        "label": "DATE"
      },
      {
        "text": "8 weeks",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "significant intragroup improvement in asthma control score was noted at 8 weeks",
    "entities": [
      {
        "text": "8 weeks",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "(p < 0.05). No adverse event was noted in either of the groups. Conclusions: The",
    "entities": []
  },
  {
    "text": "present study found no difference between the BH and the TB techniques while",
    "entities": [
      {
        "text": "BH",
        "label": "ORG"
      },
      {
        "text": "TB",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "delivering aerosols through a pMDI with a VHC. Either the BH or the TB technique",
    "entities": [
      {
        "text": "VHC",
        "label": "ORG"
      },
      {
        "text": "BH",
        "label": "ORG"
      },
      {
        "text": "TB",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "may be used in children (5-14 years) with nonsevere asthma. Clinical trial",
    "entities": [
      {
        "text": "5-14 years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "registration number: CTRI/2020/12/030078.",
    "entities": []
  },
  {
    "text": "10.2174/0127724344345143250709035643. Online ahead of print.",
    "entities": [
      {
        "text": "10.2174/0127724344345143250709035643",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Nature's Remedy: A Comprehensive Review Exploring Herbal Treatments and Natural",
    "entities": []
  },
  {
    "text": "Approaches for Preventing Acne Vulgaris.",
    "entities": []
  },
  {
    "text": "(1)Department of Pharmaceutics, Guru Gobind Singh College of Pharmacy,",
    "entities": [
      {
        "text": "Pharmaceutics",
        "label": "ORG"
      },
      {
        "text": "Guru Gobind Singh College of Pharmacy",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "BACKGROUND: Acne vulgaris is a prevailing inflammatory condition of the skin",
    "entities": []
  },
  {
    "text": "affecting areas with dense sebaceous glands, like the upper back, chest, face,",
    "entities": []
  },
  {
    "text": "and arms. It impacts approximately 85% of Americans aged 12 to 25, which can",
    "entities": [
      {
        "text": "approximately 85%",
        "label": "PERCENT"
      },
      {
        "text": "Americans",
        "label": "NORP"
      },
      {
        "text": "12 to 25",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "persist into adulthood. The condition is identified with pustules, comedones,",
    "entities": []
  },
  {
    "text": "papules, and nodules, comprising psychological and social effects comparable to",
    "entities": []
  },
  {
    "text": "chronic diseases like asthma.",
    "entities": []
  },
  {
    "text": "OBJECTIVES: This study explores the potential of herbal treatments as",
    "entities": []
  },
  {
    "text": "alternatives to conventional allopathic therapies for acne vulgaris, aiming to",
    "entities": []
  },
  {
    "text": "address underlying causes with fewer side effects.",
    "entities": []
  },
  {
    "text": "METHODOLOGY: A comprehensive literature review was conducted, examining clinical",
    "entities": []
  },
  {
    "text": "studies, traditional medicinal sources, and recent research on various herbs,",
    "entities": []
  },
  {
    "text": "(green tea), Salvia rosmarinus (rosemary), and AmaranthushypochondriacusLinn(",
    "entities": [
      {
        "text": "AmaranthushypochondriacusLinn",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "amaranths). Both topical and internal applications were considered, with a focus",
    "entities": []
  },
  {
    "text": "on topical treatments for ease of use. The databases PubMed, Web of Science,",
    "entities": [
      {
        "text": "PubMed",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Cochrane Library, Google Scholar, ResearchGate, and ScienceDirect were the main",
    "entities": [
      {
        "text": "Cochrane Library",
        "label": "PERSON"
      },
      {
        "text": "Google Scholar",
        "label": "ORG"
      },
      {
        "text": "ResearchGate",
        "label": "ORG"
      },
      {
        "text": "ScienceDirect",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "sources of the data and content included in this review article. This helped to",
    "entities": []
  },
  {
    "text": "preserve transparency and increased the credibility of this review article.",
    "entities": []
  },
  {
    "text": "RESULTS: Herbal medicines are gaining traction due to their minimal adverse",
    "entities": []
  },
  {
    "text": "effects and holistic approach. This study highlights promising results from",
    "entities": []
  },
  {
    "text": "several herbs in reducing acne symptoms and improving skin health, emphasizing",
    "entities": []
  },
  {
    "text": "the need for further clinical trials to substantiate these findings.",
    "entities": []
  },
  {
    "text": "CONCLUSION: Herbal therapies offer a viable alternative for managing acne",
    "entities": []
  },
  {
    "text": "vulgaris, potentially providing a holistic solution beyond symptomatic relief.",
    "entities": [
      {
        "text": "vulgaris",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Continued research is important to understand their effectiveness and mechanisms",
    "entities": []
  },
  {
    "text": "of action fully.",
    "entities": []
  },
  {
    "text": "Copyright\u00a9 Bentham Science Publishers; For any queries, please email at",
    "entities": [
      {
        "text": "Bentham Science Publishers",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Sensory Processing Disorder Could Be a Comorbidity of Childhood Asthma: A",
    "entities": []
  },
  {
    "text": "Cross-Sectional Study.",
    "entities": [
      {
        "text": "Cross-Sectional Study",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(1)Department of Allergy and Clinical Immunology, S.B.\u00dc Dr. Beh\u00e7et Uz Pediatric",
    "entities": [
      {
        "text": "Allergy and Clinical Immunology",
        "label": "ORG"
      },
      {
        "text": "S.B.\u00dc Dr. Beh\u00e7et Uz Pediatric\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Diseases and Surgery Training and Research Hospital, \u0130zmir, Turkey.",
    "entities": [
      {
        "text": "Surgery Training and Research Hospital",
        "label": "ORG"
      },
      {
        "text": "\u0130zmir",
        "label": "GPE"
      },
      {
        "text": "Turkey",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)D\u00fcnyam Special Education and Rehabilitation Center, \u0130zmir, Turkey.",
    "entities": [
      {
        "text": "2)D\u00fcnyam",
        "label": "CARDINAL"
      },
      {
        "text": "Special Education",
        "label": "ORG"
      },
      {
        "text": "Rehabilitation Center",
        "label": "ORG"
      },
      {
        "text": "\u0130zmir",
        "label": "GPE"
      },
      {
        "text": "Turkey",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "BACKGROUND: Asthma is a chronic inflammatory disease affecting multiple organ",
    "entities": []
  },
  {
    "text": "systems, including the central nervous system (CNS). Recent studies suggest an",
    "entities": [
      {
        "text": "CNS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "association between asthma and neurodevelopmental disorders such as autism",
    "entities": []
  },
  {
    "text": "spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD).",
    "entities": []
  },
  {
    "text": "Sensory processing disorder (SPD), a neurodevelopmental condition characterized",
    "entities": []
  },
  {
    "text": "by atypical responses to sensory stimuli, may also be linked to asthma through",
    "entities": []
  },
  {
    "text": "shared inflammatory mechanisms.",
    "entities": [
      {
        "text": "shared inflammatory mechanisms",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "OBJECTIVE: This study aimed to investigate the prevalence of SPD in children",
    "entities": [
      {
        "text": "SPD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "with asthma as compared to those without asthma and explore its relationship",
    "entities": []
  },
  {
    "text": "with asthma severity.",
    "entities": []
  },
  {
    "text": "METHODS: This prospective, cross-sectional study included 182 children aged 5-12",
    "entities": [
      {
        "text": "182",
        "label": "CARDINAL"
      },
      {
        "text": "5-12",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "years, with 91 asthmatic children in the study group and 91 nonasthmatic",
    "entities": [
      {
        "text": "years",
        "label": "DATE"
      },
      {
        "text": "91",
        "label": "CARDINAL"
      },
      {
        "text": "91",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "children in the control group. Sensory processing abilities were assessed using",
    "entities": []
  },
  {
    "text": "the Sensory Processing Measure (SPM) Home-Form. Statistical analyses, including",
    "entities": [
      {
        "text": "the Sensory Processing Measure",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "logistic regression and path analysis, were performed to evaluate the",
    "entities": []
  },
  {
    "text": "association between asthma and sensory processing abnormalities.",
    "entities": []
  },
  {
    "text": "RESULTS: Atypical sensory processing was significantly more prevalent in",
    "entities": []
  },
  {
    "text": "asthmatic children compared to the control group across multiple sensory",
    "entities": []
  },
  {
    "text": "domains, including vision, auditory, tactile, body awareness, balance, and",
    "entities": []
  },
  {
    "text": "movement (p < 0.005). Logistic regression analysis revealed that asthma was",
    "entities": []
  },
  {
    "text": "associated with increased risk of atypical sensory processing, particularly in",
    "entities": []
  },
  {
    "text": "tactile (OR: 5.716, 95% CI: 2.9-11.3 p < 0.001) and balance/movement (OR: 8.8,",
    "entities": [
      {
        "text": "5.716",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "PERSON"
      },
      {
        "text": "2.9",
        "label": "CARDINAL"
      },
      {
        "text": "8.8",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "95% CI: 2.5-30.7, p = 0.001) domains. However, no significant association was",
    "entities": [
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "2.5-30.7",
        "label": "CARDINAL"
      },
      {
        "text": "0.001",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "found between asthma severity and SPD prevalence.",
    "entities": []
  },
  {
    "text": "CONCLUSION: Our findings suggest that children with asthma exhibit a higher",
    "entities": []
  },
  {
    "text": "prevalence of SPD, supporting the hypothesis that neuroinflammation may",
    "entities": [
      {
        "text": "SPD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "contribute to sensory processing abnormalities. These results highlight the need",
    "entities": []
  },
  {
    "text": "for multidisciplinary approaches in managing asthmatic children, considering",
    "entities": []
  },
  {
    "text": "both respiratory and neurodevelopmental aspects. Further research is warranted",
    "entities": []
  },
  {
    "text": "to explore underlying mechanisms and potential interventions.",
    "entities": []
  },
  {
    "text": "\u00a9 2025 Wiley Periodicals LLC.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Wiley Periodicals",
        "label": "ORG"
      },
      {
        "text": "LLC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "PMID: 40662480 [Indexed for MEDLINE]",
    "entities": []
  },
  {
    "text": "Dupilumab adverse reactions in eosinophilic esophagitis treatment: a Food and",
    "entities": []
  },
  {
    "text": "Drug Administration Adverse Event Reporting System database analysis.",
    "entities": []
  },
  {
    "text": "Bowyer K(1), Swisher AR(2), Jiang N(3), Liang J(1)(3).",
    "entities": [
      {
        "text": "Swisher AR(2",
        "label": "PERSON"
      },
      {
        "text": "Jiang N(3",
        "label": "PERSON"
      },
      {
        "text": "Liang",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)Kaiser Permanente Bernard J. Tyson School of Medicine, Kaiser Permanente,",
    "entities": [
      {
        "text": "1)Kaiser",
        "label": "CARDINAL"
      },
      {
        "text": "Bernard J. Tyson School of Medicine",
        "label": "PERSON"
      },
      {
        "text": "Kaiser Permanente",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic Arizona,",
    "entities": [
      {
        "text": "2)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Otolaryngology-Head and Neck Surgery",
        "label": "ORG"
      },
      {
        "text": "Mayo Clinic",
        "label": "ORG"
      },
      {
        "text": "Arizona",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Department of Otolaryngology-Head and Neck Surgery, Kaiser Permanente,",
    "entities": [
      {
        "text": "Otolaryngology-Head and Neck Surgery",
        "label": "ORG"
      },
      {
        "text": "Kaiser Permanente",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Dupilumab, the first biologic approved for eosinophilic esophagitis treatment",
    "entities": [
      {
        "text": "first",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "(EoE-tx) in 2022, demonstrated favorable safety in phase-III clinical trials.",
    "entities": [
      {
        "text": "2022",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "However, real-world dupilumab-associated adverse reactions (DARs) for EoE-tx are",
    "entities": []
  },
  {
    "text": "unknown. This study aims to evaluate DAR for EoE-tx using the FDA Adverse Event",
    "entities": [
      {
        "text": "DAR for EoE",
        "label": "ORG"
      },
      {
        "text": "FDA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Reporting System. FDA Adverse Event Reporting System was queried for DAR between",
    "entities": [
      {
        "text": "FDA",
        "label": "ORG"
      },
      {
        "text": "DAR",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "2022Q1 and 2023Q4. Individual DARs (iDARs) were categorized and compared between",
    "entities": [
      {
        "text": "2022Q1",
        "label": "CARDINAL"
      },
      {
        "text": "2023Q4",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "treatment groups: EoE, asthma, atopic dermatitis, and chronic rhinosinusitis",
    "entities": []
  },
  {
    "text": "with nasal polyps. Logistic regression was used to predict serious DAR and",
    "entities": [
      {
        "text": "DAR",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "outcomes, and zero-truncated negative binomial regression was used to predict",
    "entities": [
      {
        "text": "zero",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "the number of iDAR. There were 51,000 DAR observations; 1459 for EoE-tx with 103",
    "entities": [
      {
        "text": "51,000",
        "label": "CARDINAL"
      },
      {
        "text": "DAR",
        "label": "ORG"
      },
      {
        "text": "1459",
        "label": "DATE"
      },
      {
        "text": "103",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "(7.1%) serious reactions and 44 (3.0%) serious outcomes including 3 deaths. For",
    "entities": [
      {
        "text": "7.1%",
        "label": "PERCENT"
      },
      {
        "text": "44",
        "label": "DATE"
      },
      {
        "text": "3.0%",
        "label": "PERCENT"
      },
      {
        "text": "3",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "EoE-tx, the mean iDAR was 3.68 [3.51, 3.85], and the iDAR incidence rate ratio",
    "entities": [
      {
        "text": "3.68",
        "label": "CARDINAL"
      },
      {
        "text": "3.51",
        "label": "CARDINAL"
      },
      {
        "text": "3.85",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "among men receiving EoE-tx was 0.73 [0.65, 0.83]. EoE-tx average iDAR primarily",
    "entities": [
      {
        "text": "0.73",
        "label": "CARDINAL"
      },
      {
        "text": "0.65",
        "label": "CARDINAL"
      },
      {
        "text": "0.83",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "included general (0.75 [0.70, 0.80]), injection-site (0.69 [0.63, 0.74]),",
    "entities": [
      {
        "text": "0.75",
        "label": "CARDINAL"
      },
      {
        "text": "0.70",
        "label": "CARDINAL"
      },
      {
        "text": "0.80",
        "label": "CARDINAL"
      },
      {
        "text": "0.69",
        "label": "CARDINAL"
      },
      {
        "text": "0.63",
        "label": "CARDINAL"
      },
      {
        "text": "0.74",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "reactions. Adults \u226550 years had 1.97 [1.28, 2.99] higher odds for serious DAR",
    "entities": [
      {
        "text": "1.97",
        "label": "CARDINAL"
      },
      {
        "text": "1.28",
        "label": "CARDINAL"
      },
      {
        "text": "2.99",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "compared to younger adults in EoE-tx. Overall, dupilumab demonstrated a",
    "entities": []
  },
  {
    "text": "favorable safety profile across all indications, with low rates of serious",
    "entities": []
  },
  {
    "text": "adverse events. For EoE-tx specifically, higher total iDAR rates were observed,",
    "entities": []
  },
  {
    "text": "driven largely by increased injection-site and gastrointestinal reactions",
    "entities": []
  },
  {
    "text": "compared to other indications. Additionally, women exhibited higher iDAR rates",
    "entities": []
  },
  {
    "text": "than men across all indications.",
    "entities": []
  },
  {
    "text": "\u00a9 The Author(s) 2025. Published by Oxford University Press on behalf of the",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Oxford University Press",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "International Society for Diseases of the Esophagus. All rights reserved. For",
    "entities": [
      {
        "text": "International Society for Diseases of the Esophagus",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "commercial re-use, please contact reprints@oup.com for reprints and translation",
    "entities": []
  },
  {
    "text": "rights for reprints. All other permissions can be obtained through our",
    "entities": []
  },
  {
    "text": "RightsLink service via the Permissions link on the article page on our site\u2014for",
    "entities": [
      {
        "text": "Permissions",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "further information please contact journals.permissions@oup.com.",
    "entities": [
      {
        "text": "journals.permissions@oup.com",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "PMID: 40662440 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40662440",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "23. Clin Exp Allergy. 2025 Jul 15. doi: 10.1111/cea.70117. Online ahead of print.",
    "entities": [
      {
        "text": "23",
        "label": "CARDINAL"
      },
      {
        "text": "Clin Exp Allergy",
        "label": "ORG"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "10.1111",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Biologic Prescription Patterns and Biomarker Determinants of First-Line",
    "entities": [
      {
        "text": "Biologic Prescription Patterns",
        "label": "PERSON"
      },
      {
        "text": "Biomarker Determinants",
        "label": "PERSON"
      },
      {
        "text": "First-Line",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Dupilumab in Danish Adult Patients With Severe Asthma and Comorbid Atopic",
    "entities": [
      {
        "text": "Comorbid Atopic",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "(1)Department of Respiratory Medicine, Copenhagen University Hospital -",
    "entities": [
      {
        "text": "Respiratory Medicine",
        "label": "ORG"
      },
      {
        "text": "Copenhagen University Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)Department of Dermatology, Copenhagen University Hospital - Bispebjerg,",
    "entities": [
      {
        "text": "Copenhagen University Hospital - Bispebjerg",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(3)Department of Respiratory Medicine, Copenhagen University Hospital -",
    "entities": [
      {
        "text": "Respiratory Medicine",
        "label": "ORG"
      },
      {
        "text": "Copenhagen University Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)Centre for Clinical Research and Prevention, Frederiksberg Hospital,",
    "entities": [
      {
        "text": "Clinical Research and Prevention, Frederiksberg Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(5)Department of Respiratory Diseases and Allergy, Aarhus University Hospital,",
    "entities": [
      {
        "text": "5)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Respiratory Diseases",
        "label": "ORG"
      },
      {
        "text": "Allergy",
        "label": "GPE"
      },
      {
        "text": "Aarhus University Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(6)Department of Respiratory Medicine, Odense University Hospital, Odense,",
    "entities": [
      {
        "text": "Respiratory Medicine,",
        "label": "ORG"
      },
      {
        "text": "Odense University Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(7)Allergy Clinic, Copenhagen University Hospital - Gentofte, Hellerup, Denmark.",
    "entities": [
      {
        "text": "Clinic, Copenhagen University Hospital - Gentofte",
        "label": "ORG"
      },
      {
        "text": "Hellerup",
        "label": "GPE"
      },
      {
        "text": "Denmark",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(8)Department of Respiratory Diseases, Copenhagen University Hospital -",
    "entities": [
      {
        "text": "Respiratory Diseases",
        "label": "ORG"
      },
      {
        "text": "Copenhagen University Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(9)Department of Respiratory Medicine, Aalborg University Hospital, Aalborg,",
    "entities": [
      {
        "text": "Respiratory Medicine",
        "label": "ORG"
      },
      {
        "text": "Aalborg University Hospital",
        "label": "ORG"
      },
      {
        "text": "Aalborg",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(11)Department of Respiratory Medicine, Sygehus Lillebaelt - Vejle Sygehus,",
    "entities": [
      {
        "text": "11)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Respiratory Medicine",
        "label": "ORG"
      },
      {
        "text": "Sygehus Lillebaelt - Vejle Sygehus",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "BACKGROUND: Asthma and atopic dermatitis are common type-2 (T2)-driven diseases",
    "entities": [
      {
        "text": "T2)-driven",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "that often coexist, although different T2 biomarkers indicate disease severity",
    "entities": [
      {
        "text": "T2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "in each condition. Multiple biologics target T2 inflammation, but only dupilumab",
    "entities": [
      {
        "text": "T2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "has been approved for both diseases. Little is known about patients with severe",
    "entities": []
  },
  {
    "text": "asthma and comorbid atopic dermatitis, particularly regarding how this",
    "entities": []
  },
  {
    "text": "comorbidity influences the choice of biologic for severe asthma.",
    "entities": []
  },
  {
    "text": "METHODS: We utilised the nationwide Danish Severe Asthma Register to",
    "entities": [
      {
        "text": "Danish",
        "label": "NORP"
      },
      {
        "text": "Asthma Register",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "characterise patients with severe asthma and comorbid atopic dermatitis, and",
    "entities": []
  },
  {
    "text": "describe prescription patterns of biologics in patients with and without",
    "entities": []
  },
  {
    "text": "comorbid atopic dermatitis. We compared biomarker determinants of first-line",
    "entities": [
      {
        "text": "first",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "dupilumab prescription between the two groups using a multivariate logistic",
    "entities": [
      {
        "text": "two",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "RESULTS: We identified 1137 patients initiating a biologic for severe asthma, of",
    "entities": [
      {
        "text": "1137",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "whom 192 (17%) had comorbid atopic dermatitis. Patients with comorbid atopic",
    "entities": [
      {
        "text": "192",
        "label": "CARDINAL"
      },
      {
        "text": "17%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "dermatitis more often had childhood-onset asthma with an allergic phenotype. The",
    "entities": []
  },
  {
    "text": "prescription patterns of biologics differed according to comorbid atopic",
    "entities": []
  },
  {
    "text": "dermatitis status, and patients with comorbid atopic dermatitis were more likely",
    "entities": []
  },
  {
    "text": "to switch (OR 3.02, p < 0.001). In patients with comorbid atopic dermatitis,",
    "entities": [
      {
        "text": "3.02",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "elevated IgE was the strongest biomarker determinant of first-line dupilumab",
    "entities": [
      {
        "text": "first",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "prescription (OR 8.77, p < 0.001), whereas in patients without, it was elevated",
    "entities": [
      {
        "text": "8.77",
        "label": "DATE"
      },
      {
        "text": "p < 0.001",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "CONCLUSION: Biologic prescription patterns in severe asthma vary according to",
    "entities": []
  },
  {
    "text": "comorbid atopic dermatitis status. In patients with comorbid atopic dermatitis,",
    "entities": []
  },
  {
    "text": "elevated IgE predicts first-line dupilumab prescription, indicating that the",
    "entities": [
      {
        "text": "first",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "severity of atopic dermatitis influences treatment decisions. Additional",
    "entities": []
  },
  {
    "text": "research is needed to explore the management of coexisting T2 diseases with",
    "entities": [
      {
        "text": "T2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "biological therapies.",
    "entities": []
  },
  {
    "text": "\u00a9 2025 The Author(s). Clinical & Experimental Allergy published by John Wiley &",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Clinical & Experimental Allergy",
        "label": "ORG"
      },
      {
        "text": "John Wiley &\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "24. Front Allergy. 2025 Jun 30;6:1581694. doi: 10.3389/falgy.2025.1581694.",
    "entities": [
      {
        "text": "24",
        "label": "CARDINAL"
      },
      {
        "text": "Front Allergy",
        "label": "ORG"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "10.3389",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "ULANC - EUFOREA workshop 2024: bringing the concept of global airways to the",
    "entities": [
      {
        "text": "ULANC - EUFOREA",
        "label": "ORG"
      },
      {
        "text": "workshop 2024",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "frontline of medical care.",
    "entities": []
  },
  {
    "text": "(1)The European Forum for Research and Education in Allergy and Airway Diseases",
    "entities": [
      {
        "text": "European Forum for Research and Education",
        "label": "ORG"
      },
      {
        "text": "Allergy",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Department of Otorhinolaryngology, Head & Neck Surgery, and Audiology,",
    "entities": [
      {
        "text": "Otorhinolaryngology, Head & Neck Surgery",
        "label": "ORG"
      },
      {
        "text": "Audiology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)General Practitioner Copenhagen and Ballerup Psychiatric Department,",
    "entities": [
      {
        "text": "Practitioner Copenhagen",
        "label": "ORG"
      },
      {
        "text": "Ballerup Psychiatric Department",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(5)Laboratory of Upper Airways Research, Department of Otorhinolaryngology,",
    "entities": [
      {
        "text": "Upper Airways Research",
        "label": "ORG"
      },
      {
        "text": "Department of Otorhinolaryngology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University of Ghent, Ghent, Belgium.",
    "entities": [
      {
        "text": "University of Ghent",
        "label": "ORG"
      },
      {
        "text": "Belgium",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)Allergy and Clinical Immunology Research Unit, KU Leuven Department of",
    "entities": [
      {
        "text": "Clinical Immunology Research Unit",
        "label": "ORG"
      },
      {
        "text": "KU Leuven Department",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Microbiology and Immunology, Leuven, Belgium.",
    "entities": [
      {
        "text": "Leuven",
        "label": "GPE"
      },
      {
        "text": "Belgium",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(7)Clinical Department of Otorhinolaryngology, Head and Neck Surgery, University",
    "entities": [
      {
        "text": "Department of Otorhinolaryngology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(8)Department of Pediatric Respiratory Medicine, Immunology and Critical Care",
    "entities": [
      {
        "text": "Pediatric Respiratory Medicine, Immunology and Critical Care",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(9)Department of Otorhinolaryngology, School of Medicine, University of Crete,",
    "entities": [
      {
        "text": "Otorhinolaryngology, School of Medicine, University of Crete",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Heraklion, Greece.",
    "entities": [
      {
        "text": "Greece",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(10)Department of Allergy & Rhinology, Royal National ENT Hospital, London,",
    "entities": [
      {
        "text": "10)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Allergy & Rhinology",
        "label": "ORG"
      },
      {
        "text": "Royal National ENT Hospital",
        "label": "ORG"
      },
      {
        "text": "London",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "United Kingdom.",
    "entities": [
      {
        "text": "United Kingdom",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(11)Division of Immunity and Infection, University College, London, United",
    "entities": [
      {
        "text": "Immunity and Infection, University College",
        "label": "ORG"
      },
      {
        "text": "London",
        "label": "GPE"
      },
      {
        "text": "United",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(12)Skin and Allergy Hospital, Helsinki University Hospital and University of",
    "entities": [
      {
        "text": "Allergy Hospital",
        "label": "ORG"
      },
      {
        "text": "Helsinki University Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(13)Department of Otorhinolaryngology, Institute of Clinical Medicine, Kuopio",
    "entities": [
      {
        "text": "13)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Otorhinolaryngology, Institute of Clinical Medicine",
        "label": "ORG"
      },
      {
        "text": "Kuopio",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "University Hospital and School of Medicine, University of Eastern Finland,",
    "entities": [
      {
        "text": "University Hospital and School of Medicine, University of Eastern Finland",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "The Upper and Lower Airways Northern European Consensus (ULANC) and the European",
    "entities": [
      {
        "text": "The Upper and Lower Airways Northern European Consensus",
        "label": "ORG"
      },
      {
        "text": "ULANC",
        "label": "ORG"
      },
      {
        "text": "European",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "Forum for Research and Education in Allergy and Airways diseases (EUFOREA)",
    "entities": [
      {
        "text": "Allergy and Airways",
        "label": "ORG"
      },
      {
        "text": "EUFOREA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "organized their first workshop in Copenhagen in January 2024. The aim of the",
    "entities": [
      {
        "text": "first",
        "label": "ORDINAL"
      },
      {
        "text": "Copenhagen",
        "label": "ORG"
      },
      {
        "text": "January 2024",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "\"Primary care physicians and nurses with an interest in Global Airway Diseases",
    "entities": [
      {
        "text": "Global Airway Diseases",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "2024\" was to bring the concept of the global airway to the front line of medical",
    "entities": [
      {
        "text": "2024",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "care. ULANC is a multidisciplinary European consortium, that aims to improve the",
    "entities": [
      {
        "text": "ULANC",
        "label": "ORG"
      },
      {
        "text": "European",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "management of comorbid ear, nose and throat (ENT) conditions, such as chronic",
    "entities": []
  },
  {
    "text": "rhinosinusitis with nasal polyposis (CRSwNP), in patients also suffering from",
    "entities": []
  },
  {
    "text": "asthma. EUFOREA is an international non-profit organization forming an alliance",
    "entities": [
      {
        "text": "EUFOREA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of all stakeholders dedicated to reducing the prevalence and burden of chronic",
    "entities": []
  },
  {
    "text": "respiratory diseases through the implementation of optimal patient care via",
    "entities": []
  },
  {
    "text": "educational, research, and advocacy activities. The inclusive and",
    "entities": []
  },
  {
    "text": "multidisciplinary approach of ULANC and EUFOREA was reflected in the keynote",
    "entities": [
      {
        "text": "ULANC",
        "label": "ORG"
      },
      {
        "text": "EUFOREA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "lectures and workshop faculty coming from the allergology, pulmonology, ENT, and",
    "entities": [
      {
        "text": "ENT",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "primary health care fields around the central theme of global airway diseases.",
    "entities": []
  },
  {
    "text": "The current report aims at providing a comprehensive overview of the key",
    "entities": []
  },
  {
    "text": "statements by the faculty of the \"Primary care physicians and nurses with",
    "entities": []
  },
  {
    "text": "interest in Global Airway Diseases 2024\", allowing all stakeholders in the",
    "entities": [
      {
        "text": "Global Airway Diseases",
        "label": "ORG"
      },
      {
        "text": "2024",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "respiratory field to be up-dated and ready to join forces in Europe and beyond.",
    "entities": [
      {
        "text": "Europe",
        "label": "LOC"
      }
    ]
  },
  {
    "text": "\u00a9 2025 Conti, Backer, Aanaes, Azizi, Hellings, Lau, Liva, Scadding and",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Backer",
        "label": "ORG"
      },
      {
        "text": "Aanaes",
        "label": "ORG"
      },
      {
        "text": "Azizi",
        "label": "PERSON"
      },
      {
        "text": "Hellings, Lau, Liva, Scadding",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: DC: Serves as academic manager at the European",
    "entities": [
      {
        "text": "European",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) and as",
    "entities": [
      {
        "text": "Allergy",
        "label": "GPE"
      },
      {
        "text": "EUFOREA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "review editor at Frontiers in Allergy, rhinology section. PH: Is recipient of",
    "entities": [
      {
        "text": "Frontiers in Allergy",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "consultancy/lecture fees or unrestricted research grants from Sanofi/Regeneron,",
    "entities": [
      {
        "text": "Sanofi/Regeneron",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Novartis, GSK, Medtronic and Viatris. SL.: Received honoraria for lectures and",
    "entities": [
      {
        "text": "Novartis",
        "label": "ORG"
      },
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "Medtronic",
        "label": "ORG"
      },
      {
        "text": "Viatris",
        "label": "PERSON"
      },
      {
        "text": "SL",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "advisory boards from Sanofi-Aventis, Allergopharma, ALK, GSK, Leo Pharma, Leti,",
    "entities": [
      {
        "text": "Sanofi-Aventis",
        "label": "ORG"
      },
      {
        "text": "Allergopharma",
        "label": "PERSON"
      },
      {
        "text": "ALK",
        "label": "ORG"
      },
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "Leo Pharma",
        "label": "PERSON"
      },
      {
        "text": "Leti",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Viatris, Lilly and DBV. ExCom member of the DGAKI (German Society of Allergology",
    "entities": [
      {
        "text": "Viatris",
        "label": "PERSON"
      },
      {
        "text": "Lilly",
        "label": "ORG"
      },
      {
        "text": "DBV",
        "label": "ORG"
      },
      {
        "text": "Society of Allergology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and Clinical Immunology) and GPP (Society of Pediatric Pneumology). GS:",
    "entities": [
      {
        "text": "Society of Pediatric Pneumology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Honoraria for articles, speaker and advisory boards: ALK, Bayer,",
    "entities": [
      {
        "text": "ALK",
        "label": "ORG"
      },
      {
        "text": "Bayer",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "GlaxoSmithKline, Haleon, Noucor, Sanofi-Regeneron, and Viatris. Chair of BSACI",
    "entities": [
      {
        "text": "GlaxoSmithKline",
        "label": "PERSON"
      },
      {
        "text": "Haleon",
        "label": "GPE"
      },
      {
        "text": "Noucor",
        "label": "GPE"
      },
      {
        "text": "Sanofi-Regeneron",
        "label": "ORG"
      },
      {
        "text": "Viatris",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "rhinitis guidelines, Scientific Chief Editor, Rhinology Section of Frontiers in",
    "entities": [
      {
        "text": "Scientific",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Allergy, Board member and AR lead for EUFOREA, and Chair/member Data Monitoring",
    "entities": [
      {
        "text": "Allergy, Board",
        "label": "ORG"
      },
      {
        "text": "AR",
        "label": "ORG"
      },
      {
        "text": "EUFOREA",
        "label": "ORG"
      },
      {
        "text": "Chair",
        "label": "ORG"
      },
      {
        "text": "Data Monitoring",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Committees on SLIT for ALK. SL: Received honoraria for lectures and advisory",
    "entities": [
      {
        "text": "SLIT",
        "label": "ORG"
      },
      {
        "text": "ALK",
        "label": "ORG"
      },
      {
        "text": "SL",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "boards from Sanofi-Aventis, Allergopharma, ALK, GSK, Leo Pharma, Leti, Viatris,",
    "entities": [
      {
        "text": "Sanofi-Aventis",
        "label": "ORG"
      },
      {
        "text": "Allergopharma",
        "label": "PERSON"
      },
      {
        "text": "ALK",
        "label": "ORG"
      },
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "Leo Pharma",
        "label": "PERSON"
      },
      {
        "text": "Leti",
        "label": "PERSON"
      },
      {
        "text": "Viatris",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Lilly and DBV. ST-S: Reports consultancies for ALK-Abell\u00f3, AstraZeneca, ERT,",
    "entities": [
      {
        "text": "Lilly",
        "label": "ORG"
      },
      {
        "text": "DBV",
        "label": "ORG"
      },
      {
        "text": "ALK-Abell\u00f3",
        "label": "ORG"
      },
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "ERT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "GSK, Novartis, Sanofi, and Roche Products outside the submitted work, as well as",
    "entities": [
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "Novartis",
        "label": "ORG"
      },
      {
        "text": "Roche Products",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "grant of GSK outside the submitted work. The remaining authors declare that the",
    "entities": [
      {
        "text": "GSK",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "research was conducted in the absence of any commercial or financial",
    "entities": []
  },
  {
    "text": "relationships that could be construed as a potential conflict of interest. The",
    "entities": []
  },
  {
    "text": "author(s) declared that they were an editorial board member of Frontiers, at the",
    "entities": [
      {
        "text": "Frontiers",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "time of submission. This had no impact on the peer review process and the final",
    "entities": []
  },
  {
    "text": "Association and risk factors analysis of FeNO and CRP in bronchial asthma",
    "entities": [
      {
        "text": "FeNO",
        "label": "ORG"
      },
      {
        "text": "CRP",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "combined with obstructive sleep apnea.",
    "entities": []
  },
  {
    "text": "(1)Department of Respiratory and Critical Care Medicine, Affiliated Hospital of",
    "entities": [
      {
        "text": "Respiratory and Critical Care Medicine",
        "label": "ORG"
      },
      {
        "text": "Affiliated Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Hebei University of Engineering, Handan, Hebei, China.",
    "entities": [
      {
        "text": "Hebei University of Engineering",
        "label": "ORG"
      },
      {
        "text": "Handan",
        "label": "GPE"
      },
      {
        "text": "Hebei",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Neurosurgery, Affiliated Hospital of Hebei University of",
    "entities": [
      {
        "text": "Neurosurgery, Affiliated Hospital of Hebei University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Bronchial asthma (BA) and obstructive sleep apnea (OSA) are chronic disorders of",
    "entities": [
      {
        "text": "Bronchial",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "the respiratory system; both diseases are widespread and can cause a decrease in",
    "entities": []
  },
  {
    "text": "the quality of life. The latter contrasts the airway inflammation and excessive",
    "entities": []
  },
  {
    "text": "reactivity that define BA, and the intermittent airway obstruction during sleep",
    "entities": [
      {
        "text": "BA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "that defines OSA results in periods of hypoxemia and disruptive breathing. BA",
    "entities": []
  },
  {
    "text": "appears when children have OSA in addition to other disorders, including night",
    "entities": [
      {
        "text": "night",
        "label": "TIME"
      }
    ]
  },
  {
    "text": "ventilation, breathlessness, and sleep conflicts. Current studies have focused",
    "entities": []
  },
  {
    "text": "on inflammatory indicators such as the FeNO and CRP in these diseases. FeNO is a",
    "entities": [
      {
        "text": "FeNO",
        "label": "LOC"
      },
      {
        "text": "CRP",
        "label": "ORG"
      },
      {
        "text": "FeNO",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "measure of eosinophilic airway inflammation, which is usually high in asthma.",
    "entities": []
  },
  {
    "text": "In, contrast, CRP is a measure of systemic inflammation that is usually high in",
    "entities": [
      {
        "text": "CRP",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "both forms of asthma. This review paper will focus on FeNO and CRP in connection",
    "entities": [
      {
        "text": "FeNO",
        "label": "ORG"
      },
      {
        "text": "CRP",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "to the pathophysiology of BA and OSA with further descriptions of how these",
    "entities": [
      {
        "text": "BA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "markers relate to inflammation in both disorders. The review also focuses on how",
    "entities": []
  },
  {
    "text": "these markers interlink in patients with both diseases and how FeNO and CRP can",
    "entities": [
      {
        "text": "FeNO",
        "label": "ORG"
      },
      {
        "text": "CRP",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "also reflect the severity of the disease and the effectiveness of the treatments",
    "entities": []
  },
  {
    "text": "being used. Finally, identifying the interaction between these markers might",
    "entities": []
  },
  {
    "text": "advance the identification and management of patients with both BA and OSA.",
    "entities": [
      {
        "text": "BA",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "Copyright \u00a9 2025 Yan, Peng Fei and Zhu.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Yan",
        "label": "PERSON"
      },
      {
        "text": "Peng Fei",
        "label": "PERSON"
      },
      {
        "text": "Zhu",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: The authors declare that the research was",
    "entities": []
  },
  {
    "text": "conducted in the absence of any commercial or financial relationships that could",
    "entities": []
  },
  {
    "text": "be construed as a potential conflict of interest.",
    "entities": []
  },
  {
    "text": "circ-0001875 downregulation is associated with M1 macrophage activation and lung",
    "entities": [
      {
        "text": "circ-0001875",
        "label": "DATE"
      },
      {
        "text": "M1",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "inflammation in severe asthma.",
    "entities": []
  },
  {
    "text": "Guangdong Medical University, Zhanjiang, China.",
    "entities": [
      {
        "text": "Guangdong Medical University",
        "label": "ORG"
      },
      {
        "text": "Zhanjiang",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "BACKGROUND: Asthma is a heterogeneous group of diseases. The mechanism by which",
    "entities": []
  },
  {
    "text": "dysregulated circRNAs affect severe asthma by regulating macrophage polarization",
    "entities": []
  },
  {
    "text": "METHODS: High-throughput RNA sequencing technology was used to analyze circRNA",
    "entities": [
      {
        "text": "RNA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "expression in peripheral blood mononuclear cells (PBMCs) from patients with",
    "entities": []
  },
  {
    "text": "severe asthma. RT-qPCR and ELISA were used to analyze the expression of",
    "entities": [
      {
        "text": "RT-qPCR",
        "label": "PERSON"
      },
      {
        "text": "ELISA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "inflammatory factors in a mouse model of severe asthma induced by",
    "entities": []
  },
  {
    "text": "ovalbumin-lipopolysaccharide. The effect of circ-0001875 on macrophage",
    "entities": [
      {
        "text": "circ-0001875",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "activation and the underlying mechanism were analyzed by RT-qPCR, Western blot,",
    "entities": [
      {
        "text": "RT-qPCR",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and ELISA. Subsequently, the regulatory relationships among circ-0001875,",
    "entities": [
      {
        "text": "ELISA",
        "label": "ORG"
      },
      {
        "text": "circ-0001875",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "miR-31-5p, and SP1 were examined through dual luciferase reporter gene assay,",
    "entities": []
  },
  {
    "text": "and the mechanism by which they regulate macrophage polarization was analyzed by",
    "entities": []
  },
  {
    "text": "RESULTS: Compared with the healthy control group, 420 circRNAs were",
    "entities": [
      {
        "text": "420",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "differentially expressed in PBMCs from patients with severe asthma. Among them,",
    "entities": []
  },
  {
    "text": "circ-0001875, which was mainly expressed in the cytoplasm of monocytes, was",
    "entities": [
      {
        "text": "circ-0001875",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "significantly downregulated in asthmatics, especially those with severe disease.",
    "entities": []
  },
  {
    "text": "circ-0001875 overexpression inhibited M1 macrophage activation in vitro and",
    "entities": [
      {
        "text": "circ-0001875",
        "label": "DATE"
      },
      {
        "text": "M1",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "alleviated lung inflammation in a mouse model of severe asthma. Mechanistically,",
    "entities": []
  },
  {
    "text": "circ-0001875 promoted SP1 translation by competitively binding to miR-31-5p,",
    "entities": [
      {
        "text": "circ-0001875",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "thereby reducing its inhibitory effect on SP1 translation; SP1 then inhibited M1",
    "entities": [
      {
        "text": "M1\n",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "macrophage polarization, which is associated with severe asthma, through the",
    "entities": []
  },
  {
    "text": "CONCLUSIONS: We found that circ-0001875 plays an important role in regulating M1",
    "entities": [
      {
        "text": "circ-0001875",
        "label": "DATE"
      },
      {
        "text": "M1\n",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "macrophage polarization, which is associated with a severe pro-inflammatory",
    "entities": []
  },
  {
    "text": "PMID: 40661956 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40661956",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Chronic inducible urticaria - having more than one is common and clinically",
    "entities": [
      {
        "text": "more than one",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "(1)Global Allergy and Asthma European Network (GA2LEN) Urticaria Center of",
    "entities": [
      {
        "text": "Allergy",
        "label": "NORP"
      },
      {
        "text": "Asthma European Network",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Reference and Excellence (UCARE), Moscow City Research and Practical Center of",
    "entities": [
      {
        "text": "UCARE",
        "label": "ORG"
      },
      {
        "text": "Moscow City Research",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Allergy and Immunology, City Clinical Hospital 52, Moscow Healthcare Department,",
    "entities": [
      {
        "text": "52",
        "label": "DATE"
      },
      {
        "text": "Moscow Healthcare Department",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Moscow, Russia.",
    "entities": [
      {
        "text": "Moscow",
        "label": "GPE"
      },
      {
        "text": "Russia",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Clinical Immunology and Allergy, The First Sechenov State",
    "entities": [
      {
        "text": "Clinical Immunology and Allergy",
        "label": "ORG"
      },
      {
        "text": "First",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "Medical University, Moscow, Russia.",
    "entities": [
      {
        "text": "Medical University",
        "label": "ORG"
      },
      {
        "text": "Moscow",
        "label": "GPE"
      },
      {
        "text": "Russia",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Department of Surgery, Central Military Clinical Hospital Named After A.A.",
    "entities": [
      {
        "text": "Surgery, Central Military Clinical Hospital Named After",
        "label": "ORG"
      },
      {
        "text": "A.A.",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Vishnevsky, Moscow, Russia.",
    "entities": [
      {
        "text": "Vishnevsky",
        "label": "GPE"
      },
      {
        "text": "Moscow",
        "label": "GPE"
      },
      {
        "text": "Russia",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Life Improvement by Future Technologies (LIFT) Center, Skolkovo, Russia.",
    "entities": [
      {
        "text": "Future Technologies",
        "label": "ORG"
      },
      {
        "text": "Skolkovo",
        "label": "GPE"
      },
      {
        "text": "Russia",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Therapy Department, The Russian National Research Medical University Named",
    "entities": [
      {
        "text": "5)Therapy Department",
        "label": "ORG"
      },
      {
        "text": "The Russian National Research Medical University Named",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "After N.I. Pirogov, Moscow, Russia.",
    "entities": [
      {
        "text": "N.I. Pirogov",
        "label": "ORG"
      },
      {
        "text": "Moscow",
        "label": "GPE"
      },
      {
        "text": "Russia",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)Global Allergy and Asthma European Network (GA2LEN) Urticaria Center of",
    "entities": [
      {
        "text": "6)Global",
        "label": "CARDINAL"
      },
      {
        "text": "Asthma European Network",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Reference and Excellence (UCARE), Institute of Allergology, Charit\u00e9 -",
    "entities": [
      {
        "text": "UCARE",
        "label": "ORG"
      },
      {
        "text": "Institute of Allergology",
        "label": "ORG"
      },
      {
        "text": "Charit\u00e9",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "(7)Department of Allergology and Immunology, Fraunhofer Institute for",
    "entities": [
      {
        "text": "Allergology and Immunology, Fraunhofer Institute",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Translational Medicine and Pharmacology (ITMP), Berlin, Germany.",
    "entities": [
      {
        "text": "Translational Medicine and Pharmacology",
        "label": "ORG"
      },
      {
        "text": "Berlin",
        "label": "GPE"
      },
      {
        "text": "Germany",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(8)Department of Dermatology, Bah\u00e7e\u015fehir University School of Medicine,",
    "entities": [
      {
        "text": "Bah\u00e7e\u015fehir University School of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(9)Department of Pulmonology, Astana Medical University, Astana, Kazakhstan.",
    "entities": [
      {
        "text": "Astana Medical University",
        "label": "ORG"
      },
      {
        "text": "Astana",
        "label": "GPE"
      },
      {
        "text": "Kazakhstan",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "BACKGROUND: Chronic inducible urticaria (CIndU) is characterized by wheals",
    "entities": []
  },
  {
    "text": "and/or angioedema (AE) for 6 weeks or more in response to specific and definite",
    "entities": [
      {
        "text": "and/or angioedema",
        "label": "PERSON"
      },
      {
        "text": "6 weeks",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "triggers. Individual patients can have more than one type of CIndU. Reports on",
    "entities": [
      {
        "text": "more than one",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "this come from single cases or small case series, most epidemiological studies",
    "entities": []
  },
  {
    "text": "did not assess whether these urticaria are standalone or mixed.",
    "entities": []
  },
  {
    "text": "OBJECTIVE: Determine the features of mixed CIndU and how they differ from",
    "entities": []
  },
  {
    "text": "standalone forms.",
    "entities": []
  },
  {
    "text": "METHODS: In a prospective cohort study we performed provocative testing in 210",
    "entities": [
      {
        "text": "210",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "patients with CIndU. A total of 188 patients were included (125 with the",
    "entities": [
      {
        "text": "188",
        "label": "CARDINAL"
      },
      {
        "text": "125",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "standalone CIndU and 63 with the mixed CIndU. Within each group, patients were",
    "entities": [
      {
        "text": "63",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "divided into subgroups: symptomatic dermographism (SD), cold (ColdU) and",
    "entities": [
      {
        "text": "ColdU",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "cholinergic urticaria (CholU).",
    "entities": [
      {
        "text": "cholinergic urticaria",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "RESULTS: Mixed CIndU most commonly were SD+ColdU (n=19, 30.2%), SD+CholU (n=15,",
    "entities": [
      {
        "text": "SD+ColdU",
        "label": "PERSON"
      },
      {
        "text": "30.2%",
        "label": "PERCENT"
      },
      {
        "text": "n=15",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "23.8%), SD+DPU (n=12, 19%) and ColdU+CholU (n=9, 14.3%). Comorbid chronic",
    "entities": [
      {
        "text": "23.8%",
        "label": "PERCENT"
      },
      {
        "text": "n=12",
        "label": "PERSON"
      },
      {
        "text": "19%",
        "label": "PERCENT"
      },
      {
        "text": "ColdU+CholU",
        "label": "ORG"
      },
      {
        "text": "14.3%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "p=0.014) were more common in patients with mixed CIndUs. In patients with mixed",
    "entities": [
      {
        "text": "CIndUs",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "CIndUs, their onset time is more closely linked to each other (n=43; 68.2%) as",
    "entities": [
      {
        "text": "CIndUs",
        "label": "GPE"
      },
      {
        "text": "68.2%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "compared to that of comorbid CSU (12 of 32, 37.5%). MixedSD patients are",
    "entities": [
      {
        "text": "CSU",
        "label": "ORG"
      },
      {
        "text": "12",
        "label": "CARDINAL"
      },
      {
        "text": "32",
        "label": "DATE"
      },
      {
        "text": "37.5%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "younger, show earlier onset of disease and have higher rates of AE and lower",
    "entities": [
      {
        "text": "AE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "rates of atopic dermatitis (AtD), as compared to patients with standalone SD.",
    "entities": [
      {
        "text": "AtD",
        "label": "WORK_OF_ART"
      }
    ]
  },
  {
    "text": "MixedColdU patients have higher rates of comorbid CSU and lower rates of AtD,",
    "entities": [
      {
        "text": "CSU",
        "label": "ORG"
      },
      {
        "text": "AtD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "higher levels of total IgE and eosinophils. MixedCholU patients are older, have",
    "entities": []
  },
  {
    "text": "a high rate of comorbid CSU, a lower incidence of allergic disease.",
    "entities": [
      {
        "text": "CSU",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "CONCLUSION: This study shows for the first time that each combinations of mixed",
    "entities": [
      {
        "text": "first",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "CIndU represent a distinct phenotype with its own features. These phenotypes",
    "entities": [
      {
        "text": "CIndU",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "require special attention of specialists.",
    "entities": []
  },
  {
    "text": "PMID: 40661948 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40661948",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "be construed as a potential conflict of interest. The author(s) declared that",
    "entities": []
  },
  {
    "text": "they were an editorial board member of Frontiers, at the time of submission.",
    "entities": [
      {
        "text": "Frontiers",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "This had no impact on the peer review process and the final decision.",
    "entities": []
  },
  {
    "text": "Exploring the Efficacy of Benralizumab in Chronic Eosinophilic Pneumonia",
    "entities": []
  },
  {
    "text": "Following Corticosteroid Therapeutic Failure: A Case Report.",
    "entities": []
  },
  {
    "text": "(2)Pulmonology, Christus Muguerza Chihuahua / University of Monterrey,",
    "entities": [
      {
        "text": "Christus",
        "label": "ORG"
      },
      {
        "text": "Muguerza Chihuahua / University of Monterrey",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Chronic eosinophilic pneumonia is a rare idiopathic disease characterized by",
    "entities": []
  },
  {
    "text": "eosinophilic infiltrates in the alveoli and interstitial lung spaces. There are",
    "entities": []
  },
  {
    "text": "no specific diagnostic tests for this condition, but it is suspected in patients",
    "entities": []
  },
  {
    "text": "presenting with dyspnea, cough, a tomographic pattern of consolidations,",
    "entities": []
  },
  {
    "text": "peripheral ground-glass opacities, and peripheral eosinophilia. This report",
    "entities": []
  },
  {
    "text": "presents the case of a male patient with chronic eosinophilic pneumonia that was",
    "entities": []
  },
  {
    "text": "Conflict of interest statement: Human subjects: Consent for treatment and open",
    "entities": []
  },
  {
    "text": "access publication was obtained or waived by all participants in this study.",
    "entities": []
  },
  {
    "text": "Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all",
    "entities": [
      {
        "text": "ICMJE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "authors declare the following: Payment/services info: All authors have declared",
    "entities": []
  },
  {
    "text": "that no financial support was received from any organization for the submitted",
    "entities": []
  },
  {
    "text": "work. Financial relationships: All authors have declared that they have no",
    "entities": []
  },
  {
    "text": "financial relationships at present or within the previous three years with any",
    "entities": [
      {
        "text": "the previous three years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "organizations that might have an interest in the submitted work. Other",
    "entities": []
  },
  {
    "text": "relationships: All authors have declared that there are no other relationships",
    "entities": []
  },
  {
    "text": "or activities that could appear to have influenced the submitted work.",
    "entities": []
  },
  {
    "text": "29. Pulm Med. 2025 Jul 7;2025:7675935. doi: 10.1155/pm/7675935. eCollection 2025.",
    "entities": [
      {
        "text": "29",
        "label": "CARDINAL"
      },
      {
        "text": "10.1155",
        "label": "CARDINAL"
      },
      {
        "text": "2025",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Relation of Changes in PEF and FEV(1) During Salbutamol-Induced Bronchodilation",
    "entities": [
      {
        "text": "Relation of Changes",
        "label": "ORG"
      },
      {
        "text": "PEF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(1)Faculty of Medicine and Health Technology, Tampere University, Tampere,",
    "entities": [
      {
        "text": "Medicine and Health Technology",
        "label": "ORG"
      },
      {
        "text": "Tampere University",
        "label": "ORG"
      },
      {
        "text": "Tampere",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)Department of Clinical Physiology and Nuclear Medicine, Tampere University",
    "entities": [
      {
        "text": "Clinical Physiology and Nuclear Medicine",
        "label": "ORG"
      },
      {
        "text": "Tampere University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Hospital, Tampere, Finland.",
    "entities": [
      {
        "text": "Tampere",
        "label": "GPE"
      },
      {
        "text": "Finland",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Allergy Centre, Tampere University Hospital, Tampere, Finland.",
    "entities": [
      {
        "text": "Centre, Tampere University Hospital",
        "label": "ORG"
      },
      {
        "text": "Tampere",
        "label": "GPE"
      },
      {
        "text": "Finland",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Asthma diagnosis can be confirmed by observing significant bronchodilator",
    "entities": []
  },
  {
    "text": "response (BDR) through peak expiratory flow (PEF) at home or forced expiratory",
    "entities": [
      {
        "text": "BDR",
        "label": "ORG"
      },
      {
        "text": "PEF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "volume in 1 s (FEV1) via spirometry in a clinical setting. We aimed to use the",
    "entities": [
      {
        "text": "1",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "administration of salbutamol after a methacholine challenge test as a model of",
    "entities": [
      {
        "text": "salbutamol",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "bronchodilation to study how accurately the change in PEF predicts improvement",
    "entities": [
      {
        "text": "PEF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "in lung function, as defined by an increase in FEV1. We analyzed 869 adult",
    "entities": [
      {
        "text": "FEV1",
        "label": "GPE"
      },
      {
        "text": "869",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "patients who were administered salbutamol after a methacholine challenge. To",
    "entities": []
  },
  {
    "text": "compare relative changes in PEF and FEV1 during bronchodilation, we used",
    "entities": [
      {
        "text": "PEF",
        "label": "ORG"
      },
      {
        "text": "FEV1",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "regression analysis and constructed a Bland and Altman plot. ROC analysis,",
    "entities": [
      {
        "text": "Bland",
        "label": "GPE"
      },
      {
        "text": "Altman",
        "label": "ORG"
      },
      {
        "text": "ROC",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "sensitivity, specificity, positive and negative predictive values, and kappa",
    "entities": []
  },
  {
    "text": "coefficient assessed how precisely increases in PEF detected a 12% and 0.2-L",
    "entities": [
      {
        "text": "PEF",
        "label": "ORG"
      },
      {
        "text": "12%",
        "label": "PERCENT"
      },
      {
        "text": "0.2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "improvement in FEV1. The average relative increase in FEV1 was significantly",
    "entities": [
      {
        "text": "FEV1",
        "label": "GPE"
      },
      {
        "text": "FEV1",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "greater than that in PEF. The area under the curve in the ROC analysis was 0.844",
    "entities": [
      {
        "text": "PEF",
        "label": "ORG"
      },
      {
        "text": "ROC",
        "label": "GPE"
      },
      {
        "text": "0.844",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "for PEF change to detect a 12% and 0.2-L increase in FEV1. The kappa values for",
    "entities": [
      {
        "text": "PEF",
        "label": "ORG"
      },
      {
        "text": "12%",
        "label": "PERCENT"
      },
      {
        "text": "0.2",
        "label": "CARDINAL"
      },
      {
        "text": "FEV1",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "changes in PEF and FEV1 ranged from fair to moderate. BDR detected by the",
    "entities": [
      {
        "text": "PEF",
        "label": "ORG"
      },
      {
        "text": "FEV1",
        "label": "GPE"
      },
      {
        "text": "BDR",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "recommended 15% and 60 L/min cut-off for PEF identified less than half of true",
    "entities": [
      {
        "text": "15%",
        "label": "PERCENT"
      },
      {
        "text": "60",
        "label": "CARDINAL"
      },
      {
        "text": "PEF",
        "label": "ORG"
      },
      {
        "text": "less than half",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "positives, while a 10% cut-off correctly identified close to 75% of them. PEF",
    "entities": [
      {
        "text": "10%",
        "label": "PERCENT"
      },
      {
        "text": "75%",
        "label": "PERCENT"
      },
      {
        "text": "PEF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "increase is not a reliable measure of BDR in comparison to FEV1 increase, and a",
    "entities": [
      {
        "text": "BDR",
        "label": "ORG"
      },
      {
        "text": "FEV1",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "10% improvement in PEF was the least inaccurate cut-off. Substituting the PEF",
    "entities": [
      {
        "text": "10%",
        "label": "PERCENT"
      },
      {
        "text": "PEF",
        "label": "ORG"
      },
      {
        "text": "PEF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "meter with a handheld spirometer should be further investigated for asthma home",
    "entities": []
  },
  {
    "text": "Copyright \u00a9 2025 Leon L. Csonka et al. Pulmonary Medicine published by John",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Leon L. Csonka",
        "label": "PERSON"
      },
      {
        "text": "John\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Wiley & Sons Ltd.",
    "entities": [
      {
        "text": "Wiley & Sons Ltd.",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "PMID: 40661699 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40661699",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: The authors declare no conflicts of interest.",
    "entities": []
  },
  {
    "text": "Fe(2)O(3) nanoparticles disrupt microstructure and reduce the viscoelasticity of",
    "entities": []
  },
  {
    "text": "simulated asthma airway mucus for potential airway mucus clearance applications.",
    "entities": []
  },
  {
    "text": "(1)Changzhou Key Laboratory of Respiratory Medical Engineering, Institute of",
    "entities": [
      {
        "text": "1)Changzhou",
        "label": "CARDINAL"
      },
      {
        "text": "Key Laboratory of Respiratory Medical Engineering",
        "label": "ORG"
      },
      {
        "text": "Institute of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Biomedical Engineering and Health Sciences, School of Medical and Health",
    "entities": [
      {
        "text": "Biomedical Engineering",
        "label": "ORG"
      },
      {
        "text": "Health Sciences",
        "label": "ORG"
      },
      {
        "text": "School of Medical and Health\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Engineering, Changzhou University, Changzhou, China.",
    "entities": [
      {
        "text": "Changzhou University",
        "label": "ORG"
      },
      {
        "text": "Changzhou",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Respiratory and Critical Care Medicine, The Affiliated",
    "entities": [
      {
        "text": "Respiratory and Critical Care Medicine",
        "label": "ORG"
      },
      {
        "text": "Affiliated",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou,",
    "entities": [
      {
        "text": "Changzhou",
        "label": "GPE"
      },
      {
        "text": "2",
        "label": "CARDINAL"
      },
      {
        "text": "Changzhou",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Wenzhou Key Laboratory of Biomaterials and Engineering, Wenzhou Institute,",
    "entities": [
      {
        "text": "3)Wenzhou",
        "label": "CARDINAL"
      },
      {
        "text": "Key Laboratory of Biomaterials",
        "label": "ORG"
      },
      {
        "text": "Engineering",
        "label": "GPE"
      },
      {
        "text": "Wenzhou Institute",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University of Chinese Academy of Sciences, Wenzhou, China.",
    "entities": [
      {
        "text": "University of Chinese Academy of Sciences",
        "label": "ORG"
      },
      {
        "text": "Wenzhou",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Fe2O3 nanoparticles have been developed as carriers to transport drugs through",
    "entities": []
  },
  {
    "text": "airway mucus (AM); however, their impacts on the rheological properties of AM,",
    "entities": []
  },
  {
    "text": "especially in disease states, are unknown. In this study, we investigated the",
    "entities": []
  },
  {
    "text": "abilities of Fe2O3 nanoparticles dispersed in various media to alter the",
    "entities": []
  },
  {
    "text": "microstructure and rheological behaviors of simulated asthmatic AM. Here, the",
    "entities": []
  },
  {
    "text": "simulated AM was prepared via reconstituted mucins and other components in a",
    "entities": []
  },
  {
    "text": "composition resembling that of human AM reported in asthma, followed by",
    "entities": []
  },
  {
    "text": "treatment with Fe2O3 nanoparticles before and after curing. Subsequently, the AM",
    "entities": []
  },
  {
    "text": "samples treated with and without Fe2O3 nanoparticles were examined for their",
    "entities": []
  },
  {
    "text": "microstructures by optical immunofluorescence microscopy and for the rheological",
    "entities": []
  },
  {
    "text": "behaviors via steady-state and dynamic rotational rheometry. The results",
    "entities": []
  },
  {
    "text": "indicate that the Fe2O3 nanoparticles disrupt the mucus microstructure by",
    "entities": []
  },
  {
    "text": "inducing protein aggregation to increase the pore size and fiber diameter of the",
    "entities": []
  },
  {
    "text": "AM. However, the Fe2O3 nanoparticles significantly reduced the magnitudes of the",
    "entities": []
  },
  {
    "text": "viscoelastic properties of AM, including apparent viscosity, yield stress, and",
    "entities": []
  },
  {
    "text": "dynamic viscoelastic modulus. Although the addition of Fe2O3 nanoparticles",
    "entities": []
  },
  {
    "text": "before and after curing of AM appeared to produce similar effects, these effects",
    "entities": []
  },
  {
    "text": "had greater magnitudes when the nanoparticles were added before curing. The",
    "entities": []
  },
  {
    "text": "effects were also dependent on the concentration and surface property determined",
    "entities": []
  },
  {
    "text": "by the dispersion medium of the nanoparticles; accordingly, Fe2O3 nanoparticles",
    "entities": []
  },
  {
    "text": "dispersed at a concentration of 0.4 mg/mL in H2O were the most potent at",
    "entities": [
      {
        "text": "0.4 mg/mL",
        "label": "QUANTITY"
      },
      {
        "text": "H2O",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "altering the microstructure and rheology of AM, producing better results than",
    "entities": []
  },
  {
    "text": "the concentration of 0.4 mg/mL of the conventional mucolytic chymotrypsin.",
    "entities": [
      {
        "text": "0.4 mg/mL",
        "label": "QUANTITY"
      }
    ]
  },
  {
    "text": "Furthermore, tests on mucus samples collected from asthmatic patients showed",
    "entities": []
  },
  {
    "text": "similar results to those obtained with the simulated AM. Together, these",
    "entities": []
  },
  {
    "text": "findings suggest that Fe2O3 nanoparticles per se are useful as not only drug",
    "entities": []
  },
  {
    "text": "carriers but also expectorant agents for AM clearance therapy; they may also be",
    "entities": []
  },
  {
    "text": "more beneficial than pharmaceutical mucolytics owing to their wide availability",
    "entities": []
  },
  {
    "text": "and high biocompatibility.",
    "entities": []
  },
  {
    "text": "31. Open Med (Wars). 2025 Jul 8;20(1):20251177. doi: 10.1515/med-2025-1177.",
    "entities": [
      {
        "text": "31",
        "label": "CARDINAL"
      },
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "10.1515/med-2025-1177",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Causal relationship between asthma and ankylosing spondylitis: A bidirectional",
    "entities": []
  },
  {
    "text": "two-sample univariable and multivariable Mendelian randomization study.",
    "entities": [
      {
        "text": "two",
        "label": "CARDINAL"
      },
      {
        "text": "Mendelian",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "(1)Department of Respiratory and Critical Care Medicine, Guangzhou University of",
    "entities": [
      {
        "text": "Respiratory and Critical Care Medicine",
        "label": "ORG"
      },
      {
        "text": "Guangzhou University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Chinese Medicine, Guangzhou, Guangdong Province, 510000, China.",
    "entities": [
      {
        "text": "Chinese Medicine",
        "label": "ORG"
      },
      {
        "text": "Guangzhou",
        "label": "GPE"
      },
      {
        "text": "Guangdong Province",
        "label": "GPE"
      },
      {
        "text": "510000",
        "label": "DATE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Traumatology, Guangzhou University of Chinese Medicine,",
    "entities": [
      {
        "text": "Traumatology",
        "label": "ORG"
      },
      {
        "text": "Guangzhou University of Chinese Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(3)Department of Respiratory and Critical Care Medicine, Guangzhou University of",
    "entities": [
      {
        "text": "Respiratory and Critical Care Medicine",
        "label": "ORG"
      },
      {
        "text": "Guangzhou University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Chinese Medicine, 16 Jichang Road, Baiyun District, Guangzhou, Guangdong",
    "entities": [
      {
        "text": "Chinese Medicine",
        "label": "ORG"
      },
      {
        "text": "16",
        "label": "CARDINAL"
      },
      {
        "text": "Guangzhou",
        "label": "GPE"
      },
      {
        "text": "Guangdong",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Province, 510000, China.",
    "entities": [
      {
        "text": "510000",
        "label": "DATE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "BACKGROUND: Previous research has indicated a possible association between",
    "entities": []
  },
  {
    "text": "asthma and ankylosing spondylitis (AS).",
    "entities": []
  },
  {
    "text": "METHODS: We pinpointed single nucleotide polymorphisms linked to various forms",
    "entities": []
  },
  {
    "text": "of asthma and AS, employing them as instrumental variables for a bidirectional",
    "entities": []
  },
  {
    "text": "two-sample Mendelian randomization (TSMR) analysis. Our TSMR analysis focused on",
    "entities": [
      {
        "text": "two",
        "label": "CARDINAL"
      },
      {
        "text": "Mendelian",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "European populations to minimize racial confounding. Multivariate adjustments",
    "entities": [
      {
        "text": "European",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "for body mass index (BMI), smoking, and alcohol use were performed to control",
    "entities": [
      {
        "text": "BMI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "for confounders. Colocalization analysis was used to validate MR findings and",
    "entities": []
  },
  {
    "text": "explore genetic links between asthma and AS.",
    "entities": []
  },
  {
    "text": "RESULTS: Individuals with asthma and eosinophilic asthma exhibited a relatively",
    "entities": []
  },
  {
    "text": "higher risk of AS (asthma: OR 1.31, 95% CI 1.07-1.62, P = 0.008; eosinophilic",
    "entities": [
      {
        "text": "1.31",
        "label": "DATE"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "1.07-1.62",
        "label": "CARDINAL"
      },
      {
        "text": "0.008",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "asthma: OR 1.24, 95% CI 1.005-1.544, P = 0.044). Allergic asthma,",
    "entities": [
      {
        "text": "1.24",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "1.005-1.544",
        "label": "PRODUCT"
      },
      {
        "text": "0.044",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "childhood-onset asthma, and obesity-related asthma showed no causal relationship",
    "entities": []
  },
  {
    "text": "with AS (allergic asthma: IVW P = 0.27; childhood-onset asthma: IVW P = 0.66;",
    "entities": [
      {
        "text": "0.27",
        "label": "CARDINAL"
      },
      {
        "text": "0.66",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "obesity-related asthma: IVW P = 0.53). After adjusting for cigarette smoking,",
    "entities": [
      {
        "text": "0.53",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "alcohol consumption, and BMI, the results supported a direct causal effect of",
    "entities": [
      {
        "text": "BMI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "asthma on the increased risk of AS onset (IVW P = 0.001).",
    "entities": [
      {
        "text": "0.001",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "CONCLUSION: This study revealed that a positive causal connection between",
    "entities": []
  },
  {
    "text": "asthma, specifically eosinophilic asthma, and AS.",
    "entities": []
  },
  {
    "text": "\u00a9 2025 the author(s), published by De Gruyter.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "De Gruyter",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Conflict of interest: The authors declare that",
    "entities": []
  },
  {
    "text": "the research was conducted in the absence of any commercial or financial",
    "entities": []
  },
  {
    "text": "relationships that could be construed as a potential conflict of interest.",
    "entities": []
  },
  {
    "text": "32. Geriatr Gerontol Int. 2025 Jul 14. doi: 10.1111/ggi.70123. Online ahead of",
    "entities": [
      {
        "text": "32",
        "label": "CARDINAL"
      },
      {
        "text": "Gerontol Int",
        "label": "PERSON"
      },
      {
        "text": "14",
        "label": "CARDINAL"
      },
      {
        "text": "10.1111",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Impact of sarcopenia on mortality risk and sustained peak expiratory flow",
    "entities": []
  },
  {
    "text": "changes in an asthmatic population: A 7-year longitudinal cohort study.",
    "entities": [
      {
        "text": "7-year",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "(1)Department of Respiratory and Critical Care Medicine, The First Affiliated",
    "entities": [
      {
        "text": "Respiratory and Critical Care Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Hospital of Shantou University Medical College, Shantou, China.",
    "entities": [
      {
        "text": "Hospital of Shantou University Medical College",
        "label": "ORG"
      },
      {
        "text": "Shantou",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Cardiology, The First Affiliated Hospital of Shantou University",
    "entities": [
      {
        "text": "Cardiology",
        "label": "ORG"
      },
      {
        "text": "The First Affiliated Hospital of Shantou University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Medical College, Shantou, China.",
    "entities": [
      {
        "text": "Medical College",
        "label": "ORG"
      },
      {
        "text": "Shantou",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "AIM: Sarcopenia causes death in the general population, but its relationship",
    "entities": [
      {
        "text": "AIM",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "with asthma-specific populations remains unknown. This study aimed to",
    "entities": []
  },
  {
    "text": "investigate the relationship between sarcopenia and mortality risk, as well as",
    "entities": []
  },
  {
    "text": "lung function in asthmatic population.",
    "entities": []
  },
  {
    "text": "METHODS: All participants in this study were drawn from the China Health and",
    "entities": [
      {
        "text": "the China Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Retirement Longitudinal Study, which primarily involved longitudinal data for",
    "entities": []
  },
  {
    "text": "the period 2011-2018. All participants were asthmatic and divided into",
    "entities": [
      {
        "text": "2011-2018",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "sarcopenia and non-sarcopenia groups. The Kaplan-Meier method was used to",
    "entities": [
      {
        "text": "Kaplan",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "calculate the cumulative mortality rate in each group. Cox proportional hazards",
    "entities": []
  },
  {
    "text": "and linear mixed models were used to assess the effect of sarcopenia on",
    "entities": [
      {
        "text": "linear",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "mortality risk and peak expiratory flow in an asthmatic population.",
    "entities": []
  },
  {
    "text": "RESULTS: A total of 606 participants were included in the baseline analysis, of",
    "entities": [
      {
        "text": "606",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "which 32.5% had sarcopenia. During the 7-year follow-up period, the cumulative",
    "entities": [
      {
        "text": "32.5%",
        "label": "PERCENT"
      },
      {
        "text": "7-year",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "mortality rates were 29.9% (59/197) and 13.7% (56/409) in the sarcopenic and",
    "entities": [
      {
        "text": "29.9%",
        "label": "PERCENT"
      },
      {
        "text": "59/197",
        "label": "CARDINAL"
      },
      {
        "text": "13.7%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "non-sarcopenic groups, respectively. Survival analysis showed that the asthmatic",
    "entities": []
  },
  {
    "text": "population in the sarcopenia group showed a higher risk of death than the",
    "entities": []
  },
  {
    "text": "non-sarcopenia group (HR 2.49, 95% CI 1.74-3.57, P < 0.001). In the subgroup",
    "entities": [
      {
        "text": "2.49",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "1.74-3.57",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "analyses, there was an interaction between the effects of cardiovascular disease",
    "entities": []
  },
  {
    "text": "and sarcopenia on the mortality risk of asthma. Linear mixed modeling results",
    "entities": [
      {
        "text": "Linear",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "showed that asthmatics with sarcopenia had lower lung function (P < 0.001), and",
    "entities": []
  },
  {
    "text": "that this effect did not change over time.",
    "entities": []
  },
  {
    "text": "CONCLUSIONS: The results showed a significant association between sarcopenia and",
    "entities": []
  },
  {
    "text": "higher mortality events and lower lung function in the asthmatic population.",
    "entities": []
  },
  {
    "text": "Geriatr Gerontol Int 2025; \u2022\u2022: \u2022\u2022-\u2022\u2022.",
    "entities": [
      {
        "text": "Gerontol Int",
        "label": "PERSON"
      },
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "\u2022\u2022",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "\u00a9 2025 Japan Geriatrics Society.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Japan",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "33. J Asthma. 2025 Jul 14:1-10. doi: 10.1080/02770903.2025.2531493. Online ahead",
    "entities": [
      {
        "text": "33",
        "label": "CARDINAL"
      },
      {
        "text": "2025",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "of print.",
    "entities": []
  },
  {
    "text": "Inhaled Muscarinic Antagonists during Pregnancy in Women with Asthma: Case",
    "entities": []
  },
  {
    "text": "Series from a Dutch Prospective Observational Cohort Study.",
    "entities": [
      {
        "text": "Series",
        "label": "EVENT"
      },
      {
        "text": "Dutch",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "(1)Department of pulmonology, Leiden University Medical Center, Leiden, the",
    "entities": [
      {
        "text": "Leiden University Medical Center",
        "label": "ORG"
      },
      {
        "text": "Leiden",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of pulmonology, Haga Teaching Hospital, The Hague, the",
    "entities": [
      {
        "text": "2)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Haga Teaching Hospital",
        "label": "ORG"
      },
      {
        "text": "The Hague",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Department of pulmonology, Haaglanden Medical Center, The Hague, the",
    "entities": [
      {
        "text": "Haaglanden Medical Center",
        "label": "ORG"
      },
      {
        "text": "The Hague",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Department of pharmacy, Haga Teaching Hospital, The Hague, the Netherlands.",
    "entities": [
      {
        "text": "Haga Teaching Hospital",
        "label": "ORG"
      },
      {
        "text": "The Hague",
        "label": "GPE"
      },
      {
        "text": "Netherlands",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Royal Dutch Pharmacists Association, Special Interest Group Pulmonary",
    "entities": [
      {
        "text": "5)Royal",
        "label": "CARDINAL"
      },
      {
        "text": "Dutch Pharmacists Association",
        "label": "ORG"
      },
      {
        "text": "Special Interest Group Pulmonary",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Diseases, The Hague, The Netherlands.",
    "entities": [
      {
        "text": "The Hague",
        "label": "GPE"
      },
      {
        "text": "The Netherlands",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)Department of pulmonology, Deventer Hospital, Deventer, The Netherlands.",
    "entities": [
      {
        "text": "6)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Deventer Hospital",
        "label": "ORG"
      },
      {
        "text": "The Netherlands",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "A large proportion of women with asthma experience worsening of asthma during",
    "entities": []
  },
  {
    "text": "pregnancy. Well-controlled asthma during pregnancy decreases risk of maternal",
    "entities": []
  },
  {
    "text": "and foetal complications. Long-acting muscarinic antagonists (LAMA) are part of",
    "entities": []
  },
  {
    "text": "treatment guidelines for poorly controlled asthma. There are no clinical safety",
    "entities": []
  },
  {
    "text": "data available on LAMA and short-acting muscarinic antagonists (SAMA) use in",
    "entities": [
      {
        "text": "SAMA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "pregnancy. The aim was to evaluate asthma control and pregnancy outcomes in",
    "entities": []
  },
  {
    "text": "pregnant women with asthma using muscarinic antagonists.A prospective",
    "entities": []
  },
  {
    "text": "observational cohort of pregnant women with asthma referred to the asthma",
    "entities": []
  },
  {
    "text": "pregnancy outpatient clinic of the Haga Hospital, between 2018 and 2023, was",
    "entities": [
      {
        "text": "the Haga Hospital",
        "label": "ORG"
      },
      {
        "text": "between 2018 and 2023",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "obtained and retrospectively analysed. Women using muscarinic antagonists were",
    "entities": []
  },
  {
    "text": "included. Outcomes were asthma control, asthma exacerbations and pregnancy",
    "entities": []
  },
  {
    "text": "outcomes.Fourteen (8.9%) of 158 recruited pregnant women used muscarinic",
    "entities": [
      {
        "text": "Fourteen",
        "label": "CARDINAL"
      },
      {
        "text": "8.9%",
        "label": "PERCENT"
      },
      {
        "text": "158",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "antagonists. Most women had poor asthma control with a mean (\u00b1SD) asthma control",
    "entities": []
  },
  {
    "text": "questionnaire (ACQ) score of 2.4 (\u00b11.3). Six (43%) women experienced an asthma",
    "entities": [
      {
        "text": "ACQ",
        "label": "ORG"
      },
      {
        "text": "2.4",
        "label": "CARDINAL"
      },
      {
        "text": "Six",
        "label": "CARDINAL"
      },
      {
        "text": "43%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "exacerbation. One woman using LAMA throughout pregnancy had pre-eclampsia",
    "entities": [
      {
        "text": "One",
        "label": "CARDINAL"
      },
      {
        "text": "pre-eclampsia",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "resulting in preterm birth, low birth weight and neonatal hospitalization.",
    "entities": []
  },
  {
    "text": "Another child was born with low birth weight and was small for gestational age.",
    "entities": []
  },
  {
    "text": "Two women developed maternal fever.A minority of women with asthma used",
    "entities": [
      {
        "text": "Two",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "muscarinic antagonists during pregnancy. Despite the use of muscarinic",
    "entities": []
  },
  {
    "text": "antagonists, asthma control remained poor during pregnancy. There were no major",
    "entities": []
  },
  {
    "text": "adverse pregnancy outcomes or congenital malformations in this case series.",
    "entities": []
  },
  {
    "text": "Since well-controlled asthma during pregnancy leads to fewer complications,",
    "entities": []
  },
  {
    "text": "pregnant woman with poorly controlled asthma on ICS/LABA should be encouraged to",
    "entities": [
      {
        "text": "ICS/LABA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "continue add-on asthma medication.",
    "entities": []
  },
  {
    "text": "The impact of m6A methyltransferase METTL3 on airway remodeling in bronchial",
    "entities": [
      {
        "text": "m6A",
        "label": "PRODUCT"
      },
      {
        "text": "METTL3",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "(1)Department of Respiratory and Critical Care Medicine, The Second Affiliated",
    "entities": [
      {
        "text": "Respiratory and Critical Care Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Hospital of Guilin Medical University, Guilin, China.",
    "entities": [
      {
        "text": "Guilin Medical University",
        "label": "ORG"
      },
      {
        "text": "Guilin",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)The Laboratory of Respiratory Disease, Affiliated Hospital of Guilin Medical",
    "entities": [
      {
        "text": "2)The Laboratory of Respiratory Disease",
        "label": "ORG"
      },
      {
        "text": "Affiliated Hospital of Guilin Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University, Guilin, China.",
    "entities": [
      {
        "text": "Guilin",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Laboratory of Basic Research on Respiratory Diseases, Guangxi Health",
    "entities": [
      {
        "text": "Basic Research on Respiratory Diseases",
        "label": "ORG"
      },
      {
        "text": "Guangxi Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Commission, Guilin Medical University, Guilin, China.",
    "entities": [
      {
        "text": "Guilin Medical University",
        "label": "ORG"
      },
      {
        "text": "Guilin",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Guangxi Clinical Research Center for Diabetes and Metabolic Diseases, Guangxi",
    "entities": [
      {
        "text": "Clinical Research Center for Diabetes and",
        "label": "ORG"
      },
      {
        "text": "Metabolic Diseases",
        "label": "ORG"
      },
      {
        "text": "Guangxi",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Health Commission Key Laboratory of Glucose and Lipid Metabolism Disorders, The",
    "entities": [
      {
        "text": "Health Commission Key Laboratory",
        "label": "ORG"
      },
      {
        "text": "Glucose and Lipid Metabolism Disorders",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Second Affiliated Hospital of Guilin Medical University, Guilin, China.",
    "entities": [
      {
        "text": "Second Affiliated Hospital of Guilin Medical University",
        "label": "ORG"
      },
      {
        "text": "Guilin",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Guangxi Key Laboratory of Metabolic Reprogramming and Intelligent Medical",
    "entities": [
      {
        "text": "Key Laboratory",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Engineering for Chronic Diseases, The Key Laboratory of Respiratory Diseases,",
    "entities": [
      {
        "text": "The Key Laboratory of Respiratory Diseases",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Education Department of Guangxi Zhuang Autonomous Region, Guilin Medical",
    "entities": [
      {
        "text": "Education Department",
        "label": "ORG"
      },
      {
        "text": "Guilin Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "BACKGROUND: Methyltransferase-like 3 (METTL3) is known to play a role in asthma",
    "entities": [
      {
        "text": "3",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "airway remodeling and cell proliferation. Adenylate kinase 4 (AK4) regulates the",
    "entities": [
      {
        "text": "4",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "proliferation of pulmonary artery smooth muscle cells and exerts its effects",
    "entities": []
  },
  {
    "text": "through the protein kinase B (AKT) pathway. However, the role of METTL3 and",
    "entities": [
      {
        "text": "METTL3",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "AK4-AKT in bronchial smooth muscle cells remains unclear.",
    "entities": [
      {
        "text": "AK4-AKT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "METHODS: Systemic METTL3 knockout mice and a mouse model of asthma were",
    "entities": []
  },
  {
    "text": "established. Airway remodeling was assessed using pulmonary function tests,",
    "entities": []
  },
  {
    "text": "histopathological staining, and Western blot analysis. RNA sequencing (RNA-seq)",
    "entities": [
      {
        "text": "Western",
        "label": "NORP"
      },
      {
        "text": "RNA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "was performed to detect changes in gene expression following METTL3 knockdown.",
    "entities": [
      {
        "text": "METTL3",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "The 5-Ethynyl-2'-deoxyuridine (EdU) assay was used to evaluate cell",
    "entities": [
      {
        "text": "5-Ethynyl-2'-deoxyuridine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "proliferation. Finally, the expression levels of relevant proteins were",
    "entities": []
  },
  {
    "text": "validated by Western blotting.",
    "entities": []
  },
  {
    "text": "RESULTS: Compared with the control model group, the METTL3 knockout group showed",
    "entities": [
      {
        "text": "METTL3",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "significantly reduced inflammatory cell infiltration, decreased collagen fiber",
    "entities": []
  },
  {
    "text": "deposition, and attenuated airway smooth muscle hyperplasia. RNA-seq revealed",
    "entities": []
  },
  {
    "text": "that the expression of numerous proliferation-related genes, including AK4, was",
    "entities": [
      {
        "text": "AK4",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "upregulated following METTL3 knockdown. Kyoto Encyclopedia of Genes and Genomes",
    "entities": [
      {
        "text": "METTL3",
        "label": "NORP"
      },
      {
        "text": "Kyoto Encyclopedia of",
        "label": "ORG"
      },
      {
        "text": "Genes and Genomes\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(KEGG) analysis indicated that these genes were primarily enriched in the",
    "entities": [
      {
        "text": "KEGG",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway. The EdU assay",
    "entities": [
      {
        "text": "3",
        "label": "CARDINAL"
      },
      {
        "text": "EdU",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "demonstrated that METTL3 knockdown inhibited cell proliferation. Western blot",
    "entities": [
      {
        "text": "METTL3",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "validation showed increased AK4 expression in lung tissues of the METTL3",
    "entities": [
      {
        "text": "METTL3",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "knockout group compared to the control group, while phosphorylated AKT (p-AKT)",
    "entities": [
      {
        "text": "AKT",
        "label": "ORG"
      },
      {
        "text": "p-AKT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "levels were reduced.",
    "entities": []
  },
  {
    "text": "CONCLUSION: METTL3 knockout inhibits airway smooth muscle hyperplasia and",
    "entities": []
  },
  {
    "text": "alleviates airway remodeling in asthma. This effect may be mediated through the",
    "entities": []
  },
  {
    "text": "regulation of AK4 and the AKT signaling pathway.",
    "entities": [
      {
        "text": "AK4",
        "label": "ORG"
      },
      {
        "text": "AKT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "COVID-19 vaccination status and the risk of developing lung diseases: A",
    "entities": [
      {
        "text": "COVID-19",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(1)Department of Respiratory Medicine, Nantong Third People's Hospital,",
    "entities": [
      {
        "text": "Respiratory Medicine",
        "label": "ORG"
      },
      {
        "text": "Nantong Third People's Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Affiliated Nantong Hospital 3 of Nantong University, Nantong, Jiangsu, China.",
    "entities": [
      {
        "text": "Nantong Hospital 3",
        "label": "ORG"
      },
      {
        "text": "Nantong University",
        "label": "ORG"
      },
      {
        "text": "Nantong",
        "label": "GPE"
      },
      {
        "text": "Jiangsu",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Emergency Medicine, Shanghai Eighth People's Hospital,",
    "entities": [
      {
        "text": "Emergency Medicine",
        "label": "ORG"
      },
      {
        "text": "Shanghai Eighth People's Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(3)Department of Respiratory and Critical Care Medicine, Shanghai Sixth People's",
    "entities": [
      {
        "text": "Respiratory and Critical Care Medicine",
        "label": "ORG"
      },
      {
        "text": "Shanghai",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,",
    "entities": [
      {
        "text": "Hospital Affiliated",
        "label": "FAC"
      },
      {
        "text": "Shanghai",
        "label": "GPE"
      },
      {
        "text": "Tong University School of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)Eye Institute, Affiliated Hospital of Nantong University, Medical School of",
    "entities": [
      {
        "text": "4)Eye Institute",
        "label": "ORG"
      },
      {
        "text": "Affiliated Hospital",
        "label": "ORG"
      },
      {
        "text": "Nantong University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Recent studies have suggested an increased incidence of various lung diseases",
    "entities": []
  },
  {
    "text": "following COVID-19 vaccination. However, causal relationships have not been",
    "entities": [
      {
        "text": "COVID-19",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "definitively established. We conducted a two-sample Mendelian randomization (MR)",
    "entities": [
      {
        "text": "two",
        "label": "CARDINAL"
      },
      {
        "text": "Mendelian",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "study using publicly available genome-wide association study data to investigate",
    "entities": []
  },
  {
    "text": "potential causal relationships between COVID-19 vaccination status as the",
    "entities": [
      {
        "text": "potential causal",
        "label": "PERSON"
      },
      {
        "text": "COVID-19",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "exposure and 14 different lung diseases as outcomes. The analytical methods",
    "entities": [
      {
        "text": "14",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "included random-effects inverse-variance weighting, MR Egger, and weighted",
    "entities": [
      {
        "text": "Egger",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "median, with additional heterogeneity and sensitivity analyses. Seven",
    "entities": [
      {
        "text": "Seven",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "instrumental variables for exposure were selected (P < 5 \u00d7 10-8). MR analyses",
    "entities": [
      {
        "text": "5",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "revealed that COVID-19 vaccination status was not associated with an increased",
    "entities": [
      {
        "text": "COVID-19",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "risk of developing overall lung cancer (P = .78), lung adenocarcinoma",
    "entities": []
  },
  {
    "text": "(P = .173), asthma (P = .905), chronic obstructive pulmonary disease,",
    "entities": [
      {
        "text": ".173",
        "label": "CARDINAL"
      },
      {
        "text": ".905",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "bronchiectasis (P = .669), forced vital capacity (FVC), forced expiratory volume",
    "entities": [
      {
        "text": ".669",
        "label": "CARDINAL"
      },
      {
        "text": "FVC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "in 1 second/FVC (P = .794), pneumonia (P = .282), idiopathic pulmonary fibrosis",
    "entities": [
      {
        "text": "1 second",
        "label": "TIME"
      },
      {
        "text": ".794",
        "label": "CARDINAL"
      },
      {
        "text": ".282",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "(P = .486), pulmonary embolism (P = .267), pneumothorax (P = .73), or",
    "entities": [
      {
        "text": ".486",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "sarcoidosis (P = .732). Evidence of heterogeneity was observed in the",
    "entities": [
      {
        "text": ".732",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "inverse-variance weighting model for overall lung cancer, chronic obstructive",
    "entities": []
  },
  {
    "text": "pulmonary disease, and FVC, whereas no indications of horizontal pleiotropy or",
    "entities": [
      {
        "text": "FVC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "significant heterogeneity were noted for other lung diseases. COVID-19",
    "entities": []
  },
  {
    "text": "vaccination does not appear to increase the risk of developing various lung",
    "entities": []
  },
  {
    "text": "diseases. These findings support the safety of COVID-19 vaccines in terms of",
    "entities": [
      {
        "text": "COVID-19",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "respiratory health, reinforcing their role in public health interventions and",
    "entities": []
  },
  {
    "text": "Copyright \u00a9 2025 the Author(s). Published by Wolters Kluwer Health, Inc.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Wolters Kluwer Health, Inc.",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "PMID: 40660535 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40660535",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: The authors have no funding and conflicts of",
    "entities": []
  },
  {
    "text": "36. Arch Public Health. 2025 Jul 14;83(1):186. doi: 10.1186/s13690-025-01675-4.",
    "entities": [
      {
        "text": "36",
        "label": "CARDINAL"
      },
      {
        "text": "Arch Public Health",
        "label": "ORG"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "14;83(1):186",
        "label": "CARDINAL"
      },
      {
        "text": "10.1186",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Chronic lung diseases (Asthma and COPD) among middle-aged and older populations",
    "entities": []
  },
  {
    "text": "in India: social, individual, and household determinants and their associations",
    "entities": [
      {
        "text": "India",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "with geriatric syndromes.",
    "entities": []
  },
  {
    "text": "(1)Department of Bio-statistics & Epidemiology, International Institute for",
    "entities": [
      {
        "text": "Bio-statistics & Epidemiology",
        "label": "ORG"
      },
      {
        "text": "International Institute",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Population Sciences, Mumbai, 400088, India. aditi325@gmail.com.",
    "entities": [
      {
        "text": "Population Sciences",
        "label": "ORG"
      },
      {
        "text": "Mumbai",
        "label": "GPE"
      },
      {
        "text": "400088",
        "label": "DATE"
      },
      {
        "text": "India",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Bio-statistics & Epidemiology, International Institute for",
    "entities": [
      {
        "text": "Bio-statistics & Epidemiology",
        "label": "ORG"
      },
      {
        "text": "International Institute",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Population Sciences, Mumbai, 400088, India.",
    "entities": [
      {
        "text": "Population Sciences",
        "label": "ORG"
      },
      {
        "text": "Mumbai",
        "label": "GPE"
      },
      {
        "text": "400088",
        "label": "DATE"
      },
      {
        "text": "India",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Division of Medical Research, SRM Medical College Hospital & Research Centre,",
    "entities": [
      {
        "text": "Medical Research",
        "label": "ORG"
      },
      {
        "text": "SRM Medical College Hospital & Research Centre",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "SRM Institute of Science and Technology, Kattankulathur, 603203, Tamil Nadu,",
    "entities": [
      {
        "text": "SRM Institute of Science and Technology",
        "label": "ORG"
      },
      {
        "text": "Kattankulathur",
        "label": "PERSON"
      },
      {
        "text": "603203",
        "label": "DATE"
      },
      {
        "text": "Tamil Nadu",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "BACKGROUND: India's ageing population presents new health challenges,",
    "entities": [
      {
        "text": "India",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "particularly the rising burden of lung diseases like Asthma and COPD among",
    "entities": [
      {
        "text": "Asthma",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "middle-aged and older adults. These conditions weaken individuals and heighten",
    "entities": [
      {
        "text": "heighten",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "the risk of geriatric complications. Understanding their interplay with",
    "entities": []
  },
  {
    "text": "socio-economic, demographic, and household factors is essential for informed",
    "entities": []
  },
  {
    "text": "public health interventions.",
    "entities": []
  },
  {
    "text": "OBJECTIVES AND METHODS: This study investigates the growing burden of Asthma and",
    "entities": [
      {
        "text": "OBJECTIVES",
        "label": "ORG"
      },
      {
        "text": "Asthma",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "COPD among Indian individuals aged 45 years and above using LASI Wave 1 data.",
    "entities": [
      {
        "text": "Indian",
        "label": "NORP"
      },
      {
        "text": "45 years",
        "label": "DATE"
      },
      {
        "text": "LASI Wave 1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Unadjusted prevalence was calculated across predictor variables. Poisson",
    "entities": [
      {
        "text": "Poisson",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "regression identified factors associated with Asthma and COPD, while logistic",
    "entities": [
      {
        "text": "Asthma",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "regression examined their unadjusted and adjusted associations with geriatric",
    "entities": []
  },
  {
    "text": "RESULTS: The study reveals that the prevalence of Asthma and COPD among",
    "entities": [
      {
        "text": "Asthma",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "individuals aged 45 years and above is 4.38% and 2.1%. It reveals distinct yet",
    "entities": [
      {
        "text": "45 years",
        "label": "DATE"
      },
      {
        "text": "4.38%",
        "label": "PERCENT"
      },
      {
        "text": "2.1%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "overlapping risk patterns for both Asthma and COPD. For both diseases, the risk",
    "entities": [
      {
        "text": "Asthma",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "increases significantly with age, particularly for those aged 60 years and",
    "entities": [
      {
        "text": "60 years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "above, and is higher among wealthier individuals and those belonging to SC, OBC,",
    "entities": [
      {
        "text": "SC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "or non-classified social groups. Women are less likely to suffer from both",
    "entities": []
  },
  {
    "text": "diseases, while discontinued smoking elevates the risk for both. Employment",
    "entities": []
  },
  {
    "text": "status influences both conditions differently, those currently working are less",
    "entities": []
  },
  {
    "text": "likely to have COPD and Asthma. Household factors such as the absence of a",
    "entities": [
      {
        "text": "Asthma",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "separate kitchen increase the risk for both diseases. Cooking on open fires and",
    "entities": []
  },
  {
    "text": "exposure to passive smoking significantly heighten the risk of COPD. Regional",
    "entities": [
      {
        "text": "COPD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "variations persist, with lower risk in the North-East and elevated risks in the",
    "entities": [
      {
        "text": "the North-East",
        "label": "LOC"
      }
    ]
  },
  {
    "text": "South. Both diseases show significant association with geriatric syndromes such",
    "entities": [
      {
        "text": "South",
        "label": "LOC"
      }
    ]
  },
  {
    "text": "as ADL (1.418 for Asthma and 1.424 for COPD), IADL (1.587 for Asthma and 1.542",
    "entities": [
      {
        "text": "ADL",
        "label": "ORG"
      },
      {
        "text": "1.418",
        "label": "CARDINAL"
      },
      {
        "text": "Asthma",
        "label": "ORG"
      },
      {
        "text": "1.424",
        "label": "CARDINAL"
      },
      {
        "text": "IADL",
        "label": "ORG"
      },
      {
        "text": "1.587",
        "label": "CARDINAL"
      },
      {
        "text": "Asthma",
        "label": "PRODUCT"
      },
      {
        "text": "1.542",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "for COPD), and Falls ((1.172 for Asthma and 1.320 for COPD)), after adjusting",
    "entities": [
      {
        "text": "Falls",
        "label": "PERSON"
      },
      {
        "text": "1.172",
        "label": "CARDINAL"
      },
      {
        "text": "Asthma",
        "label": "ORG"
      },
      {
        "text": "1.320",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "for various individual and household determinants.",
    "entities": []
  },
  {
    "text": "CONCLUSION: The study reveals complex relationships between social, individual",
    "entities": []
  },
  {
    "text": "and household factors, chronic lung diseases (Asthma and COPD), and age-related",
    "entities": []
  },
  {
    "text": "complications in India's older population.It highlights the need for targeted",
    "entities": [
      {
        "text": "India",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "treatments addressing both lung diseases and geriatric complications, guiding",
    "entities": []
  },
  {
    "text": "policymakers in framing healthcare policies to promote healthy aging in India's",
    "entities": [
      {
        "text": "India",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "diverse older population.",
    "entities": []
  },
  {
    "text": "DOI: 10.1186/s13690-025-01675-4",
    "entities": [
      {
        "text": "10.1186",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "participate: The study conducted a secondary analysis of identified data",
    "entities": []
  },
  {
    "text": "available in the public domain. Further ethics approval was not needed. Consent",
    "entities": []
  },
  {
    "text": "for publication: Not applicable. Competing interests: The authors declare no",
    "entities": []
  },
  {
    "text": "Expression analysis of the IL-23/Th17 pathway in children with rhinovirus",
    "entities": [
      {
        "text": "IL-23",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "infection.",
    "entities": []
  },
  {
    "text": "(1)Department of Infectious Diseases and Hepatology, Hangzhou Children's",
    "entities": [
      {
        "text": "Hepatology",
        "label": "GPE"
      },
      {
        "text": "Hangzhou Children's",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(2)Department of Infectious Diseases and Hepatology, Hangzhou Children's",
    "entities": [
      {
        "text": "Hepatology",
        "label": "GPE"
      },
      {
        "text": "Hangzhou Children's",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "BACKGROUND: The inflammatory response is critical in Human Rhinovirus (HRV)",
    "entities": [
      {
        "text": "Human Rhinovirus",
        "label": "ORG"
      },
      {
        "text": "HRV",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "infection-related acute asthma attacks, but its biological mechanisms remain",
    "entities": []
  },
  {
    "text": "unclear. The interleukin-23 (IL-23)/T helper 17 (Th17) pathway is a key",
    "entities": [
      {
        "text": "interleukin-23",
        "label": "DATE"
      },
      {
        "text": "IL-23)/T",
        "label": "ORG"
      },
      {
        "text": "17",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "inflammatory pathway that regulates abnormal inflammatory responses. Therefore,",
    "entities": []
  },
  {
    "text": "this study aims to investigate the role of the IL-23/Th17 pathway in the",
    "entities": [
      {
        "text": "IL-23",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "pathogenesis of wheezing in children with HRV infection by examining the",
    "entities": [
      {
        "text": "HRV",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "expression of signaling molecules within this pathway.",
    "entities": []
  },
  {
    "text": "METHOD: Seventy-five pediatric patients hospitalized with HRV infection and 21",
    "entities": [
      {
        "text": "METHOD",
        "label": "ORG"
      },
      {
        "text": "Seventy-five",
        "label": "CARDINAL"
      },
      {
        "text": "HRV",
        "label": "ORG"
      },
      {
        "text": "21",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "healthy children (as a control group) were randomly enrolled from Hangzhou",
    "entities": [
      {
        "text": "Hangzhou",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Children's Hospital between July 2022 and November 2023. HRV-infected patients",
    "entities": [
      {
        "text": "between July 2022",
        "label": "DATE"
      },
      {
        "text": "November 2023",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "were stratified into wheezing (n = 42) and non-wheezing (n = 33) groups based on",
    "entities": [
      {
        "text": "42",
        "label": "DATE"
      },
      {
        "text": "33",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "wheezing symptoms. Nasopharyngeal swabs and peripheral venous blood samples were",
    "entities": [
      {
        "text": "Nasopharyngeal",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "collected on admission. An additional set of peripheral venous blood samples was",
    "entities": []
  },
  {
    "text": "collected from 22 children in the wheezing group during their recovery phase",
    "entities": [
      {
        "text": "22",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "(day 7 after symptom onset). Th17 cell percentages in peripheral blood",
    "entities": []
  },
  {
    "text": "lymphocytes were determined using flow cytometry. ELISA was utilized to measure",
    "entities": [
      {
        "text": "ELISA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "the serum levels of IL-23 and IL-17 and the expression of IL-23R, JAK2, p-JAK2,",
    "entities": [
      {
        "text": "IL-23",
        "label": "PRODUCT"
      },
      {
        "text": "IL-17",
        "label": "PRODUCT"
      },
      {
        "text": "IL-23R",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "STAT3, and p-STAT3 in peripheral blood mononuclear cells. Comparisons of",
    "entities": [
      {
        "text": "STAT3",
        "label": "ORG"
      },
      {
        "text": "p-STAT3",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "expression levels were made among the wheezing, non-wheezing, and control",
    "entities": []
  },
  {
    "text": "groups, as well as between the acute and recovery phases in the wheezing group.",
    "entities": []
  },
  {
    "text": "RESULTS: Children with wheezing due to HRV infection exhibited significantly",
    "entities": [
      {
        "text": "HRV",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "higher levels of IL-23 and IL-17 compared to the non-wheezing and control groups",
    "entities": [
      {
        "text": "IL-23",
        "label": "PRODUCT"
      },
      {
        "text": "IL-17",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "(p < 0.05). No significant differences were observed in the expression of other",
    "entities": []
  },
  {
    "text": "molecules in the IL-23/Th17 pathway across the groups (p > 0.05). During the",
    "entities": [
      {
        "text": "IL-23",
        "label": "PRODUCT"
      },
      {
        "text": "0.05",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "recovery phase, the levels of IL-23 and IL-17 significantly decreased compared",
    "entities": [
      {
        "text": "IL-23",
        "label": "PRODUCT"
      },
      {
        "text": "IL-17",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "to the acute phase (p < 0.05).",
    "entities": []
  },
  {
    "text": "CONCLUSION: IL-23 and IL-17 significantly contribute to the development of",
    "entities": [
      {
        "text": "IL-17",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "HRV-associated wheezing in children. However, the IL-23/Th17 pathway may not be",
    "entities": [
      {
        "text": "HRV",
        "label": "ORG"
      },
      {
        "text": "IL-23",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "the primary mechanism behind HRV-related wheezing illnesses.",
    "entities": [
      {
        "text": "HRV",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "PMID: 40660335 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40660335",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "participate: This study was approved by the Institutional Ethical Review Board",
    "entities": [
      {
        "text": "the Institutional Ethical Review Board",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of Hangzhou Children\u2019s Hospital (Approval No: 2021-59). All subjects enrolled in",
    "entities": [
      {
        "text": "Hangzhou Children\u2019s Hospital",
        "label": "ORG"
      },
      {
        "text": "2021-59",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "the study, or their parents or guardians, were fully informed of the objectives",
    "entities": []
  },
  {
    "text": "of the study before recruitment and finally signed an informed consent form. All",
    "entities": []
  },
  {
    "text": "methods were performed per the ethical standards as laid down in the Declaration",
    "entities": [
      {
        "text": "the Declaration\n",
        "label": "WORK_OF_ART"
      }
    ]
  },
  {
    "text": "of Helsinki and its later amendments or comparable ethical standards. Consent",
    "entities": [
      {
        "text": "Helsinki",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "for publication: Not applicable. Conflict of interest: The authors have no",
    "entities": []
  },
  {
    "text": "funding or conflicts of interest to disclose.",
    "entities": []
  },
  {
    "text": "Impact of natal and childhood metabolic markers on childhood asthma burden - a",
    "entities": []
  },
  {
    "text": "nationwide cohort study.",
    "entities": []
  },
  {
    "text": "(1)Division of Pulmonary and Sleep Medicine, Children's National Health System,",
    "entities": [
      {
        "text": "National Health System",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Washington, DC, USA.",
    "entities": [
      {
        "text": "Washington",
        "label": "GPE"
      },
      {
        "text": "DC",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Respiratory Medicine, Copenhagen University Hospital -",
    "entities": [
      {
        "text": "Respiratory Medicine",
        "label": "ORG"
      },
      {
        "text": "Copenhagen University Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(3)Institute of Clinical Medicine, University of Copenhagen, Copenhagen,",
    "entities": [
      {
        "text": "Clinical Medicine",
        "label": "ORG"
      },
      {
        "text": "University of Copenhagen",
        "label": "ORG"
      },
      {
        "text": "Copenhagen",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)Division of Respiratory and Sleep Medicine, Department of Pediatrics, Albert",
    "entities": [
      {
        "text": "Respiratory and Sleep Medicine, Department of Pediatrics",
        "label": "ORG"
      },
      {
        "text": "Albert",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Einstein College of Medicine, 3415 Bainbridge Ave, Bronx, NY, 10467, USA.",
    "entities": [
      {
        "text": "Einstein College of Medicine",
        "label": "ORG"
      },
      {
        "text": "3415",
        "label": "CARDINAL"
      },
      {
        "text": "Bronx",
        "label": "GPE"
      },
      {
        "text": "NY",
        "label": "GPE"
      },
      {
        "text": "10467",
        "label": "DATE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "BACKGROUND: Pediatric obesity, a risk factor for asthma, is increasing in",
    "entities": []
  },
  {
    "text": "prevalence. Obesity-mediated metabolic abnormalities are one of the mechanisms",
    "entities": [
      {
        "text": "one",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "that link asthma and obesity. While maternal obesity contributes to obesity and",
    "entities": []
  },
  {
    "text": "respiratory morbidity in the child, the contribution of paternal obesity and",
    "entities": []
  },
  {
    "text": "parental metabolic abnormalities to the child's asthma is not known.",
    "entities": []
  },
  {
    "text": "METHODS: To quantify the impact of parental and child's body weight and",
    "entities": []
  },
  {
    "text": "metabolic traits, including elevated HbA1c, and blood cholesterol levels based",
    "entities": []
  },
  {
    "text": "on national, age-specific cut-off values, on asthma exacerbations, control, and",
    "entities": []
  },
  {
    "text": "severity, in a Danish nationwide cohort of 29,851 children aged 2-17 years with",
    "entities": [
      {
        "text": "Danish",
        "label": "NORP"
      },
      {
        "text": "29,851",
        "label": "CARDINAL"
      },
      {
        "text": "2-17 years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "inhaled corticosteroid-treated asthma during 2015-17.",
    "entities": [
      {
        "text": "2015-17",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "RESULTS: Among the 29,851 children, 1,430 had severe asthma, 4,750 had poor",
    "entities": [
      {
        "text": "29,851",
        "label": "CARDINAL"
      },
      {
        "text": "1,430",
        "label": "CARDINAL"
      },
      {
        "text": "4,750",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "asthma control, and 2,353 had exacerbating asthma. Elevated LDL in the child was",
    "entities": [
      {
        "text": "2,353",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "associated with 2.2-fold higher odds of severe asthma and elevated triglycerides",
    "entities": [
      {
        "text": "2.2-fold",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "with 1.5-fold higher odds of exacerbating asthma, while reduced HDL was",
    "entities": [
      {
        "text": "1.5-fold",
        "label": "CARDINAL"
      },
      {
        "text": "HDL",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "associated with 1.5-fold higher odds of poor control. Both triglycerides and HDL",
    "entities": [
      {
        "text": "1.5-fold",
        "label": "CARDINAL"
      },
      {
        "text": "HDL",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "were associated with 1.5-fold higher odds of exacerbating asthma. Maternal",
    "entities": [
      {
        "text": "1.5-fold",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "parameters including elevated LDL cholesterol, triglycerides, and HbA1C were",
    "entities": []
  },
  {
    "text": "associated with 1.2 to 1.4-fold higher odds of uncontrolled asthma in the child.",
    "entities": [
      {
        "text": "1.2 to 1.4-fold",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Elevated paternal HbA1C was associated with exacerbating asthma.",
    "entities": []
  },
  {
    "text": "CONCLUSION: Dyslipidemia, including elevated LDL and decreased HDL, in the child",
    "entities": [
      {
        "text": "HDL",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and their parents was associated with high asthma burden in a Danish pediatric",
    "entities": [
      {
        "text": "Danish",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "cohort with persistent asthma. These observations highlight the need to",
    "entities": []
  },
  {
    "text": "investigate the underlying mechanisms driven by fat metabolism that are",
    "entities": []
  },
  {
    "text": "PMID: 40660253 [Indexed for MEDLINE]",
    "entities": []
  },
  {
    "text": "participate: Study approvals were granted by the Captial Region of Copenhagen\u2019s",
    "entities": [
      {
        "text": "the Captial Region of Copenhagen",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Data Safety Board (ref. P-2021-602). Consent for publication: As per Danish law,",
    "entities": [
      {
        "text": "Data Safety Board",
        "label": "ORG"
      },
      {
        "text": "ref",
        "label": "ORG"
      },
      {
        "text": "Danish",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "participant consent is not required for participation in and/or publication of",
    "entities": []
  },
  {
    "text": "aggregated data from nationwide cohorts sourced from Statistics Denmark.",
    "entities": [
      {
        "text": "Statistics Denmark",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "Competing interests: The authors declare no competing interests.",
    "entities": []
  },
  {
    "text": "Inhaled biologics for respiratory diseases: clinical potential and emerging",
    "entities": []
  },
  {
    "text": "technologies.",
    "entities": []
  },
  {
    "text": "Shaibie NA(1), Mohammad Faizal NDF(1), Buang F(1), Srichana T(2), Mohd Amin",
    "entities": [
      {
        "text": "Shaibie NA(1",
        "label": "FAC"
      },
      {
        "text": "Mohammad Faizal NDF(1",
        "label": "PERSON"
      },
      {
        "text": "Buang F(1",
        "label": "PERSON"
      },
      {
        "text": "Srichana T(2",
        "label": "ORG"
      },
      {
        "text": "Mohd Amin",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)Centre for Drug Delivery Technology and Vaccine, Faculty of Pharmacy,",
    "entities": [
      {
        "text": "Drug Delivery Technology",
        "label": "ORG"
      },
      {
        "text": "Vaccine, Faculty of Pharmacy",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)Drug Delivery System Excellence Centre, Department of Pharmaceutical",
    "entities": [
      {
        "text": "Department of Pharmaceutical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Technology, Faculty of Pharmaceutical Sciences, Prince of Songkla University,",
    "entities": [
      {
        "text": "Technology, Faculty of Pharmaceutical Sciences",
        "label": "ORG"
      },
      {
        "text": "Prince of Songkla University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(3)Centre for Drug Delivery Technology and Vaccine, Faculty of Pharmacy,",
    "entities": [
      {
        "text": "3)Centre",
        "label": "CARDINAL"
      },
      {
        "text": "Vaccine, Faculty of Pharmacy",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "The pulmonary route has gained significant attention as a drug delivery method,",
    "entities": []
  },
  {
    "text": "particularly for managing respiratory diseases. This approach provides several",
    "entities": []
  },
  {
    "text": "benefits, such as rapid therapeutic action, minimized systemic exposure,",
    "entities": []
  },
  {
    "text": "improved patient adherence, and the ability to deliver high drug concentrations",
    "entities": []
  },
  {
    "text": "directly to the lungs. Advances in inhalation devices, including pressurized",
    "entities": []
  },
  {
    "text": "established the pulmonary route as effective for administering both",
    "entities": []
  },
  {
    "text": "small-molecule drugs and complex biologics. Recent research has showcased the",
    "entities": []
  },
  {
    "text": "successful use of inhaled biologics such as monoclonal antibodies, nanobodies,",
    "entities": []
  },
  {
    "text": "and protein-based treatments in conditions like asthma, chronic obstructive",
    "entities": []
  },
  {
    "text": "pulmonary disease (COPD), pulmonary fibrosis, COVID-19, and respiratory",
    "entities": [
      {
        "text": "COVID-19",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "syncytial virus (RSV). These treatments employ innovative mechanisms, such as",
    "entities": [
      {
        "text": "RSV",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "muco-trapping and immune modulation, to optimize site-specific drug delivery and",
    "entities": []
  },
  {
    "text": "minimize systemic side effects. As technologies for pulmonary administration",
    "entities": []
  },
  {
    "text": "continue to evolve, they provide a non-invasive and highly promising platform",
    "entities": []
  },
  {
    "text": "for enhancing respiratory therapies and broadening the applications of",
    "entities": []
  },
  {
    "text": "DOI: 10.1007/s13346-025-01909-6",
    "entities": [
      {
        "text": "10.1007",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "participate: No ethics approvals were required for this review and no human",
    "entities": []
  },
  {
    "text": "subjects were involved. Consent for publication: No consents were required for",
    "entities": []
  },
  {
    "text": "this review and no human subjects were involved. Competing interests: The",
    "entities": []
  },
  {
    "text": "authors declare that they have no known competing financial interests or",
    "entities": []
  },
  {
    "text": "personal relationships that could have appeared to influence the work reported",
    "entities": []
  },
  {
    "text": "in this paper.",
    "entities": []
  },
  {
    "text": "Initial Survival and Short-term Pulmonary Comorbidities in Infants with",
    "entities": [
      {
        "text": "Initial Survival",
        "label": "ORG"
      },
      {
        "text": "Pulmonary Comorbidities",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Congenital Diaphragmatic Hernia of Differing Indices of Social Determinants of",
    "entities": []
  },
  {
    "text": "Health.",
    "entities": []
  },
  {
    "text": "(1)Division of Pediatric Surgery, Department of Surgery. Columbia University",
    "entities": [
      {
        "text": "Columbia University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Irving Medical Center / NewYork Presbyterian Morgan Stanley Children's Hospital,",
    "entities": [
      {
        "text": "Irving Medical Center / NewYork Presbyterian Morgan Stanley Children's Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "New York, NY, USA.",
    "entities": [
      {
        "text": "New York",
        "label": "GPE"
      },
      {
        "text": "NY",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Columbia University Vagelos College of Physicians & Surgeons, New York, NY,",
    "entities": [
      {
        "text": "2)Columbia",
        "label": "CARDINAL"
      },
      {
        "text": "University Vagelos College of Physicians & Surgeons",
        "label": "ORG"
      },
      {
        "text": "New York",
        "label": "GPE"
      },
      {
        "text": "NY",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(3)Center for Innovation and Outcomes Research, Department of Surgery. Columbia",
    "entities": [
      {
        "text": "Innovation and Outcomes Research, Department of Surgery",
        "label": "ORG"
      },
      {
        "text": "Columbia",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University Irving Medical Center, New York, NY.",
    "entities": [
      {
        "text": "University Irving Medical Center",
        "label": "ORG"
      },
      {
        "text": "New York",
        "label": "GPE"
      },
      {
        "text": "NY",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)Division of Cardiac, Thoracic, and Vascular Surgery, Department of Surgery.",
    "entities": [
      {
        "text": "Cardiac",
        "label": "ORG"
      },
      {
        "text": "Thoracic",
        "label": "ORG"
      },
      {
        "text": "Vascular Surgery",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Columbia University Irving Medical Center / NewYork Presbyterian Morgan Stanley",
    "entities": [
      {
        "text": "Columbia University Irving Medical Center / NewYork Presbyterian Morgan Stanley",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Children's Hospital, New York, NY, USA.",
    "entities": [
      {
        "text": "New York",
        "label": "GPE"
      },
      {
        "text": "NY",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Division of Pediatric Cardiology, Department of Pediatrics. Columbia",
    "entities": [
      {
        "text": "Pediatric Cardiology",
        "label": "ORG"
      },
      {
        "text": "Department of Pediatrics",
        "label": "ORG"
      },
      {
        "text": "Columbia",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University Irving Medical Center / NewYork Presbyterian-Morgan Stanley",
    "entities": [
      {
        "text": "University Irving Medical Center / NewYork Presbyterian-Morgan Stanley",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(6)Division of Pediatric Pulmonology, Department of Pediatrics. Columbia",
    "entities": [
      {
        "text": "Pediatric Pulmonology, Department of Pediatrics",
        "label": "ORG"
      },
      {
        "text": "Columbia",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(7)Division of Pediatric Surgery, Department of Surgery. Columbia University",
    "entities": [
      {
        "text": "Pediatric Surgery, Department of Surgery",
        "label": "ORG"
      },
      {
        "text": "Columbia University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "New York, NY, USA. Electronic address: vd2312@cumc.columbia.edu.",
    "entities": [
      {
        "text": "New York",
        "label": "GPE"
      },
      {
        "text": "NY",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "PURPOSE: To assess the association between social determinants of health (SDoH)",
    "entities": [
      {
        "text": "PURPOSE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and both mortality and pulmonary outcomes in infants with congenital",
    "entities": []
  },
  {
    "text": "diaphragmatic hernia (CDH).",
    "entities": [
      {
        "text": "CDH",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "METHODS: We conducted a retrospective observational cohort study of all patients",
    "entities": []
  },
  {
    "text": "with CDH at our institution from January 2004 to July 2023. Child opportunity",
    "entities": [
      {
        "text": "CDH",
        "label": "ORG"
      },
      {
        "text": "January 2004 to July 2023",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "index (COI) and area deprivation index (ADI) were determined from reported",
    "entities": [
      {
        "text": "ADI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "addresses at birth. Baseline demographics and details from initial",
    "entities": []
  },
  {
    "text": "hospitalization were described by COI quintiles. Outcomes of mortality and",
    "entities": []
  },
  {
    "text": "CDH-associated pulmonary outcomes were compared between COI quintiles.",
    "entities": []
  },
  {
    "text": "RESULTS: Among the 281 patients, there were unequal distributions of race",
    "entities": [
      {
        "text": "281",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "(p<0.001) and ethnicity (p=0.006) among the COI quintiles, with Black patients",
    "entities": []
  },
  {
    "text": "comprising a quarter of the very low COI quintile. In-hospital mortality,",
    "entities": [
      {
        "text": "a quarter",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "supplemental oxygen at discharge, reactive airway disease (RAD)/asthma, and",
    "entities": []
  },
  {
    "text": "differed significantly among the COI quintiles (p=0.02, p=0.024, p=0.04).",
    "entities": [
      {
        "text": "p=0.04",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Multivariable regression analyses of composite outcomes (mortality or pulmonary",
    "entities": []
  },
  {
    "text": "comorbidities) demonstrated those in the very high vs. very low COI quintile had",
    "entities": []
  },
  {
    "text": "20-31% lower odds of requiring oxygen (O2) support and having pulmonary",
    "entities": [
      {
        "text": "20-31%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "hypertension (PH) at discharge (p=0.006, p=0.029) and at 6 months (p=0.01,",
    "entities": [
      {
        "text": "6 months",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "p=0.003), respectively. ADI similarly correlated with need for O2 support and PH",
    "entities": [
      {
        "text": "ADI",
        "label": "ORG"
      },
      {
        "text": "O2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "in CDH infants at 6 months, AOR 1.03 (95% CI 1.01-1.04), p=0.001 and 1.02 (95%",
    "entities": [
      {
        "text": "CDH",
        "label": "ORG"
      },
      {
        "text": "6 months",
        "label": "DATE"
      },
      {
        "text": "AOR",
        "label": "ORG"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "1.01-1.04",
        "label": "DATE"
      },
      {
        "text": "1.02",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "CI 1-1.03), p=0.029, respectively.",
    "entities": [
      {
        "text": "CI 1-1.03",
        "label": "PERSON"
      },
      {
        "text": "p=0.029",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "CONCLUSION: Children of very low COI and higher ADI with CDH may be at increased",
    "entities": [
      {
        "text": "ADI",
        "label": "ORG"
      },
      {
        "text": "CDH",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "risk of mortality or pulmonary morbidities. Further studies are needed to better",
    "entities": []
  },
  {
    "text": "characterize this vulnerable population and to improve these SDoH-related",
    "entities": [
      {
        "text": "SDoH",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Declaration of Competing Interest The authors",
    "entities": []
  },
  {
    "text": "have no conflicts of interest to disclose.",
    "entities": []
  },
  {
    "text": "41. Respir Med. 2025 Jul 12:108255. doi: 10.1016/j.rmed.2025.108255. Online ahead",
    "entities": [
      {
        "text": "41",
        "label": "CARDINAL"
      },
      {
        "text": "Respir Med",
        "label": "PERSON"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "10.1016",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Spirometry and impulse oscillometry in the diagnosis of cough variant asthma in",
    "entities": []
  },
  {
    "text": "(1)Capital Center for Children's Health, Capital Medical University, Beijing,",
    "entities": [
      {
        "text": "Center for Children's Health",
        "label": "ORG"
      },
      {
        "text": "Capital Medical University",
        "label": "ORG"
      },
      {
        "text": "Beijing",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Xi'an Children's Hospital, Shanxi, China. Electronic address:",
    "entities": [
      {
        "text": "2)Xi'an Children's Hospital",
        "label": "MONEY"
      },
      {
        "text": "Shanxi",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Capital Center for Children's Health, Capital Medical University, Beijing,",
    "entities": [
      {
        "text": "Capital Medical University",
        "label": "ORG"
      },
      {
        "text": "Beijing",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "China. Electronic address: xin.mail@163.com.",
    "entities": [
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Capital Center for Children's Health, Capital Medical University, Beijing,",
    "entities": [
      {
        "text": "Capital Medical University",
        "label": "ORG"
      },
      {
        "text": "Beijing",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "China. Electronic address: lishuo21@126.com.",
    "entities": [
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Capital Center for Children's Health, Capital Medical University, Beijing,",
    "entities": [
      {
        "text": "Center for Children's Health",
        "label": "ORG"
      },
      {
        "text": "Capital Medical University",
        "label": "ORG"
      },
      {
        "text": "Beijing",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)Capital Center for Children's Health, Capital Medical University, Beijing,",
    "entities": [
      {
        "text": "Center for Children's Health",
        "label": "ORG"
      },
      {
        "text": "Capital Medical University",
        "label": "ORG"
      },
      {
        "text": "Beijing",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "China. Electronic address: 446593115@qq.com.",
    "entities": [
      {
        "text": "China",
        "label": "GPE"
      },
      {
        "text": "446593115@qq.com",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "(7)Capital Center for Children's Health, Capital Medical University, Beijing,",
    "entities": [
      {
        "text": "Center for Children's Health",
        "label": "ORG"
      },
      {
        "text": "Capital Medical University",
        "label": "ORG"
      },
      {
        "text": "Beijing",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "China. Electronic address: 1097886416@qq.com.",
    "entities": [
      {
        "text": "China",
        "label": "GPE"
      },
      {
        "text": "1097886416@qq.com",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "(8)Capital Center for Children's Health, Capital Medical University, Beijing,",
    "entities": [
      {
        "text": "Center for Children's Health",
        "label": "ORG"
      },
      {
        "text": "Capital Medical University",
        "label": "ORG"
      },
      {
        "text": "Beijing",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(9)Capital Center for Children's Health, Capital Medical University, Beijing,",
    "entities": [
      {
        "text": "Center for Children's Health",
        "label": "ORG"
      },
      {
        "text": "Capital Medical University",
        "label": "ORG"
      },
      {
        "text": "Beijing",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "China. Electronic address: liuchcip@126.com.",
    "entities": [
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "OBJECTIVE: This study aimed to assess the diagnostic utility of spirometry and",
    "entities": []
  },
  {
    "text": "impulse oscillometry, focusing on their correlation and diagnostic advantages,",
    "entities": []
  },
  {
    "text": "in children with cough variant asthma (CVA).",
    "entities": [
      {
        "text": "CVA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "METHODS: This study included children aged 5-12 years with a diagnosis of CVA",
    "entities": [
      {
        "text": "5-12 years",
        "label": "DATE"
      },
      {
        "text": "CVA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "who underwent sequential IOS and spirometry pulmonary function with",
    "entities": [
      {
        "text": "IOS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "bronchodilation (BD) tests. A control group of healthy children was matched.",
    "entities": []
  },
  {
    "text": "Receiver operating characteristic (ROC) curves were plotted, and the area under",
    "entities": [
      {
        "text": "ROC",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "the curve (AUC) was calculated to assess the discriminatory potential of these",
    "entities": []
  },
  {
    "text": "spirometry and IOS parameters for CVA. The correlation and diagnostic",
    "entities": [
      {
        "text": "IOS",
        "label": "ORG"
      },
      {
        "text": "CVA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "consistency between spirometry and IOS parameters were compared.",
    "entities": [
      {
        "text": "IOS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "RESULTS: A total of 177 patients with CVA and 45 control subjects were included.",
    "entities": [
      {
        "text": "177",
        "label": "CARDINAL"
      },
      {
        "text": "CVA",
        "label": "ORG"
      },
      {
        "text": "45",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "The ROC curve results for pre-BD parameters and the improvement rate showed that",
    "entities": [
      {
        "text": "ROC",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "the combinations of \"pre-MMEF(%pred) and \u25b3MMEF\" and \"pre-Z5(%pred) and -\u25b3Z5(%)\"",
    "entities": []
  },
  {
    "text": "achieved the highest AUC value of 0.892 and 0.836, with threshold probabilities",
    "entities": [
      {
        "text": "0.892",
        "label": "CARDINAL"
      },
      {
        "text": "0.836",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "of 0.868, 0.786, respectively. The AUC values of these combined parameters",
    "entities": [
      {
        "text": "0.868",
        "label": "CARDINAL"
      },
      {
        "text": "0.786",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "surpassed those of individual ones. The correlation between spirometry and IOS",
    "entities": [
      {
        "text": "IOS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "parameters showed that pre-FEF25(%pred) has a moderately negative correlation",
    "entities": []
  },
  {
    "text": "with pre-Z5(%pred) and pre-R5(%pred) (r=-0.415, -0.404; P< 0.001), \u25b3FEF75% has a",
    "entities": [
      {
        "text": "P< 0.001",
        "label": "ORG"
      },
      {
        "text": "\u25b3FEF75%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "weak positive correlation with -\u25b3Z5%, -\u25b3R5%(r=0.154, 0.155; P< 0.05). The",
    "entities": [
      {
        "text": "Z5%",
        "label": "PERCENT"
      },
      {
        "text": "0.155",
        "label": "CARDINAL"
      },
      {
        "text": "P< 0.05",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "comparison of diagnostic consistency between pre-BD spirometry and pre-BD IOS",
    "entities": []
  },
  {
    "text": "parameters showed a weak correlation(kappa=0.150, P=0.007).",
    "entities": []
  },
  {
    "text": "CONCLUSIONS: The changes in spirometry and IOS parameters during the BD test",
    "entities": [
      {
        "text": "IOS",
        "label": "ORG"
      },
      {
        "text": "BD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "provided valuable diagnostic information for CVA and can help pediatricians",
    "entities": [
      {
        "text": "CVA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "accurately identify CVA in children.",
    "entities": [
      {
        "text": "CVA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Copyright \u00a9 2025. Published by Elsevier Ltd.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Elsevier Ltd.",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Declaration of Competing Interest \u2612 The authors",
    "entities": []
  },
  {
    "text": "10.1016/j.jaci.2025.07.002. Online ahead of print.",
    "entities": [
      {
        "text": "10.1016",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Environmental Risk Factors and Asthma Primary Prevention: from Birth Cohort",
    "entities": [
      {
        "text": "Asthma Primary Prevention",
        "label": "ORG"
      },
      {
        "text": "Birth Cohort",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "Studies to Clinical Trials.",
    "entities": [
      {
        "text": "Clinical Trials",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(1)Division of Allergy and Clinical Immunology, Department of Internal Medicine,",
    "entities": [
      {
        "text": "Allergy and Clinical Immunology",
        "label": "ORG"
      },
      {
        "text": "Department of Internal Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Henry Ford Health + Michigan State University Health Sciences Center, Detroit",
    "entities": [
      {
        "text": "Henry Ford",
        "label": "PERSON"
      },
      {
        "text": "Michigan State University Health Sciences Center",
        "label": "ORG"
      },
      {
        "text": "Detroit",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Institute of Asthma and Allergy Prevention, Helmholtz Munich, Neuherberg,",
    "entities": [
      {
        "text": "2)Institute",
        "label": "CARDINAL"
      },
      {
        "text": "Asthma and Allergy Prevention",
        "label": "ORG"
      },
      {
        "text": "Helmholtz Munich",
        "label": "PERSON"
      },
      {
        "text": "Neuherberg",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Germany.",
    "entities": [
      {
        "text": "Germany",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Institute of Asthma and Allergy Prevention, Helmholtz Munich, Neuherberg,",
    "entities": [
      {
        "text": "Asthma and Allergy Prevention",
        "label": "ORG"
      },
      {
        "text": "Helmholtz Munich",
        "label": "PERSON"
      },
      {
        "text": "Neuherberg",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "of the German Center for Lung Research (DZL), Munich, Germany.",
    "entities": [
      {
        "text": "the German Center for Lung Research (DZL",
        "label": "ORG"
      },
      {
        "text": "Munich",
        "label": "GPE"
      },
      {
        "text": "Germany",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Department of Public Health Sciences, Henry Ford Health + Michigan State",
    "entities": [
      {
        "text": "Public Health Sciences",
        "label": "ORG"
      },
      {
        "text": "Henry Ford",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University Health Sciences Center, Detroit, MI.",
    "entities": [
      {
        "text": "University Health Sciences Center",
        "label": "ORG"
      },
      {
        "text": "Detroit",
        "label": "GPE"
      },
      {
        "text": "MI",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "With the prevalence of pediatric asthma and allergy rising substantially since",
    "entities": []
  },
  {
    "text": "last mid-century, birth cohort studies starting in pregnancy have been pivotal",
    "entities": [
      {
        "text": "last mid-century",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "in identifying prenatal and early life environmental factors that influence risk",
    "entities": []
  },
  {
    "text": "of these diseases. With these findings, researchers have been able to identify",
    "entities": []
  },
  {
    "text": "biological mechanisms at play with the eventual goal of engineering tailored",
    "entities": []
  },
  {
    "text": "interventions to optimize immune system development and decrease the risk of",
    "entities": []
  },
  {
    "text": "allergic disorders. In this review, we describe the critical role birth cohort",
    "entities": []
  },
  {
    "text": "studies have played in starting to disentangle the environmental epidemiology",
    "entities": []
  },
  {
    "text": "and etiology of childhood-onset asthma and other allergic diseases, and how",
    "entities": []
  },
  {
    "text": "these studies have guided ongoing clinical trials for asthma and allergy",
    "entities": []
  },
  {
    "text": "prevention. Lastly, we highlight important questions that remain unanswered and",
    "entities": []
  },
  {
    "text": "potential approaches to help fill these gaps in knowledge.",
    "entities": []
  },
  {
    "text": "43. Int Arch Allergy Immunol. 2025 Jul 14:1-17. doi: 10.1159/000547301. Online",
    "entities": [
      {
        "text": "43",
        "label": "CARDINAL"
      },
      {
        "text": "Int Arch Allergy Immunol",
        "label": "ORG"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "10.1159/000547301",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Changes of pollen allergens in northern China.",
    "entities": [
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "BACKGROUND: Allergic rhinitis (AR) is a significant global health issue, with",
    "entities": []
  },
  {
    "text": "pollen allergens being a major cause of seasonal AR and asthma. In northern",
    "entities": []
  },
  {
    "text": "China, the prevalence of pollen-related allergies is notably higher than in the",
    "entities": [
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "south due to higher pollen levels. Over the past few decades, climate change and",
    "entities": [
      {
        "text": "the past few decades",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "urbanization have considerably transformed pollen profile in northern China.",
    "entities": [
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "SUMMARY: Northern China experiences two annual pollen peaks: a spring peak",
    "entities": [
      {
        "text": "Northern China",
        "label": "LOC"
      },
      {
        "text": "two",
        "label": "CARDINAL"
      },
      {
        "text": "spring",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "(March to May) dominated by tree pollens (e.g., Cupressaceae, Ulmaceae) and a",
    "entities": [
      {
        "text": "March to May",
        "label": "DATE"
      },
      {
        "text": "Cupressaceae",
        "label": "PERSON"
      },
      {
        "text": "Ulmaceae",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "summer/autumn peak (August to September) dominated by weed pollens, particularly",
    "entities": [
      {
        "text": "summer/autumn",
        "label": "DATE"
      },
      {
        "text": "August to September",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "from Artemisia, Humulus, and Chenopodiaceae. Climate change has accelerated the",
    "entities": [
      {
        "text": "Artemisia",
        "label": "GPE"
      },
      {
        "text": "Chenopodiaceae",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "onset of flowering periods, increased pollen production, and extended pollen",
    "entities": []
  },
  {
    "text": "seasons, with extreme weather events and air pollution further exacerbating",
    "entities": []
  },
  {
    "text": "pollen production and sensitization. Urbanization has increased tree pollens,",
    "entities": []
  },
  {
    "text": "resulting in spring peak pollen levels gradually exceeding those of",
    "entities": [
      {
        "text": "spring",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "summer/autumn in most northern regions. As ecological construction concepts have",
    "entities": [
      {
        "text": "summer/autumn",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "advanced, the selection of plant species for the shelterbelt and ornamental",
    "entities": []
  },
  {
    "text": "trees in cities has evolved, leads to changes in the dominant pollens in the",
    "entities": []
  },
  {
    "text": "north and northeast. Artemisia has been extensively planted in the Northwest for",
    "entities": [
      {
        "text": "Artemisia",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "windbreak and sand fixation purposes, resulting in a significant rise in",
    "entities": []
  },
  {
    "text": "Artemisia pollen levels and sensitization rate with a widespread influence",
    "entities": [
      {
        "text": "Artemisia",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "across northern China.",
    "entities": [
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "KEY MESSAGES: Pollen allergens in northern China are a major driver of AR and",
    "entities": [
      {
        "text": "Pollen",
        "label": "PERSON"
      },
      {
        "text": "China",
        "label": "GPE"
      },
      {
        "text": "AR",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "asthma, with two distinct seasonal peaks. Changes in pollen profiles are",
    "entities": [
      {
        "text": "two",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "influenced by natural factors such as geographical location and climate change,",
    "entities": []
  },
  {
    "text": "as well as social factors, including urbanization, national policies, and urban",
    "entities": []
  },
  {
    "text": "planning. In northern China, Spring pollen is predominantly composed of tree",
    "entities": [
      {
        "text": "China",
        "label": "GPE"
      },
      {
        "text": "Spring",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "pollens, significantly influenced by urban planning across different regions. In",
    "entities": [
      {
        "text": "pollens",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "contrast, summer and autumn pollen is primarily dominated by weed and grass",
    "entities": [
      {
        "text": "summer",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "pollens, with weed pollens exhibiting strong allergenic potential and widespread",
    "entities": []
  },
  {
    "text": "dispersal. The Northwest region is a major potential source for these weed",
    "entities": []
  },
  {
    "text": "The Author(s). Published by S. Karger AG, Basel.",
    "entities": [
      {
        "text": "S. Karger AG",
        "label": "ORG"
      },
      {
        "text": "Basel",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "44. Clin Nucl Med. 2025 Jul 14. doi: 10.1097/RLU.0000000000005768. Online ahead",
    "entities": [
      {
        "text": "44",
        "label": "CARDINAL"
      },
      {
        "text": "Clin Nucl Med",
        "label": "PERSON"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "14",
        "label": "CARDINAL"
      },
      {
        "text": "10.1097",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Myositis Associated With Eosinophilic Granulomatosis With Polyangiitis",
    "entities": [
      {
        "text": "Myositis",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Demonstrated by FDG PET/CT.",
    "entities": [
      {
        "text": "FDG PET/CT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(1)Department of Nuclear Medicine and Radiology, National Center for Global",
    "entities": [
      {
        "text": "Nuclear Medicine and Radiology",
        "label": "ORG"
      },
      {
        "text": "National Center for Global\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Health and Medicine, Tokyo, Japan.",
    "entities": [
      {
        "text": "Health and Medicine",
        "label": "ORG"
      },
      {
        "text": "Tokyo",
        "label": "GPE"
      },
      {
        "text": "Japan",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "A 54-year-old woman with a history of adult-onset asthma presented with",
    "entities": [
      {
        "text": "54-year-old",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "prolonged fever, rash, joint pain, and hypesthesia. Laboratory findings showed",
    "entities": []
  },
  {
    "text": "elevated eosinophils (22%). FDG PET/CT demonstrated uptake in consolidations in",
    "entities": [
      {
        "text": "22%",
        "label": "PERCENT"
      },
      {
        "text": "FDG PET/CT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "both lungs, consistent with eosinophilic pneumonia, and revealed systemic",
    "entities": []
  },
  {
    "text": "myositis with increased uptake (SUVmax 5.5) in muscles, predominantly in the",
    "entities": [
      {
        "text": "myositis",
        "label": "GPE"
      },
      {
        "text": "5.5",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "lower extremities. Based on the 2022 ACR/EULAR criteria, she was diagnosed with",
    "entities": [
      {
        "text": "2022",
        "label": "DATE"
      },
      {
        "text": "ACR/EULAR",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "eosinophilic granulomatosis with polyangiitis (EGPA). This case highlights the",
    "entities": []
  },
  {
    "text": "value of FDG PET/CT in demonstrating eosinophilic pneumonia and in myositis",
    "entities": [
      {
        "text": "FDG PET/CT",
        "label": "ORG"
      },
      {
        "text": "myositis",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "associated with EGPA, suggesting its potential role in diagnosing EGPA in",
    "entities": [
      {
        "text": "EGPA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "patients with fever of unknown origin.",
    "entities": []
  },
  {
    "text": "Conflict of interest statement: Conflicts of interest and sources of funding:",
    "entities": []
  },
  {
    "text": "This work was supported in part by a Grant from the National Center for Global",
    "entities": [
      {
        "text": "the National Center for Global\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Health and Medicine (24\u2013203, 26\u2013116 and 29\u20131038). The authors have no conflicts",
    "entities": [
      {
        "text": "Health and Medicine",
        "label": "ORG"
      },
      {
        "text": "24\u2013203",
        "label": "CARDINAL"
      },
      {
        "text": "26\u2013116",
        "label": "CARDINAL"
      },
      {
        "text": "29\u20131038",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "of interest to declare.",
    "entities": []
  },
  {
    "text": "45. Ann Intern Med. 2025 Jul 15. doi: 10.7326/ANNALS-25-00997. Online ahead of",
    "entities": [
      {
        "text": "45",
        "label": "CARDINAL"
      },
      {
        "text": "Ann Intern Med",
        "label": "PERSON"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "15",
        "label": "CARDINAL"
      },
      {
        "text": "10.7326",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Aluminum-Adsorbed Vaccines and Chronic Diseases in Childhood : A Nationwide",
    "entities": [
      {
        "text": "Aluminum-Adsorbed Vaccines",
        "label": "PERSON"
      },
      {
        "text": "Childhood",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Cohort Study.",
    "entities": [
      {
        "text": "Cohort Study",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)Department of Epidemiology Research, Statens Serum Institut, Copenhagen,",
    "entities": [
      {
        "text": "Epidemiology Research",
        "label": "ORG"
      },
      {
        "text": "Statens Serum Institut",
        "label": "PERSON"
      },
      {
        "text": "Copenhagen",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)National Allergy Research Centre, Department of Dermatology and Allergy,",
    "entities": [
      {
        "text": "Allergy Research Centre",
        "label": "ORG"
      },
      {
        "text": "Department of Dermatology and Allergy",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(3)Department of Epidemiology Research, Statens Serum Institut, and",
    "entities": [
      {
        "text": "Epidemiology Research",
        "label": "ORG"
      },
      {
        "text": "Statens Serum Institut",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Pharmacovigilance Research Center, Department of Drug Design and Pharmacology,",
    "entities": [
      {
        "text": "Pharmacovigilance Research Center",
        "label": "ORG"
      },
      {
        "text": "Department of Drug Design",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen,",
    "entities": [
      {
        "text": "Faculty of Health and Medical Sciences",
        "label": "ORG"
      },
      {
        "text": "University of Copenhagen",
        "label": "ORG"
      },
      {
        "text": "Copenhagen",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "BACKGROUND: Aluminum is used as an adjuvant in nonlive vaccines administered in",
    "entities": []
  },
  {
    "text": "early childhood. Concerns persist about potential associations between",
    "entities": []
  },
  {
    "text": "vaccination with aluminum-adsorbed vaccines and increased risk for chronic",
    "entities": []
  },
  {
    "text": "autoimmunity, atopy or allergy, and neurodevelopmental disorders. Large-scale",
    "entities": []
  },
  {
    "text": "safety data remain limited.",
    "entities": []
  },
  {
    "text": "OBJECTIVE: To assess the association between cumulative aluminum exposure from",
    "entities": []
  },
  {
    "text": "early childhood vaccination and risk for autoimmune, atopic or allergic, and",
    "entities": []
  },
  {
    "text": "DESIGN: A cohort study linking nationwide registry data on childhood",
    "entities": []
  },
  {
    "text": "vaccinations, outcome diagnoses, and potential confounders, leveraging the",
    "entities": []
  },
  {
    "text": "variations in the aluminum content of childhood vaccines over time.",
    "entities": []
  },
  {
    "text": "PARTICIPANTS: 1 224 176 children born in Denmark between 1997 and 2018 who were",
    "entities": [
      {
        "text": "1",
        "label": "CARDINAL"
      },
      {
        "text": "176",
        "label": "CARDINAL"
      },
      {
        "text": "Denmark",
        "label": "GPE"
      },
      {
        "text": "between 1997 and 2018",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "alive and residing in the country at age 2 years.",
    "entities": [
      {
        "text": "age 2 years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "INTERVENTION: Cumulative aluminum amount received (per 1-mg increase) through",
    "entities": [
      {
        "text": "1",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "vaccination during the first 2 years of life.",
    "entities": [
      {
        "text": "the first 2 years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "MEASUREMENTS: Incident events of 50 chronic disorders, including autoimmune",
    "entities": [
      {
        "text": "50",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "atopic or allergic (asthma, atopic dermatitis, rhinoconjunctivitis, and",
    "entities": []
  },
  {
    "text": "allergy), and neurodevelopmental (autism spectrum disorder and attention",
    "entities": []
  },
  {
    "text": "deficit-hyperactivity disorder).",
    "entities": []
  },
  {
    "text": "RESULTS: Cumulative aluminum exposure from vaccination during the first 2 years",
    "entities": [
      {
        "text": "the first 2 years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "of life was not associated with increased rates of any of the 50 disorders",
    "entities": [
      {
        "text": "50",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "assessed. For groups of combined outcomes, adjusted hazard ratios per 1-mg",
    "entities": [
      {
        "text": "1-mg\n",
        "label": "TIME"
      }
    ]
  },
  {
    "text": "increase in aluminum exposure were 0.98 (95% CI, 0.94 to 1.02) for any",
    "entities": [
      {
        "text": "0.98",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "0.94",
        "label": "CARDINAL"
      },
      {
        "text": "1.02",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "autoimmune disorder, 0.99 (CI, 0.98 to 1.01) for any atopic or allergic",
    "entities": [
      {
        "text": "0.99",
        "label": "CARDINAL"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "0.98",
        "label": "CARDINAL"
      },
      {
        "text": "1.01",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "disorder, and 0.93 (CI, 0.90 to 0.97) for any neurodevelopmental disorder. For",
    "entities": [
      {
        "text": "0.93",
        "label": "CARDINAL"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "0.90",
        "label": "CARDINAL"
      },
      {
        "text": "0.97",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "most individually analyzed outcomes, the upper bounds of the 95% CIs were",
    "entities": [
      {
        "text": "95%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "incompatible with relative increases greater than 10% or 30%.",
    "entities": [
      {
        "text": "greater than",
        "label": "PERCENT"
      },
      {
        "text": "10% or 30%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "LIMITATION: Individual medical records were not reviewed.",
    "entities": []
  },
  {
    "text": "CONCLUSION: This nationwide cohort study did not find evidence supporting an",
    "entities": []
  },
  {
    "text": "increased risk for autoimmune, atopic or allergic, or neurodevelopmental",
    "entities": []
  },
  {
    "text": "disorders associated with early childhood exposure to aluminum-adsorbed",
    "entities": []
  },
  {
    "text": "vaccines. For most outcomes, the findings were inconsistent with moderate to",
    "entities": []
  },
  {
    "text": "large relative increases in risk, although small relative effects, particularly",
    "entities": []
  },
  {
    "text": "for some rarer disorders, could not be statistically excluded.",
    "entities": []
  },
  {
    "text": "Conflict of interest statement: Disclosures: Disclosure forms are available with",
    "entities": []
  },
  {
    "text": "the article online.",
    "entities": []
  },
  {
    "text": "eCollection 2025 Jul 1.",
    "entities": []
  },
  {
    "text": "Troubleshooting Severe Airflow Obstruction With a Pressure-Limited Transport",
    "entities": []
  },
  {
    "text": "Ventilator: Lessons From Two Cases.",
    "entities": [
      {
        "text": "Two",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Reardon PM(1)(2), Bishop MJ(3), Yarnell CJ(1)(2)(4)(5), Benaim JA(3)(6), Barclay",
    "entities": [
      {
        "text": "Reardon",
        "label": "GPE"
      },
      {
        "text": "Bishop MJ(3",
        "label": "ORG"
      },
      {
        "text": "Yarnell CJ(1)(2)(4)(5",
        "label": "PERSON"
      },
      {
        "text": "Benaim JA(3)(6",
        "label": "PERSON"
      },
      {
        "text": "Barclay\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(1)Department of Critical Care, Scarborough Health Network, Toronto, ON, Canada.",
    "entities": [
      {
        "text": "Critical Care",
        "label": "ORG"
      },
      {
        "text": "Scarborough Health Network",
        "label": "ORG"
      },
      {
        "text": "Toronto",
        "label": "GPE"
      },
      {
        "text": "ON",
        "label": "GPE"
      },
      {
        "text": "Canada",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Medicine, University of Toronto, Toronto, ON, Canada.",
    "entities": [
      {
        "text": "Medicine, University of Toronto",
        "label": "ORG"
      },
      {
        "text": "Toronto",
        "label": "GPE"
      },
      {
        "text": "ON",
        "label": "GPE"
      },
      {
        "text": "Canada",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Clinical Affairs, Ornge Transport Medicine, Mississauga, ON, Canada.",
    "entities": [
      {
        "text": "3)Clinical Affairs",
        "label": "ORG"
      },
      {
        "text": "Ornge Transport Medicine",
        "label": "ORG"
      },
      {
        "text": "Mississauga",
        "label": "PERSON"
      },
      {
        "text": "ON",
        "label": "GPE"
      },
      {
        "text": "Canada",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Scarborough Health Network Research Institute, Toronto, ON, Canada.",
    "entities": [
      {
        "text": "Health Network Research Institute",
        "label": "ORG"
      },
      {
        "text": "Toronto",
        "label": "GPE"
      },
      {
        "text": "ON",
        "label": "GPE"
      },
      {
        "text": "Canada",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Interdepartmental Division of Critical Care Medicine, Faculty of Medicine,",
    "entities": [
      {
        "text": "Division of Critical Care Medicine, Faculty of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University of Toronto, Toronto, ON, Canada.",
    "entities": [
      {
        "text": "University of Toronto",
        "label": "ORG"
      },
      {
        "text": "Toronto",
        "label": "GPE"
      },
      {
        "text": "ON",
        "label": "GPE"
      },
      {
        "text": "Canada",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)Critical Care Transport Unit, Toronto Paramedic Services, Toronto, ON,",
    "entities": [
      {
        "text": "6)Critical Care Transport Unit",
        "label": "ORG"
      },
      {
        "text": "Toronto Paramedic Services",
        "label": "ORG"
      },
      {
        "text": "Toronto",
        "label": "GPE"
      },
      {
        "text": "ON",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(7)Department of Emergency Medicine, Faculty of Medicine, University of Ottawa,",
    "entities": [
      {
        "text": "Emergency Medicine, Faculty of Medicine, University of Ottawa",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(8)Division of Critical Care Medicine, Department of Medicine, Montfort",
    "entities": [
      {
        "text": "Critical Care Medicine,",
        "label": "ORG"
      },
      {
        "text": "Department of Medicine, Montfort",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Presentations of status asthmaticus or severe chronic obstructive pulmonary",
    "entities": []
  },
  {
    "text": "disease exacerbation can present a formidable challenge to effective invasive",
    "entities": []
  },
  {
    "text": "ventilation. The optimal ventilation strategy targets low respiratory rates and",
    "entities": []
  },
  {
    "text": "high inspiratory flow rates to prolong the expiratory time and minimize dynamic",
    "entities": []
  },
  {
    "text": "hyperinflation. Although the resulting high peak pressures can usually be",
    "entities": []
  },
  {
    "text": "accommodated by ICU ventilators, some ventilators have a relatively limited peak",
    "entities": [
      {
        "text": "ICU",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "pressure capacity as determined by the turbine. Here, we describe two cases of",
    "entities": [
      {
        "text": "two",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "severe airflow obstruction where the desired ventilation strategy required a",
    "entities": []
  },
  {
    "text": "peak pressure over the capacity of the Hamilton T1 transport ventilator.",
    "entities": [
      {
        "text": "Hamilton T1",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Changing to a pressure regulated strategy, maximizing the driving pressure, and",
    "entities": []
  },
  {
    "text": "titrating the inspiratory time overcame the limitation. But, this strategy comes",
    "entities": []
  },
  {
    "text": "at a cost. Clinicians should be made aware of the possibility of a pressure",
    "entities": [
      {
        "text": "Clinicians",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "limitation in their ventilator and understand how to adjust their ventilation",
    "entities": []
  },
  {
    "text": "strategy appropriately during transitions.",
    "entities": []
  },
  {
    "text": "Copyright \u00a9 2025 The Authors. Published by Wolters Kluwer Health, Inc. on behalf",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Wolters Kluwer Health, Inc.",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of the Society of Critical Care Medicine.",
    "entities": [
      {
        "text": "the Society of Critical Care Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "DOI: 10.1097/CCE.0000000000001285",
    "entities": [
      {
        "text": "10.1097",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "PMID: 40658881 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40658881",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Dr. Yarnell reports support from a J.P. Bickell",
    "entities": [
      {
        "text": "Yarnell",
        "label": "PERSON"
      },
      {
        "text": "J.P. Bickell",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Foundation Medical Research Grant. Dr. Pan reports support from an institutional",
    "entities": [
      {
        "text": "Foundation Medical Research Grant",
        "label": "ORG"
      },
      {
        "text": "Pan",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "research grant from the Institut du Savoir Montfort, Montfort Hospital, Ottawa,",
    "entities": [
      {
        "text": "the Institut du Savoir Montfort, Montfort Hospital",
        "label": "ORG"
      },
      {
        "text": "Ottawa",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "ON, Canada. The remaining authors have disclosed that they do not have any",
    "entities": [
      {
        "text": "ON,",
        "label": "ORG"
      },
      {
        "text": "Canada",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "potential conflicts of interest.",
    "entities": []
  },
  {
    "text": "47. Br J Dermatol. 2025 Jul 14:ljaf275. doi: 10.1093/bjd/ljaf275. Online ahead of",
    "entities": [
      {
        "text": "47",
        "label": "CARDINAL"
      },
      {
        "text": "Br J Dermatol",
        "label": "PERSON"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "14",
        "label": "CARDINAL"
      },
      {
        "text": "ljaf275",
        "label": "PERSON"
      },
      {
        "text": "10.1093",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Tape Strips in Inflammatory Skin Disease: A Noninvasive Method for Molecular",
    "entities": [
      {
        "text": "Tape Strips",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Insights and Personalized Care.",
    "entities": []
  },
  {
    "text": "(1)Department of Dermatology, Icahn School of Medicine at Mount Sinai, 1425",
    "entities": [
      {
        "text": "Mount Sinai",
        "label": "FAC"
      },
      {
        "text": "1425",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Madison Ave, New York, NY, USA.",
    "entities": [
      {
        "text": "Madison Ave",
        "label": "PERSON"
      },
      {
        "text": "New York",
        "label": "GPE"
      },
      {
        "text": "NY",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Tape-stripping, a skin sampling technique that uses adhesives to collect cells",
    "entities": []
  },
  {
    "text": "from the stratum corneum, offers a minimally invasive method that provides",
    "entities": []
  },
  {
    "text": "valuable molecular insights into various skin and systemic diseases. Initially",
    "entities": []
  },
  {
    "text": "developed in the 1930s, tape stripping has evolved from a research tool into a",
    "entities": [
      {
        "text": "the 1930s",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "validated method for omics research in clinical settings. In dermatology, tape",
    "entities": []
  },
  {
    "text": "strips have been validated to study chronic inflammatory skin disorders, such as",
    "entities": []
  },
  {
    "text": "atopic dermatitis, psoriasis, and hidradenitis suppurativa, as well as various",
    "entities": [
      {
        "text": "hidradenitis suppurativa",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "cutaneous malignancies, providing insight into pathophysiology, aiding in",
    "entities": []
  },
  {
    "text": "disease differentiation, and tracking treatment response. Tape strips circumvent",
    "entities": []
  },
  {
    "text": "the pain, scarring, infection risk, and follow-up requirements associated with",
    "entities": []
  },
  {
    "text": "traditional skin biopsies. Moreover, tape strips allow for higher enrollment",
    "entities": []
  },
  {
    "text": "rates for clinical trials and longitudinal studies, especially in the pediatric",
    "entities": []
  },
  {
    "text": "population where biopsies are particularly challenging. This tool has enabled",
    "entities": []
  },
  {
    "text": "researchers and clinicians to monitor disease activity and evaluate therapeutic",
    "entities": [
      {
        "text": "clinicians",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "response, especially in patients who cannot tolerate repetitive biopsies. Beyond",
    "entities": []
  },
  {
    "text": "skin conditions, tape strips are also being used to advance biomarker research",
    "entities": []
  },
  {
    "text": "in food allergy, asthma, and other systemic and autoimmune diseases, and to",
    "entities": []
  },
  {
    "text": "assess epidermal and skin barrier restoration and transepithelial water loss",
    "entities": []
  },
  {
    "text": "(TEWL). By facilitating data collection across diverse patient populations, tape",
    "entities": [
      {
        "text": "TEWL",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "strips are an important technological advancement towards precision medicine. As",
    "entities": []
  },
  {
    "text": "this technology continues to improve, tape stripping promises to become an asset",
    "entities": []
  },
  {
    "text": "in diagnosing and monitoring a wide range of diseases.",
    "entities": []
  },
  {
    "text": "\u00a9 The Author(s) 2025. Published by Oxford University Press on behalf of British",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Oxford University Press",
        "label": "ORG"
      },
      {
        "text": "British",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "Association of Dermatologists. All rights reserved. For commercial re-use,",
    "entities": [
      {
        "text": "Association of Dermatologists",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "please contact reprints@oup.com for reprints and translation rights for",
    "entities": []
  },
  {
    "text": "reprints. All other permissions can be obtained through our RightsLink service",
    "entities": []
  },
  {
    "text": "via the Permissions link on the article page on our site\u2014for further information",
    "entities": [
      {
        "text": "Permissions",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "please contact journals.permissions@oup.com.",
    "entities": [
      {
        "text": "journals.permissions@oup.com",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "48. JAMA. 2025 Jul 14. doi: 10.1001/jama.2025.11227. Online ahead of print.",
    "entities": [
      {
        "text": "48",
        "label": "CARDINAL"
      },
      {
        "text": "JAMA",
        "label": "PERSON"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "14",
        "label": "CARDINAL"
      },
      {
        "text": "10.1001",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Discovering Residual Pathways Driving Asthma Exacerbations in the Era of",
    "entities": [
      {
        "text": "Discovering Residual Pathways Driving Asthma Exacerbations",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Biologic Therapy.",
    "entities": [
      {
        "text": "Biologic Therapy",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Powell WT(1)(2), Debley JS(1)(2).",
    "entities": [
      {
        "text": "Debley JS(1)(2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)Center for Respiratory Biology and Therapeutics, Seattle Children's Research",
    "entities": [
      {
        "text": "Respiratory Biology and Therapeutics",
        "label": "WORK_OF_ART"
      },
      {
        "text": "Seattle Children's",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Institute, Seattle, Washington.",
    "entities": [
      {
        "text": "Seattle",
        "label": "GPE"
      },
      {
        "text": "Washington",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Division of Pulmonary and Sleep Medicine, Department of Pediatrics, Seattle",
    "entities": [
      {
        "text": "Pulmonary",
        "label": "PERSON"
      },
      {
        "text": "Department of Pediatrics",
        "label": "ORG"
      },
      {
        "text": "Seattle",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Children's Hospital, University of Washington, Seattle.",
    "entities": [
      {
        "text": "University of Washington",
        "label": "ORG"
      },
      {
        "text": "Seattle",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Inflammatory Pathways in Residual Asthma Exacerbations Among Mepolizumab-Treated",
    "entities": []
  },
  {
    "text": "Urban Children: A Secondary Analysis of a Randomized Clinical Trial.",
    "entities": []
  },
  {
    "text": "Kattan M(4), Gill MA(5), Stokes J(5), Liu AH(6), Khurana Hershey GK(7),",
    "entities": [
      {
        "text": "Kattan M(4",
        "label": "PERSON"
      },
      {
        "text": "Gill MA(5",
        "label": "PERSON"
      },
      {
        "text": "Stokes",
        "label": "PERSON"
      },
      {
        "text": "Liu AH(6",
        "label": "PERSON"
      },
      {
        "text": "Khurana Hershey GK(7",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "DJ(15)(16); Inner City Asthma Consortium and Childhood Asthma in Urban Settings",
    "entities": [
      {
        "text": "Inner City Asthma Consortium",
        "label": "ORG"
      },
      {
        "text": "Childhood Asthma",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Network.",
    "entities": []
  },
  {
    "text": "(1)Department of Medicine, University of Washington, Seattle.",
    "entities": [
      {
        "text": "Medicine, University of Washington",
        "label": "ORG"
      },
      {
        "text": "Seattle",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Center for Systems Immunology, Benaroya Research Institute, Seattle,",
    "entities": [
      {
        "text": "2)Center",
        "label": "CARDINAL"
      },
      {
        "text": "Benaroya Research Institute",
        "label": "ORG"
      },
      {
        "text": "Seattle",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Washington.",
    "entities": [
      {
        "text": "Washington",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Rho Inc, Chapel Hill, North Carolina.",
    "entities": [
      {
        "text": "3)Rho Inc",
        "label": "ORG"
      },
      {
        "text": "North Carolina",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Department of Pediatrics, Columbia University, New York, New York.",
    "entities": [
      {
        "text": "Pediatrics, Columbia University",
        "label": "ORG"
      },
      {
        "text": "New York",
        "label": "GPE"
      },
      {
        "text": "New York",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Department of Pediatrics, Washington University, St Louis, Missouri.",
    "entities": [
      {
        "text": "Pediatrics",
        "label": "ORG"
      },
      {
        "text": "Washington University",
        "label": "ORG"
      },
      {
        "text": "St Louis",
        "label": "GPE"
      },
      {
        "text": "Missouri",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)Department of Pediatrics, Children's Hospital Colorado, University of",
    "entities": [
      {
        "text": "Pediatrics, Children's Hospital Colorado",
        "label": "ORG"
      },
      {
        "text": "University of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Colorado School of Medicine, Aurora.",
    "entities": [
      {
        "text": "Colorado School of Medicine",
        "label": "ORG"
      },
      {
        "text": "Aurora",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(7)Department of Pediatrics, Cincinnati Children's Hospital, Cincinnati, Ohio.",
    "entities": [
      {
        "text": "Pediatrics",
        "label": "ORG"
      },
      {
        "text": "Cincinnati Children's Hospital",
        "label": "ORG"
      },
      {
        "text": "Cincinnati",
        "label": "GPE"
      },
      {
        "text": "Ohio",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(8)Department of Pediatrics, Ann and Robert H. Lurie Children's Hospital of",
    "entities": [
      {
        "text": "Pediatrics",
        "label": "GPE"
      },
      {
        "text": "Ann",
        "label": "PERSON"
      },
      {
        "text": "Robert H. Lurie Children's",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Chicago, Chicago, Illinois.",
    "entities": [
      {
        "text": "Chicago",
        "label": "GPE"
      },
      {
        "text": "Chicago",
        "label": "GPE"
      },
      {
        "text": "Illinois",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(9)Department of Medicine, University of Texas Southwestern Medical Center,",
    "entities": [
      {
        "text": "Medicine, University of Texas Southwestern Medical Center",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(10)Department of Medicine, Boston University School of Medicine, Boston,",
    "entities": [
      {
        "text": "10)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Medicine, Boston University School of Medicine",
        "label": "ORG"
      },
      {
        "text": "Boston",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(11)Department of Internal Medicine, Henry Ford Health System, Detroit,",
    "entities": [
      {
        "text": "11)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Internal Medicine",
        "label": "ORG"
      },
      {
        "text": "Henry Ford Health System",
        "label": "ORG"
      },
      {
        "text": "Detroit",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(12)Children's National Hospital, Washington, DC.",
    "entities": [
      {
        "text": "12)Children",
        "label": "CARDINAL"
      },
      {
        "text": "National Hospital",
        "label": "ORG"
      },
      {
        "text": "Washington, DC",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(13)Department of Medicine, University of California, San Francisco.",
    "entities": [
      {
        "text": "13)Department of Medicine, University of California,",
        "label": "MONEY"
      },
      {
        "text": "San Francisco",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(14)National Institute of Allergy and Infectious Diseases, National Institutes",
    "entities": [
      {
        "text": "14)National Institute of Allergy and Infectious Diseases",
        "label": "ORG"
      },
      {
        "text": "National Institutes\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of Health, Bethesda, Maryland.",
    "entities": [
      {
        "text": "Bethesda",
        "label": "GPE"
      },
      {
        "text": "Maryland",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(15)Department of Pediatrics, University of Wisconsin School of Medicine and",
    "entities": [
      {
        "text": "15)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Pediatrics, University of Wisconsin School of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Public Health, Madison.",
    "entities": [
      {
        "text": "Madison",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(16)Department of Medicine, University of Wisconsin School of Medicine and",
    "entities": [
      {
        "text": "16)Department of Medicine, University of Wisconsin School of Medicine",
        "label": "MONEY"
      }
    ]
  },
  {
    "text": "(17)Department of Pediatrics, Monroe Carell Jr Children's Hospital at",
    "entities": [
      {
        "text": "17)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Monroe Carell Jr Children's Hospital",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "IMPORTANCE: While biologic therapies targeting type 2 (T2) inflammation reduce",
    "entities": [
      {
        "text": "2",
        "label": "CARDINAL"
      },
      {
        "text": "T2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "acute exacerbation rates in children with asthma and T2 inflammation,",
    "entities": [
      {
        "text": "T2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "exacerbations still occur, and the underlying molecular mechanisms are poorly",
    "entities": []
  },
  {
    "text": "OBJECTIVE: To identify multiple distinct molecular mechanisms implicated in",
    "entities": []
  },
  {
    "text": "asthma exacerbations by characterizing respiratory illnesses among urban",
    "entities": []
  },
  {
    "text": "children with eosinophilic asthma enrolled in a clinical trial comparing",
    "entities": []
  },
  {
    "text": "treatment with mepolizumab vs placebo.",
    "entities": []
  },
  {
    "text": "DESIGN, SETTING, AND PARTICIPANTS: This is a secondary analysis of the",
    "entities": []
  },
  {
    "text": "Mechanisms Underlying Asthma Exacerbations Prevented and Persistent With",
    "entities": [
      {
        "text": "Mechanisms Underlying Asthma Exacerbations Prevented and Persistent With",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Immune-Based Therapy: A Systems Approach Phase 2 (MUPPITS-2) double-blind,",
    "entities": [
      {
        "text": "Immune-Based Therapy:",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "treatment with mepolizumab vs placebo among children with exacerbation-prone",
    "entities": []
  },
  {
    "text": "asthma in low-income urban centers in 9 US cities. Data analysis was performed",
    "entities": [
      {
        "text": "9",
        "label": "CARDINAL"
      },
      {
        "text": "US",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "from September 2022 to April 2025.",
    "entities": [
      {
        "text": "September 2022 to April 2025",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "INTERVENTION: Participants were randomized to receive either mepolizumab (aged",
    "entities": []
  },
  {
    "text": "6-11 years: 40 mg; aged 12-17 years: 100 mg) or matching placebo by subcutaneous",
    "entities": [
      {
        "text": "6-11 years",
        "label": "DATE"
      },
      {
        "text": "40",
        "label": "CARDINAL"
      },
      {
        "text": "12-17 years",
        "label": "DATE"
      },
      {
        "text": "100",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "injection once every 4 weeks for 52 weeks.",
    "entities": [
      {
        "text": "every 4 weeks",
        "label": "DATE"
      },
      {
        "text": "52 weeks",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "MAIN OUTCOMES AND MEASURES: The primary measurement was a transcriptomic modular",
    "entities": [
      {
        "text": "MAIN",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "analysis by RNA sequencing of nasal samples obtained during acute respiratory",
    "entities": [
      {
        "text": "RNA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "illnesses. Associations among upper airway transcriptional signatures, the",
    "entities": []
  },
  {
    "text": "clinical outcome of respiratory illnesses, and pulmonary functions were",
    "entities": []
  },
  {
    "text": "investigated.",
    "entities": []
  },
  {
    "text": "RESULTS: Of the 290 participants enrolled in the MUPPITS-2 trial, 108",
    "entities": [
      {
        "text": "290",
        "label": "CARDINAL"
      },
      {
        "text": "MUPPITS-2",
        "label": "GPE"
      },
      {
        "text": "108",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "participants (median [IQR] age, 10.0 [9.0-13.0] years; 48 [44%] female) were",
    "entities": [
      {
        "text": "10.0",
        "label": "CARDINAL"
      },
      {
        "text": "9.0-13.0",
        "label": "CARDINAL"
      },
      {
        "text": "48",
        "label": "CARDINAL"
      },
      {
        "text": "44%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "sampled during 176 acute respiratory illness events. During illness events",
    "entities": [
      {
        "text": "176",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "resulting in asthma exacerbations, children receiving mepolizumab demonstrated",
    "entities": []
  },
  {
    "text": "decreased expression of an eosinophil-associated module associated with T2",
    "entities": [
      {
        "text": "T2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "inflammation (log2 fold change [FC] estimate, -0.60; false discovery rate",
    "entities": []
  },
  {
    "text": "[FDR] < .05) but increased expression of gene modules associated with epithelial",
    "entities": []
  },
  {
    "text": "and macrophage inflammatory pathways relative to children receiving placebo",
    "entities": []
  },
  {
    "text": "(log2 FC estimates, 0.22-0.85; FDR < .05). Both groups showed higher expression",
    "entities": [
      {
        "text": "FC",
        "label": "ORG"
      },
      {
        "text": "0.22-0.85",
        "label": "CARDINAL"
      },
      {
        "text": "FDR",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "of mucus secretion and cellular stress response pathways during exacerbations",
    "entities": []
  },
  {
    "text": "relative to nonexacerbation illnesses. The mepolizumab group demonstrated",
    "entities": []
  },
  {
    "text": "upregulation of epithelial inflammatory pathways in exacerbations irrespective",
    "entities": []
  },
  {
    "text": "of a respiratory virus, while macrophage pathways contributed specifically to",
    "entities": []
  },
  {
    "text": "viral exacerbations. Three distinct, semiorthogonal inflammatory axes were shown",
    "entities": [
      {
        "text": "Three",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "to underlie the majority of the heterogeneity among exacerbations in the 2",
    "entities": [
      {
        "text": "2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "CONCLUSIONS AND RELEVANCE: The study's findings implicate multiple alternative",
    "entities": [
      {
        "text": "CONCLUSIONS",
        "label": "ORG"
      },
      {
        "text": "RELEVANCE",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "inflammatory pathways associated with the epithelium and macrophages, as well as",
    "entities": []
  },
  {
    "text": "mucus hypersecretion, as mechanisms of residual acute exacerbations in children",
    "entities": [
      {
        "text": "mucus hypersecretion",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "receiving mepolizumab. Further, they indicate that multiple distinct",
    "entities": []
  },
  {
    "text": "inflammatory axes can independently contribute to asthma exacerbations.",
    "entities": []
  },
  {
    "text": "Conflict of interest statement: Conflict of Interest Disclosures: Dr Kattan",
    "entities": [
      {
        "text": "Conflict of Interest Disclosures",
        "label": "ORG"
      },
      {
        "text": "Kattan",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "reported personal fees from Regeneron outside the submitted work. Dr Gill",
    "entities": [
      {
        "text": "Regeneron",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "reported grants and honoraria from the National Institute of Allergy and",
    "entities": [
      {
        "text": "the National Institute of Allergy",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Infectious Diseases, National Institutes of Health during the conduct of the",
    "entities": [
      {
        "text": "National Institutes of Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "study; and honoraria from the American Academy of Pediatrics outside the",
    "entities": [
      {
        "text": "the American Academy of Pediatrics",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "submitted work. Dr Stokes reported grants from the National Institutes of Health",
    "entities": [
      {
        "text": "Dr Stokes",
        "label": "PERSON"
      },
      {
        "text": "the National Institutes of Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "during the conduct of the study; and grants from the National Heart, Lung, and",
    "entities": [
      {
        "text": "the National Heart",
        "label": "ORG"
      },
      {
        "text": "Lung",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Blood Institute and National Institutes of Health outside the submitted work. Dr",
    "entities": [
      {
        "text": "Blood Institute and National Institutes of Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Liu reported grants from the National Institutes of Health during the conduct of",
    "entities": [
      {
        "text": "Liu",
        "label": "PERSON"
      },
      {
        "text": "the National Institutes of Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "the study; and personal fees from ThermoFisher Scientific, Phadia, AstraZeneca,",
    "entities": [
      {
        "text": "ThermoFisher Scientific",
        "label": "ORG"
      },
      {
        "text": "Phadia",
        "label": "GPE"
      },
      {
        "text": "AstraZeneca",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "OM Pharma, Avillion, and Labcorp, grants from OM Pharma, ResMed/Propeller",
    "entities": [
      {
        "text": "Labcorp",
        "label": "ORG"
      },
      {
        "text": "Pharma",
        "label": "PERSON"
      },
      {
        "text": "ResMed/Propeller",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Health, and Avillion, and nonfinancial support from Revenio and ResMed/Propeller",
    "entities": [
      {
        "text": "Avillion",
        "label": "ORG"
      },
      {
        "text": "Revenio",
        "label": "PERSON"
      },
      {
        "text": "ResMed/Propeller",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Health outside the submitted work. Dr Khurana Hershey reported grants from Adare",
    "entities": [
      {
        "text": "Khurana Hershey",
        "label": "PERSON"
      },
      {
        "text": "Adare",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "during the conduct of the study. Dr Sherenian reported employment with AbbVie",
    "entities": [
      {
        "text": "Dr Sherenian",
        "label": "PERSON"
      },
      {
        "text": "AbbVie",
        "label": "LAW"
      }
    ]
  },
  {
    "text": "outside the submitted work. Dr Robison reported grants from Sanofi and",
    "entities": [
      {
        "text": "Dr Robison",
        "label": "PERSON"
      },
      {
        "text": "Sanofi",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "AstraZeneca outside the submitted work. Dr Gruchalla reported employment with",
    "entities": [
      {
        "text": "AstraZeneca",
        "label": "NORP"
      },
      {
        "text": "Gruchalla",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "the Center for Biologics Evaluation and Research and personal fees from the",
    "entities": [
      {
        "text": "the Center for Biologics Evaluation and Research",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Massachusetts Medical Society outside the submitted work. Dr O\u2019Connor reported",
    "entities": [
      {
        "text": "Massachusetts Medical Society",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "grants from the National Institutes of Health during the conduct of the study.",
    "entities": [
      {
        "text": "the National Institutes of Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Dr Zoratti reported grants from the National Institute of Allergy and Infectious",
    "entities": [
      {
        "text": "Zoratti",
        "label": "ORG"
      },
      {
        "text": "the National Institute of Allergy and Infectious\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Diseases, National Institutes of Health during the conduct of the study; and",
    "entities": [
      {
        "text": "National Institutes of Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "grants from the National Institute of Allergy and Infectious Diseases, National",
    "entities": [
      {
        "text": "the National Institute of Allergy and Infectious Diseases",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Institutes of Health outside the submitted work. Dr Teach reported grants from",
    "entities": [
      {
        "text": "Institutes of Health",
        "label": "ORG"
      },
      {
        "text": "Dr Teach",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "the National Institutes of Health during the conduct of the study; and grants",
    "entities": [
      {
        "text": "the National Institutes of Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "from the National Heart, Lung, and Blood Institute, National Institutes of",
    "entities": [
      {
        "text": "the National Heart",
        "label": "ORG"
      },
      {
        "text": "Lung",
        "label": "PERSON"
      },
      {
        "text": "Blood Institute",
        "label": "ORG"
      },
      {
        "text": "National Institutes of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Health and personal fees from Medscape and UpToDate outside the submitted work.",
    "entities": [
      {
        "text": "Medscape",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Dr Lynch reported grants from the National Institute of Allergy and Infectious",
    "entities": [
      {
        "text": "Dr Lynch",
        "label": "ORG"
      },
      {
        "text": "the National Institute of Allergy and Infectious\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "personal fees from Siolta Therapeutics Inc and Sanofi, a patent issued for",
    "entities": [
      {
        "text": "Siolta Therapeutics Inc",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "reductive prodrug cancer chemothera (Stan449-PRV), patent WO 2010091189 A1",
    "entities": [
      {
        "text": "Stan449-PRV",
        "label": "ORG"
      },
      {
        "text": "WO 2010091189",
        "label": "DATE"
      },
      {
        "text": "A1",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "issued (combination antibiotic and antibody therapy for the treatment of",
    "entities": []
  },
  {
    "text": "Pseudomonas aeruginosa infection) with royalties paid to KaloBios Inc, a patent",
    "entities": [
      {
        "text": "KaloBios Inc",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "for therapeutic microbial consortium for induction of immune tolerance licensed",
    "entities": []
  },
  {
    "text": "to Siolta Therapeutics, patent WO 2012027302 A3 issued (systems and methods for",
    "entities": [
      {
        "text": "Siolta Therapeutics",
        "label": "ORG"
      },
      {
        "text": "WO 2012027302",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "detecting antibiotic resistance), a patent US 7687474 B2 issued (nitroreductase",
    "entities": [
      {
        "text": "US 7687474 B2",
        "label": "EVENT"
      }
    ]
  },
  {
    "text": "enzymes), patent WO 2013155370 A1 issued (sinusitis diagnostics and treatments),",
    "entities": [
      {
        "text": "WO 2013155370",
        "label": "DATE"
      },
      {
        "text": "A1",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "patent US 20120264637 A1 issued (methods and systems for phylogenetic analysis),",
    "entities": [
      {
        "text": "US",
        "label": "GPE"
      },
      {
        "text": "20120264637",
        "label": "DATE"
      },
      {
        "text": "A1",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "a patent for methods and compositions relating to epoxide hydrolase genes issued",
    "entities": []
  },
  {
    "text": "to Siolta Therapeutics, and being a cofounder of Siolta Therapeutics outside the",
    "entities": [
      {
        "text": "Siolta Therapeutics",
        "label": "ORG"
      },
      {
        "text": "Siolta Therapeutics",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "submitted work. Dr Dill-McFarland reported personal fees from EuropaDX and",
    "entities": [
      {
        "text": "Dr Dill-McFarland",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Seattle BioSoftware outside the submitted work. Dr Togias reported employment",
    "entities": [
      {
        "text": "Seattle",
        "label": "GPE"
      },
      {
        "text": "BioSoftware",
        "label": "ORG"
      },
      {
        "text": "Dr Togias",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "with the National Institute of Allergy and Infectious Diseases, National",
    "entities": [
      {
        "text": "the National Institute of Allergy and Infectious Diseases",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Institutes of Health outside the submitted work. Dr Gern reported personal fees",
    "entities": [
      {
        "text": "Institutes of Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "from Meissa Vaccines Inc, Arrowhead Pharmaceuticals, Via Nova Therapeutics Inc,",
    "entities": [
      {
        "text": "Meissa Vaccines Inc",
        "label": "ORG"
      },
      {
        "text": "Arrowhead Pharmaceuticals",
        "label": "ORG"
      },
      {
        "text": "Via Nova Therapeutics Inc",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and AstraZeneca, stock options with Meissa Vaccines Inc, and 2 patents for",
    "entities": [
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "Meissa Vaccines Inc",
        "label": "ORG"
      },
      {
        "text": "2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "methods to enhance the production of rhinoviruses outside the submitted work. Dr",
    "entities": []
  },
  {
    "text": "Bacharier reported personal fees from GlaxoSmithKline, Sanofi/Regeneron,",
    "entities": [
      {
        "text": "Bacharier",
        "label": "PERSON"
      },
      {
        "text": "GlaxoSmithKline",
        "label": "ORG"
      },
      {
        "text": "Sanofi/Regeneron",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "AstraZeneca, and Novartis during the conduct of the study; and personal fees",
    "entities": [
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "Novartis",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "GlaxoSmithKline, DBV Technologies, Teva, Medscape, Kinaset, OM Pharma, and",
    "entities": [
      {
        "text": "GlaxoSmithKline",
        "label": "ORG"
      },
      {
        "text": "DBV Technologies",
        "label": "ORG"
      },
      {
        "text": "Kinaset",
        "label": "ORG"
      },
      {
        "text": "Pharma",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "AstraZeneca, book royalties from Elsevier, honoraria from Sanofi, Regeneron, and",
    "entities": [
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "Sanofi",
        "label": "GPE"
      },
      {
        "text": "Regeneron",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "GlaxoSmithKline, advisory board participation for DBV Technologies, AstraZeneca",
    "entities": [
      {
        "text": "GlaxoSmithKline",
        "label": "ORG"
      },
      {
        "text": "DBV Technologies",
        "label": "ORG"
      },
      {
        "text": "AstraZeneca",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "and Vertex, leadership roles for the American Academy of Allergy, Asthma, and",
    "entities": [
      {
        "text": "Vertex",
        "label": "GPE"
      },
      {
        "text": "the American Academy of Allergy",
        "label": "ORG"
      },
      {
        "text": "Asthma",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Immunology and the American Board of Allergy and Immunology, and medical writing",
    "entities": [
      {
        "text": "the American Board of Allergy and Immunology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "services for Sanofi/Regeneron. outside the submitted work. Dr Busse reported",
    "entities": [
      {
        "text": "Sanofi/Regeneron",
        "label": "ORG"
      },
      {
        "text": "Busse",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "personal fees from Sanofi, Regeneron, GlaxoSmithKline, Novartis, Genentech, and",
    "entities": [
      {
        "text": "Sanofi",
        "label": "GPE"
      },
      {
        "text": "Regeneron",
        "label": "GPE"
      },
      {
        "text": "GlaxoSmithKline",
        "label": "PERSON"
      },
      {
        "text": "Novartis",
        "label": "ORG"
      },
      {
        "text": "Genentech",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "AstraZeneca and royalties from Elsevier outside the submitted work. Dr Jackson",
    "entities": [
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "Dr Jackson",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "reported grants from the National Institute of Allergy and Infectious Diseases,",
    "entities": [
      {
        "text": "the National Institute of Allergy and Infectious Diseases",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "National Institutes of Health and GlaxoSmithKline during the conduct of the",
    "entities": [
      {
        "text": "National Institutes of Health",
        "label": "ORG"
      },
      {
        "text": "GlaxoSmithKline",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "study; personal fees from Avillion, AstraZeneca, Areteia, Genentech,",
    "entities": [
      {
        "text": "Avillion",
        "label": "NORP"
      },
      {
        "text": "Areteia",
        "label": "ORG"
      },
      {
        "text": "Genentech",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "GlaxoSmithKline, Regeneron, Sanofi, Upstream Bio, Pfizer, Novartis, and Vifor",
    "entities": [
      {
        "text": "GlaxoSmithKline",
        "label": "PERSON"
      },
      {
        "text": "Regeneron",
        "label": "GPE"
      },
      {
        "text": "Sanofi",
        "label": "GPE"
      },
      {
        "text": "Upstream Bio",
        "label": "PERSON"
      },
      {
        "text": "Pfizer",
        "label": "PERSON"
      },
      {
        "text": "Novartis",
        "label": "ORG"
      },
      {
        "text": "Vifor",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Pharma and grants from Regeneron, GlaxoSmithKline, and the National Heart, Lung,",
    "entities": [
      {
        "text": "Pharma",
        "label": "PERSON"
      },
      {
        "text": "Regeneron",
        "label": "GPE"
      },
      {
        "text": "GlaxoSmithKline",
        "label": "PERSON"
      },
      {
        "text": "the National Heart",
        "label": "ORG"
      },
      {
        "text": "Lung",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "and Blood Institute, National Institutes of Health outside the submitted work.",
    "entities": [
      {
        "text": "Blood Institute",
        "label": "ORG"
      },
      {
        "text": "National Institutes of Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "No other disclosures were reported.",
    "entities": []
  },
  {
    "text": "''Unraveling the effects of smoking in asthmatic adolescents: clinical outcomes,",
    "entities": []
  },
  {
    "text": "spirometry findings, and risk analysis''.",
    "entities": []
  },
  {
    "text": "(1)Department of Pediatric Allergy/Immunology, Ankara Bilkent City Hospital,",
    "entities": [
      {
        "text": "Pediatric Allergy/Immunology",
        "label": "ORG"
      },
      {
        "text": "Ankara Bilkent City Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)Department of Pediatrics, Division of Adolescent Medicine, Ankara Y\u0131ld\u0131r\u0131m",
    "entities": [
      {
        "text": "Pediatrics, Division of Adolescent Medicine",
        "label": "ORG"
      },
      {
        "text": "Ankara Y\u0131ld\u0131r\u0131m",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(3)Department of Pediatric Allergy/Immunology, Ankara Bilkent City Hospital,",
    "entities": [
      {
        "text": "Pediatric Allergy/Immunology",
        "label": "ORG"
      },
      {
        "text": "Ankara Bilkent City Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)Department of Pediatric Allergy/Immunology, University of Health Sciences,",
    "entities": [
      {
        "text": "Pediatric Allergy/Immunology",
        "label": "ORG"
      },
      {
        "text": "University of Health Sciences",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Adolescent smoking and asthma are major global public health concerns. This",
    "entities": []
  },
  {
    "text": "study aims to comprehensively assess the impact of smoking on asthma control,",
    "entities": []
  },
  {
    "text": "pulmonary function, and risk factors for uncontrolled asthma in adolescents. A",
    "entities": []
  },
  {
    "text": "total of 126 adolescents aged 10 to 18 years were categorized into three groups:",
    "entities": [
      {
        "text": "126",
        "label": "CARDINAL"
      },
      {
        "text": "10 to 18 years",
        "label": "DATE"
      },
      {
        "text": "three",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "(1) smoking asthmatics, (2) non-smoking asthmatics, and (3) smoking",
    "entities": [
      {
        "text": "1",
        "label": "CARDINAL"
      },
      {
        "text": "2",
        "label": "CARDINAL"
      },
      {
        "text": "3",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "non-asthmatics. Asthma symptom control was determined according to the Global",
    "entities": []
  },
  {
    "text": "Initiative for Asthma (GINA). Demographic and clinical characteristics,",
    "entities": []
  },
  {
    "text": "pulmonary function test (PFT) results, and healthcare utilization data were",
    "entities": [
      {
        "text": "PFT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "compared across the groups. Univariate and multivariate logistic regression",
    "entities": []
  },
  {
    "text": "analyses were performed to identify risk factors for uncontrolled asthma.",
    "entities": []
  },
  {
    "text": "Smoking asthmatics exhibited significantly lower FEV\u2081%, FEF\u2082\u2085\u208b\u2087\u2085%, and PEF%",
    "entities": []
  },
  {
    "text": "values compared to non-smoking asthmatics (p = 0.042, p = 0.045, p = 0.002,",
    "entities": [
      {
        "text": "0.042",
        "label": "CARDINAL"
      },
      {
        "text": "0.045",
        "label": "CARDINAL"
      },
      {
        "text": "0.002",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "respectively). The prevalence of uncontrolled asthma was significantly higher in",
    "entities": []
  },
  {
    "text": "smoking asthmatics (p = 0.005). Additionally, short-acting bronchodilator use in",
    "entities": [
      {
        "text": "0.005",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "the past year (p = 0.004) and hospital admissions and/or emergency department",
    "entities": [
      {
        "text": "the past year",
        "label": "DATE"
      },
      {
        "text": "0.004",
        "label": "CARDINAL"
      },
      {
        "text": "admissions and/or emergency department\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "visits due to breathlessness (p < 0.001) were significantly increased in this",
    "entities": []
  },
  {
    "text": "group. In multivariate analysis, current smoking status (OR = 4.973, 95%",
    "entities": [
      {
        "text": "4.973",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "CI:1.120-22.089, p = 0.035), lower FEV\u2081% (OR = 1.155, 95% CI:1.077-1.240,",
    "entities": [
      {
        "text": "0.035",
        "label": "CARDINAL"
      },
      {
        "text": "1.155",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "p < 0.001), and atopic status (OR = 3.977, 95% CI:1.100-14.382, p = 0.035)",
    "entities": [
      {
        "text": "p < 0.001",
        "label": "ORG"
      },
      {
        "text": "3.977",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "0.035",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "emerged as independent predictors of poor asthma control.",
    "entities": []
  },
  {
    "text": "CONCLUSION: These findings highlight smoking as a key determinant of worsened",
    "entities": []
  },
  {
    "text": "pulmonary function, poor asthma control, and increased healthcare utilization",
    "entities": []
  },
  {
    "text": "among adolescents with asthma. The results underscore the urgent need for",
    "entities": []
  },
  {
    "text": "smoking cessation strategies in this population, emphasizing their crucial role",
    "entities": []
  },
  {
    "text": "in preventing long-term pulmonary function decline and improving clinical",
    "entities": []
  },
  {
    "text": "WHAT IS KNOWN: \u2022 Smoking increases asthma severity and reduces treatment",
    "entities": []
  },
  {
    "text": "response. However, its specific effects on asthma control and lung function in",
    "entities": []
  },
  {
    "text": "adolescents remain underexplored.",
    "entities": []
  },
  {
    "text": "WHAT IS NEW: \u2022 This study shows that adolescent smokers have significantly",
    "entities": []
  },
  {
    "text": "higher rates of uncontrolled asthma, make more frequent visits to the emergency",
    "entities": []
  },
  {
    "text": "department, and use bronchodilators more often. Smoking, reduced FEV\u2081%, and",
    "entities": []
  },
  {
    "text": "atopic status were identified as independent predictors of poor asthma control.",
    "entities": []
  },
  {
    "text": "These findings highlight the importance of early spirometric evaluation and",
    "entities": []
  },
  {
    "text": "targeted smoking cessation strategies for adolescents.",
    "entities": []
  },
  {
    "text": "PMID: 40658260 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40658260",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Declarations. Ethics approval : It was approved",
    "entities": []
  },
  {
    "text": "by the Ankara Bilkent City Hospital Clinical Trials Board and conducted",
    "entities": [
      {
        "text": "the Ankara Bilkent City Hospital Clinical Trials Board",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "following the ethical principles of the Declaration of Helsinki. Consent to",
    "entities": [
      {
        "text": "the Declaration of Helsinki",
        "label": "WORK_OF_ART"
      }
    ]
  },
  {
    "text": "participate: Written informed consent was obtained from the parents of all",
    "entities": []
  },
  {
    "text": "participants included in the study. Consent to publish: Written informed consent",
    "entities": []
  },
  {
    "text": "for publication was obtained from the parents of all participants included in",
    "entities": []
  },
  {
    "text": "the study. All authors have read and approved the submitted version of this",
    "entities": []
  },
  {
    "text": "paper and have met the requirements for authorship. The undersigned authors",
    "entities": []
  },
  {
    "text": "warrant that the article is original and has not been submitted to any other",
    "entities": []
  },
  {
    "text": "journal. The authors certify that they have (collectively) personally written at",
    "entities": []
  },
  {
    "text": "least 90 percent of the manuscript. Competing interests: The authors declare no",
    "entities": []
  },
  {
    "text": "51. ACS Appl Mater Interfaces. 2025 Jul 14. doi: 10.1021/acsami.5c04325. Online",
    "entities": [
      {
        "text": "51",
        "label": "CARDINAL"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "14",
        "label": "CARDINAL"
      },
      {
        "text": "10.1021",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "High-Performance Biocompatible Moisture-Enabled Nanogenerators Using a",
    "entities": []
  },
  {
    "text": "Gelatin-SnS(2) Composite for Sustainable Energy Harvesting.",
    "entities": [
      {
        "text": "Gelatin-SnS(2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)School of Nano Science and Technology, Indian Institute of Technology",
    "entities": [
      {
        "text": "Nano Science and Technology",
        "label": "ORG"
      },
      {
        "text": "Indian Institute of Technology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)Organic Electronics Laboratory, Department of Physics, Indian Institute of",
    "entities": [
      {
        "text": "2)Organic Electronics Laboratory",
        "label": "ORG"
      },
      {
        "text": "Department of Physics",
        "label": "ORG"
      },
      {
        "text": "Indian Institute",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "The rising global energy demand and environmental concerns necessitate the",
    "entities": []
  },
  {
    "text": "development of sustainable energy-harvesting technologies. Among these,",
    "entities": []
  },
  {
    "text": "moisture-enabled nanogenerators (MEGs) have emerged as a promising solution,",
    "entities": []
  },
  {
    "text": "harnessing ubiquitous moisture in the environment to generate clean energy. MEGs",
    "entities": []
  },
  {
    "text": "operate through diffusion-induced micro- or nanofluidic proton transport between",
    "entities": []
  },
  {
    "text": "two electrodes; however, existing devices often produce only transient outputs.",
    "entities": [
      {
        "text": "two",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Addressing this limitation, we developed a biocompatible MEG utilizing a",
    "entities": [
      {
        "text": "MEG",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "continuous open-circuit voltage of 0.95 V, a short-circuit current of 241.6 \u03bcA,",
    "entities": [
      {
        "text": "0.95",
        "label": "CARDINAL"
      },
      {
        "text": "241.6",
        "label": "CARDINAL"
      },
      {
        "text": "\u03bcA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and a power density of approximately 358.6 \u03bcW/cm2 at 90% relative humidity (RH).",
    "entities": [
      {
        "text": "approximately 358.6",
        "label": "CARDINAL"
      },
      {
        "text": "90%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "Furthermore, the device demonstrates the capability to generate electricity from",
    "entities": []
  },
  {
    "text": "human breath and hand proximity, opening avenues for self-powered medical",
    "entities": []
  },
  {
    "text": "devices. The fast response of humidity makes it suitable for health monitoring",
    "entities": []
  },
  {
    "text": "applications in conditions such as sleep apnea, asthma, and respiratory",
    "entities": []
  },
  {
    "text": "disorders. A comparative performance analysis with other protein/2D",
    "entities": []
  },
  {
    "text": "material-based MEGs highlights the superior efficiency and stability of our",
    "entities": []
  },
  {
    "text": "device. The integration of gelatin with SnS2 enhances energy output while",
    "entities": [
      {
        "text": "gelatin",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "maintaining environmental friendliness, paving the way for next-generation",
    "entities": []
  },
  {
    "text": "autonomous electronics. This study underscores the potential of biocompatible",
    "entities": []
  },
  {
    "text": "MEGs in addressing energy challenges through innovative and sustainable",
    "entities": []
  },
  {
    "text": "approaches.",
    "entities": []
  },
  {
    "text": "Human Neutrophils are a Cellular Source of Apolipoprotein A-I.",
    "entities": [
      {
        "text": "a Cellular Source of Apolipoprotein A-I.",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Yao X(1), Mills J(1), Dagur PK(2), Lin WC(2), Lopez-Ocasio M(2), Gao M(1), Yu",
    "entities": [
      {
        "text": "Yao X(1",
        "label": "PERSON"
      },
      {
        "text": "Dagur PK(2",
        "label": "PERSON"
      },
      {
        "text": "Lin",
        "label": "PERSON"
      },
      {
        "text": "Lopez-Ocasio",
        "label": "PERSON"
      },
      {
        "text": "Gao",
        "label": "PERSON"
      },
      {
        "text": "Yu\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)Laboratory of Asthma and Lung Inflammation, Critical Care Medicine and",
    "entities": [
      {
        "text": "Asthma",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes",
    "entities": [
      {
        "text": "Pulmonary Branch",
        "label": "PERSON"
      },
      {
        "text": "National Heart",
        "label": "ORG"
      },
      {
        "text": "Lung",
        "label": "PERSON"
      },
      {
        "text": "Blood Institute",
        "label": "ORG"
      },
      {
        "text": "National Institutes\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of Health, Bethesda, Maryland 20892.",
    "entities": [
      {
        "text": "Bethesda",
        "label": "GPE"
      },
      {
        "text": "Maryland",
        "label": "GPE"
      },
      {
        "text": "20892",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "(2)Flow Cytometry Core Facility, National Heart, Lung, and Blood Institute,",
    "entities": [
      {
        "text": "2)Flow Cytometry Core Facility",
        "label": "ORG"
      },
      {
        "text": "Lung",
        "label": "PERSON"
      },
      {
        "text": "Blood Institute",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "National Institutes of Health, Bethesda, Maryland 20892.",
    "entities": [
      {
        "text": "National Institutes of Health",
        "label": "ORG"
      },
      {
        "text": "Bethesda",
        "label": "GPE"
      },
      {
        "text": "Maryland",
        "label": "GPE"
      },
      {
        "text": "20892",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "(3)Pathology Core Facility, National Heart, Lung, and Blood Institute, National",
    "entities": [
      {
        "text": "Core Facility",
        "label": "ORG"
      },
      {
        "text": "Lung",
        "label": "PERSON"
      },
      {
        "text": "Blood Institute",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Institutes of Health, Bethesda, Maryland 20892.",
    "entities": [
      {
        "text": "Institutes of Health",
        "label": "ORG"
      },
      {
        "text": "Bethesda",
        "label": "GPE"
      },
      {
        "text": "Maryland",
        "label": "GPE"
      },
      {
        "text": "20892",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "(4)Animal Surgery and Resources Core Facility, National Heart, Lung, and Blood",
    "entities": [
      {
        "text": "Lung",
        "label": "PERSON"
      },
      {
        "text": "Blood",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "Institute, National Institutes of Health, Bethesda, Maryland 20892.",
    "entities": [
      {
        "text": "Institute, National Institutes of Health",
        "label": "ORG"
      },
      {
        "text": "Bethesda",
        "label": "GPE"
      },
      {
        "text": "Maryland",
        "label": "GPE"
      },
      {
        "text": "20892",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Apolipoprotein A-I (APOA1), the major protein of high-density lipoproteins, has",
    "entities": []
  },
  {
    "text": "anti-inflammatory functions. APOA1 is primarily produced in the liver, however,",
    "entities": [
      {
        "text": "APOA1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "it is not known whether neutrophils are a cellular source. Here, we assessed",
    "entities": []
  },
  {
    "text": "whether human neutrophils express APOA1. Peripheral blood and bronchoalveolar",
    "entities": [
      {
        "text": "APOA1",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "lavage fluid (BALF) were obtained from healthy volunteers (HVs) and asthmatics.",
    "entities": [
      {
        "text": "lavage fluid",
        "label": "PERSON"
      },
      {
        "text": "BALF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Peripheral blood neutrophils from HVs expressed APOA1 at both the mRNA and",
    "entities": [
      {
        "text": "APOA1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "protein levels, while confocal microscopy demonstrated that APOA1 was localized",
    "entities": [
      {
        "text": "APOA1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "to a unique population of intracytoplasmic granules. In HVs and asthmatics,",
    "entities": []
  },
  {
    "text": "APOA1 was preferentially expressed by neutrophils with high side-scatter",
    "entities": [
      {
        "text": "APOA1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(SSChigh) in blood and BALF. Furthermore, APOA1+ SSChigh neutrophils were",
    "entities": [
      {
        "text": "SSChigh",
        "label": "ORG"
      },
      {
        "text": "BALF",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "characterized as a population with high levels of caspase-3/7 activation and",
    "entities": []
  },
  {
    "text": "CCR5 expression. Since APOA1 has anti-inflammatory functions, this suggests that",
    "entities": [
      {
        "text": "APOA1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "APOA1 expression by neutrophils may represent a mechanism to attenuate excessive",
    "entities": []
  },
  {
    "text": "inflammatory responses in health and disease.",
    "entities": []
  },
  {
    "text": "Published by Oxford University Press on behalf of Society for Leukocyte Biology",
    "entities": [
      {
        "text": "Oxford University Press",
        "label": "ORG"
      },
      {
        "text": "Society for Leukocyte Biology\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "eCollection 2025 Jun 20.",
    "entities": [
      {
        "text": "eCollection",
        "label": "ORG"
      },
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "20",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Method for Extracellular Electrochemical Impedance Spectroscopy on Epithelial",
    "entities": [
      {
        "text": "Method for Extracellular Electrochemical Impedance Spectroscopy on Epithelial",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Cell Monolayers.",
    "entities": []
  },
  {
    "text": "Chien AJ(1), Lewallen CF(2), Khor H(3), Cegla AV(4), Guo R(5), Watson AL(6),",
    "entities": [
      {
        "text": "Chien AJ(1)",
        "label": "PERSON"
      },
      {
        "text": "Lewallen CF(2",
        "label": "PERSON"
      },
      {
        "text": "Cegla",
        "label": "PERSON"
      },
      {
        "text": "Guo",
        "label": "PERSON"
      },
      {
        "text": "Watson AL(6",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Hatcher C(6), McCarty NA(4), Bharti K(2), Forest CR(1)(5).",
    "entities": [
      {
        "text": "McCarty NA(4",
        "label": "PERSON"
      },
      {
        "text": "Bharti",
        "label": "ORG"
      },
      {
        "text": "Forest CR(1)(5",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of",
    "entities": [
      {
        "text": "H. Coulter Department of Biomedical Engineering",
        "label": "ORG"
      },
      {
        "text": "Georgia Institute",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Technology, Atlanta, GA, USA.",
    "entities": [
      {
        "text": "Atlanta",
        "label": "GPE"
      },
      {
        "text": "GA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Ocular and Stem Cell Translational Research Section, Ophthalmic Genetics and",
    "entities": [
      {
        "text": "Stem Cell Translational Research Section",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Visual Function Branch, National Eye Institute, National Institutes of Health,",
    "entities": [
      {
        "text": "Visual Function Branch",
        "label": "ORG"
      },
      {
        "text": "National Eye Institute",
        "label": "ORG"
      },
      {
        "text": "National Institutes of Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Bethesda, MD, USA.",
    "entities": [
      {
        "text": "Bethesda",
        "label": "GPE"
      },
      {
        "text": "MD",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)School of Electrical and Computer Engineering, Georgia Institute of",
    "entities": [
      {
        "text": "Electrical and Computer Engineering",
        "label": "ORG"
      },
      {
        "text": "Georgia Institute",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)Division of Pulmonology, Asthma, Cystic Fibrosis, and Sleep, Department of",
    "entities": [
      {
        "text": "Sleep, Department",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Pediatrics, Emory + Children's Center for Cystic Fibrosis and Airways Disease",
    "entities": [
      {
        "text": "Center for Cystic Fibrosis and Airways Disease",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Research, Emory University, Atlanta, GA, USA.",
    "entities": [
      {
        "text": "Research, Emory University",
        "label": "ORG"
      },
      {
        "text": "Atlanta",
        "label": "GPE"
      },
      {
        "text": "GA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)G.W. Woodruff School of Mechanical Engineering, Georgia Institute of",
    "entities": [
      {
        "text": "5)G.W. Woodruff School of Mechanical Engineering",
        "label": "ORG"
      },
      {
        "text": "Georgia Institute",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(6)World Precision Instruments, Sarasota, FL, USA.",
    "entities": [
      {
        "text": "Precision Instruments",
        "label": "ORG"
      },
      {
        "text": "Sarasota",
        "label": "GPE"
      },
      {
        "text": "FL",
        "label": "ORG"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Epithelial tissues form barriers to the flow of ions, nutrients, waste products,",
    "entities": []
  },
  {
    "text": "bacteria, and viruses. The conventional electrophysiology measurement of",
    "entities": []
  },
  {
    "text": "transepithelial resistance (TEER/TER) can quantify epithelial barrier integrity,",
    "entities": [
      {
        "text": "TEER/TER",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "but does not capture all the electrical behavior of the tissue or provide",
    "entities": []
  },
  {
    "text": "insight into membrane-specific properties. Electrochemical impedance",
    "entities": []
  },
  {
    "text": "spectroscopy, in addition to measurement of TER, enables measurement of",
    "entities": [
      {
        "text": "TER",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "transepithelial capacitance (TEC) and a ratio of electrical time constants for",
    "entities": [
      {
        "text": "TEC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "the tissue, which we term the membrane ratio. This protocol describes how to",
    "entities": []
  },
  {
    "text": "perform galvanostatic electrochemical impedance spectroscopy on epithelia using",
    "entities": []
  },
  {
    "text": "commercially available cell culture inserts and chambers, detailing the",
    "entities": []
  },
  {
    "text": "apparatus, electrical signal, fitting technique, and error quantification. The",
    "entities": []
  },
  {
    "text": "measurement can be performed in under 1 min on commercially available cell",
    "entities": []
  },
  {
    "text": "culture inserts and electrophysiology chambers using instrumentation capable of",
    "entities": []
  },
  {
    "text": "fits to the model have less than 10 \u03a9 mean absolute error, revealing repeatable",
    "entities": [
      {
        "text": "less than 10",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "values distinct for each cell type. On representative retinal pigment (n = 3)",
    "entities": [
      {
        "text": "3",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "and bronchiolar epithelial samples (n = 4), TER measurements were 500-667 \u03a9\u00b7cm2",
    "entities": [
      {
        "text": "4",
        "label": "CARDINAL"
      },
      {
        "text": "TER",
        "label": "ORG"
      },
      {
        "text": "500-667",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "and 955-1,034 \u03a9\u00b7cm2 (within the expected range), TEC measurements were 3.65-4.10",
    "entities": [
      {
        "text": "955",
        "label": "CARDINAL"
      },
      {
        "text": "TEC",
        "label": "ORG"
      },
      {
        "text": "3.65-4.10",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "\u03bcF/cm2 and 1.07-1.10 \u03bcF/cm2, and membrane ratio measurements were 18-22 and",
    "entities": [
      {
        "text": "1.07-1.10",
        "label": "CARDINAL"
      },
      {
        "text": "18-22",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "1.9-2.2, respectively. Key features \u2022 This protocol requires preexisting",
    "entities": [
      {
        "text": "1.9",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "experience with culturing epithelial cells (such as Caco-2, RPE, and 16HBE) for",
    "entities": [
      {
        "text": "Caco-2",
        "label": "ORG"
      },
      {
        "text": "RPE",
        "label": "ORG"
      },
      {
        "text": "16HBE",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "a successful outcome. \u2022 Builds upon methods by Lewallen et al. [1] and Linz et",
    "entities": [
      {
        "text": "Lewallen et al",
        "label": "PERSON"
      },
      {
        "text": "1",
        "label": "CARDINAL"
      },
      {
        "text": "Linz et\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "al. [2], integrating commercial chambers and providing a quantitative estimate",
    "entities": [
      {
        "text": "2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "of error. \u2022 Provides code to run measurement, process data, and report error;",
    "entities": []
  },
  {
    "text": "requires access to MATLAB software, but no coding experience is necessary. \u2022",
    "entities": [
      {
        "text": "MATLAB",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Allows for repeated measurements on the same sample. Graphical overview",
    "entities": []
  },
  {
    "text": "Electrochemical impedance spectroscopy measurement involves sending a",
    "entities": []
  },
  {
    "text": "galvanostatic signal through the electrophysiology chamber and across the",
    "entities": []
  },
  {
    "text": "epithelial cell monolayer (left) and results in complex impedance data at each",
    "entities": [
      {
        "text": "epithelial cell",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "frequency. This data is then fit to an electrical circuit model to output",
    "entities": []
  },
  {
    "text": "transepithelial resistance (TER), transepithelial capacitance (TEC), and",
    "entities": [
      {
        "text": "TER",
        "label": "ORG"
      },
      {
        "text": "TEC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "membrane ratio (\u03b1) (right).",
    "entities": []
  },
  {
    "text": "\u00a9Copyright : \u00a9 2025 The Authors; This is an open access article under the CC",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "CC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Competing interestsThis research was partially",
    "entities": []
  },
  {
    "text": "supported under a Sponsored Research Agreement between the Georgia Tech Research",
    "entities": [
      {
        "text": "the Georgia Tech Research",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Corporation and World Precision Instruments. C.R. Forest, C. Lewallen, and K.",
    "entities": [
      {
        "text": "World Precision Instruments",
        "label": "ORG"
      },
      {
        "text": "C.R. Forest",
        "label": "ORG"
      },
      {
        "text": "C. Lewallen",
        "label": "PERSON"
      },
      {
        "text": "K.",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "Bharti, as well as A. Maminishkis are co-inventors on a patent pending related",
    "entities": [
      {
        "text": "Bharti",
        "label": "ORG"
      },
      {
        "text": "A. Maminishkis",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "to this protocol, entitled \u201cApparatus and method for Extracellular Impedance",
    "entities": [
      {
        "text": "Apparatus",
        "label": "ORG"
      },
      {
        "text": "Extracellular Impedance\n",
        "label": "WORK_OF_ART"
      }
    ]
  },
  {
    "text": "Spectroscopy of epithelia\u201d, filed Jan 15, 2024, GTRC 9153, utility application",
    "entities": [
      {
        "text": "Jan 15, 2024",
        "label": "DATE"
      },
      {
        "text": "GTRC 9153",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "18/412,842, and PCT filed. The patent is exclusively licensed by Georgia Tech",
    "entities": [
      {
        "text": "18/412,842",
        "label": "CARDINAL"
      },
      {
        "text": "PCT",
        "label": "ORG"
      },
      {
        "text": "Georgia Tech",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Research Corporation and National Institute of Health to World Precision",
    "entities": [
      {
        "text": "Research Corporation",
        "label": "ORG"
      },
      {
        "text": "National Institute of Health to World Precision",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "54. Ther Adv Med Oncol. 2025 Jul 10;17:17588359251355412. doi:",
    "entities": [
      {
        "text": "54",
        "label": "CARDINAL"
      },
      {
        "text": "2025",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Impact of asthma and/or chronic obstructive pulmonary disease on the survival of",
    "entities": []
  },
  {
    "text": "patients with lung adenocarcinoma.",
    "entities": []
  },
  {
    "text": "(1)Division of Pulmonary and Critical Care Medicine, Sun Yat-Sen Cancer Center,",
    "entities": []
  },
  {
    "text": "(2)School of Medicine, College of Medicine, National Yang Ming Chiao Tung",
    "entities": [
      {
        "text": "Medicine, College of Medicine",
        "label": "ORG"
      },
      {
        "text": "Yang Ming Chiao Tung",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "University, Taipei, Taiwan.",
    "entities": [
      {
        "text": "Taipei",
        "label": "GPE"
      },
      {
        "text": "Taiwan",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Office of Epidemiology and Biostatistics, Sun Yat-Sen Cancer Center, Taipei,",
    "entities": [
      {
        "text": "Taipei",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Department of Medical Oncology, Sun Yat-Sen Cancer Center, Taipei, Taiwan.",
    "entities": [
      {
        "text": "Medical Oncology",
        "label": "ORG"
      },
      {
        "text": "Taipei",
        "label": "GPE"
      },
      {
        "text": "Taiwan",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)School of Medical Laboratory Science and Biotechnology, College of Medical",
    "entities": [
      {
        "text": "5)School of Medical Laboratory Science and Biotechnology, College of Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Science and Technology, Taipei Medical University, Taipei, Taiwan.",
    "entities": [
      {
        "text": "Science and Technology",
        "label": "ORG"
      },
      {
        "text": "Taipei Medical University",
        "label": "ORG"
      },
      {
        "text": "Taipei",
        "label": "GPE"
      },
      {
        "text": "Taiwan",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)Ph.D. Program in Medical Biotechnology, College of Medical Science and",
    "entities": [
      {
        "text": "6)Ph",
        "label": "CARDINAL"
      },
      {
        "text": "D. Program",
        "label": "ORG"
      },
      {
        "text": "Medical Biotechnology, College of Medical Science",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Technology, Taipei Medical University, Taipei, Taiwan.",
    "entities": [
      {
        "text": "Taipei Medical University",
        "label": "ORG"
      },
      {
        "text": "Taipei",
        "label": "GPE"
      },
      {
        "text": "Taiwan",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "BACKGROUND: Chronic airway inflammation in asthma and/or chronic obstructive",
    "entities": []
  },
  {
    "text": "pulmonary disease (COPD) is presumed to be protumorigenic. The tumor inhibitory",
    "entities": []
  },
  {
    "text": "effect of inhaled corticosteroids (ICSs) used to reduce airway inflammation in",
    "entities": []
  },
  {
    "text": "patients with asthma and COPD remains unclear.",
    "entities": []
  },
  {
    "text": "OBJECTIVES: This study aimed to evaluate the impact of coexisting asthma and/or",
    "entities": []
  },
  {
    "text": "COPD on the survival of patients with lung adenocarcinoma. The effects of ICS",
    "entities": [
      {
        "text": "ICS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "treatment were also assessed.",
    "entities": []
  },
  {
    "text": "DESIGN: This retrospective, real-world cohort study was conducted at a cancer",
    "entities": []
  },
  {
    "text": "METHODS: The overall survival of a cohort of 1524 consecutive patients with lung",
    "entities": [
      {
        "text": "1524",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "adenocarcinoma who were enrolled between January 2011 and December 2019 and",
    "entities": [
      {
        "text": "between January 2011 and December 2019",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "followed up until December 2022 was analyzed, followed by subgroup comparisons.",
    "entities": [
      {
        "text": "December 2022",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "RESULTS: A total of 283 patients had coexisting asthma and/or COPD. Among them,",
    "entities": [
      {
        "text": "283",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "212 had used ICSs. ICS users were predominantly women, older, and had more",
    "entities": [
      {
        "text": "212",
        "label": "CARDINAL"
      },
      {
        "text": "ICS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "advanced-stage disease; moreover, there were fewer tobacco smokers, fewer",
    "entities": []
  },
  {
    "text": "comorbidities, and relatively severe obstructive impairments than non-ICS users.",
    "entities": []
  },
  {
    "text": "When restricted to stage 0-II diseases, patients with coexisting asthma and/or",
    "entities": [
      {
        "text": "0-II",
        "label": "TIME"
      }
    ]
  },
  {
    "text": "COPD had a lower 5-year overall survival rate (77% vs 90%, p < 0.001), with a",
    "entities": [
      {
        "text": "5-year",
        "label": "DATE"
      },
      {
        "text": "77%",
        "label": "PERCENT"
      },
      {
        "text": "90%",
        "label": "PERCENT"
      },
      {
        "text": "p < 0.001",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "hazard ratio of 1.8, in contrast to no difference among patients with stage",
    "entities": [
      {
        "text": "1.8",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "III-IV disease. ICS users had a lower 5-year overall survival rate in both",
    "entities": [
      {
        "text": "ICS",
        "label": "ORG"
      },
      {
        "text": "5-year",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "subgroups, although the difference was not statistically significant.",
    "entities": []
  },
  {
    "text": "CONCLUSION: The impact of cancer on prognosis may overwhelm the effects of",
    "entities": []
  },
  {
    "text": "asthma and/or COPD in patients with advanced-stage lung adenocarcinoma. The",
    "entities": [
      {
        "text": "asthma and/or COPD",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "evaluation of the effects of ICS treatment appears to be confounded by intent",
    "entities": [
      {
        "text": "ICS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and compliance, which can introduce bias in the opposite direction. However,",
    "entities": []
  },
  {
    "text": "investigating the treatment effects on asthma and/or COPD control would be",
    "entities": []
  },
  {
    "text": "beneficial. A systematic prospective study is required to define the role of the",
    "entities": []
  },
  {
    "text": "ICS.",
    "entities": [
      {
        "text": "ICS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "\u00a9 The Author(s), 2025.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: The authors declare that there is no conflict of",
    "entities": []
  },
  {
    "text": "Association of advanced lung cancer inflammation index with all-cause and",
    "entities": []
  },
  {
    "text": "cardiovascular mortality in US patients with asthma.",
    "entities": [
      {
        "text": "US",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(1)Department of Emergency Medicine, Beijing Tiantan Hospital, Capital Medical",
    "entities": [
      {
        "text": "Emergency Medicine",
        "label": "ORG"
      },
      {
        "text": "Beijing Tiantan Hospital",
        "label": "ORG"
      },
      {
        "text": "Capital Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University, Beijing, China.",
    "entities": [
      {
        "text": "Beijing",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Surgery, International Medical Service, Peking Union Medical",
    "entities": [
      {
        "text": "Surgery, International Medical Service",
        "label": "ORG"
      },
      {
        "text": "Peking Union Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "College Hospital, Beijing, China.",
    "entities": [
      {
        "text": "College Hospital",
        "label": "ORG"
      },
      {
        "text": "Beijing",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "BACKGROUND: Asthma poses a significant global health challenge, representing a",
    "entities": []
  },
  {
    "text": "chronic respiratory disorder marked by airway inflammation. The advanced lung",
    "entities": []
  },
  {
    "text": "cancer inflammation index (ALI) served as a comprehensive index to assess",
    "entities": [
      {
        "text": "ALI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "inflammation. However, few studies have investigated the association between ALI",
    "entities": [
      {
        "text": "ALI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and both all-cause and cardiovascular mortality in US patients with asthma.",
    "entities": [
      {
        "text": "US",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "METHODS: We used data from the National Health and Nutrition Examination Survey",
    "entities": [
      {
        "text": "the National Health and Nutrition Examination Survey",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(NHANES) to explore the association of ALI with all-cause and cardiovascular",
    "entities": [
      {
        "text": "NHANES",
        "label": "ORG"
      },
      {
        "text": "ALI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "mortality in US patients with asthma. This study used Kaplan-Meier curves to",
    "entities": [
      {
        "text": "US",
        "label": "GPE"
      },
      {
        "text": "Kaplan-Meier",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "examine the ALI index's impact on asthma patients' survival. We applied weighted",
    "entities": [
      {
        "text": "ALI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Cox models and restricted cubic splines (RCS) analysis to assess the",
    "entities": []
  },
  {
    "text": "ALI-mortality link, identifying non-linear thresholds with a recursive",
    "entities": [
      {
        "text": "ALI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "algorithm. Subgroup analyses and sensitivity analyses were conducted, excluding",
    "entities": []
  },
  {
    "text": "those with missing covariates and cancer patients.",
    "entities": []
  },
  {
    "text": "RESULTS: A total of 6,211 asthma patients were enrolled and categorized into",
    "entities": [
      {
        "text": "6,211",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "three groups based on ALI tertiles. The risk of all-cause mortality decreased as",
    "entities": [
      {
        "text": "three",
        "label": "CARDINAL"
      },
      {
        "text": "ALI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "ALI increased in the fully adjusted multivariate Cox regression analysis; the",
    "entities": [
      {
        "text": "ALI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "hazard ratio (HR) is 0.95 (95% CI: 0.91-0.99, P = 0.01). Compared with the",
    "entities": [
      {
        "text": "0.95",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "PERSON"
      },
      {
        "text": "0.91-0.99",
        "label": "CARDINAL"
      },
      {
        "text": "0.01",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "lowest ALI group, T1, the fully adjusted HR values for ALI and all-cause",
    "entities": [
      {
        "text": "ALI",
        "label": "ORG"
      },
      {
        "text": "T1",
        "label": "NORP"
      },
      {
        "text": "ALI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "mortality in T2, T3 were 0.68 (95% CI: 0.55-0.85, P < 0.001), 0.53 (95% CI:",
    "entities": [
      {
        "text": "T2",
        "label": "CARDINAL"
      },
      {
        "text": "T3",
        "label": "ORG"
      },
      {
        "text": "0.68",
        "label": "DATE"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "0.55-0.85",
        "label": "CARDINAL"
      },
      {
        "text": "P < 0.001",
        "label": "ORG"
      },
      {
        "text": "0.53",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "0.41-0.68, P < 0.001). The risk of cardiovascular mortality was also lower in",
    "entities": [
      {
        "text": "0.41",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "the groups of T2 (HR: 0.84, 95% CI: 0.55-1.28) and T3 (HR: 0.47, 95% CI:",
    "entities": [
      {
        "text": "T2",
        "label": "CARDINAL"
      },
      {
        "text": "0.84",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "0.55-1.28",
        "label": "CARDINAL"
      },
      {
        "text": "T3",
        "label": "ORG"
      },
      {
        "text": "0.47",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "0.31-0.71, P for trend < 0.001), respectively. In addition, the results of the",
    "entities": [
      {
        "text": "0.31",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "subgroup analyses were robust.",
    "entities": []
  },
  {
    "text": "CONCLUSIONS: This cohort study demonstrated the higher accuracy of ALI in",
    "entities": [
      {
        "text": "ALI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "predicting mortality in asthma patients, highlighting its important clinical",
    "entities": []
  },
  {
    "text": "value of ALI in risk assessment and prognosis evaluation.",
    "entities": [
      {
        "text": "ALI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Copyright \u00a9 2025 Li, Liu and Xu.",
    "entities": [
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "Li",
        "label": "PERSON"
      },
      {
        "text": "Liu",
        "label": "PERSON"
      },
      {
        "text": "Xu",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "56. Int J Chron Obstruct Pulmon Dis. 2025 Jul 7;20:2311-2324. doi:",
    "entities": [
      {
        "text": "56",
        "label": "CARDINAL"
      },
      {
        "text": "Int J Chron Obstruct",
        "label": "ORG"
      },
      {
        "text": "Pulmon Dis",
        "label": "PERSON"
      },
      {
        "text": "7;20:2311-2324",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "10.2147/COPD.S531435. eCollection 2025.",
    "entities": [
      {
        "text": "10.2147",
        "label": "CARDINAL"
      },
      {
        "text": "2025",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Predictors of Clinical Stability and Mortality in COPD: A Longitudinal Study.",
    "entities": []
  },
  {
    "text": "Loo WTW(1), Chew SY(1), Tan JHY(2), Soh RY(2), Koh MS(1)(3), Lapperre TS(4)(5),",
    "entities": [
      {
        "text": "Chew SY(1",
        "label": "PERSON"
      },
      {
        "text": "Tan JHY(2",
        "label": "PERSON"
      },
      {
        "text": "Soh",
        "label": "PERSON"
      },
      {
        "text": "Koh MS(1)(3",
        "label": "ORG"
      },
      {
        "text": "Lapperre TS(4)(5",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)Department of Respiratory and Critical Care Medicine, Singapore General",
    "entities": [
      {
        "text": "Respiratory and Critical Care Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)Department of Respiratory Medicine, Sengkang General Hospital, Singapore.",
    "entities": [
      {
        "text": "Respiratory Medicine",
        "label": "ORG"
      },
      {
        "text": "Sengkang General Hospital",
        "label": "ORG"
      },
      {
        "text": "Singapore",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Duke-NUS Medical School, Singapore.",
    "entities": [
      {
        "text": "3)Duke-NUS Medical School",
        "label": "ORG"
      },
      {
        "text": "Singapore",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Department of Pulmonology, University Hospital of Antwerp, Edegem, Belgium.",
    "entities": [
      {
        "text": "Pulmonology, University Hospital of Antwerp",
        "label": "ORG"
      },
      {
        "text": "Edegem",
        "label": "GPE"
      },
      {
        "text": "Belgium",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Laboratory of Experimental Medicine and Pediatrics, Division of Respiratory",
    "entities": [
      {
        "text": "Experimental Medicine and Pediatrics",
        "label": "ORG"
      },
      {
        "text": "Division of Respiratory",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(6)Lee Kong Chian, School of Medicine, Nanyang Technological University,",
    "entities": [
      {
        "text": "6)Lee",
        "label": "CARDINAL"
      },
      {
        "text": "Chian, School of Medicine",
        "label": "ORG"
      },
      {
        "text": "Nanyang Technological University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "BACKGROUND: There is no consensus on the definition of clinical stability in",
    "entities": []
  },
  {
    "text": "chronic obstructive pulmonary disease (COPD), and it is less frequently used as",
    "entities": []
  },
  {
    "text": "a treatment target compared to severe asthma. The factors that determine",
    "entities": []
  },
  {
    "text": "clinical stability and their effects on mortality are less well-studied in",
    "entities": []
  },
  {
    "text": "patients with COPD.",
    "entities": [
      {
        "text": "COPD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "METHODS: To address this gap, we conducted a prospective longitudinal cohort",
    "entities": []
  },
  {
    "text": "study to identify predictors of two-year clinical stability, defined as no",
    "entities": [
      {
        "text": "two-year",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "exacerbations and stable symptoms (<2 point change in CAT score from baseline),",
    "entities": [
      {
        "text": "2",
        "label": "CARDINAL"
      },
      {
        "text": "CAT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and the impact of comorbid cardiovascular disease (CVD) on clinical stability",
    "entities": []
  },
  {
    "text": "and mortality in COPD patients.",
    "entities": []
  },
  {
    "text": "RESULTS: A total of 463 patients (mean age 71 \u00b1 9 years) were enrolled in this",
    "entities": [
      {
        "text": "463",
        "label": "CARDINAL"
      },
      {
        "text": "age 71 \u00b1 9 years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "study. The cohort was predominantly Chinese (81.7%) and 45.6% of participants",
    "entities": [
      {
        "text": "Chinese",
        "label": "NORP"
      },
      {
        "text": "81.7%",
        "label": "PERCENT"
      },
      {
        "text": "45.6%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "were current smokers. The majority (55.7%) had a history of CVD. Approximately",
    "entities": [
      {
        "text": "55.7%",
        "label": "PERCENT"
      },
      {
        "text": "CVD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "36% of the cohort achieved clinical stability at one year, and one-third",
    "entities": [
      {
        "text": "36%",
        "label": "PERCENT"
      },
      {
        "text": "one year",
        "label": "DATE"
      },
      {
        "text": "one-third",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "achieved stability at two years. Predictors of 2-year clinical stability",
    "entities": [
      {
        "text": "two years",
        "label": "DATE"
      },
      {
        "text": "2-year",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "included higher body mass index (BMI) (p<0.001), higher post-bronchodilator",
    "entities": [
      {
        "text": "BMI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "FEV1/FVC ratio (p=0.0132), fewer baseline exacerbations (p=0.007), absence of",
    "entities": []
  },
  {
    "text": "bronchiectasis (p=0.045), preserved hemoglobin levels (p=0.019), and successful",
    "entities": []
  },
  {
    "text": "smoking cessation (p=0.039). Notably, while 2-year clinical stability did not",
    "entities": [
      {
        "text": "2-year",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "predict subsequent mortality, the presence of CVD was a significant predictor of",
    "entities": [
      {
        "text": "CVD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "5-years mortality (HR 1.48, 95% CI 0.99-2.22; p=0.05).",
    "entities": [
      {
        "text": "5-years",
        "label": "DATE"
      },
      {
        "text": "1.48",
        "label": "DATE"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "CONCLUSION: Our study identified several predictors of 2-year clinical stability",
    "entities": [
      {
        "text": "2-year",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "in patients with COPD. However, clinical stability at 2 years did not predict",
    "entities": [
      {
        "text": "2 years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "subsequent mortality. These findings suggest that clinical stability and",
    "entities": []
  },
  {
    "text": "mortality are distinct outcomes that are driven by different sets of predictive",
    "entities": []
  },
  {
    "text": "variables. This underscores the need for a comprehensive approach to COPD",
    "entities": []
  },
  {
    "text": "management that not only addresses exacerbations and symptoms, but also",
    "entities": []
  },
  {
    "text": "considers a broader range of factors influencing survival, particularly the",
    "entities": []
  },
  {
    "text": "management of comorbidities such as cardiovascular disease.",
    "entities": []
  },
  {
    "text": "PMID: 40655184 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40655184",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: P.Y.T was on advisory boards for AstraZeneca and",
    "entities": [
      {
        "text": "P.Y.T",
        "label": "GPE"
      },
      {
        "text": "AstraZeneca",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Sanofi outside the submitted work. M. S. K has received research grants from",
    "entities": [
      {
        "text": "M. S. K",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "AstraZeneca and honorarium paid to her employer (Singapore General Hospital)",
    "entities": [
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "Singapore General Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "from GSK, AstraZeneca, Sanofi, Novartis and Boehringer Ingelheim outside the",
    "entities": [
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "Novartis",
        "label": "PERSON"
      },
      {
        "text": "Boehringer Ingelheim",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "submitted work. The authors report no other conflicts of interest in this work.",
    "entities": []
  },
  {
    "text": "Tropomyosin-based cross-reactivity and asymptomatic shellfish sensitization in",
    "entities": [
      {
        "text": "Tropomyosin",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "patients with perennial allergy.",
    "entities": []
  },
  {
    "text": "(1)Department of Dermatology, Venereology and Allergology, University Medical",
    "entities": [
      {
        "text": "Dermatology, Venereology and Allergology, University Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)Lower Saxony Institute of Occupational Dermatology, University Medical Centre",
    "entities": [
      {
        "text": "Saxony Institute of Occupational Dermatology, University Medical Centre",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "BACKGROUND: Mite, cockroach, and shellfish (crab, clam, and shrimp) proteins",
    "entities": []
  },
  {
    "text": "share allergenic epitopes. The determination of specific IgE (sIgE) against",
    "entities": []
  },
  {
    "text": "cockroach (Blattella germanica, relevant in asthma) and shellfish allergens",
    "entities": []
  },
  {
    "text": "(relevant in food allergy) using whole-body extracts necessitates detailed",
    "entities": []
  },
  {
    "text": "knowledge of IgE cross-reactivity.",
    "entities": []
  },
  {
    "text": "OBJECTIVE: This study aimed to evaluate whether cross-reactivity between",
    "entities": []
  },
  {
    "text": "aeroallergens and food allergens is clinically relevant and whether subjects",
    "entities": []
  },
  {
    "text": "with mite and/or cockroach sensitization are at risk of false-positive results",
    "entities": []
  },
  {
    "text": "in shellfish food allergy diagnostics.",
    "entities": []
  },
  {
    "text": "METHODS: In this cross-sectional, single-center study, we recruited 200 patients",
    "entities": [
      {
        "text": "200",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "with elevated sIgE against \u22651 allergen at random from our outpatient clinic and",
    "entities": [
      {
        "text": "sIgE",
        "label": "GPE"
      },
      {
        "text": "\u22651",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "assessed allergic comorbidity. We analyzed sIgE against mites (Dermatophagoides",
    "entities": [
      {
        "text": "sIgE",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "pteronyssinus, Dermatophagoides farinae, or Blomia tropicalis), German cockroach",
    "entities": [
      {
        "text": "Dermatophagoides",
        "label": "NORP"
      },
      {
        "text": "Blomia",
        "label": "PERSON"
      },
      {
        "text": "German",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "(B. germanica), crab, clam, and shrimp whole allergen extract, as well as sIgE",
    "entities": [
      {
        "text": "sIgE",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "against mite tropomyosin Der p 10 and shrimp tropomyosin Pen a 1 (in a",
    "entities": [
      {
        "text": "Der p 10",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "subpopulation), using automated ImmunoCAP Specific IgE Tests.",
    "entities": []
  },
  {
    "text": "RESULTS: During allergologic assessment, two participants reported previous",
    "entities": [
      {
        "text": "two",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "anaphylaxis to fish and/or seafood and were excluded from further analysis. The",
    "entities": []
  },
  {
    "text": "final study population comprised 150 female and 48 male participants. Of these,",
    "entities": [
      {
        "text": "150",
        "label": "CARDINAL"
      },
      {
        "text": "48",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "93 presented with positive sIgE against mites. As expected, participants with",
    "entities": [
      {
        "text": "93",
        "label": "CARDINAL"
      },
      {
        "text": "sIgE",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "mite sensitization displayed an elevated prevalence of perennial asthma or",
    "entities": []
  },
  {
    "text": "allergic rhinitis (p < 0.001). Further, they were more often sensitized to",
    "entities": []
  },
  {
    "text": "German cockroach, crab, claw, or shrimp (each p < 0.001). Der p 10 and Pen a 1",
    "entities": [
      {
        "text": "German",
        "label": "NORP"
      },
      {
        "text": "Der p 10",
        "label": "ORG"
      },
      {
        "text": "1",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "sIgE levels were below the cutoff level (<0.35 kU/L) in all subjects. However,",
    "entities": []
  },
  {
    "text": "the correlation analyses revealed that tropomyosin sIgE explained between 24%",
    "entities": [
      {
        "text": "sIgE",
        "label": "GPE"
      },
      {
        "text": "between 24%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "and 55% of the variance (R2) in sIgE against clam, crab, German cockroach, or",
    "entities": [
      {
        "text": "55%",
        "label": "PERCENT"
      },
      {
        "text": "R2",
        "label": "PRODUCT"
      },
      {
        "text": "sIgE",
        "label": "GPE"
      },
      {
        "text": "German",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "shrimp (each p < 0.001).",
    "entities": []
  },
  {
    "text": "CONCLUSION: Patients with mite sensitization have higher asymptomatic sIgE",
    "entities": [
      {
        "text": "sIgE",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "levels to shellfish. Even in patients with anti-tropomyosin sIgE levels below",
    "entities": []
  },
  {
    "text": "the cutoff level, anti-tropomyosin sIgE correlates strongly with sIgE against",
    "entities": [
      {
        "text": "sIgE",
        "label": "FAC"
      },
      {
        "text": "sIgE",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "German cockroach, crab, clam, and shrimp. Our findings suggest large-scale",
    "entities": [
      {
        "text": "German",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "false-positive results for sIgE to shellfish when analyzing patients with mite-",
    "entities": [
      {
        "text": "sIgE",
        "label": "GPE"
      },
      {
        "text": "mite-\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "or cockroach sensitization.",
    "entities": []
  },
  {
    "text": "PDE4B Inhibition: Exploring the Landscape of Chemistry Behind Specific PDE4B",
    "entities": []
  },
  {
    "text": "Inhibitors, Drug Design, and Discovery.",
    "entities": [
      {
        "text": "Inhibitors, Drug Design",
        "label": "ORG"
      },
      {
        "text": "Discovery",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "(1)Department of Medicinal Chemistry, National Institute of Pharmaceutical",
    "entities": [
      {
        "text": "Medicinal Chemistry",
        "label": "ORG"
      },
      {
        "text": "National Institute of Pharmaceutical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Education and Research Guwahati, Department of Pharmaceuticals, Ministry of",
    "entities": [
      {
        "text": "Research Guwahati",
        "label": "ORG"
      },
      {
        "text": "Department of Pharmaceuticals",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Phosphodiesterase 4 (i.e., PDE4A, PDE4B, PDE4C, and PDE4D) is an enzyme group",
    "entities": [
      {
        "text": "PDE4B",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "that regulates intracellular cyclic adenosine monophosphate (cAMP) levels, which",
    "entities": []
  },
  {
    "text": "are involved in multiple physiological activities. PDE4B and PDE4D have closely",
    "entities": []
  },
  {
    "text": "identical amino acid sequences (~80%) and are highly expressed due to increases",
    "entities": []
  },
  {
    "text": "in cAMP levels and other factors like hormones, neurotransmitters, etc. Thus,",
    "entities": []
  },
  {
    "text": "selective PDE4B suppression and discovery of its inhibitors are quite",
    "entities": []
  },
  {
    "text": "challenging. The PDE4B isoform, highly expressed in inflammatory disorders,",
    "entities": []
  },
  {
    "text": "cancers, cognitive and metabolic disorders, represents a potential target for",
    "entities": []
  },
  {
    "text": "therapy and drug discovery. PDE4B inhibition is what produces the positive",
    "entities": []
  },
  {
    "text": "therapeutic results, whereas nonselective PDE4D inhibition leads to unfavorable",
    "entities": []
  },
  {
    "text": "side effects. In the realm of modern research, selective PDE4B inhibition is",
    "entities": []
  },
  {
    "text": "important and ought to be achieved to improve the safety and effectiveness of",
    "entities": []
  },
  {
    "text": "its inhibitors. This article highlights the advances in the development of",
    "entities": []
  },
  {
    "text": "selective PDE4BIs during the past decade. The chemical architecture for",
    "entities": [
      {
        "text": "the past decade",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "selective inhibitors includes different functional groups capable of producing",
    "entities": []
  },
  {
    "text": "the essential interactions with the catalytic domain of PDE4B. The In Silico",
    "entities": []
  },
  {
    "text": "interaction analysis revealed the importance of PDE4BIs' interaction with the Q",
    "entities": []
  },
  {
    "text": "(PHE-446 and GLU-443), M (Zn2+ and Mg2+), and S pockets, along with the CR3",
    "entities": []
  },
  {
    "text": "domain of the enzyme. Additionally, a few of the natural products and their",
    "entities": []
  },
  {
    "text": "derivatives are also being explored as PDE4BIs. Dual activities of the PDE4BIs,",
    "entities": []
  },
  {
    "text": "i.e., PDE4B inhibition along with TRPA1 and M3 inhibition and \u03b22 activation, are",
    "entities": [
      {
        "text": "TRPA1",
        "label": "GPE"
      },
      {
        "text": "M3",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "the future perspective for the treatment of inflammatory diseases like",
    "entities": []
  },
  {
    "text": "psoriasis, chronic obstructive pulmonary disease (COPD), asthma, autoimmune",
    "entities": []
  },
  {
    "text": "PMID: 40654275 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40654275",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Association between corticosteroid use and fracture risk in children with",
    "entities": []
  },
  {
    "text": "asthma: A nationwide cohort study.",
    "entities": []
  },
  {
    "text": "(1)Department of Health Science and Technology, Seoul National University,",
    "entities": [
      {
        "text": "Health Science and Technology",
        "label": "ORG"
      },
      {
        "text": "Seoul National University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)Department of Pediatrics, Seoul National University Bundang Hospital,",
    "entities": [
      {
        "text": "Pediatrics, Seoul National University Bundang Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(3)Department of Pediatrics, Seoul National University College of Medicine,",
    "entities": [
      {
        "text": "Pediatrics, Seoul National University College of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)Department of Pediatrics, Chonnam National University Hospital, Chonnam",
    "entities": [
      {
        "text": "Pediatrics, Chonnam National University Hospital",
        "label": "ORG"
      },
      {
        "text": "Chonnam",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "National University Medical School, Gwangju, Korea.",
    "entities": [
      {
        "text": "National University Medical School, Gwangju",
        "label": "ORG"
      },
      {
        "text": "Korea",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Department of Pediatrics, College of Medicine, The Catholic University of",
    "entities": [
      {
        "text": "Pediatrics, College of Medicine",
        "label": "ORG"
      },
      {
        "text": "The Catholic University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(6)Department of Pediatrics, Soonchunhyang University Seoul Hospital,",
    "entities": [
      {
        "text": "Pediatrics, Soonchunhyang University Seoul Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Soonchunhyang University College of Medicine, Seoul, Korea.",
    "entities": [
      {
        "text": "Soonchunhyang University College of Medicine",
        "label": "ORG"
      },
      {
        "text": "Seoul",
        "label": "GPE"
      },
      {
        "text": "Korea",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(7)Graduate School of Convergence Science and Technology, Seoul National",
    "entities": [
      {
        "text": "Seoul National",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University, Seoul, Korea.",
    "entities": [
      {
        "text": "Seoul",
        "label": "GPE"
      },
      {
        "text": "Korea",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "BACKGROUND: Pediatric asthma, as a chronic inflammatory condition, has been",
    "entities": []
  },
  {
    "text": "associated with increased fracture risk due to persistent inflammation and",
    "entities": []
  },
  {
    "text": "corticosteroid treatment. This study investigates the association between",
    "entities": []
  },
  {
    "text": "pediatric asthma and fracture risk using data from the National Health Insurance",
    "entities": [
      {
        "text": "the National Health Insurance\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Service database of South Korea.",
    "entities": [
      {
        "text": "South Korea",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "METHODS: Children born from 2002 to 2004 were selected for the analysis,",
    "entities": [
      {
        "text": "2002",
        "label": "DATE"
      },
      {
        "text": "2004",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "utilizing information from the Korean National Health Insurance Service National",
    "entities": [
      {
        "text": "the Korean National Health Insurance Service National",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Sample Cohort up to 2019. Exclusion criteria included asthma diagnosis before",
    "entities": [
      {
        "text": "up to 2019",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "age 6, history of prior fractures, and the presence of severe comorbidities.",
    "entities": [
      {
        "text": "age 6",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Asthma cases were identified by the Korean Standard Classification of Diseases,",
    "entities": [
      {
        "text": "the Korean Standard Classification of Diseases",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "8th Revision (KCD-8) codes J45 and J46, and fractures were determined using all",
    "entities": [
      {
        "text": "8th Revision",
        "label": "ORG"
      },
      {
        "text": "J45",
        "label": "PERSON"
      },
      {
        "text": "J46",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "relevant KCD-8 codes. Propensity score matching was used to balance demographic",
    "entities": [
      {
        "text": "KCD-8",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "and clinical characteristics between the asthma and non-asthma groups. Fracture",
    "entities": []
  },
  {
    "text": "risk was analyzed using logistic regression models adjusted for covariates.",
    "entities": []
  },
  {
    "text": "Within the asthma cohort, the analysis investigated corticosteroid exposure,",
    "entities": []
  },
  {
    "text": "focusing on both recent and cumulative exposure to inhaled corticosteroids (ICS)",
    "entities": [
      {
        "text": "ICS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and systemic corticosteroids within 1 year before the occurrence of fractures.",
    "entities": [
      {
        "text": "1 year",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "RESULTS: From an initial cohort of 30,409 children, 13,275 were included in the",
    "entities": [
      {
        "text": "30,409",
        "label": "CARDINAL"
      },
      {
        "text": "13,275",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "final analysis, comprising 2325 asthma patients and 10,950 non-asthma controls.",
    "entities": [
      {
        "text": "2325",
        "label": "DATE"
      },
      {
        "text": "10,950",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Asthma was associated with a higher risk of fractures (Odds Ratio [OR]: 1.22,",
    "entities": [
      {
        "text": "1.22",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "95% CI: 1.12-1.34, p < .001). Among asthma patients, recent ICS use within",
    "entities": [
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "1.12-1.34",
        "label": "CARDINAL"
      },
      {
        "text": "ICS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "90 days before a fracture was linked to the highest risk (Adjusted Odds Ratio",
    "entities": [
      {
        "text": "90 days",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "[Adjusted OR]: 2.98, 95% CI: 2.95-3.05, p < .001). Systemic corticosteroid use",
    "entities": [
      {
        "text": "2.98",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "2.95-3.05",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "showed a dose-dependent relationship with increased fracture risk.",
    "entities": []
  },
  {
    "text": "CONCLUSION: Pediatric asthma and corticosteroid treatment are both significantly",
    "entities": []
  },
  {
    "text": "associated with elevated fracture risk. These results emphasize the necessity",
    "entities": []
  },
  {
    "text": "for comprehensive asthma management strategies that prioritize bone health.",
    "entities": []
  },
  {
    "text": "\u00a9 2025 European Academy of Allergy and Clinical Immunology and John Wiley & Sons",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "European Academy of Allergy and Clinical Immunology",
        "label": "ORG"
      },
      {
        "text": "John Wiley & Sons",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "PMID: 40654110 [Indexed for MEDLINE]",
    "entities": []
  },
  {
    "text": "60. Respir Med. 2025 Jul 11:108252. doi: 10.1016/j.rmed.2025.108252. Online ahead",
    "entities": [
      {
        "text": "60",
        "label": "CARDINAL"
      },
      {
        "text": "Respir Med",
        "label": "PERSON"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "10.1016",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Public health insights of patients with asthma receiving primary, specialist or",
    "entities": []
  },
  {
    "text": "mixed care in Singapore using data from the SDG-CARE Asthma Registry.",
    "entities": [
      {
        "text": "Singapore",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Hock Ong ME(7), Tan NC(8), Loo CM(9), Matchar DB(10).",
    "entities": [
      {
        "text": "Tan NC(8",
        "label": "PERSON"
      },
      {
        "text": "Matchar",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Hospital, Singapore, Singapore; Duke-NUS Medical School, National University of",
    "entities": [
      {
        "text": "Singapore",
        "label": "GPE"
      },
      {
        "text": "Singapore",
        "label": "GPE"
      },
      {
        "text": "Duke-NUS Medical School",
        "label": "ORG"
      },
      {
        "text": "National University of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Singapore, Singapore, Singapore. Electronic address:",
    "entities": [
      {
        "text": "Singapore",
        "label": "GPE"
      },
      {
        "text": "Singapore",
        "label": "GPE"
      },
      {
        "text": "Singapore",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Medical, GSK, Singapore, Singapore. Electronic address:",
    "entities": [
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "Singapore",
        "label": "GPE"
      },
      {
        "text": "Singapore",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Health Services and Systems Research, Duke-NUS Medical School, Singapore,",
    "entities": [
      {
        "text": "3)Health Services and Systems Research",
        "label": "ORG"
      },
      {
        "text": "Duke-NUS Medical School",
        "label": "ORG"
      },
      {
        "text": "Singapore",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Singapore; Health Services Research Centre, SingHealth, Singapore, Singapore;",
    "entities": [
      {
        "text": "Singapore",
        "label": "GPE"
      },
      {
        "text": "Health Services Research Centre",
        "label": "ORG"
      },
      {
        "text": "SingHealth",
        "label": "ORG"
      },
      {
        "text": "Singapore",
        "label": "GPE"
      },
      {
        "text": "Singapore",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Health Services Research Institute, SingHealth Duke-NUS Academic Medical Centre,",
    "entities": [
      {
        "text": "Health Services Research Institute",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Singapore, Singapore; Lee Kong Chian School of Business, Singapore Management",
    "entities": [
      {
        "text": "Singapore",
        "label": "GPE"
      },
      {
        "text": "Singapore",
        "label": "GPE"
      },
      {
        "text": "Lee Kong Chian School of Business",
        "label": "ORG"
      },
      {
        "text": "Singapore Management",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University, Singapore, Singapore. Electronic address: gmslasws@nus.edu.sg.",
    "entities": [
      {
        "text": "Singapore",
        "label": "GPE"
      },
      {
        "text": "Singapore",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Health Services and Systems Research, Duke-NUS Medical School, Singapore,",
    "entities": [
      {
        "text": "4)Health Services and Systems Research",
        "label": "ORG"
      },
      {
        "text": "Duke-NUS Medical School",
        "label": "ORG"
      },
      {
        "text": "Singapore",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "NUS Yong Loo Lin School of Medicine, National University of Singapore,",
    "entities": [
      {
        "text": "NUS Yong Loo Lin School of Medicine",
        "label": "PERSON"
      },
      {
        "text": "National University of Singapore",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Singapore, Singapore. Electronic address: wu.jun.tian@singhealth.com.sg.",
    "entities": [
      {
        "text": "Singapore",
        "label": "GPE"
      },
      {
        "text": "Singapore",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Medical, GSK, Singapore, Singapore. Electronic address:",
    "entities": [
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "Singapore",
        "label": "GPE"
      },
      {
        "text": "Singapore",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)Medical, GSK, Singapore, Singapore. Electronic address:",
    "entities": [
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "Singapore",
        "label": "GPE"
      },
      {
        "text": "Singapore",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(7)Health Services and Systems Research, Duke-NUS Medical School, Singapore,",
    "entities": [
      {
        "text": "7)Health Services and Systems Research",
        "label": "ORG"
      },
      {
        "text": "Duke-NUS Medical School",
        "label": "ORG"
      },
      {
        "text": "Singapore",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Singapore; Department of Emergency Medicine, Singapore General Hospital,",
    "entities": [
      {
        "text": "Singapore",
        "label": "GPE"
      },
      {
        "text": "Department of Emergency Medicine",
        "label": "ORG"
      },
      {
        "text": "Singapore General Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Singapore, Singapore. Electronic address: marcus.ong@duke-nus.edu.sg.",
    "entities": [
      {
        "text": "Singapore",
        "label": "GPE"
      },
      {
        "text": "Singapore",
        "label": "GPE"
      },
      {
        "text": "marcus.ong@duke-nus.edu.sg",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "(8)Duke-NUS Medical School, National University of Singapore, Singapore,",
    "entities": [
      {
        "text": "8)Duke-NUS Medical School",
        "label": "ORG"
      },
      {
        "text": "National University of Singapore",
        "label": "ORG"
      },
      {
        "text": "Singapore",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Singapore; SingHealth Polyclinics, SingHealth, Singapore, Singapore. Electronic",
    "entities": [
      {
        "text": "Singapore",
        "label": "GPE"
      },
      {
        "text": "SingHealth Polyclinics",
        "label": "ORG"
      },
      {
        "text": "SingHealth",
        "label": "ORG"
      },
      {
        "text": "Singapore",
        "label": "GPE"
      },
      {
        "text": "Singapore",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(9)Department of Respiratory and Critical Care Medicine, Singapore General",
    "entities": [
      {
        "text": "Respiratory and Critical Care Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(10)Duke-NUS Medical School, National University of Singapore, Singapore,",
    "entities": [
      {
        "text": "10)Duke-NUS Medical School",
        "label": "ORG"
      },
      {
        "text": "National University of Singapore",
        "label": "ORG"
      },
      {
        "text": "Singapore",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Singapore; Department of Internal Medicine (General Internal Medicine), Duke",
    "entities": [
      {
        "text": "Singapore",
        "label": "GPE"
      },
      {
        "text": "Department of Internal Medicine (General Internal Medicine",
        "label": "ORG"
      },
      {
        "text": "Duke",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University Medical School, Durham, NC, USA; Department of Internal Medicine,",
    "entities": [
      {
        "text": "University Medical School",
        "label": "ORG"
      },
      {
        "text": "Durham",
        "label": "GPE"
      },
      {
        "text": "NC",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      },
      {
        "text": "Department of Internal Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Singapore General Hospital, Singapore, Singapore. Electronic address:",
    "entities": [
      {
        "text": "Singapore General Hospital",
        "label": "ORG"
      },
      {
        "text": "Singapore",
        "label": "GPE"
      },
      {
        "text": "Singapore",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "PURPOSE: The prevalence and economic burden of asthma across the public",
    "entities": [
      {
        "text": "PURPOSE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "healthcare landscape in Singapore is substantial, where the asthma patient",
    "entities": [
      {
        "text": "Singapore",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "journey often transitions between primary care (PC) and specialty care (SC)",
    "entities": [
      {
        "text": "SC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "PATIENTS AND METHODS: This study used the SingHealth COPD and Asthma Data Mart,",
    "entities": [
      {
        "text": "SingHealth",
        "label": "ORG"
      },
      {
        "text": "Asthma Data Mart",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "a repository of clinical and administrative data from patients with asthma or",
    "entities": []
  },
  {
    "text": "chronic obstructive pulmonary disease, to collect real-time, real-world data",
    "entities": []
  },
  {
    "text": "across a range of demographics, disease severities and treatment pathways.",
    "entities": []
  },
  {
    "text": "RESULTS: Key differences were identified among patients treated in PC, SC, or",
    "entities": [
      {
        "text": "SC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "both (PC/SC). There were more patients of Chinese ethnicity and ex-smokers among",
    "entities": [
      {
        "text": "Chinese",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "those treated in SC versus PC or PC/SC. Patients in SC also had a lower mean",
    "entities": [
      {
        "text": "SC",
        "label": "ORG"
      },
      {
        "text": "SC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Asthma Control Test score (17.93 [standard deviation: 4.92]) versus the other",
    "entities": [
      {
        "text": "Asthma Control Test",
        "label": "ORG"
      },
      {
        "text": "17.93",
        "label": "CARDINAL"
      },
      {
        "text": "4.92",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "used low-dose inhaled corticosteroids in the PC (76.95%) than SC group (60.1%).",
    "entities": [
      {
        "text": "76.95%",
        "label": "PERCENT"
      },
      {
        "text": "SC",
        "label": "ORG"
      },
      {
        "text": "60.1%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "Patients treated in PC/SC were older and had more frequent emergency department",
    "entities": []
  },
  {
    "text": "visits (0.54 [1.17] vs PC: 0.04 [0.16], p<0.001; SC: 0.35 [0.92], p<0.001) and",
    "entities": [
      {
        "text": "0.54",
        "label": "CARDINAL"
      },
      {
        "text": "1.17",
        "label": "CARDINAL"
      },
      {
        "text": "0.04",
        "label": "CARDINAL"
      },
      {
        "text": "0.16",
        "label": "CARDINAL"
      },
      {
        "text": "SC",
        "label": "ORG"
      },
      {
        "text": "0.35",
        "label": "CARDINAL"
      },
      {
        "text": "0.92",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "exacerbations per patient/year (2.31 [3.37] vs PC: 1.48 [2.56], p<0.001; SC:",
    "entities": [
      {
        "text": "/year",
        "label": "DATE"
      },
      {
        "text": "2.31",
        "label": "CARDINAL"
      },
      {
        "text": "3.37",
        "label": "CARDINAL"
      },
      {
        "text": "1.48",
        "label": "CARDINAL"
      },
      {
        "text": "2.56",
        "label": "CARDINAL"
      },
      {
        "text": "SC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "0.96 [2.67], p<0.001), and higher proportions had comorbidities versus PC or SC.",
    "entities": [
      {
        "text": "0.96",
        "label": "CARDINAL"
      },
      {
        "text": "2.67",
        "label": "CARDINAL"
      },
      {
        "text": "SC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Overall, nearly half of patients had uncontrolled asthma, 58.88% of whom were in",
    "entities": [
      {
        "text": "nearly half",
        "label": "CARDINAL"
      },
      {
        "text": "58.88%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "the PC group.",
    "entities": []
  },
  {
    "text": "CONCLUSION: Findings of this study provide greater understanding of the asthma",
    "entities": []
  },
  {
    "text": "public healthcare landscape in Singapore, allowing for the identification of",
    "entities": [
      {
        "text": "Singapore",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "current gaps in care, particularly for high-risk groups that may benefit from",
    "entities": []
  },
  {
    "text": "optimised treatment.",
    "entities": []
  },
  {
    "text": "declare the following financial interests/personal relationships which may be",
    "entities": []
  },
  {
    "text": "considered as potential competing interests:Mariko Siyue Koh reports financial",
    "entities": [
      {
        "text": "Mariko Siyue Koh",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "support, administrative support, article publishing charges, and writing",
    "entities": []
  },
  {
    "text": "assistance were provided by GSK. Ricco Marsel reports a relationship with GSK",
    "entities": [
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "Marsel",
        "label": "GPE"
      },
      {
        "text": "GSK",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "that includes: employment. Xiaomeng Xu reports a relationship with GSK that",
    "entities": [
      {
        "text": "Xiaomeng Xu",
        "label": "PERSON"
      },
      {
        "text": "GSK",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "includes: employment and equity or stocks. Mariko Siyue Koh reports a",
    "entities": [
      {
        "text": "Mariko Siyue Koh",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "relationship with AstraZeneca PLC that includes: consulting or advisory, funding",
    "entities": [
      {
        "text": "AstraZeneca PLC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "grants, and speaking and lecture fees. Mariko Siyue Koh reports a relationship",
    "entities": [
      {
        "text": "Mariko Siyue Koh",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "with Novartis that includes: consulting or advisory. Mariko Siyue Koh reports a",
    "entities": [
      {
        "text": "Novartis",
        "label": "ORG"
      },
      {
        "text": "Mariko Siyue Koh",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "relationship with Sanofi that includes: consulting or advisory. Mariko Siyue Koh",
    "entities": [
      {
        "text": "Sanofi",
        "label": "ORG"
      },
      {
        "text": "Mariko Siyue Koh\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "reports a relationship with Boehringer Ingelheim GmbH that includes: consulting",
    "entities": [
      {
        "text": "Boehringer Ingelheim GmbH",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "or advisory. Priyan Ratnasingham reports a relationship with GSK that includes:",
    "entities": [
      {
        "text": "Priyan Ratnasingham",
        "label": "PERSON"
      },
      {
        "text": "GSK",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "employment. The SGD-CARE collaboration is funded by GSK. David Bruce Matchar,",
    "entities": [
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "David Bruce Matchar",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Sean Shao Wei Lam, Ngiap Chuan Tan, Marcus Eng Hock Ong, Chian Min Loo and Jun",
    "entities": [
      {
        "text": "Sean Shao Wei Lam",
        "label": "PERSON"
      },
      {
        "text": "Ngiap Chuan Tan",
        "label": "PERSON"
      },
      {
        "text": "Marcus Eng Hock Ong",
        "label": "PERSON"
      },
      {
        "text": "Jun\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Tian Wu declare no competing interests. If there are other authors, they declare",
    "entities": [
      {
        "text": "Tian Wu",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "that they have no known competing financial interests or personal relationships",
    "entities": []
  },
  {
    "text": "that could have appeared to influence the work reported in this paper.61. Respir Med. 2025 Jul 11:108251. doi: 10.1016/j.rmed.2025.108251. Online ahead",
    "entities": [
      {
        "text": "Respir Med",
        "label": "PERSON"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "10.1016",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Shared decision making and inhaled medication adherence in patients with COPD,",
    "entities": [
      {
        "text": "COPD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "asthma and cystic fibrosis: a systematic review.",
    "entities": []
  },
  {
    "text": "(1)Department of Clinical Pharmacy & Pharmacology, University Medical Center",
    "entities": [
      {
        "text": "Clinical Pharmacy & Pharmacology",
        "label": "ORG"
      },
      {
        "text": "University Medical Center",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Groningen (UMCG), University of Groningen, Groningen, The Netherlands.",
    "entities": [
      {
        "text": "Groningen",
        "label": "PERSON"
      },
      {
        "text": "UMCG",
        "label": "ORG"
      },
      {
        "text": "University of Groningen",
        "label": "ORG"
      },
      {
        "text": "Groningen",
        "label": "PERSON"
      },
      {
        "text": "The Netherlands",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Isala Academy, Department of Medical Education and Faculty Development, Isala",
    "entities": [
      {
        "text": "2)Isala Academy, Department of Medical Education",
        "label": "ORG"
      },
      {
        "text": "Faculty Development",
        "label": "ORG"
      },
      {
        "text": "Isala",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Hospital, Zwolle, the Netherlands, and Wenckebach Institute for Medical",
    "entities": [
      {
        "text": "Zwolle",
        "label": "GPE"
      },
      {
        "text": "Netherlands",
        "label": "GPE"
      },
      {
        "text": "Wenckebach Institute for Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Education, University of Groningen and University Medical Centre Groningen,",
    "entities": [
      {
        "text": "University of Groningen and University Medical Centre Groningen",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Groningen, the Netherlands.",
    "entities": [
      {
        "text": "Groningen",
        "label": "PERSON"
      },
      {
        "text": "Netherlands",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Nivel, Netherlands institute for health services research, Utrecht, the",
    "entities": [
      {
        "text": "Netherlands institute for health services",
        "label": "ORG"
      },
      {
        "text": "Utrecht",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Netherlands; University of Groningen, Groningen Research Institute of Pharmacy,",
    "entities": [
      {
        "text": "Netherlands",
        "label": "GPE"
      },
      {
        "text": "University of Groningen",
        "label": "ORG"
      },
      {
        "text": "Groningen Research Institute of Pharmacy",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Department of Pharmacotherapy-, epidemiology and -economics, Groningen, the",
    "entities": [
      {
        "text": "Groningen",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Netherlands; Medication Adherence Expertise Centre of the northern Netherlands",
    "entities": [
      {
        "text": "Netherlands",
        "label": "GPE"
      },
      {
        "text": "Netherlands",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Department of Clinical Pharmacy & Pharmacology, University Medical Center",
    "entities": [
      {
        "text": "Clinical Pharmacy & Pharmacology",
        "label": "ORG"
      },
      {
        "text": "University Medical Center",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Groningen (UMCG), University of Groningen, Groningen, The Netherlands;",
    "entities": [
      {
        "text": "Groningen",
        "label": "PERSON"
      },
      {
        "text": "UMCG",
        "label": "ORG"
      },
      {
        "text": "University of Groningen",
        "label": "ORG"
      },
      {
        "text": "Groningen",
        "label": "PERSON"
      },
      {
        "text": "The Netherlands",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Medication Adherence Expertise Centre of the northern Netherlands (MAECON),",
    "entities": [
      {
        "text": "Netherlands",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Groningen, The Netherlands; Groningen Research Institute for Asthma and COPD",
    "entities": [
      {
        "text": "Groningen",
        "label": "PERSON"
      },
      {
        "text": "The Netherlands",
        "label": "GPE"
      },
      {
        "text": "Groningen Research Institute for Asthma",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(GRIAC), Groningen, The Netherlands. Electronic address:",
    "entities": [
      {
        "text": "Groningen",
        "label": "PERSON"
      },
      {
        "text": "The Netherlands",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Declaration of Competing Interest LvD received",
    "entities": []
  },
  {
    "text": "funding from TEVA Pharmaceuticals and Biogen for studies not related to this",
    "entities": [
      {
        "text": "TEVA Pharmaceuticals",
        "label": "ORG"
      },
      {
        "text": "Biogen",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "study. JFMvB received a research grant from Chiesi paid to his institution for",
    "entities": [
      {
        "text": "Chiesi",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "the study and reports grants and/or consultancy fees from ALK, AstraZeneca,",
    "entities": [
      {
        "text": "ALK",
        "label": "ORG"
      },
      {
        "text": "AstraZeneca",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Chiesi, European Commission COST (COST Action 19132), GSK, Novartis, Pfizer,",
    "entities": [
      {
        "text": "Chiesi",
        "label": "GPE"
      },
      {
        "text": "European Commission",
        "label": "ORG"
      },
      {
        "text": "19132",
        "label": "DATE"
      },
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "Novartis",
        "label": "ORG"
      },
      {
        "text": "Pfizer",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Teva, Trudell Medical and Vertex, outside the submitted work and all paid to his",
    "entities": [
      {
        "text": "Trudell Medical",
        "label": "ORG"
      },
      {
        "text": "Vertex",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "institution. CMEH received a fee from VERTEX for one presentation on cystic",
    "entities": [
      {
        "text": "CMEH",
        "label": "ORG"
      },
      {
        "text": "VERTEX",
        "label": "ORG"
      },
      {
        "text": "one",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "fibrosis and studies concerning this disease. The other authors has no",
    "entities": []
  },
  {
    "text": "relationships to disclose.",
    "entities": []
  },
  {
    "text": "10.12932/AP-240525-2082.",
    "entities": [
      {
        "text": "10.12932",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Asthma remission: A path to cure?",
    "entities": []
  },
  {
    "text": "H(10), Athipongarporn A(11), Hachai S(12), Boonsawat W(13), Brannan JD(14), Song",
    "entities": [
      {
        "text": "Athipongarporn",
        "label": "PERSON"
      },
      {
        "text": "Hachai S(12",
        "label": "PERSON"
      },
      {
        "text": "Brannan",
        "label": "PERSON"
      },
      {
        "text": "Song",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)Department of Medicine, Panyananthaphikkhu Chonprathan Medical Center,",
    "entities": [
      {
        "text": "Chonprathan Medical Center",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Srinakharinwirot University, Nonthaburi, Thailand.",
    "entities": [
      {
        "text": "Srinakharinwirot University",
        "label": "ORG"
      },
      {
        "text": "Nonthaburi",
        "label": "GPE"
      },
      {
        "text": "Thailand",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Center of Research Excellence in Allergy & Immunology, Faculty of Medicine",
    "entities": [
      {
        "text": "2)Center",
        "label": "CARDINAL"
      },
      {
        "text": "Research Excellence",
        "label": "ORG"
      },
      {
        "text": "Allergy & Immunology,",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(3)Biodesign Innovation Center, Department of Parasitology, Faculty of Medicine",
    "entities": [
      {
        "text": "Innovation Center,",
        "label": "ORG"
      },
      {
        "text": "Department of Parasitology, Faculty of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)Division of Pulmonary and Critical Care Medicine, Department of Internal",
    "entities": [
      {
        "text": "Pulmonary and Critical Care Medicine, Department of Internal",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Medicine, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand.",
    "entities": [
      {
        "text": "Medicine, Faculty of Medicine, Thammasat University",
        "label": "ORG"
      },
      {
        "text": "Pathum Thani",
        "label": "PERSON"
      },
      {
        "text": "Thailand",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Division of Pulmonary and Critical Care Medicine, Department of Medicine,",
    "entities": [
      {
        "text": "Pulmonary and Critical Care Medicine, Department of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial",
    "entities": []
  },
  {
    "text": "Hospital, Thai Red Cross Society, Bangkok, Thailand.",
    "entities": [
      {
        "text": "Thai Red Cross Society",
        "label": "ORG"
      },
      {
        "text": "Bangkok",
        "label": "GPE"
      },
      {
        "text": "Thailand",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)Excellence Center for Sleep Disorders, King Chulalongkorn Memorial Hospital,",
    "entities": [
      {
        "text": "Center for Sleep Disorders, King Chulalongkorn Memorial Hospital",
        "label": "WORK_OF_ART"
      }
    ]
  },
  {
    "text": "Thai Red Cross Society, Bangkok, Thailand.",
    "entities": [
      {
        "text": "Thai Red Cross Society",
        "label": "ORG"
      },
      {
        "text": "Bangkok",
        "label": "GPE"
      },
      {
        "text": "Thailand",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(7)Division of Allergy and Immunology, Department of Pediatrics, Faculty of",
    "entities": [
      {
        "text": "Allergy and Immunology, Department of Pediatrics, Faculty of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Medicine, Chulalongkorn University, Bangkok, Thailand.",
    "entities": [
      {
        "text": "Medicine, Chulalongkorn University",
        "label": "ORG"
      },
      {
        "text": "Bangkok",
        "label": "GPE"
      },
      {
        "text": "Thailand",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(8)BNH Asthma and Allergy center, BNH hospital, Bangkok, Thailand.",
    "entities": [
      {
        "text": "Asthma and Allergy",
        "label": "ORG"
      },
      {
        "text": "BNH",
        "label": "ORG"
      },
      {
        "text": "Bangkok",
        "label": "GPE"
      },
      {
        "text": "Thailand",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(9)Department of Physiology, Faculty of Medicine, Chulalongkorn University,",
    "entities": [
      {
        "text": "Physiology, Faculty of Medicine, Chulalongkorn University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(10)Division of Pulmonology, Department of Pediatrics, Faculty of Medicine,",
    "entities": [
      {
        "text": "10)Division of Pulmonology, Department of Pediatrics, Faculty of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Ramathibodi hospital, Mahidol University, Bangkok, Thailand.",
    "entities": [
      {
        "text": "Mahidol University",
        "label": "ORG"
      },
      {
        "text": "Bangkok",
        "label": "GPE"
      },
      {
        "text": "Thailand",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(11)Department of Pediatrics, Phra Nakhon Si Ayutthaya Hospital, Phra Nakhon Si",
    "entities": [
      {
        "text": "11)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Phra Nakhon Si\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(12)Center of Excellence for Allergy, Asthma and Pulmonary Diseases, Thammasat",
    "entities": [
      {
        "text": "12)Center",
        "label": "CARDINAL"
      },
      {
        "text": "Excellence for Allergy",
        "label": "ORG"
      },
      {
        "text": "Pulmonary Diseases",
        "label": "PERSON"
      },
      {
        "text": "Thammasat",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University, Pathum Thani, Thailand.",
    "entities": [
      {
        "text": "University",
        "label": "ORG"
      },
      {
        "text": "Pathum Thani",
        "label": "PERSON"
      },
      {
        "text": "Thailand",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(13)Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon",
    "entities": [
      {
        "text": "13)Department of Medicine, Faculty of Medicine",
        "label": "MONEY"
      },
      {
        "text": "Kaen University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Kaen, Thailand.",
    "entities": [
      {
        "text": "Kaen",
        "label": "GPE"
      },
      {
        "text": "Thailand",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(14)School of Medicine and Public Health, University of Newcastle, University",
    "entities": [
      {
        "text": "14)School",
        "label": "CARDINAL"
      },
      {
        "text": "Medicine and Public Health",
        "label": "ORG"
      },
      {
        "text": "University of Newcastle",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Drive, Callaghan, Australia.",
    "entities": [
      {
        "text": "Callaghan",
        "label": "GPE"
      },
      {
        "text": "Australia",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(15)Department of Allergy and Clinical Immunology Allergy, Asthma & COPD Center",
    "entities": [
      {
        "text": "15)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Allergy and Clinical Immunology Allergy",
        "label": "ORG"
      },
      {
        "text": "Asthma & COPD Center",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Airway Sensation & Cough Research Laboratory Asan Medical Center, University of",
    "entities": [
      {
        "text": "Airway Sensation & Cough Research Laboratory",
        "label": "ORG"
      },
      {
        "text": "Asan Medical Center, University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Ulsan College of Medicine, Seoul, South Korea.",
    "entities": [
      {
        "text": "Ulsan College of Medicine",
        "label": "ORG"
      },
      {
        "text": "Seoul",
        "label": "GPE"
      },
      {
        "text": "South Korea",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(16)Division of Allergy and Clinical Immunology, Department of Medicine, Faculty",
    "entities": [
      {
        "text": "16)Division",
        "label": "CARDINAL"
      },
      {
        "text": "Department of Medicine, Faculty",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of Medicine, Chulalongkorn university, King Chulalongkorn Memorial Hospital, The",
    "entities": [
      {
        "text": "Medicine, Chulalongkorn",
        "label": "ORG"
      },
      {
        "text": "King Chulalongkorn Memorial Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(17)Center of Excellence in Vaccine Research and Development, Faculty of",
    "entities": [
      {
        "text": "17)Center",
        "label": "CARDINAL"
      },
      {
        "text": "Excellence in Vaccine Research and Development, Faculty of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, The",
    "entities": [
      {
        "text": "Medicine, Chulalongkorn University",
        "label": "ORG"
      },
      {
        "text": "King Chulalongkorn Memorial Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Asthma is a chronic inflammatory airway disease characterized by variable",
    "entities": []
  },
  {
    "text": "respiratory symptoms and reversible airflow limitation. Despite significant",
    "entities": []
  },
  {
    "text": "advances in pharmacologic and immunotherapeutic treatment, definitive remission",
    "entities": []
  },
  {
    "text": "or cure remains elusive. Asthma remission is defined as a sustained absence of",
    "entities": []
  },
  {
    "text": "symptoms, exacerbations, and lung function decline, with or without ongoing",
    "entities": []
  },
  {
    "text": "therapy. In contrast, an asthma cure implies permanent disease eradication",
    "entities": []
  },
  {
    "text": "marked by lifelong symptom resolution, no need for maintenance or rescue",
    "entities": []
  },
  {
    "text": "medication, preserved lung function, and absence of airway inflammation. To",
    "entities": []
  },
  {
    "text": "date, no intervention has been proven to cure asthma. Consequently, clinical",
    "entities": []
  },
  {
    "text": "remission has emerged as a more achievable and meaningful goal in asthma",
    "entities": []
  },
  {
    "text": "management. This review summarizes recent findings on remission rates, key",
    "entities": []
  },
  {
    "text": "factors influencing asthma remission, and the impact of various therapeutic",
    "entities": []
  },
  {
    "text": "strategies-including immunotherapy and advanced biologics. We also highlight",
    "entities": []
  },
  {
    "text": "evidence underscoring the foundational role of comprehensive asthma care. Asthma",
    "entities": []
  },
  {
    "text": "should be managed within the context of a unified allergic airway disease; thus,",
    "entities": []
  },
  {
    "text": "systematic identification and treatment of coexisting conditions such as",
    "entities": []
  },
  {
    "text": "allergic rhinitis and rhinosinusitis, nasal polyps is essential, as they often",
    "entities": []
  },
  {
    "text": "exacerbate lower airway symptoms. Routine nasal irrigation, environmental",
    "entities": []
  },
  {
    "text": "control measures, and attention to modifiable lifestyle factors-such as sleep",
    "entities": []
  },
  {
    "text": "hygiene, physical activity, and weight management-are critical. When",
    "entities": []
  },
  {
    "text": "consistently implemented, these holistic approaches may significantly improve",
    "entities": []
  },
  {
    "text": "disease control and support the achievement of clinical remission. Achieving a",
    "entities": []
  },
  {
    "text": "cure for asthma remains the ultimate goal, necessitating a long-term commitment",
    "entities": []
  },
  {
    "text": "and strategically designed basic and clinical research to determine its",
    "entities": []
  },
  {
    "text": "viability.",
    "entities": []
  },
  {
    "text": "PMID: 40652405 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40652405",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "63. BMC Pulm Med. 2025 Jul 12;25(1):338. doi: 10.1186/s12890-025-03793-9.",
    "entities": [
      {
        "text": "63",
        "label": "CARDINAL"
      },
      {
        "text": "BMC Pulm Med",
        "label": "ORG"
      },
      {
        "text": "12;25(1):338",
        "label": "CARDINAL"
      },
      {
        "text": "10.1186",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Annual household income and chronic pulmonary conditions in long-term survivors",
    "entities": [
      {
        "text": "Annual",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "of blood or marrow transplantation: a BMTSS report.",
    "entities": [
      {
        "text": "BMTSS",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "L(2), Ross E(2), Bosworth A(3), Te HS(4), Wong FL(3), Bhatia R(2), Forman SJ(3),",
    "entities": [
      {
        "text": "Ross E(2",
        "label": "PERSON"
      },
      {
        "text": "Wong",
        "label": "PERSON"
      },
      {
        "text": "Bhatia R(2",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)Division of Pulmonary and Critical Care, University of Texas Dell Medical",
    "entities": [
      {
        "text": "University of Texas Dell Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "School, 1601 Trinity Street Building A, Austin, TX, 78712, USA.",
    "entities": [
      {
        "text": "1601",
        "label": "DATE"
      },
      {
        "text": "Trinity Street Building A",
        "label": "ORG"
      },
      {
        "text": "Austin",
        "label": "GPE"
      },
      {
        "text": "TX",
        "label": "ORG"
      },
      {
        "text": "78712",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)University of Alabama at Birmingham, Birmingham, AL, USA.",
    "entities": [
      {
        "text": "2)University",
        "label": "CARDINAL"
      },
      {
        "text": "Alabama at Birmingham",
        "label": "GPE"
      },
      {
        "text": "Birmingham",
        "label": "GPE"
      },
      {
        "text": "AL",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)City of Hope, Duarte, CA, USA.",
    "entities": [
      {
        "text": "Hope, Duarte",
        "label": "ORG"
      },
      {
        "text": "CA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)University of Minnesota, Minneapolis, MN, USA.",
    "entities": [
      {
        "text": "Minnesota",
        "label": "GPE"
      },
      {
        "text": "Minneapolis",
        "label": "GPE"
      },
      {
        "text": "MN,",
        "label": "ORG"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "INTRODUCTION: Whether socioeconomic status is associated with pulmonary",
    "entities": []
  },
  {
    "text": "conditions in BMT survivors is unknown. In this study, we used data from the BMT",
    "entities": [
      {
        "text": "BMT",
        "label": "ORG"
      },
      {
        "text": "BMT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Survivor Study (BMTSS) to determine the association between low annual household",
    "entities": []
  },
  {
    "text": "income and adverse pulmonary conditions (asthma, chronic cough or dyspnea,",
    "entities": []
  },
  {
    "text": "dyspnea at rest, recurrent pneumonia, current oxygen use) and health status in a",
    "entities": []
  },
  {
    "text": "retrospective cohort of BMT survivors.",
    "entities": [
      {
        "text": "BMT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "METHODS: BMTSS includes individuals who received BMT between 1974 and 2014 and",
    "entities": [
      {
        "text": "BMT",
        "label": "ORG"
      },
      {
        "text": "between 1974 and 2014",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "survived for \u2265 2y after BMT at one of three participating sites. BMT survivors",
    "entities": [
      {
        "text": "\u2265",
        "label": "PERSON"
      },
      {
        "text": "2y",
        "label": "CARDINAL"
      },
      {
        "text": "BMT",
        "label": "ORG"
      },
      {
        "text": "one",
        "label": "CARDINAL"
      },
      {
        "text": "three",
        "label": "CARDINAL"
      },
      {
        "text": "BMT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "completed the BMTSS survey, providing details on demographics (including annual",
    "entities": [
      {
        "text": "BMTSS",
        "label": "ORG"
      },
      {
        "text": "annual",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "household income) and chronic health conditions as diagnosed by their healthcare",
    "entities": []
  },
  {
    "text": "providers. We used logistic regression models to determine the odds of low",
    "entities": []
  },
  {
    "text": "annual household income (\u2264$49,999) associated with a post-BMT pulmonary",
    "entities": [
      {
        "text": "annual",
        "label": "DATE"
      },
      {
        "text": "\u2264$49,999",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "condition in BMT survivors, adjusting for relevant clinical and sociodemographic",
    "entities": [
      {
        "text": "BMT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "RESULTS: Our analysis included 2,814 participants (median age 58y; 44% female;",
    "entities": [
      {
        "text": "2,814",
        "label": "CARDINAL"
      },
      {
        "text": "age 58y",
        "label": "DATE"
      },
      {
        "text": "44%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "75% non-Hispanic White). Compared to survivors with annual household income",
    "entities": [
      {
        "text": "75%",
        "label": "PERCENT"
      },
      {
        "text": "non-Hispanic",
        "label": "NORP"
      },
      {
        "text": "annual",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "\u2265$100,000, those with income \u2264$49,999 had higher odds of pulmonary conditions",
    "entities": [
      {
        "text": "\u2264$49,999",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(asthma: OR = 1.80, 95%CI = 1.04-3.12, chronic cough or dyspnea: OR = 1.96,",
    "entities": [
      {
        "text": "1.80",
        "label": "CARDINAL"
      },
      {
        "text": "1.04",
        "label": "CARDINAL"
      },
      {
        "text": "1.96",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "95%CI = 1.37-2.81, and recurrent pneumonia: OR = 1.90, 95%CI = 1.00-3.60. Low",
    "entities": [
      {
        "text": "1.37",
        "label": "CARDINAL"
      },
      {
        "text": "1.90",
        "label": "CARDINAL"
      },
      {
        "text": "1.00",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "income was also associated with suboptimal health status (poor/fair/good:",
    "entities": []
  },
  {
    "text": "OR = 2.36, 95%CI = 1.84-3.01; reference: very good/excellent).",
    "entities": [
      {
        "text": "2.36",
        "label": "CARDINAL"
      },
      {
        "text": "1.84-3.01",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "CONCLUSIONS: The association between low annual household income and post-BMT",
    "entities": []
  },
  {
    "text": "pulmonary compromise in BMT survivors presents a need to understand the",
    "entities": [
      {
        "text": "BMT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "individual and environmental causes for this association. Future research should",
    "entities": []
  },
  {
    "text": "evaluate interventions to prevent post-transplant pulmonary morbidity in the",
    "entities": []
  },
  {
    "text": "lower-income survivor population.",
    "entities": []
  },
  {
    "text": "DOI: 10.1186/s12890-025-03793-9",
    "entities": [
      {
        "text": "10.1186",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "PMID: 40652197 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40652197",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "participate: The University of Alabama at Birmingham Institutional Review Board",
    "entities": [
      {
        "text": "The University of Alabama at Birmingham Institutional Review Board",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "reviewed and approved the BMTSS study. Consent for publication: Not applicable.",
    "entities": [
      {
        "text": "BMTSS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "64. J Allergy Clin Immunol Pract. 2025 Jul 10:S2213-2198(25)00634-8. doi:",
    "entities": [
      {
        "text": "64",
        "label": "CARDINAL"
      },
      {
        "text": "Allergy Clin Immunol Pract",
        "label": "PERSON"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "10",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "10.1016/j.jaip.2025.07.002. Online ahead of print.",
    "entities": [
      {
        "text": "10.1016/j.jaip.2025.07.002",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Small airway dysfunction is an independent exacerbation risk biomarker in the",
    "entities": []
  },
  {
    "text": "mild, well-controlled asthmatic; a frequently unrecognized high-risk phenotype.",
    "entities": []
  },
  {
    "text": "(1)Children's Hospital of Orange County, University California, Irvine, Orange",
    "entities": [
      {
        "text": "1)Children",
        "label": "PERSON"
      },
      {
        "text": "Hospital of Orange County",
        "label": "LOC"
      },
      {
        "text": "California",
        "label": "GPE"
      },
      {
        "text": "Irvine",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "County, Calif.",
    "entities": [
      {
        "text": "County",
        "label": "GPE"
      },
      {
        "text": "Calif.",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Allergy and Pneumology Outpatient Clinic, Bergamo, Italy.",
    "entities": [
      {
        "text": "Pneumology Outpatient Clinic",
        "label": "ORG"
      },
      {
        "text": "Bergamo",
        "label": "GPE"
      },
      {
        "text": "Italy",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Center for Medical Sciences (CISMed), Department of Cellular, Computational",
    "entities": [
      {
        "text": "Medical Sciences",
        "label": "ORG"
      },
      {
        "text": "Department of Cellular",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and Integrative Biology (CIBIO), University of Trento, Italy Santa Chiara",
    "entities": [
      {
        "text": "Integrative Biology",
        "label": "ORG"
      },
      {
        "text": "University of Trento",
        "label": "ORG"
      },
      {
        "text": "Italy",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Department of Clinical and Experimental Medicine, Section of Paediatrics,",
    "entities": [
      {
        "text": "Clinical",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "University of Pisa, Italy.",
    "entities": [
      {
        "text": "University of Pisa, Italy",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(5)Departmental Unit of Allergology, Immunology and Pulmonary Diseases,",
    "entities": [
      {
        "text": "5)Departmental Unit of Allergology, Immunology",
        "label": "ORG"
      },
      {
        "text": "Pulmonary Diseases",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Trevigiana, Italy.",
    "entities": [
      {
        "text": "Trevigiana",
        "label": "GPE"
      },
      {
        "text": "Italy",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(7)Department of Statistical Sciences, University of Padova, Padova, Italy.",
    "entities": [
      {
        "text": "Statistical Sciences",
        "label": "ORG"
      },
      {
        "text": "University of Padova",
        "label": "ORG"
      },
      {
        "text": "Padova",
        "label": "GPE"
      },
      {
        "text": "Italy",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(8)University of Dundee, School of Medicine, Dundee, UK. Electronic address:",
    "entities": [
      {
        "text": "Dundee, School of Medicine, Dundee",
        "label": "ORG"
      },
      {
        "text": "UK",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "BACKGROUND: Although current guidelines for asthma diagnosis and management have",
    "entities": []
  },
  {
    "text": "proven relatively successful, many asthmatics continue to experience poor asthma",
    "entities": []
  },
  {
    "text": "control and exacerbations. This may be due to a failure to recognize that mild,",
    "entities": []
  },
  {
    "text": "well-controlled asthmatics commonly have small airway dysfunction (SAD), which",
    "entities": []
  },
  {
    "text": "is associated with a significant exacerbation risk.",
    "entities": []
  },
  {
    "text": "OBJECTIVE: We aimed to better characterize how well SAD, determined by impulse",
    "entities": [
      {
        "text": "SAD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "oscillometry (IOS), is associated with prior exacerbations in the GINA defined",
    "entities": [
      {
        "text": "IOS",
        "label": "ORG"
      },
      {
        "text": "GINA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "mild, well-controlled asthma phenotype.",
    "entities": []
  },
  {
    "text": "METHODS: In 170 adults with mild, well-controlled asthma we determined the",
    "entities": [
      {
        "text": "170",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "presence of SAD by IOS metrics of peripheral airway resistance between 5Hz and",
    "entities": [
      {
        "text": "SAD",
        "label": "ORG"
      },
      {
        "text": "IOS metrics",
        "label": "ORG"
      },
      {
        "text": "between 5Hz",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "20Hz (Rrs5 - Rrs20) and peripheral airway reactance as area under the reactance",
    "entities": [
      {
        "text": "20Hz",
        "label": "CARDINAL"
      },
      {
        "text": "Rrs5 - Rrs20",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "curve (AX) at cut points of 0.10 kPa/L/s and 1.0 kPa/L respectively. We also",
    "entities": [
      {
        "text": "0.10",
        "label": "CARDINAL"
      },
      {
        "text": "kPa",
        "label": "GPE"
      },
      {
        "text": "1.0",
        "label": "CARDINAL"
      },
      {
        "text": "kPa/L",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "assessed the association between SAD, FEV1, FeNO, blood eosinophilia, and extra",
    "entities": [
      {
        "text": "SAD",
        "label": "ORG"
      },
      {
        "text": "FEV1",
        "label": "GPE"
      },
      {
        "text": "FeNO",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "fine inhaled corticosteroids (ICS) with prior exacerbations. A multivariate",
    "entities": [
      {
        "text": "ICS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "analysis evaluated which variables were independently associated with prior",
    "entities": []
  },
  {
    "text": "RESULTS: SAD was present in 27.6% and prior exacerbations in 34.1% of the",
    "entities": [
      {
        "text": "27.6%",
        "label": "PERCENT"
      },
      {
        "text": "34.1%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "population. Exacerbations were greater in those with SAD (82.9% versus 15.4%, p",
    "entities": [
      {
        "text": "SAD",
        "label": "ORG"
      },
      {
        "text": "82.9%",
        "label": "PERCENT"
      },
      {
        "text": "15.4%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "< .001), lower in those receiving extra fine ICS (27.7% versus 55.3% p< .05).",
    "entities": [
      {
        "text": "ICS",
        "label": "ORG"
      },
      {
        "text": "27.7%",
        "label": "PERCENT"
      },
      {
        "text": "55.3%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "SAD and extra fine ICS were both independently associated with prior",
    "entities": [
      {
        "text": "SAD",
        "label": "ORG"
      },
      {
        "text": "ICS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "exacerbations, with SAD increasing and extra fine ICS decreasing exacerbation",
    "entities": [
      {
        "text": "SAD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "CONCLUSIONS: In the mild, well-controlled asthmatic, SAD and prior exacerbations",
    "entities": [
      {
        "text": "SAD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "are common. SAD and extra fine ICS are independently associated with increased",
    "entities": [
      {
        "text": "ICS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "or decreased exacerbations respectively. Detecting SAD could result in early",
    "entities": []
  },
  {
    "text": "extra fine ICS intervention potentially preventing future exacerbations in this",
    "entities": [
      {
        "text": "ICS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "phenotype.",
    "entities": []
  },
  {
    "text": "65. Life Sci. 2025 Jul 10:123849. doi: 10.1016/j.lfs.2025.123849. Online ahead of",
    "entities": [
      {
        "text": "65",
        "label": "CARDINAL"
      },
      {
        "text": "10.1016",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "CXCL10 modulates airway inflammation in asthma via Sirt3-dependent macrophage",
    "entities": []
  },
  {
    "text": "(1)Department of Pediatrics, the First Affiliated Hospital of Anhui Medical",
    "entities": [
      {
        "text": "Pediatrics",
        "label": "ORG"
      },
      {
        "text": "the First Affiliated Hospital of Anhui Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University, Hefei 230022, China.",
    "entities": [
      {
        "text": "Hefei 230022",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)School of Clinical Medicine, Wannan Medical College, Wuhu 241002, China.",
    "entities": [
      {
        "text": "Clinical Medicine",
        "label": "ORG"
      },
      {
        "text": "Wannan Medical College",
        "label": "ORG"
      },
      {
        "text": "241002",
        "label": "DATE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Department of Clinical Laboratory, The First Affiliated Hospital of Anhui",
    "entities": [
      {
        "text": "Clinical Laboratory",
        "label": "ORG"
      },
      {
        "text": "The First Affiliated Hospital of Anhui",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Medical University, Hefei 230022, China.",
    "entities": [
      {
        "text": "Medical University",
        "label": "ORG"
      },
      {
        "text": "Hefei 230022",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Department of Pediatrics, the First Affiliated Hospital of Anhui Medical",
    "entities": [
      {
        "text": "Pediatrics",
        "label": "ORG"
      },
      {
        "text": "the First Affiliated Hospital of Anhui Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University, Hefei 230022, China.; Beijing Children's Hospital, Capital Medical",
    "entities": [
      {
        "text": "Hefei 230022,",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      },
      {
        "text": "Beijing Children's Hospital",
        "label": "ORG"
      },
      {
        "text": "Capital Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University, China National Clinical Research Center of Respiratory Diseases,",
    "entities": [
      {
        "text": "China National Clinical Research Center of Respiratory Diseases",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Beijing 100045, China. Electronic address: dingsg@ahmu.edu.cn.",
    "entities": [
      {
        "text": "Beijing",
        "label": "GPE"
      },
      {
        "text": "100045",
        "label": "DATE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "BACKGROUND: In recent years, it has been found that Th1 inflammation",
    "entities": [
      {
        "text": "recent years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "characterized by elevated levels of IFN-\u03b3 can be observed in the airways of",
    "entities": [
      {
        "text": "IFN",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "patients with severe asthma, accompanied by polarization of M1 macrophages.",
    "entities": [
      {
        "text": "M1",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "However, the specific pathogenic role of M1 macrophages and their intrinsic",
    "entities": [
      {
        "text": "M1",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "regulatory factors in the development of asthma is still unclear.",
    "entities": []
  },
  {
    "text": "OBJECTIVE: We sought to investigate whether CXCL10 regulates M1 macrophage",
    "entities": [
      {
        "text": "M1 macrophage",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "polarization through Sirt3.",
    "entities": []
  },
  {
    "text": "METHODS: Collecting peripheral blood samples from asthmatic children, ELISA was",
    "entities": [
      {
        "text": "ELISA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "used to detect the levels of CXCL9, CXCL10, and CXCL11, and Western blot",
    "entities": [
      {
        "text": "CXCL9, CXCL10",
        "label": "ORG"
      },
      {
        "text": "CXCL11",
        "label": "ORG"
      },
      {
        "text": "Western",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "analyses was used to detect of the levels of Sirt3. We constructed an asthma",
    "entities": []
  },
  {
    "text": "mouse model and observed changes in macrophage polarization and Sirt3 by",
    "entities": [
      {
        "text": "mouse",
        "label": "PERSON"
      },
      {
        "text": "Sirt3",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "neutralizing CXCL10 or injecting CXCR antagonist AMG487. In addition, the effect",
    "entities": [
      {
        "text": "AMG487",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "of CXCL10 on Sirt3 mediated macrophage polarization was elucidated through in",
    "entities": []
  },
  {
    "text": "vitro experiments. The effect of M1 macrophage polarization on airway epithelial",
    "entities": [
      {
        "text": "M1",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "cells was investigated by co-culturing with conditioned medium.",
    "entities": []
  },
  {
    "text": "RESULTS: Clinical investigations showed that CXCL10 was highly expressed in",
    "entities": []
  },
  {
    "text": "peripheral blood of children with asthma, and was associated with impaired lung",
    "entities": []
  },
  {
    "text": "function (FEV1/FVC). Sirt3 expression in peripheral blood mononuclear cell was",
    "entities": []
  },
  {
    "text": "decreased. CXCL10 was found to the development of disease by promoting the M1",
    "entities": [
      {
        "text": "M1",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "polarization of macrophages. Mechanistically, Sirt3 overexpression improved",
    "entities": [
      {
        "text": "Sirt3",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "CXCL10-induced macrophage polarization.",
    "entities": []
  },
  {
    "text": "CONCLUSIONS: CXCL10 promotes M1 macrophage polarization by inhibiting Sirt3,",
    "entities": [
      {
        "text": "M1",
        "label": "PRODUCT"
      },
      {
        "text": "Sirt3",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "which plays an important role in the development of asthma.",
    "entities": []
  },
  {
    "text": "66. Ann Allergy Asthma Immunol. 2025 Jul 10:S1081-1206(25)00347-3. doi:",
    "entities": [
      {
        "text": "66",
        "label": "CARDINAL"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "10.1016/j.anai.2025.07.007. Online ahead of print.",
    "entities": [
      {
        "text": "10.1016",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Oh Eosinophil, what can you tell us about asthma?",
    "entities": []
  },
  {
    "text": "(1)Professor of Medicine Emeritus, University of Wisconsin School of Medicine",
    "entities": [
      {
        "text": "Medicine Emeritus",
        "label": "ORG"
      },
      {
        "text": "University of Wisconsin School of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and Public Health, Department of Medicine, Division of Allergy, Pulmonary and",
    "entities": [
      {
        "text": "Public Health, Department of Medicine, Division of Allergy",
        "label": "ORG"
      },
      {
        "text": "Pulmonary",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Critical Care Medicine, Madison, WI. Electronic address: wwb@medicine.wisc.edu.",
    "entities": [
      {
        "text": "Critical Care Medicine",
        "label": "ORG"
      },
      {
        "text": "Madison",
        "label": "PERSON"
      },
      {
        "text": "WI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Conflict of competing interests W. W. Busse",
    "entities": [
      {
        "text": "W. W. Busse",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "reports consulting fees/honoraria from GlaxoSmithKline, Regeneron, and Sanofi,",
    "entities": [
      {
        "text": "GlaxoSmithKline",
        "label": "GPE"
      },
      {
        "text": "Regeneron",
        "label": "GPE"
      },
      {
        "text": "Sanofi",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and royalties from Elsevier.",
    "entities": []
  },
  {
    "text": "67. Ann Allergy Asthma Immunol. 2025 Jul 10:S1081-1206(25)00346-1. doi:",
    "entities": [
      {
        "text": "67",
        "label": "CARDINAL"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "10.1016/j.anai.2025.07.005. Online ahead of print.",
    "entities": [
      {
        "text": "10.1016",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "ALERT (ChAracterizing uncontroLled sevERe asThma in Canada): oral corticosteroid",
    "entities": [
      {
        "text": "ALERT",
        "label": "ORG"
      },
      {
        "text": "Canada",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "and short-acting \u03b2(2)-agonist overuse.",
    "entities": []
  },
  {
    "text": "C\u00f4t\u00e9 A(1), Beach J(2), Reynolds J(2), Usuba K(3), Tusin J(3), Jayakumar MK(4),",
    "entities": [
      {
        "text": "Reynolds",
        "label": "ORG"
      },
      {
        "text": "Usuba",
        "label": "GPE"
      },
      {
        "text": "Jayakumar",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)Quebec Heart and Lung Institute - Universit\u00e9 Laval, Qu\u00e9bec City, QC, Canada.",
    "entities": [
      {
        "text": "Lung Institute - Universit\u00e9 Laval",
        "label": "ORG"
      },
      {
        "text": "Qu\u00e9bec City",
        "label": "GPE"
      },
      {
        "text": "QC",
        "label": "GPE"
      },
      {
        "text": "Canada",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Division of Allergy Clinical Immunology, McMaster University, Hamilton, ON,",
    "entities": [
      {
        "text": "Allergy Clinical Immunology",
        "label": "ORG"
      },
      {
        "text": "McMaster University",
        "label": "ORG"
      },
      {
        "text": "Hamilton",
        "label": "PERSON"
      },
      {
        "text": "ON",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "BACKGROUND: Approximately 230,000-465,000 patients in Canada have severe asthma;",
    "entities": [
      {
        "text": "Approximately 230,000-465,000",
        "label": "CARDINAL"
      },
      {
        "text": "Canada",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "of these, 4-31% are uncontrolled. Despite increased availability of biologics,",
    "entities": [
      {
        "text": "4-31%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "many rely on oral corticosteroids (OCS) or short-acting \u03b22-agonists (SABA),",
    "entities": [
      {
        "text": "OCS",
        "label": "ORG"
      },
      {
        "text": "SABA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "which are associated with substantial short- and long-term adverse effects.",
    "entities": []
  },
  {
    "text": "OBJECTIVE: ALERT aimed to characterize the demographics of patients with severe",
    "entities": [
      {
        "text": "ALERT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "asthma and uncontrolled severe asthma with and/or without biologics in Canada",
    "entities": [
      {
        "text": "Canada",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "and describe OCS/SABA and biologic treatment patterns.",
    "entities": []
  },
  {
    "text": "METHODS: ALERT was a retrospective descriptive study using longitudinal claims",
    "entities": [
      {
        "text": "ALERT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "data from IQVIA's private drug plan database and the Ontario drug benefits",
    "entities": [
      {
        "text": "IQVIA",
        "label": "ORG"
      },
      {
        "text": "Ontario",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "database. Adult patients with an inferred asthma diagnosis were assessed and",
    "entities": []
  },
  {
    "text": "selected using a rule-based inference algorithm and further classified as having",
    "entities": []
  },
  {
    "text": "severe asthma, uncontrolled severe asthma and uncontrolled severe asthma without",
    "entities": []
  },
  {
    "text": "biologics, based on eligibility criteria including inhaled therapies and OCS",
    "entities": [
      {
        "text": "biologics",
        "label": "ORG"
      },
      {
        "text": "OCS\n",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "use. Patients were assessed for OCS, SABA and biologic use in the 12-month",
    "entities": [
      {
        "text": "OCS",
        "label": "ORG"
      },
      {
        "text": "SABA",
        "label": "ORG"
      },
      {
        "text": "12-month",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "analysis period; regional variation was described.",
    "entities": []
  },
  {
    "text": "RESULTS: Patients with severe asthma, uncontrolled severe asthma and",
    "entities": []
  },
  {
    "text": "uncontrolled severe asthma without biologics had a mean of 2.7, 4.4 and 4.2 OCS",
    "entities": [
      {
        "text": "2.7",
        "label": "CARDINAL"
      },
      {
        "text": "4.4",
        "label": "DATE"
      },
      {
        "text": "4.2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "claims per patient/year, respectively. Of patients with uncontrolled severe",
    "entities": []
  },
  {
    "text": "asthma, 8.3% had \u226510 OCS claims. Combined OCS/SABA overuse (\u22652 OCS/\u22653 SABA",
    "entities": [
      {
        "text": "8.3%",
        "label": "PERCENT"
      },
      {
        "text": "OCS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "claims in the study period) was recorded in 6.1% of patients with severe asthma.",
    "entities": [
      {
        "text": "6.1%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "Most patients with uncontrolled severe asthma (71.8%) had no biologic claims.",
    "entities": [
      {
        "text": "71.8%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "Regional disparities in OCS use were observed.",
    "entities": [
      {
        "text": "OCS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "CONCLUSION: Optimization of asthma management through improved diagnosis,",
    "entities": []
  },
  {
    "text": "patient education, earlier specialist referral and region-specific improvements",
    "entities": []
  },
  {
    "text": "is needed to reduce OCS/SABA use and increase biologic uptake for eligible",
    "entities": []
  },
  {
    "text": "Conflict of interest statement: Declaration of competing interest AC has",
    "entities": [
      {
        "text": "AC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "received speaker fees and consulting fees from AstraZeneca, Sanofi-Regeneron and",
    "entities": [
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "Sanofi-Regeneron",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "GSK, and research grants from AstraZeneca and GSK. JB and JR are employees of",
    "entities": [
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "JB",
        "label": "PERSON"
      },
      {
        "text": "JR",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Asthma Canada, which has received funding from AstraZeneca, Bausch Health, CSL",
    "entities": [
      {
        "text": "Asthma Canada",
        "label": "ORG"
      },
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "Bausch Health",
        "label": "ORG"
      },
      {
        "text": "CSL",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Seqirus, GSK, Sanofi Genzyme, Sanofi Pasteur, Pfizer and Novartis and consulting",
    "entities": [
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "Sanofi Genzyme",
        "label": "ORG"
      },
      {
        "text": "Pfizer",
        "label": "PERSON"
      },
      {
        "text": "Novartis",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "fees from Roche. KU and JT are employed by GSK and hold financial equities in",
    "entities": [
      {
        "text": "Roche",
        "label": "ORG"
      },
      {
        "text": "JT",
        "label": "GPE"
      },
      {
        "text": "GSK",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "GSK. MJ and TH were employees of IQVIA at the time of the study, which received",
    "entities": [
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "TH",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "funding from GSK. SW reports grants/research support from ALK and Pfizer Canada,",
    "entities": [
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "SW",
        "label": "ORG"
      },
      {
        "text": "ALK",
        "label": "ORG"
      },
      {
        "text": "Pfizer Canada",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "speakers\u2019 bureau/honoraria and consulting fees from AbbVie, ALK, AstraZeneca,",
    "entities": [
      {
        "text": "AbbVie",
        "label": "ORG"
      },
      {
        "text": "ALK",
        "label": "ORG"
      },
      {
        "text": "AstraZeneca",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "MiravaHealth, Novartis, Pfizer Canada, Sanofi Regeneron and Takeda, and is the",
    "entities": [
      {
        "text": "MiravaHealth",
        "label": "ORG"
      },
      {
        "text": "Novartis",
        "label": "ORG"
      },
      {
        "text": "Pfizer Canada",
        "label": "ORG"
      },
      {
        "text": "Sanofi Regeneron",
        "label": "PERSON"
      },
      {
        "text": "Takeda",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "President of Canadian Allergy, Asthma, and Immunology Foundation (CAAIF), BOD",
    "entities": [
      {
        "text": "Canadian Allergy",
        "label": "ORG"
      },
      {
        "text": "Asthma",
        "label": "ORG"
      },
      {
        "text": "Immunology Foundation",
        "label": "ORG"
      },
      {
        "text": "BOD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Asthma Canada and The Canadian Hereditary Angioedema Network (CHAEN).",
    "entities": [
      {
        "text": "Asthma Canada",
        "label": "ORG"
      },
      {
        "text": "The Canadian Hereditary Angioedema Network",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "68. Ann Allergy Asthma Immunol. 2025 Jul 10:S1081-1206(25)00345-X. doi:",
    "entities": [
      {
        "text": "68",
        "label": "CARDINAL"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "10.1016/j.anai.2025.07.006. Online ahead of print.",
    "entities": [
      {
        "text": "10.1016",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "FRESH CLOTHES, HARD BREATHS: Laundry washing habits, Detergents, Softeners, and",
    "entities": []
  },
  {
    "text": "Impaired Respiratory Functions in Wheezy Children.",
    "entities": [
      {
        "text": "Impaired Respiratory Functions",
        "label": "ORG"
      },
      {
        "text": "Wheezy Children",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "(1)Department of Paediatric Allergy and Immunology, Adnan Menderes University",
    "entities": [
      {
        "text": "Paediatric Allergy and Immunology",
        "label": "ORG"
      },
      {
        "text": "Adnan Menderes University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Faculty of Medicine, Aydin; Ayd\u0131n Adnan Menderes University School of Medicine,",
    "entities": [
      {
        "text": "Aydin",
        "label": "GPE"
      },
      {
        "text": "Ayd\u0131n Adnan Menderes University School of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Department of Pediatric Allergy and Immunology (ADU Hospital, E Block, Room",
    "entities": [
      {
        "text": "Department of Pediatric Allergy and Immunology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Number:42), 09100, Efeler, Aydin, T\u00fcrkiye. Electronic address:",
    "entities": [
      {
        "text": "Number:42",
        "label": "PERSON"
      },
      {
        "text": "09100",
        "label": "DATE"
      },
      {
        "text": "Efeler",
        "label": "PERSON"
      },
      {
        "text": "Aydin",
        "label": "GPE"
      },
      {
        "text": "T\u00fcrkiye",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Paediatric Allergy and Immunology, Adnan Menderes University",
    "entities": [
      {
        "text": "Paediatric Allergy and Immunology",
        "label": "ORG"
      },
      {
        "text": "Adnan Menderes University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(3)Department of Paediatric Allergy and Immunology, Adnan Menderes University",
    "entities": [
      {
        "text": "Paediatric Allergy and Immunology",
        "label": "ORG"
      },
      {
        "text": "Adnan Menderes University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)Department of Paediatric Allergy and Immunology, Adnan Menderes University",
    "entities": [
      {
        "text": "Paediatric Allergy and Immunology",
        "label": "ORG"
      },
      {
        "text": "Adnan Menderes University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(5)Department of Paediatric Allergy and Immunology, Adnan Menderes University",
    "entities": [
      {
        "text": "Paediatric Allergy and Immunology",
        "label": "ORG"
      },
      {
        "text": "Adnan Menderes University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(6)Department of Paediatric Allergy and Immunology, Adnan Menderes University",
    "entities": [
      {
        "text": "Paediatric Allergy and Immunology",
        "label": "ORG"
      },
      {
        "text": "Adnan Menderes University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "BACKGROUND: Early childhood wheezing may indicate asthma risk, making assessment",
    "entities": []
  },
  {
    "text": "of environmental triggers crucial. Recent research has identified potential",
    "entities": []
  },
  {
    "text": "effects of laundry product chemicals on airway epithelial barriers.",
    "entities": []
  },
  {
    "text": "OBJECTIVE: To evaluate the relationship between the chemical contents and usage",
    "entities": []
  },
  {
    "text": "habits of household laundry products and pulmonary function in preschool",
    "entities": []
  },
  {
    "text": "children with recurrent wheezing and the effect of using soap-based detergent",
    "entities": []
  },
  {
    "text": "without additives on respiratory parameters measured by impulse oscillometry.",
    "entities": []
  },
  {
    "text": "METHODS: This prospective case-control study enrolled 80 recently diagnosed",
    "entities": [
      {
        "text": "80",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "wheezy children (CW) and 80 healthy children (HC) between August 2023-February",
    "entities": [
      {
        "text": "80",
        "label": "CARDINAL"
      },
      {
        "text": "August 2023-February",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "2024. Laundry habits and product chemical ingredients were recorded. Respiratory",
    "entities": [
      {
        "text": "2024",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "function was measured by impulse oscillometry (IOS), assessing airway resistance",
    "entities": [
      {
        "text": "IOS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "RESULTS: Softener use was higher in the CW group (p=0.011). Chemical analysis",
    "entities": [
      {
        "text": "Softener",
        "label": "PERSON"
      },
      {
        "text": "CW",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "revealed significantly higher frequency of sodium laurylsulphate (SLS), nonionic",
    "entities": []
  },
  {
    "text": "butylphenylmethylpropional, linolol, coumarin, and oxygen-based bleaching agents",
    "entities": []
  },
  {
    "text": "in detergents used by the CW group compared to HCs (p<0.05). Similarly, cationic",
    "entities": [
      {
        "text": "CW",
        "label": "ORG"
      },
      {
        "text": "p<0.05",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "in softeners used by CW families (p<0.05). The CW group exhibited higher",
    "entities": [
      {
        "text": "p<0.05",
        "label": "ORG"
      },
      {
        "text": "CW",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "resistance values (zR5, zR20, R5-20, Fres, AX) and lower zX5 compared to HC",
    "entities": [
      {
        "text": "zR5",
        "label": "PERSON"
      },
      {
        "text": "R5-20",
        "label": "CARDINAL"
      },
      {
        "text": "zX5",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(p<0.05). Children using additive-free detergents showed lower airway resistance",
    "entities": [
      {
        "text": "p<0.05",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(zR5, zR20) (p<0.05), while those using soap-free products had higher resistance",
    "entities": [
      {
        "text": "zR5",
        "label": "PERSON"
      },
      {
        "text": "p<0.05",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "CONCLUSION: Wheezy children have greater exposure to laundry softener chemicals",
    "entities": []
  },
  {
    "text": "than healthy counterparts. Additive-containing products were associated with",
    "entities": []
  },
  {
    "text": "increased airway resistance, while soap-based detergents showed no detectable",
    "entities": []
  },
  {
    "text": "impact on respiratory function. These findings suggest a potential link between",
    "entities": []
  },
  {
    "text": "chemical laundry products and impaired respiratory function in preschool wheezy",
    "entities": []
  },
  {
    "text": "Conflict of interest statement: Declerations of competing interest The author",
    "entities": []
  },
  {
    "text": "declares no conflict of interest.",
    "entities": []
  },
  {
    "text": "69. Ann Allergy Asthma Immunol. 2025 Jul 10:S1081-1206(25)00343-6. doi:",
    "entities": [
      {
        "text": "69",
        "label": "CARDINAL"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "10.1016/j.anai.2025.07.003. Online ahead of print.",
    "entities": [
      {
        "text": "10.1016",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Implications of removing race from spirometry reference equations in children",
    "entities": []
  },
  {
    "text": "with asthma.",
    "entities": []
  },
  {
    "text": "Mahmood LZ(1), Perry TT(2), Jefferson AA(3), Berlinski A(4).",
    "entities": [
      {
        "text": "Perry TT(2",
        "label": "ORG"
      },
      {
        "text": "Jefferson",
        "label": "PERSON"
      },
      {
        "text": "Berlinski A(4",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(1)Department of Pediatrics, Division of Allergy and Immunology, University of",
    "entities": [
      {
        "text": "Pediatrics, Division of Allergy and Immunology, University of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock,",
    "entities": [
      {
        "text": "Arkansas",
        "label": "GPE"
      },
      {
        "text": "Medical Sciences",
        "label": "ORG"
      },
      {
        "text": "Arkansas Children's Hospital",
        "label": "ORG"
      },
      {
        "text": "Little Rock",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Pediatrics, Division of Allergy and Immunology, University of",
    "entities": [
      {
        "text": "Pediatrics, Division of Allergy and Immunology, University of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(3)Department of Pediatrics, Division of Allergy and Immunology, University of",
    "entities": [
      {
        "text": "Pediatrics, Division of Allergy and Immunology, University of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)Department of Pediatrics, Division of Allergy and Immunology, University of",
    "entities": [
      {
        "text": "Pediatrics, Division of Allergy and Immunology, University of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Arkansas, USA; Department of Pediatrics, Division of Pulmonary and Sleep",
    "entities": [
      {
        "text": "Arkansas",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      },
      {
        "text": "Department of Pediatrics",
        "label": "ORG"
      },
      {
        "text": "Division of Pulmonary",
        "label": "ORG"
      },
      {
        "text": "Sleep\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Medicine, University of Arkansas for Medical Sciences and Arkansas Children's",
    "entities": [
      {
        "text": "Medicine, University of Arkansas for Medical Sciences",
        "label": "ORG"
      },
      {
        "text": "Arkansas Children's",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "Hospital, Little Rock, Arkansas, USA. Electronic address:",
    "entities": [
      {
        "text": "Little Rock",
        "label": "GPE"
      },
      {
        "text": "Arkansas",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "BACKGROUND: The Global Lung Initiative (GLI) recently developed a race-neutral",
    "entities": []
  },
  {
    "text": "reference equation in 2022 (GLI-2022); however, the implications of its use in",
    "entities": [
      {
        "text": "2022",
        "label": "DATE"
      },
      {
        "text": "GLI-2022",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "children with asthma, especially Latino children, have not been extensively",
    "entities": []
  },
  {
    "text": "OBJECTIVE: Assess the difference in spirometry results, asthma severity and",
    "entities": []
  },
  {
    "text": "airways obstruction classification for African American (AA), Latino and White",
    "entities": [
      {
        "text": "African American",
        "label": "NORP"
      },
      {
        "text": "Latino",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "children with asthma after implementing GLI-2022.",
    "entities": [
      {
        "text": "GLI-2022",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "METHODS: This retrospective cross-sectional study evaluated the first spirometry",
    "entities": [
      {
        "text": "first",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "performed by children with asthma aged 5-17 years between 01/01/2018 and",
    "entities": [
      {
        "text": "5-17 years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "12/31/2023. Z-scores and percent predicted (pp) values for forced vital capacity",
    "entities": [
      {
        "text": "12/31/2023",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "(FVC), forced expiratory volume in 1 second (FEV1), and FEV1 /FVC were",
    "entities": [
      {
        "text": "FVC",
        "label": "ORG"
      },
      {
        "text": "1 second",
        "label": "TIME"
      },
      {
        "text": "FEV1",
        "label": "GPE"
      },
      {
        "text": "FEV1",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "calculated using GLI-2022 and race-adjusted Global Lung Function Initiative 2012",
    "entities": [
      {
        "text": "GLI-2022",
        "label": "ORG"
      },
      {
        "text": "Global Lung Function Initiative",
        "label": "ORG"
      },
      {
        "text": "2012",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "RESULTS: A total of 7138 children: 3543 AA, 2795 White, and 800 Latino were",
    "entities": [
      {
        "text": "7138",
        "label": "DATE"
      },
      {
        "text": "3543",
        "label": "CARDINAL"
      },
      {
        "text": "2795",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "included (median age = 10.3 years). FEV1 z-score median difference was -0.872,",
    "entities": [
      {
        "text": "10.3 years",
        "label": "DATE"
      },
      {
        "text": "FEV1",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "-0.360, and +0.267 in AA, Latino, and White children, respectively (p < 0.0001)",
    "entities": [
      {
        "text": "Latino",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "after implementing GLI-2022. FVC z-scores, ppFEV1 and ppFVC values showed",
    "entities": [
      {
        "text": "GLI-2022",
        "label": "ORG"
      },
      {
        "text": "FVC",
        "label": "ORG"
      },
      {
        "text": "ppFEV1",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "similar patterns. Adopting GLI-2022 worsened asthma severity (based on ppFEV1)",
    "entities": [
      {
        "text": "GLI-2022",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and degree of airways obstruction (based on FEV1 z-score) classifications in AA",
    "entities": [
      {
        "text": "FEV1",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "children, improved them in White children, and did not affect Latino children.",
    "entities": []
  },
  {
    "text": "CONCLUSION: Implementing GLI-2022 impacted asthma severity and airway",
    "entities": []
  },
  {
    "text": "obstruction classifications and resulted in a lower FVC and FEV1 in AA and",
    "entities": [
      {
        "text": "FVC",
        "label": "ORG"
      },
      {
        "text": "FEV1",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Latino children and greater values in White children. Using GLI-2022 may uncover",
    "entities": [
      {
        "text": "GLI-2022",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "more cases of underdiagnosed asthma in AA and Latino children, which may",
    "entities": []
  },
  {
    "text": "contribute to alleviating disparate asthma outcomes.",
    "entities": []
  },
  {
    "text": "70. Ann Allergy Asthma Immunol. 2025 Jul 10:S1081-1206(25)00344-8. doi:",
    "entities": [
      {
        "text": "70",
        "label": "CARDINAL"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "10.1016/j.anai.2025.07.004. Online ahead of print.",
    "entities": [
      {
        "text": "10.1016",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Inflight Epinephrine Access During Allergic Emergencies: The Allergists",
    "entities": [
      {
        "text": "Allergists",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "Kodoth SM(1), Patel NC(2), Park HJ(3), Brooks JP(4).",
    "entities": [
      {
        "text": "Patel NC(2",
        "label": "PERSON"
      },
      {
        "text": "Park",
        "label": "PERSON"
      },
      {
        "text": "Brooks",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)Allergy Specialists of Knoxville, 1346 Dowell Springs Blvd, Knoxville, TN,",
    "entities": [
      {
        "text": "Knoxville",
        "label": "GPE"
      },
      {
        "text": "1346",
        "label": "DATE"
      },
      {
        "text": "Dowell Springs Blvd",
        "label": "ORG"
      },
      {
        "text": "Knoxville",
        "label": "GPE"
      },
      {
        "text": "TN",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)Division of Pediatric Allergy and Immunology, Duke University Medical Center,",
    "entities": [
      {
        "text": "Pediatric Allergy and Immunology",
        "label": "ORG"
      },
      {
        "text": "Duke University Medical Center",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)Columbia University Vagelos College of Physicians and Surgeons, 3959",
    "entities": [
      {
        "text": "4)Columbia",
        "label": "ORG"
      },
      {
        "text": "University Vagelos College of Physicians and Surgeons",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Broadway, 7 Central, New York, NY, 10024, USA.",
    "entities": [
      {
        "text": "Broadway",
        "label": "FAC"
      },
      {
        "text": "New York",
        "label": "GPE"
      },
      {
        "text": "NY",
        "label": "GPE"
      },
      {
        "text": "10024",
        "label": "DATE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "71. Ann Allergy Asthma Immunol. 2025 Jul 10:S1081-1206(25)00341-2. doi:",
    "entities": [
      {
        "text": "71",
        "label": "CARDINAL"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "10.1016/j.anai.2025.07.001. Online ahead of print.",
    "entities": [
      {
        "text": "10.1016",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "From the Pages of Allergy Watch.",
    "entities": [
      {
        "text": "the Pages of Allergy Watch",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(1)Atlanta Allergy & Asthma, Department of Pediatrics, Emory University School",
    "entities": [
      {
        "text": "Allergy & Asthma, Department of Pediatrics",
        "label": "ORG"
      },
      {
        "text": "Emory University School",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of Medicine, Atlanta, Georgia. Electronic address: sfineman@atlantaallergy.com.",
    "entities": [
      {
        "text": "Medicine",
        "label": "GPE"
      },
      {
        "text": "Atlanta",
        "label": "GPE"
      },
      {
        "text": "Georgia",
        "label": "GPE"
      },
      {
        "text": "sfineman@atlantaallergy.com",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "(2)Allergy and Immunology Care Center of South Florida, Miami Lakes, Florida;",
    "entities": [
      {
        "text": "Immunology Care Center of South Florida",
        "label": "ORG"
      },
      {
        "text": "Miami Lakes",
        "label": "GPE"
      },
      {
        "text": "Florida",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Division of Allergy and Immunology, Nicklaus Children's Hospital, Miami,",
    "entities": [
      {
        "text": "Division of Allergy and Immunology",
        "label": "ORG"
      },
      {
        "text": "Nicklaus Children's",
        "label": "PERSON"
      },
      {
        "text": "Miami",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Associate Professor of Pediatrics and Medicine, Director, Allergy/Immunology",
    "entities": [
      {
        "text": "Allergy/Immunology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Fellowship, Section of Allergy and Immunology, Emory University School of",
    "entities": [
      {
        "text": "Emory University School",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)Assistant Professor of Medicine, Medical Director, Allergy and Immunology",
    "entities": [
      {
        "text": "Allergy and Immunology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Clinic, Section of Allergy and Immunology, Oregon Health and Science University,",
    "entities": [
      {
        "text": "Oregon Health and Science University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Portland, OR. Electronic address: sjoshi4@gmail.com.",
    "entities": [
      {
        "text": "Portland",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "72. Respir Med. 2025 Jul 10;246:108253. doi: 10.1016/j.rmed.2025.108253. Online",
    "entities": [
      {
        "text": "72",
        "label": "CARDINAL"
      },
      {
        "text": "Respir Med",
        "label": "PERSON"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "10.1016",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Mortality and its predictive factors in participants with asthma: a 26-year",
    "entities": [
      {
        "text": "26-year",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "follow-up.",
    "entities": []
  },
  {
    "text": "(1)Department of Medical Sciences, Occupational and Environmental Medicine,",
    "entities": [
      {
        "text": "Medical Sciences",
        "label": "ORG"
      },
      {
        "text": "Occupational and Environmental Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Uppsala University, Sweden. Electronic address: marta.kisiel@medsci.uu.se.",
    "entities": [
      {
        "text": "Uppsala University",
        "label": "ORG"
      },
      {
        "text": "Sweden",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Medical Sciences: Clinical Physiology, Uppsala University,",
    "entities": [
      {
        "text": "Medical Sciences: Clinical Physiology",
        "label": "ORG"
      },
      {
        "text": "Uppsala University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(3)Department of Statistics, Uppsala University, Uppsala, Sweden.",
    "entities": [
      {
        "text": "Statistics",
        "label": "ORG"
      },
      {
        "text": "Uppsala University",
        "label": "ORG"
      },
      {
        "text": "Uppsala",
        "label": "GPE"
      },
      {
        "text": "Sweden",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Department of Medical Sciences, Uppsala University, Uppsala, Sweden.",
    "entities": [
      {
        "text": "Medical Sciences",
        "label": "ORG"
      },
      {
        "text": "Uppsala University",
        "label": "ORG"
      },
      {
        "text": "Uppsala",
        "label": "GPE"
      },
      {
        "text": "Sweden",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Department of Clinical Sciences in Malm\u00f6, Lund University, Occupational and",
    "entities": [
      {
        "text": "5)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Clinical Sciences",
        "label": "ORG"
      },
      {
        "text": "Malm\u00f6, Lund University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Environmental Medicine, Lund, Sweden.",
    "entities": [
      {
        "text": "Lund",
        "label": "GPE"
      },
      {
        "text": "Sweden",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)Department of Medical Sciences: Respiratory, Allergy and Sleep Research,",
    "entities": [
      {
        "text": "Medical Sciences: Respiratory",
        "label": "ORG"
      },
      {
        "text": "Sleep Research",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Uppsala University, Sweden.",
    "entities": [
      {
        "text": "Uppsala University",
        "label": "ORG"
      },
      {
        "text": "Sweden",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(7)Department of Medical Sciences, Occupational and Environmental Medicine,",
    "entities": [
      {
        "text": "Medical Sciences",
        "label": "ORG"
      },
      {
        "text": "Occupational and Environmental Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "BACKGROUND: The long-term impact of asthma on mortality remains uncertain. This",
    "entities": []
  },
  {
    "text": "study aimed to assess mortality and its predictors over 26 years in asthmatic",
    "entities": [
      {
        "text": "26 years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "participants compared to those with or without other respiratory symptoms.",
    "entities": []
  },
  {
    "text": "METHODS: This longitudinal cohort study included participants recruited from the",
    "entities": []
  },
  {
    "text": "general Swedish population, followed from 1990 to 2016. The younger (30-39",
    "entities": [
      {
        "text": "Swedish",
        "label": "NORP"
      },
      {
        "text": "1990",
        "label": "DATE"
      },
      {
        "text": "2016",
        "label": "DATE"
      },
      {
        "text": "30",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "years, n = 938) and older (60-69 years, at baseline, n = 1020) groups were",
    "entities": [
      {
        "text": "years",
        "label": "DATE"
      },
      {
        "text": "938",
        "label": "CARDINAL"
      },
      {
        "text": "60-69 years",
        "label": "DATE"
      },
      {
        "text": "1020",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "divided into asthma, other and no respiratory symptoms. Baseline data included",
    "entities": []
  },
  {
    "text": "spirometry, allergy testing, smoking status, and quality of life. Survival",
    "entities": []
  },
  {
    "text": "analyses were conducted using Kaplan-Meier and Cox proportional hazards models.",
    "entities": [
      {
        "text": "Kaplan-Meier and",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "RESULTS: At 26-years follow-up the survival rates were 34 % and 95 % for",
    "entities": [
      {
        "text": "26-years",
        "label": "DATE"
      },
      {
        "text": "34 % and",
        "label": "PERCENT"
      },
      {
        "text": "95 %",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "asthmatics in the older and younger age groups, respectively. Asthma was not",
    "entities": []
  },
  {
    "text": "found to be a statistically significant independent predictor of mortality when",
    "entities": []
  },
  {
    "text": "compared to non-asthmatics in either age group (older group HR 95 % CI: 0.94",
    "entities": [
      {
        "text": "95 %",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "0.94",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "(0.77-1.15); younger group: 1.39 (0.63-3.09). Significant mortality predictors",
    "entities": [
      {
        "text": "0.77",
        "label": "CARDINAL"
      },
      {
        "text": "1.39",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "included increasing age ((1.13 (1.10-1.16)), male sex (1.73 (1.44-2.07), smoking",
    "entities": [
      {
        "text": "1.13",
        "label": "CARDINAL"
      },
      {
        "text": "1.10-1.16",
        "label": "DATE"
      },
      {
        "text": "1.73",
        "label": "CARDINAL"
      },
      {
        "text": "1.44-2.07",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "(2.01 (1.65-2.44), lower forced expiratory volume in 1 s (FEV1) (0.67",
    "entities": [
      {
        "text": "2.01",
        "label": "CARDINAL"
      },
      {
        "text": "1.65-2.44",
        "label": "CARDINAL"
      },
      {
        "text": "1",
        "label": "CARDINAL"
      },
      {
        "text": "0.67",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "(0.60-0.76), and more symptoms (1.21 (1.01-1.45) in the older group, while age",
    "entities": [
      {
        "text": "0.60-0.76",
        "label": "CARDINAL"
      },
      {
        "text": "1.21",
        "label": "CARDINAL"
      },
      {
        "text": "1.01-1.45",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "(1.14 (1.02-1.27) and other respiratory symptoms (2.44 (1.18-5.03) were",
    "entities": [
      {
        "text": "1.14",
        "label": "CARDINAL"
      },
      {
        "text": "1.02-1.27",
        "label": "DATE"
      },
      {
        "text": "2.44",
        "label": "CARDINAL"
      },
      {
        "text": "1.18-5.03",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "predictors in the younger group. Risk factors significantly linked to mortality",
    "entities": []
  },
  {
    "text": "among older asthmatics included older age, male sex and current passive smoking,",
    "entities": []
  },
  {
    "text": "and only male sex in younger asthmatics.",
    "entities": []
  },
  {
    "text": "CONCLUSION: Asthma was not a strong independent predictor of mortality in either",
    "entities": []
  },
  {
    "text": "age group, whereas age, male sex, other respiratory symptoms, smoking, and lower",
    "entities": []
  },
  {
    "text": "FEV1, but not quality of life, were key risk factors. These findings highlight",
    "entities": []
  },
  {
    "text": "the importance of identifying high-risk individuals and addressing modifiable",
    "entities": []
  },
  {
    "text": "lifestyle factors such as smoking in mortality prevention strategies.",
    "entities": []
  },
  {
    "text": "declare that they have no competing financial or personal interests that could",
    "entities": []
  },
  {
    "text": "have influenced the work reported in this manuscript (below). No funding bodies",
    "entities": []
  },
  {
    "text": "had any role in the study design, data collection, analysis, or interpretation,",
    "entities": []
  },
  {
    "text": "nor in the decision to submit this manuscript for publication.",
    "entities": []
  },
  {
    "text": "10.1016/S2213-2600(25)00044-X. Online ahead of print.",
    "entities": [
      {
        "text": "10.1016",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Type 2 inflammation biomarkers and their association with response to dupilumab",
    "entities": [
      {
        "text": "2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3",
    "entities": [
      {
        "text": "3",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "(1)Division of Pulmonary, Critical Care, Allergy, & Sleep Medicine, University",
    "entities": [
      {
        "text": "Allergy",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "of California San Francisco, San Francisco, CA, USA. Electronic address:",
    "entities": [
      {
        "text": "California",
        "label": "GPE"
      },
      {
        "text": "San Francisco",
        "label": "GPE"
      },
      {
        "text": "San Francisco",
        "label": "GPE"
      },
      {
        "text": "CA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Medicine, Section of Pulmonary and Critical Care Medicine,",
    "entities": []
  },
  {
    "text": "Baylor College of Medicine, Houston, TX, USA.",
    "entities": [
      {
        "text": "Baylor College of Medicine",
        "label": "ORG"
      },
      {
        "text": "Houston",
        "label": "GPE"
      },
      {
        "text": "TX",
        "label": "ORG"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Division of Pulmonary, Allergy, and Critical Care Medicine, University of",
    "entities": [
      {
        "text": "Pulmonary",
        "label": "GPE"
      },
      {
        "text": "Allergy",
        "label": "GPE"
      },
      {
        "text": "Critical Care Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)King's Centre for Lung Health, School of Immunology & Microbial Sciences,",
    "entities": [
      {
        "text": "Centre for Lung Health, School of Immunology & Microbial Sciences",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "Faculty of Life Sciences & Medicine, King's College London, London, UK.",
    "entities": [
      {
        "text": "Faculty of Life Sciences & Medicine",
        "label": "ORG"
      },
      {
        "text": "King's College London",
        "label": "ORG"
      },
      {
        "text": "London",
        "label": "GPE"
      },
      {
        "text": "UK",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)LungenClinic Grosshansdorf and Christian Albrechts University of Kiel, Airway",
    "entities": [
      {
        "text": "Grosshansdorf",
        "label": "PERSON"
      },
      {
        "text": "Christian Albrechts University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Research Center North, German Center for Lung Research, Grosshansdorf, Germany.",
    "entities": [
      {
        "text": "Center North",
        "label": "PERSON"
      },
      {
        "text": "German Center",
        "label": "ORG"
      },
      {
        "text": "Grosshansdorf",
        "label": "GPE"
      },
      {
        "text": "Germany",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)Department of Medicine, Pulmonary and Critical Care Medicine, University of",
    "entities": [
      {
        "text": "Medicine, Pulmonary and Critical Care Medicine, University of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Marburg, German Center for Lung Research (DZL), Marburg, Germany.",
    "entities": [
      {
        "text": "Marburg",
        "label": "GPE"
      },
      {
        "text": "German Center",
        "label": "ORG"
      },
      {
        "text": "DZL",
        "label": "ORG"
      },
      {
        "text": "Marburg",
        "label": "GPE"
      },
      {
        "text": "Germany",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(7)Department of Cardiorespiratory Medicine, Respiratory Medicine Unit,",
    "entities": [
      {
        "text": "Cardiorespiratory Medicine",
        "label": "ORG"
      },
      {
        "text": "Respiratory Medicine Unit",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University of Ferrara, S. Anna University Hospital, Ferrara, Italy.",
    "entities": [
      {
        "text": "University of Ferrara",
        "label": "ORG"
      },
      {
        "text": "Ferrara",
        "label": "GPE"
      },
      {
        "text": "Italy",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(8)Medicines Evaluation Unit, Manchester University NHS Foundation Trust,",
    "entities": [
      {
        "text": "Evaluation Unit",
        "label": "ORG"
      },
      {
        "text": "Manchester University NHS Foundation Trust",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University of Manchester, Manchester, UK.",
    "entities": [
      {
        "text": "University of Manchester",
        "label": "ORG"
      },
      {
        "text": "Manchester",
        "label": "GPE"
      },
      {
        "text": "UK",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(10)Regeneron Pharmaceuticals, Tarrytown, NY, USA.",
    "entities": [
      {
        "text": "10)Regeneron Pharmaceuticals",
        "label": "ORG"
      },
      {
        "text": "Tarrytown",
        "label": "GPE"
      },
      {
        "text": "NY",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(11)Sanofi, Morristown, NJ, USA.",
    "entities": [
      {
        "text": "11)Sanofi",
        "label": "CARDINAL"
      },
      {
        "text": "Morristown",
        "label": "GPE"
      },
      {
        "text": "NJ",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "BACKGROUND: A raised blood eosinophil count (\u2265300 cells per \u03bcL), a marker of",
    "entities": [
      {
        "text": "\u2265300",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "type 2 inflammation, can identify patients with chronic obstructive pulmonary",
    "entities": [
      {
        "text": "2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "disease (COPD) with higher exacerbation risk. Dupilumab reduced exacerbations in",
    "entities": []
  },
  {
    "text": "patients with COPD and type 2 inflammation in the BOREAS trial. In this post-hoc",
    "entities": [
      {
        "text": "COPD",
        "label": "ORG"
      },
      {
        "text": "2",
        "label": "CARDINAL"
      },
      {
        "text": "BOREAS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "analysis, we evaluated the predictive value and longitudinal changes in type 2",
    "entities": [
      {
        "text": "2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "inflammatory biomarkers in patients with COPD and type 2 inflammation from the",
    "entities": [
      {
        "text": "COPD",
        "label": "ORG"
      },
      {
        "text": "2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "BOREAS trial who received dupilumab treatment.",
    "entities": []
  },
  {
    "text": "METHODS: BOREAS, a phase 3, multicentre, double-blind, randomised trial was",
    "entities": [
      {
        "text": "3",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "conducted at 275 sites in 24 countries and included patients with COPD and type",
    "entities": [
      {
        "text": "275",
        "label": "CARDINAL"
      },
      {
        "text": "24",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "2 inflammation (screening blood eosinophils \u2265300 cells per \u03bcL). Patients were",
    "entities": [
      {
        "text": "2",
        "label": "CARDINAL"
      },
      {
        "text": "\u2265300",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "randomly assigned (1:1) to receive 300 mg of dupilumab every 2 weeks for 52",
    "entities": [
      {
        "text": "300",
        "label": "CARDINAL"
      },
      {
        "text": "every 2 weeks",
        "label": "DATE"
      },
      {
        "text": "52",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "weeks or matching placebo. Randomisation was stratified by country and inhaled",
    "entities": [
      {
        "text": "weeks",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "corticosteroid dose at baseline. This post-hoc analysis assessed blood",
    "entities": []
  },
  {
    "text": "eosinophil counts, fractional exhaled nitric oxide (FeNO), serum eotaxin-3,",
    "entities": []
  },
  {
    "text": "total plasma immunoglobulin E (IgE), and serum pulmonary and",
    "entities": []
  },
  {
    "text": "activation-regulated chemokine (PARC) concentrations in the safety population.",
    "entities": []
  },
  {
    "text": "The study was registered at ClinicalTrials.gov, NCT03930732 and is complete.",
    "entities": [
      {
        "text": "NCT03930732",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "FINDINGS: BOREAS was conducted between April 15, 2019, and May 2, 2023, and",
    "entities": [
      {
        "text": "between April 15, 2019",
        "label": "DATE"
      },
      {
        "text": "May 2, 2023",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "included 939 patients with COPD and type 2 inflammation. 468 patients were",
    "entities": [
      {
        "text": "939",
        "label": "CARDINAL"
      },
      {
        "text": "COPD",
        "label": "ORG"
      },
      {
        "text": "2",
        "label": "CARDINAL"
      },
      {
        "text": "468",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "randomly assigned to receive 300 mg of dupilumab every 2 weeks for 52 weeks and",
    "entities": [
      {
        "text": "300",
        "label": "CARDINAL"
      },
      {
        "text": "every 2 weeks",
        "label": "DATE"
      },
      {
        "text": "52 weeks",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "471 were randomly assigned to receive matching placebo. 319 (34%) participants",
    "entities": [
      {
        "text": "471",
        "label": "CARDINAL"
      },
      {
        "text": "319",
        "label": "CARDINAL"
      },
      {
        "text": "34%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "were female and 620 (66%) were male. 657 (70%) were former smokers and 282 (30%)",
    "entities": [
      {
        "text": "620",
        "label": "CARDINAL"
      },
      {
        "text": "66%",
        "label": "PERCENT"
      },
      {
        "text": "657",
        "label": "CARDINAL"
      },
      {
        "text": "70%",
        "label": "PERCENT"
      },
      {
        "text": "282",
        "label": "CARDINAL"
      },
      {
        "text": "30%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "were current smokers. At week 52, greater median percentage reductions were",
    "entities": [
      {
        "text": "week 52",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "observed in dupilumab versus placebo for most biomarkers (total IgE: -22\u00b75% [IQR",
    "entities": [
      {
        "text": "IQR",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "[-35\u00b77 to 25\u00b70]; eotaxin-3: -8\u00b78% [-15\u00b76 to -2\u00b79] vs -0\u00b74% [-5\u00b76 to 5\u00b70]; and",
    "entities": []
  },
  {
    "text": "PARC: -14\u00b74% [-29\u00b72 to 2\u00b71] vs -0\u00b78% [-13\u00b79 to 17\u00b72]). Reductions were similar",
    "entities": [
      {
        "text": "17\u00b72",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "across treatment groups by blood eosinophil counts. Exacerbation risk overall",
    "entities": []
  },
  {
    "text": "was reduced, with a greater magnitude of reduction in those with higher baseline",
    "entities": []
  },
  {
    "text": "blood eosinophil count (p=0\u00b70056) and baseline FeNO (p=0\u00b7043).",
    "entities": [
      {
        "text": "FeNO",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "INTERPRETATION: Patients with COPD and type 2 inflammation who were given",
    "entities": [
      {
        "text": "2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "dupilumab showed reduced type 2 inflammatory biomarkers, with elevated blood",
    "entities": [
      {
        "text": "2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "eosinophil count and FeNO predicting greater treatment response. These findings",
    "entities": [
      {
        "text": "FeNO",
        "label": "LOC"
      }
    ]
  },
  {
    "text": "support biomarker-driven treatment strategies to optimise therapy.",
    "entities": []
  },
  {
    "text": "FUNDING: Sanofi and Regeneron Pharmaceuticals.",
    "entities": [
      {
        "text": "Regeneron Pharmaceuticals",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Copyright \u00a9 2025 The Author(s). Published by Elsevier Ltd. This is an Open",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Elsevier Ltd.",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd..",
    "entities": [
      {
        "text": "NC",
        "label": "GPE"
      },
      {
        "text": "4.0",
        "label": "CARDINAL"
      },
      {
        "text": "Elsevier Ltd",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "All rights reserved.",
    "entities": []
  },
  {
    "text": "Conflict of interest statement: Declaration of interests SAC reports personal",
    "entities": [
      {
        "text": "SAC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "fees for consulting or advisory board participation on asthma and COPD",
    "entities": []
  },
  {
    "text": "therapeutics from Amgen, Apogee Therapeutics, AstraZeneca, Devpro/Uniquity",
    "entities": [
      {
        "text": "Amgen",
        "label": "ORG"
      },
      {
        "text": "Apogee Therapeutics",
        "label": "ORG"
      },
      {
        "text": "Devpro/Uniquity",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Pharma, Genentech, GlaxoSmithKline, Illuminate Health, Kymera Therapeutics,",
    "entities": [
      {
        "text": "Pharma",
        "label": "PERSON"
      },
      {
        "text": "Genentech",
        "label": "ORG"
      },
      {
        "text": "GlaxoSmithKline",
        "label": "ORG"
      },
      {
        "text": "Illuminate Health",
        "label": "ORG"
      },
      {
        "text": "Kymera Therapeutics",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Regeneron Pharmaceuticals, Sanofi, and Verona Pharma; and personal fees for",
    "entities": [
      {
        "text": "Regeneron Pharmaceuticals",
        "label": "ORG"
      },
      {
        "text": "Sanofi",
        "label": "ORG"
      },
      {
        "text": "Verona Pharma",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "non-branded COPD or asthma talks from AstraZeneca, GlaxoSmithKline, Regeneron",
    "entities": [
      {
        "text": "AstraZeneca",
        "label": "NORP"
      },
      {
        "text": "GlaxoSmithKline",
        "label": "PERSON"
      },
      {
        "text": "Regeneron",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Pharmaceuticals, and Sanofi; and personal fees for writing on genetics and",
    "entities": [
      {
        "text": "Sanofi",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "genomics from UpToDate. NAH reports honoraria for serving as a consultant or",
    "entities": [
      {
        "text": "NAH",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "advisor for Amgen, AstraZeneca, Boehringer Ingelheim, GSK, Novartis, Sanofi, and",
    "entities": [
      {
        "text": "Amgen",
        "label": "ORG"
      },
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "Boehringer Ingelheim",
        "label": "PERSON"
      },
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "Novartis",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Teva; and grant support to their institution from AstraZeneca, Boehringer",
    "entities": [
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "Boehringer",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Ingelheim, Genentech, GSK, Novartis, and Sanofi. SPB reports grant support from",
    "entities": [
      {
        "text": "Ingelheim",
        "label": "ORG"
      },
      {
        "text": "Genentech",
        "label": "ORG"
      },
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "Novartis",
        "label": "ORG"
      },
      {
        "text": "Sanofi",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "NIH; consulting fees from Apreo, Boehringer Ingelheim, Chiesi, Genentech, GSK,",
    "entities": [
      {
        "text": "NIH",
        "label": "ORG"
      },
      {
        "text": "Apreo",
        "label": "ORG"
      },
      {
        "text": "Chiesi",
        "label": "GPE"
      },
      {
        "text": "Genentech",
        "label": "ORG"
      },
      {
        "text": "GSK",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Regeneron Pharmaceuticals, Sanofi, and Verona Pharma; and honoraria from",
    "entities": [
      {
        "text": "Regeneron Pharmaceuticals",
        "label": "ORG"
      },
      {
        "text": "Sanofi",
        "label": "ORG"
      },
      {
        "text": "Verona Pharma",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Horizon, Illuminate Health, Integritas Communications, Integrity CE, and",
    "entities": [
      {
        "text": "Illuminate Health",
        "label": "ORG"
      },
      {
        "text": "Integritas Communications",
        "label": "ORG"
      },
      {
        "text": "Integrity CE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Medscape. MB reports grant funding to their institution from AstraZeneca and",
    "entities": [
      {
        "text": "MB",
        "label": "ORG"
      },
      {
        "text": "AstraZeneca",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Roche; consultancy and speaker honoraria from AstraZeneca, Chiesi, and GSK; and",
    "entities": [
      {
        "text": "Roche",
        "label": "ORG"
      },
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "Chiesi",
        "label": "GPE"
      },
      {
        "text": "GSK",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "is a scientific advisor for Albus Health and ProAxsis. KFR is an advisory board",
    "entities": [
      {
        "text": "Albus Health and ProAxsis",
        "label": "ORG"
      },
      {
        "text": "KFR",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "member and consultant for and reports speaker fees from AstraZeneca, Boehringer",
    "entities": [
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "Boehringer",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Ingelheim, Chiesi, Gilead, GSK, Medscape, Novartis, Pearl Pharmaceuticals,",
    "entities": [
      {
        "text": "Ingelheim",
        "label": "GPE"
      },
      {
        "text": "Chiesi",
        "label": "GPE"
      },
      {
        "text": "Gilead",
        "label": "GPE"
      },
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "Medscape",
        "label": "GPE"
      },
      {
        "text": "Novartis",
        "label": "GPE"
      },
      {
        "text": "Pearl Pharmaceuticals",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Sanofi, and Teva; and is a co-founder of rnatics, Germany. CFV has given",
    "entities": [
      {
        "text": "Teva",
        "label": "ORG"
      },
      {
        "text": "Germany",
        "label": "GPE"
      },
      {
        "text": "CFV",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "presentations at symposia and served on scientific advisory boards for Aerogen,",
    "entities": [
      {
        "text": "symposia",
        "label": "GPE"
      },
      {
        "text": "Aerogen",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Menarini, Novartis, Nuvaira, Roche, and Sanofi. AP reports payments to their",
    "entities": [
      {
        "text": "Menarini",
        "label": "GPE"
      },
      {
        "text": "Novartis",
        "label": "GPE"
      },
      {
        "text": "Nuvaira",
        "label": "GPE"
      },
      {
        "text": "Roche",
        "label": "ORG"
      },
      {
        "text": "Sanofi",
        "label": "ORG"
      },
      {
        "text": "AP",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "institution from AstraZeneca, Chiesi, GSK, and Sanofi; consultancy fees from",
    "entities": [
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "Chiesi",
        "label": "GPE"
      },
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "Sanofi",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "AstraZeneca, Avillion, Chiesi, Elpen Pharmaceuticals, GSK, IQVIA, Novartis, and",
    "entities": [
      {
        "text": "AstraZeneca",
        "label": "NORP"
      },
      {
        "text": "Elpen Pharmaceuticals",
        "label": "ORG"
      },
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "IQVIA",
        "label": "ORG"
      },
      {
        "text": "Novartis",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Sanofi; and payment or honoraria for lectures, presentations, speakers bureaus,",
    "entities": []
  },
  {
    "text": "manuscript writing, or educational events from AstraZeneca, Avillion, Chiesi,",
    "entities": [
      {
        "text": "AstraZeneca",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "Sanofi, and Zambon. DS reports consultancy fees and honoraria from Aerogen,",
    "entities": [
      {
        "text": "Zambon",
        "label": "GPE"
      },
      {
        "text": "Aerogen",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Pharmaceuticals, Genentech, Glenmark, Gossamer Bio, GSK, Kinaset Therapeutics,",
    "entities": [
      {
        "text": "Genentech",
        "label": "ORG"
      },
      {
        "text": "Glenmark",
        "label": "ORG"
      },
      {
        "text": "Gossamer Bio",
        "label": "PERSON"
      },
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "Kinaset Therapeutics",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Menarini, Novartis, Orion, PULMATRiX, Sanofi, Teva, Theravance Biopharma, and",
    "entities": [
      {
        "text": "Menarini",
        "label": "GPE"
      },
      {
        "text": "Novartis, Orion",
        "label": "ORG"
      },
      {
        "text": "Sanofi",
        "label": "PERSON"
      },
      {
        "text": "Teva",
        "label": "GPE"
      },
      {
        "text": "Theravance Biopharma",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Verona Pharma. EL, XL, DB, and LBR are Sanofi employees and might hold stock or",
    "entities": [
      {
        "text": "Verona Pharma",
        "label": "PERSON"
      },
      {
        "text": "XL",
        "label": "ORG"
      },
      {
        "text": "DB",
        "label": "GPE"
      },
      {
        "text": "LBR",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "stock options in the company. PD, JM, and AB are employees and shareholders of",
    "entities": [
      {
        "text": "JM",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Regeneron Pharmaceuticals. RMA is a former Sanofi employee and might hold stock",
    "entities": [
      {
        "text": "Regeneron Pharmaceuticals",
        "label": "ORG"
      },
      {
        "text": "RMA",
        "label": "EVENT"
      },
      {
        "text": "Sanofi",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "or stock options in the company.",
    "entities": []
  },
  {
    "text": "Nocturnal oximetry profile in hospitalized children with asthma exacerbation",
    "entities": []
  },
  {
    "text": "upon hospital discharge.",
    "entities": []
  },
  {
    "text": "(1)Division of Pediatric Pulmonology and Sleep Disorders Laboratory, First",
    "entities": [
      {
        "text": "Sleep Disorders Laboratory",
        "label": "ORG"
      },
      {
        "text": "First",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "Department of Pediatrics, National and Kapodistrian University of Athens School",
    "entities": [
      {
        "text": "Department of Pediatrics",
        "label": "ORG"
      },
      {
        "text": "National",
        "label": "ORG"
      },
      {
        "text": "Kapodistrian University of Athens School",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of Medicine and Aghia Sophia Children's Hospital, Athens, Greece. Electronic",
    "entities": [
      {
        "text": "Aghia Sophia Children's",
        "label": "PERSON"
      },
      {
        "text": "Athens",
        "label": "GPE"
      },
      {
        "text": "Greece",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Division of Pediatric Pulmonology and Sleep Disorders Laboratory, First",
    "entities": [
      {
        "text": "Pediatric Pulmonology",
        "label": "ORG"
      },
      {
        "text": "Sleep Disorders Laboratory",
        "label": "ORG"
      },
      {
        "text": "First",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "(3)Department of Public Health Policy, School of Public Health, University of",
    "entities": [
      {
        "text": "Public Health Policy, School of Public Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "West Attica, Athens, Greece. Electronic address: tsergentanis@uniwa.gr.",
    "entities": [
      {
        "text": "West Attica",
        "label": "GPE"
      },
      {
        "text": "Athens",
        "label": "GPE"
      },
      {
        "text": "Greece",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Division of Pediatric Pulmonology and Sleep Disorders Laboratory, First",
    "entities": [
      {
        "text": "Pediatric Pulmonology",
        "label": "ORG"
      },
      {
        "text": "Sleep Disorders Laboratory",
        "label": "ORG"
      },
      {
        "text": "First",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "(5)Division of Pediatric Pulmonology and Sleep Disorders Laboratory, First",
    "entities": [
      {
        "text": "Pediatric Pulmonology",
        "label": "ORG"
      },
      {
        "text": "Sleep Disorders Laboratory",
        "label": "ORG"
      },
      {
        "text": "First",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "(6)Division of Pediatric Pulmonology and Sleep Disorders Laboratory, First",
    "entities": [
      {
        "text": "Pediatric Pulmonology",
        "label": "ORG"
      },
      {
        "text": "Sleep Disorders Laboratory",
        "label": "ORG"
      },
      {
        "text": "First",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "(7)Division of Pediatric Pulmonology and Sleep Disorders Laboratory, First",
    "entities": [
      {
        "text": "Pediatric Pulmonology",
        "label": "ORG"
      },
      {
        "text": "Sleep Disorders Laboratory",
        "label": "ORG"
      },
      {
        "text": "First",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "BACKGROUND: Asthma exacerbation is a cause of morbidity and mortality in the",
    "entities": []
  },
  {
    "text": "pediatric population. In guidelines there is no consensus regarding discharge",
    "entities": []
  },
  {
    "text": "criteria post exacerbation. Moreover, sleep has a known impact on gas exchange,",
    "entities": []
  },
  {
    "text": "which might be clinically relevant in patients with obstructive lung disease.",
    "entities": []
  },
  {
    "text": "Therefore, the aim of this study was to investigate the nocturnal oximetry",
    "entities": []
  },
  {
    "text": "profile in hospitalized children with asthma exacerbation, pre-discharge.",
    "entities": []
  },
  {
    "text": "MATERIALS AND METHODS: Nocturnal oximetry recordings of children with asthma",
    "entities": []
  },
  {
    "text": "admitted in Aghia Sofia Children's Hospital between December 2020 and April 2024",
    "entities": [
      {
        "text": "Aghia Sofia Children's Hospital",
        "label": "ORG"
      },
      {
        "text": "between December 2020 and",
        "label": "DATE"
      },
      {
        "text": "April 2024",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "were reviewed. In this cross-sectional study we compared them with recordings of",
    "entities": []
  },
  {
    "text": "children with Sleep Disordered Breathing (SDB) and controls. Night-time basal",
    "entities": [
      {
        "text": "Sleep Disordered Breathing",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "SpO2, Oxygen Desaturation Index3 (ODI3), as well as % of time spent <95 % were",
    "entities": [
      {
        "text": "Oxygen Desaturation Index3",
        "label": "PERSON"
      },
      {
        "text": "ODI3",
        "label": "FAC"
      },
      {
        "text": "95 %",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "compared. The Kruskal-Wallis test was employed to evaluate heterogeneity,",
    "entities": []
  },
  {
    "text": "followed by Mann-Whitney-Wilcoxon test for pairwise comparisons between the",
    "entities": [
      {
        "text": "Mann-Whitney-Wilcoxon",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "RESULTS: Asthmatic patients (n = 13) had lower basal SpO2 in comparison with",
    "entities": [
      {
        "text": "13",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "control (n = 21) and SDB group (N = 37) (SpO2 93.7 % versus 96.4 % and 96.7 %",
    "entities": [
      {
        "text": "control (n =",
        "label": "ORG"
      },
      {
        "text": "21",
        "label": "CARDINAL"
      },
      {
        "text": "37",
        "label": "DATE"
      },
      {
        "text": "93.7 %",
        "label": "PERCENT"
      },
      {
        "text": "96.4 %",
        "label": "PERCENT"
      },
      {
        "text": "96.7 %",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "respectively, p < 0.0001). They spent more time in SpO2< 95 % and had similar",
    "entities": [
      {
        "text": "p < 0.0001",
        "label": "ORG"
      },
      {
        "text": "95 %",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "ODI3 with the two other groups (p < 0.001 and p < 0.001 for asthma versus SDB",
    "entities": [
      {
        "text": "two",
        "label": "CARDINAL"
      },
      {
        "text": "p < 0.001",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and asthma versus control group respectively). Moreover, in patients with asthma",
    "entities": []
  },
  {
    "text": "a higher spot SpO2 was documented during the day, versus night-time basal SpO2.",
    "entities": [
      {
        "text": "the day",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "CONCLUSION: This study highlights that clinical improvement precedes SpO2",
    "entities": []
  },
  {
    "text": "improvement in asthmatic patients. A clinical review 48 h post-discharge is",
    "entities": [
      {
        "text": "48",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "advisable. Nocturnal basal SpO2 is lower than daytime spot SpO2, which should be",
    "entities": []
  },
  {
    "text": "taken under consideration in implementation of guidelines.",
    "entities": []
  },
  {
    "text": "Copyright \u00a9 2025. Published by Elsevier B.V.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Elsevier B.V.",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "The relationship between chronic air pollution exposure, neighborhood",
    "entities": []
  },
  {
    "text": "environmental vulnerability, and adverse COVID-19 morbidities among hospitalized",
    "entities": [
      {
        "text": "COVID-19",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "New York City residents.",
    "entities": [
      {
        "text": "New York City",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Kannoth S(1), Zhang C(2), Shafiq M(2), Albrecht SS(2), Azan A(3), Chambers",
    "entities": [
      {
        "text": "Kannoth S(1",
        "label": "ORG"
      },
      {
        "text": "Zhang C(2",
        "label": "PERSON"
      },
      {
        "text": "Shafiq M(2)",
        "label": "PERSON"
      },
      {
        "text": "Albrecht SS(2",
        "label": "GPE"
      },
      {
        "text": "Azan A(3",
        "label": "PERSON"
      },
      {
        "text": "Chambers",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "EC(4), Qian M(2), Sheffield PE(5), Thompson A(6), Woo Baidal JA(7),",
    "entities": [
      {
        "text": "Qian M(2",
        "label": "PERSON"
      },
      {
        "text": "Sheffield PE(5",
        "label": "PERSON"
      },
      {
        "text": "Thompson A(6",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)Columbia University, Mailman School of Public Health, New York, NY, USA.",
    "entities": [
      {
        "text": "University, Mailman School of Public Health",
        "label": "ORG"
      },
      {
        "text": "New York",
        "label": "GPE"
      },
      {
        "text": "NY",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Columbia University, Mailman School of Public Health, New York, NY, USA.",
    "entities": [
      {
        "text": "2)Columbia University, Mailman School of Public Health",
        "label": "ORG"
      },
      {
        "text": "New York",
        "label": "GPE"
      },
      {
        "text": "NY",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)New York University Langone Health, Department of Population Health, New",
    "entities": [
      {
        "text": "York University Langone Health, Department of Population Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "York, NY, USA.",
    "entities": [
      {
        "text": "NY",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Albert Einstein College of Medicine, Department of Family and Social",
    "entities": [
      {
        "text": "Einstein College of Medicine, Department of Family and Social",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Medicine, Bronx, NY, USA.",
    "entities": [
      {
        "text": "Bronx",
        "label": "GPE"
      },
      {
        "text": "NY",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Icahn School of Medicine at Mount Sinai, Department of Environmental",
    "entities": [
      {
        "text": "School of Medicine",
        "label": "ORG"
      },
      {
        "text": "Mount Sinai",
        "label": "FAC"
      },
      {
        "text": "Department of Environmental",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Medicine, New York, NY, USA.",
    "entities": [
      {
        "text": "New York",
        "label": "GPE"
      },
      {
        "text": "NY",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)SUNY Downstate Health Sciences University, School of Public Health Brooklyn,",
    "entities": [
      {
        "text": "6)SUNY Downstate Health Sciences University",
        "label": "ORG"
      },
      {
        "text": "School of Public Health Brooklyn",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(7)Stanford University, Stanford School of Medicine Stanford, CA, USA.",
    "entities": [
      {
        "text": "University",
        "label": "ORG"
      },
      {
        "text": "Stanford School of Medicine Stanford",
        "label": "ORG"
      },
      {
        "text": "CA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(8)Columbia University, Vagelos College of Physicians and Surgeons, New York,",
    "entities": [
      {
        "text": "8)Columbia University",
        "label": "ORG"
      },
      {
        "text": "Vagelos College of Physicians and Surgeons",
        "label": "ORG"
      },
      {
        "text": "New York",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "INTRODUCTION: Communities disproportionately burdened by adverse",
    "entities": []
  },
  {
    "text": "neighborhood-level social and structural factors may experience greater",
    "entities": []
  },
  {
    "text": "vulnerability to environmental exposures, contributing to health inequities,",
    "entities": []
  },
  {
    "text": "including adverse COVID-19. We assessed the effects of chronic air pollution on",
    "entities": [
      {
        "text": "COVID-19",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "COVID-19 morbidities in NYC and examined whether these effects varied by",
    "entities": [
      {
        "text": "NYC",
        "label": "LOC"
      }
    ]
  },
  {
    "text": "neighborhood-level vulnerability.",
    "entities": []
  },
  {
    "text": "METHODS: We used NYC COVID-19 hospitalization records (3/1/2020-2/28/2021) and",
    "entities": [
      {
        "text": "NYC",
        "label": "LOC"
      },
      {
        "text": "3/1/2020-2/28/2021",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "conducted analyses in the full sample and within hospital catchment. Chronic air",
    "entities": []
  },
  {
    "text": "(BC), ozone (O3)) was assigned using residential ZIP Code (NYC Community Air",
    "entities": [
      {
        "text": "BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Survey; 2009-2019). Modified Poisson regression estimated risk of acute",
    "entities": [
      {
        "text": "2009-2019",
        "label": "DATE"
      },
      {
        "text": "Poisson",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "respiratory distress syndrome (ARDS), pneumonia, ventilation, and dialysis, and",
    "entities": []
  },
  {
    "text": "Cox regression estimated risk of discharge, adjusting for age, sex, BMI,",
    "entities": [
      {
        "text": "BMI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "smoking, asthma, diabetes, and hypertension. We assessed effect modification by",
    "entities": []
  },
  {
    "text": "neighborhood-level environmental vulnerability index (NEVI) tertiles.",
    "entities": []
  },
  {
    "text": "RESULTS: From March to June 2020 (within hospital catchment), adjusted estimates",
    "entities": [
      {
        "text": "March to June 2020",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "generally suggest greater chronic NO2, PM2.5, and BC was associated with",
    "entities": [
      {
        "text": "BC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "increased risk of ARDS, pneumonia, and dialysis, and not associated with",
    "entities": []
  },
  {
    "text": "discharge and ventilation; inverse estimates found for chronic O3. Relationships",
    "entities": [
      {
        "text": "O3",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "between air pollution and adverse COVID-19 were generally stronger among those",
    "entities": [
      {
        "text": "COVID-19",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "with greater neighborhood environmental vulnerability. For example, chronic NO2",
    "entities": []
  },
  {
    "text": "and pneumonia's relationship was stronger in individuals within higher NEVI",
    "entities": [
      {
        "text": "NEVI",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "tertiles (T1: aRR: 1.13, 95%CI: 1.02-1.25; T2: aRR: 2.11, 95%CI: 1.73-2.56; T3:",
    "entities": [
      {
        "text": "T1",
        "label": "NORP"
      },
      {
        "text": "1.13",
        "label": "CARDINAL"
      },
      {
        "text": "1.02-1.25",
        "label": "CARDINAL"
      },
      {
        "text": "T2",
        "label": "CARDINAL"
      },
      {
        "text": "2.11",
        "label": "CARDINAL"
      },
      {
        "text": "1.73",
        "label": "CARDINAL"
      },
      {
        "text": "T3",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "aRR: 6.36, 95%CI: 4.71-8.60).",
    "entities": [
      {
        "text": "6.36",
        "label": "CARDINAL"
      },
      {
        "text": "4.71-8.60",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "DISCUSSION: Differences in neighborhood-level social and structural factors",
    "entities": []
  },
  {
    "text": "contribute to unequal health burdens associated with air pollution. Public",
    "entities": []
  },
  {
    "text": "health resources targeted toward neighborhoods with greater environmental",
    "entities": []
  },
  {
    "text": "vulnerability can encourage population-level pandemic preparedness.",
    "entities": []
  },
  {
    "text": "Copyright \u00a9 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Elsevier Ltd",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "considered as potential competing interests: Sneha Kannoth reports financial",
    "entities": [
      {
        "text": "Sneha Kannoth",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "support was provided by National Institute of Allergy and Infectious Diseases.",
    "entities": [
      {
        "text": "National Institute of Allergy and Infectious Diseases",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Jeanette A. Stingone reports financial support was provided by National",
    "entities": [
      {
        "text": "Jeanette A. Stingone",
        "label": "PERSON"
      },
      {
        "text": "National",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Institute of Environmental Health Sciences. Stephanie Lovinsky-Desir reports",
    "entities": [
      {
        "text": "Institute of Environmental Health Sciences",
        "label": "ORG"
      },
      {
        "text": "Stephanie Lovinsky-Desir",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "financial support was provided by National Institute of Environmental Health",
    "entities": [
      {
        "text": "National Institute of Environmental Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Sciences. Perry E. Sheffield reports financial support was provided by National",
    "entities": [
      {
        "text": "Perry E. Sheffield",
        "label": "PERSON"
      },
      {
        "text": "National",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "financial support was provided by National Heart Lung and Blood Institute. Earle",
    "entities": [
      {
        "text": "Blood Institute",
        "label": "ORG"
      },
      {
        "text": "Earle",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "C. Chambers reports financial support was provided by National Heart Lung and",
    "entities": [
      {
        "text": "C. Chambers",
        "label": "PERSON"
      },
      {
        "text": "Heart Lung",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Blood Institute. Earle C. Chambers reports financial support was provided by",
    "entities": [
      {
        "text": "Blood Institute",
        "label": "ORG"
      },
      {
        "text": "Earle C. Chambers",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "National Institute of Diabetes, Digestive and Kidney Disorders. Sandra S.",
    "entities": [
      {
        "text": "National Institute of Diabetes",
        "label": "ORG"
      },
      {
        "text": "Kidney Disorders",
        "label": "PERSON"
      },
      {
        "text": "Sandra S.\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Albrecht reports financial support was provided by National Institute of",
    "entities": [
      {
        "text": "Albrecht",
        "label": "GPE"
      },
      {
        "text": "National Institute of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Diabetes, Digestive and Kidney Disorders. Alexander Azan reports financial",
    "entities": [
      {
        "text": "Digestive",
        "label": "PERSON"
      },
      {
        "text": "Kidney Disorders",
        "label": "PERSON"
      },
      {
        "text": "Alexander Azan",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "support was provided by National Center for Advancing Translational Sciences.",
    "entities": [
      {
        "text": "National Center for Advancing Translational Sciences",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Alexander Azan reports financial support was provided by Health Resources and",
    "entities": [
      {
        "text": "Alexander Azan",
        "label": "PERSON"
      },
      {
        "text": "Health Resources",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Services Administration. Jeanette A. Stingone reports financial support was",
    "entities": [
      {
        "text": "Jeanette A. Stingone",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "provided by Health Effects Institute. Stephanie Lovinsky-Desir reports financial",
    "entities": [
      {
        "text": "Health Effects Institute",
        "label": "ORG"
      },
      {
        "text": "Stephanie Lovinsky-Desir",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "support was provided by Robert Wood Johnson Foundation. If there are other",
    "entities": [
      {
        "text": "Robert Wood Johnson Foundation",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "authors, they declare that they have no known competing financial interests or",
    "entities": []
  },
  {
    "text": "76. J Pharmacol Exp Ther. 2025 Jun 17;392(8):103636. doi:",
    "entities": [
      {
        "text": "76",
        "label": "CARDINAL"
      },
      {
        "text": "Exp Ther",
        "label": "PERSON"
      },
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "17;392(8):103636",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "10.1016/j.jpet.2025.103636. Online ahead of print.",
    "entities": [
      {
        "text": "10.1016",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Evaluation of pharmacokinetics, pharmacodynamics, and toxicity of potential",
    "entities": []
  },
  {
    "text": "(1)Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec",
    "entities": [
      {
        "text": "Organic and Bioorganic Chemistry",
        "label": "ORG"
      },
      {
        "text": "Hradec",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Kr\u00e1lov\u00e9, Charles University, Prague, Czech Republic.",
    "entities": [
      {
        "text": "Kr\u00e1lov\u00e9, Charles University",
        "label": "ORG"
      },
      {
        "text": "Prague",
        "label": "GPE"
      },
      {
        "text": "Czech Republic",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Laboratory of Neurochemistry, Institute of Physiology, Czech Academy of",
    "entities": [
      {
        "text": "2)Laboratory",
        "label": "CARDINAL"
      },
      {
        "text": "Neurochemistry, Institute of Physiology",
        "label": "ORG"
      },
      {
        "text": "Czech Academy",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Sciences, Prague, Czech Republic.",
    "entities": [
      {
        "text": "Prague",
        "label": "GPE"
      },
      {
        "text": "Czech Republic",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec",
    "entities": [
      {
        "text": "Biological and Medical Sciences",
        "label": "ORG"
      },
      {
        "text": "Faculty of Pharmacy",
        "label": "ORG"
      },
      {
        "text": "Hradec",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec",
    "entities": [
      {
        "text": "Pharmacology and Toxicology, Faculty of Pharmacy",
        "label": "ORG"
      },
      {
        "text": "Hradec",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Department of Biophysics and Physical Chemistry, Faculty of Pharmacy in",
    "entities": [
      {
        "text": "5)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Biophysics and Physical Chemistry, Faculty of Pharmacy",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Hradec Kr\u00e1lov\u00e9, Charles University, Prague, Czech Republic.",
    "entities": [
      {
        "text": "Hradec Kr\u00e1lov\u00e9",
        "label": "PERSON"
      },
      {
        "text": "Charles University",
        "label": "ORG"
      },
      {
        "text": "Prague",
        "label": "GPE"
      },
      {
        "text": "Czech Republic",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)School of Chemistry, College of Science, University of Lincoln, Lincoln,",
    "entities": [
      {
        "text": "Chemistry, College of Science, University of Lincoln",
        "label": "ORG"
      },
      {
        "text": "Lincoln",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(8)Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec",
    "entities": [
      {
        "text": "Pharmacology and Toxicology, Faculty of Pharmacy",
        "label": "ORG"
      },
      {
        "text": "Hradec",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Kr\u00e1lov\u00e9, Charles University, Prague, Czech Republic. Electronic address:",
    "entities": [
      {
        "text": "Kr\u00e1lov\u00e9, Charles University",
        "label": "ORG"
      },
      {
        "text": "Prague",
        "label": "GPE"
      },
      {
        "text": "Czech Republic",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Various synthetic modifications of the alkaloid (-)-vasicinone are known to",
    "entities": []
  },
  {
    "text": "exhibit a remarkable bronchodilatory effect. This study aimed to examine",
    "entities": []
  },
  {
    "text": "selected pharmacological and toxicological properties of 2 quinazolines derived",
    "entities": [
      {
        "text": "2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "from vasicinone with previously proven bronchodilatory action to consider their",
    "entities": []
  },
  {
    "text": "potential applicability for further preclinical development. Both compounds were",
    "entities": []
  },
  {
    "text": "found to have relatively low in vitro toxicity in a standard hepatic cell model.",
    "entities": []
  },
  {
    "text": "Pharmacokinetic studies in rats using oral and intravenous administration showed",
    "entities": []
  },
  {
    "text": "distribution volume, and elimination parameters of the 2 tested agents (for all",
    "entities": [
      {
        "text": "2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "parameters, P < .05). The different pharmacokinetic properties offer the",
    "entities": []
  },
  {
    "text": "possibility to select more convenient compounds for inhalation or systemic",
    "entities": []
  },
  {
    "text": "administration in further stages of development. The performed pharmacodynamic",
    "entities": []
  },
  {
    "text": "studies using an in vitro model showed that the tested quinazolines bind to the",
    "entities": []
  },
  {
    "text": "allosteric site on muscarinic acetylcholine receptors with micromolar affinity",
    "entities": []
  },
  {
    "text": "(pKB higher than pKI for M1 and M3 receptors, P < .05) and exert functional",
    "entities": [
      {
        "text": "M1",
        "label": "PRODUCT"
      },
      {
        "text": "M3",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "antagonism of carbachol-induced response. The main effect is not accompanied by",
    "entities": []
  },
  {
    "text": "a concomitant antibiotic effect. The proven inhibition of muscarinic receptors",
    "entities": []
  },
  {
    "text": "including the M3 subtype is analogous to the effects of clinically used",
    "entities": [
      {
        "text": "M3",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "anticholinergic bronchodilators. Therefore, the findings suggest that the",
    "entities": []
  },
  {
    "text": "bronchodilating effect of the tested compounds is likely mediated by a similar",
    "entities": []
  },
  {
    "text": "mechanism. The muscarinic receptor blocking effect based on allosteric binding",
    "entities": []
  },
  {
    "text": "to the receptors may potentially allow the development of a new group of highly",
    "entities": []
  },
  {
    "text": "selective M3 antagonists. SIGNIFICANCE STATEMENT: Two tested synthetic",
    "entities": [
      {
        "text": "M3",
        "label": "PRODUCT"
      },
      {
        "text": "SIGNIFICANCE STATEMENT",
        "label": "PERSON"
      },
      {
        "text": "Two",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "quinazoline derivatives with proven bronchodilator action exhibit allosteric",
    "entities": []
  },
  {
    "text": "binding to muscarinic receptors. Since the extracellular domain at which",
    "entities": []
  },
  {
    "text": "allosteric modulators commonly bind varies among subtypes of muscarinic",
    "entities": []
  },
  {
    "text": "receptors, this characteristic may allow further development of highly selective",
    "entities": []
  },
  {
    "text": "M3 antagonists. The examined compounds exhibit low toxicity as well as no",
    "entities": [
      {
        "text": "M3",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "concomitant antimicrobial effect that would potentially affect the bronchial",
    "entities": []
  },
  {
    "text": "Copyright \u00a9 2025 American Society for Pharmacology and Experimental",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Therapeutics. All rights reserved.",
    "entities": []
  },
  {
    "text": "Conflict of interest statement: Conflict of interest The authors declare no",
    "entities": []
  },
  {
    "text": "conflicts of interest.",
    "entities": []
  },
  {
    "text": "77. Clin Transl Allergy. 2025 Jul;15(7):e70077. doi: 10.1002/clt2.70077.",
    "entities": [
      {
        "text": "77",
        "label": "CARDINAL"
      },
      {
        "text": "Clin Transl Allergy",
        "label": "ORG"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "10.1002",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Distinct Roles Between Eotaxin 1 and Eotaxin 2 in Asthmatic Airways.",
    "entities": [
      {
        "text": "Eotaxin 2",
        "label": "PERSON"
      },
      {
        "text": "Asthmatic Airways",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(1)Department of Allergy and Clinical Immunology, Ajou University School of",
    "entities": [
      {
        "text": "Allergy and Clinical Immunology",
        "label": "ORG"
      },
      {
        "text": "Ajou University School of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Medicine, Suwon, Korea.",
    "entities": [
      {
        "text": "Suwon",
        "label": "GPE"
      },
      {
        "text": "Korea",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Food Science and Technology, Pusan National University,",
    "entities": [
      {
        "text": "Food Science and Technology",
        "label": "ORG"
      },
      {
        "text": "Pusan National University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(3)Institute for Future Earth, Pusan National University, Busan, Korea.",
    "entities": [
      {
        "text": "Future Earth",
        "label": "ORG"
      },
      {
        "text": "Pusan National University",
        "label": "ORG"
      },
      {
        "text": "Busan",
        "label": "GPE"
      },
      {
        "text": "Korea",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Department of Biomaterials Science (BK21 FOUR Program), College of Natural",
    "entities": [
      {
        "text": "Biomaterials Science",
        "label": "ORG"
      },
      {
        "text": "FOUR Program",
        "label": "ORG"
      },
      {
        "text": "College of Natural",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Resources and Life Science, Life and Industry Convergence Research Institute,",
    "entities": [
      {
        "text": "Resources and Life Science, Life and Industry Convergence Research Institute",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Pusan National University, Miryang, Korea.",
    "entities": [
      {
        "text": "Pusan National University",
        "label": "ORG"
      },
      {
        "text": "Miryang",
        "label": "GPE"
      },
      {
        "text": "Korea",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "BACKGROUND: Eotaxins (EOTs), primarily expressed in airway epithelial cells",
    "entities": []
  },
  {
    "text": "(AECs), act as chemoattractants for eosinophils in asthma pathogenesis. Recent",
    "entities": []
  },
  {
    "text": "studies have suggested that EOTs have additional functions beyond chemotaxis.",
    "entities": []
  },
  {
    "text": "However, the distinct roles of EOTs remain incompletely understood.",
    "entities": []
  },
  {
    "text": "(MMP-9), and tissue inhibitor of metalloproteinase-1 (TIMP-1) levels were",
    "entities": []
  },
  {
    "text": "evaluated by ELISA and serum eosinophil cationic protein (ECP) levels were",
    "entities": [
      {
        "text": "ELISA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "measured by ImmunoCAP in 79 adult asthmatics. Clinical characteristics were",
    "entities": [
      {
        "text": "79",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "analyzed by inflammatory phenotype, disease severity, and serum EOT1/EOT2",
    "entities": [
      {
        "text": "EOT1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "levels. The functions of EOTs were investigated in vitro and ex vivo. For in",
    "entities": []
  },
  {
    "text": "vivo, EOT1 and EOT2 were intranasally administered to",
    "entities": [
      {
        "text": "EOT1",
        "label": "ORG"
      },
      {
        "text": "EOT2",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "ovalbumin/lipopolysaccharide-induced asthmatic mice (BALB/c). To assess",
    "entities": [
      {
        "text": "ovalbumin",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "neutralization effects, anti-EOT1 or anti-EOT2 antibodies were intranasally",
    "entities": [
      {
        "text": "anti-EOT2",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "RESULTS: Serum EOT1 and EOT2 levels were higher in patients with severe asthma",
    "entities": [
      {
        "text": "Serum EOT1",
        "label": "PERSON"
      },
      {
        "text": "EOT2",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(SA) than in those with non-SA. Serum EOT1 levels were associated with increased",
    "entities": [
      {
        "text": "SA",
        "label": "ORG"
      },
      {
        "text": "non-SA",
        "label": "ORG"
      },
      {
        "text": "Serum EOT1",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "blood/sputum eosinophil counts and serum ECP levels, but not significantly",
    "entities": []
  },
  {
    "text": "correlated with FEV1 (%) values. In contrast, serum EOT2 levels are correlated",
    "entities": [
      {
        "text": "EOT2",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "with higher serum MPO, MMP-9, and TIMP-1 levels but lower FEV1 (%). In asthmatic",
    "entities": [
      {
        "text": "MPO",
        "label": "ORG"
      },
      {
        "text": "MMP-9",
        "label": "GPE"
      },
      {
        "text": "TIMP-1",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "mice, EOT1 increased eosinophil counts and IL-5 production, whereas EOT2 induced",
    "entities": [
      {
        "text": "EOT1",
        "label": "PERSON"
      },
      {
        "text": "IL-5",
        "label": "NORP"
      },
      {
        "text": "EOT2",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "CXCL1 and MMP-9 production, junctional dysfunction and epithelial-to-mesenchymal",
    "entities": [
      {
        "text": "CXCL1",
        "label": "ORG"
      },
      {
        "text": "MMP-9",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "transition in the lungs, which were attenuated by neutralizing EOTs using each",
    "entities": []
  },
  {
    "text": "CONCLUSION: EOT1 promotes T2/eosinophilic inflammation, whereas EOT2 accelerates",
    "entities": [
      {
        "text": "EOT1",
        "label": "PERSON"
      },
      {
        "text": "T2",
        "label": "CARDINAL"
      },
      {
        "text": "EOT2",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "airway remodeling and lung function decline by activating neutrophils, providing",
    "entities": []
  },
  {
    "text": "a new insight into the distinct roles of EOTs in the pathogenesis of SA.",
    "entities": [
      {
        "text": "SA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "\u00a9 2025 The Author(s). Clinical and Translational Allergy published by John Wiley",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "John Wiley",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "& Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.",
    "entities": [
      {
        "text": "European Academy of Allergy and Clinical Immunology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "78. Br J Dermatol. 2025 Jul 12:ljaf277. doi: 10.1093/bjd/ljaf277. Online ahead of",
    "entities": [
      {
        "text": "78",
        "label": "CARDINAL"
      },
      {
        "text": "Br J Dermatol",
        "label": "PERSON"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "12",
        "label": "CARDINAL"
      },
      {
        "text": "10.1093",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Genomic loci and molecular genetic mechanisms for hidradenitis suppurativa.",
    "entities": []
  },
  {
    "text": "Harris KM(14)(16), Martin A(8)(9)(10), Cox NJ(6)(7), Liu Z(4)(5), Thomas",
    "entities": [
      {
        "text": "Harris KM(14)(16",
        "label": "PERSON"
      },
      {
        "text": "Martin",
        "label": "PERSON"
      },
      {
        "text": "Liu Z(4)(5",
        "label": "PERSON"
      },
      {
        "text": "Thomas\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "NE(4)(5), Li Y(1)(2), Mohlke KL(1), Sayed CJ(4).",
    "entities": [
      {
        "text": "NE(4)(5",
        "label": "GPE"
      },
      {
        "text": "Li Y(1)(2",
        "label": "PERSON"
      },
      {
        "text": "Mohlke KL(1",
        "label": "ORG"
      },
      {
        "text": "Sayed CJ(4",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)Department of Genetics, University of North Carolina, Chapel Hill, NC, USA.",
    "entities": [
      {
        "text": "Genetics, University of North Carolina",
        "label": "ORG"
      },
      {
        "text": "Chapel Hill",
        "label": "GPE"
      },
      {
        "text": "NC",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Biostatistics, University of North Carolina, Chapel Hill, NC,",
    "entities": [
      {
        "text": "2)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Biostatistics, University of North Carolina",
        "label": "ORG"
      },
      {
        "text": "Chapel Hill",
        "label": "GPE"
      },
      {
        "text": "NC",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Center for Computational and Genomic Medicine, Children's Hospital of",
    "entities": []
  },
  {
    "text": "(4)Department of Dermatology, University of North Carolina, Chapel Hill, NC,",
    "entities": [
      {
        "text": "Dermatology, University of North Carolina",
        "label": "ORG"
      },
      {
        "text": "Chapel Hill",
        "label": "GPE"
      },
      {
        "text": "NC",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel",
    "entities": [
      {
        "text": "Comprehensive Cancer Center, University of North Carolina",
        "label": "WORK_OF_ART"
      }
    ]
  },
  {
    "text": "(6)Department of Medicine, Division of Genetic Medicine, Vanderbilt University",
    "entities": [
      {
        "text": "Medicine, Division of Genetic Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Medical Center, Nashville, TN, USA.",
    "entities": [
      {
        "text": "Nashville",
        "label": "GPE"
      },
      {
        "text": "TN",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(7)Vanderbilt Genetics Institute, Vanderbilt University Medical Center,",
    "entities": [
      {
        "text": "7)Vanderbilt",
        "label": "CARDINAL"
      },
      {
        "text": "Genetics Institute",
        "label": "ORG"
      },
      {
        "text": "Vanderbilt University Medical Center",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Nashville, TN, USA.",
    "entities": [
      {
        "text": "Nashville",
        "label": "GPE"
      },
      {
        "text": "TN",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(8)Program in Medical and Population Genetics, Broad Institute of MIT and",
    "entities": [
      {
        "text": "Broad Institute of MIT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(9)Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard,",
    "entities": [
      {
        "text": "9)Stanley Center for Psychiatric Research",
        "label": "ORG"
      },
      {
        "text": "Broad Institute of MIT",
        "label": "ORG"
      },
      {
        "text": "Harvard",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(10)Analytic and Translational Genetics Unit, Massachusetts General Hospital,",
    "entities": [
      {
        "text": "10)Analytic",
        "label": "CARDINAL"
      },
      {
        "text": "Translational Genetics Unit",
        "label": "ORG"
      },
      {
        "text": "Massachusetts General Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Boston, MA, USA.",
    "entities": [
      {
        "text": "Boston",
        "label": "GPE"
      },
      {
        "text": "MA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(11)Nashville Skin Comprehensive Dermatology Center, Nashville, TN, USA.",
    "entities": [
      {
        "text": "11)Nashville",
        "label": "CARDINAL"
      },
      {
        "text": "Nashville",
        "label": "GPE"
      },
      {
        "text": "TN",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(12)Department of Dermatology, Howard University College of Medicine,",
    "entities": [
      {
        "text": "12)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Howard University College of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(13)School of Medicine, University of North Carolina, Chapel Hill, NC, USA.",
    "entities": [
      {
        "text": "Medicine, University of North Carolina",
        "label": "ORG"
      },
      {
        "text": "Chapel Hill",
        "label": "GPE"
      },
      {
        "text": "NC",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(14)Carolina Population Center, University of North Carolina, Chapel Hill, NC,",
    "entities": [
      {
        "text": "14)Carolina Population Center, University of North Carolina",
        "label": "ORG"
      },
      {
        "text": "Chapel Hill",
        "label": "GPE"
      },
      {
        "text": "NC",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(15)Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic",
    "entities": [
      {
        "text": "15)Psychiatric",
        "label": "CARDINAL"
      },
      {
        "text": "Neurodevelopmental Genetics Unit",
        "label": "ORG"
      },
      {
        "text": "Center for Genomic\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Medicine, Massachusetts General Hospital, Boston, MA, USA.",
    "entities": [
      {
        "text": "Massachusetts General Hospital",
        "label": "ORG"
      },
      {
        "text": "Boston",
        "label": "GPE"
      },
      {
        "text": "MA",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(16)Sociology Department, University of North Carolina at Chapel Hill, Chapel",
    "entities": [
      {
        "text": "16)Sociology Department,",
        "label": "ORG"
      },
      {
        "text": "University of North Carolina",
        "label": "ORG"
      },
      {
        "text": "Chapel Hill",
        "label": "ORG"
      },
      {
        "text": "Chapel\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "BACKGROUND: Hidradenitis suppurativa (HS) is a common, chronic, and debilitating",
    "entities": [
      {
        "text": "Hidradenitis",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "inflammatory disease that most commonly affects intertriginous skin. Despite its",
    "entities": []
  },
  {
    "text": "high heritability, the genetic underpinnings of HS remain poorly understood.",
    "entities": []
  },
  {
    "text": "OBJECTIVE: To identify genetic signals associated with HS, determine genetic",
    "entities": [
      {
        "text": "HS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "relationships with other diseases, and investigate potential molecular genetic",
    "entities": []
  },
  {
    "text": "mechanisms.",
    "entities": []
  },
  {
    "text": "METHODS: We performed a genome-wide association study meta-analysis of six",
    "entities": [
      {
        "text": "six",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "studies, totaling 4,540 cases and over 1 million controls and identified genetic",
    "entities": [
      {
        "text": "4,540",
        "label": "CARDINAL"
      },
      {
        "text": "over 1 million",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "correlations with other common diseases. We integrated the HS data with",
    "entities": []
  },
  {
    "text": "and transcriptomic data from human scalp, differential expression data from HS",
    "entities": [
      {
        "text": "HS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "lesions versus adjacent skin, and mesenchymal Hi-C chromatin looping data. To",
    "entities": []
  },
  {
    "text": "identify functional noncoding variants, we performed transcriptional reporter",
    "entities": []
  },
  {
    "text": "assays for signals near KLF5 and SOX9.",
    "entities": [
      {
        "text": "KLF5",
        "label": "GPE"
      },
      {
        "text": "SOX9",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "RESULTS: We identified eleven significant HS signals across seven loci: four",
    "entities": [
      {
        "text": "eleven",
        "label": "CARDINAL"
      },
      {
        "text": "seven",
        "label": "CARDINAL"
      },
      {
        "text": "four",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "corresponded to previously reported associations, four represented novel signals",
    "entities": [
      {
        "text": "four",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "within known loci, and three were signals in newly implicated loci. We",
    "entities": [
      {
        "text": "three",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "identified significant genetic correlation between HS and other inflammatory",
    "entities": [
      {
        "text": "HS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "conditions, particularly inflammatory bowel disease, rheumatoid arthritis, type",
    "entities": []
  },
  {
    "text": "2 diabetes, and asthma. We prioritized candidate genes for the 11 signals. The",
    "entities": [
      {
        "text": "2",
        "label": "CARDINAL"
      },
      {
        "text": "11",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "risk allele at KLF5 exhibited 10-fold greater transcriptional activity than the",
    "entities": [
      {
        "text": "KLF5",
        "label": "ORG"
      },
      {
        "text": "10-fold",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "non-risk allele, while risk alleles at SOX9 showed significantly reduced",
    "entities": [
      {
        "text": "SOX9",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "transcriptional activity.",
    "entities": []
  },
  {
    "text": "CONCLUSIONS: Our results provide insights into potential genetic mechanisms",
    "entities": []
  },
  {
    "text": "underlying HS and suggest potential therapeutic targets for this challenging",
    "entities": [
      {
        "text": "HS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Association of Dermatologists.",
    "entities": [
      {
        "text": "Association of Dermatologists",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "79. Br J Pharmacol. 2025 Jul 12. doi: 10.1111/bph.70127. Online ahead of print.",
    "entities": [
      {
        "text": "79",
        "label": "CARDINAL"
      },
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "12",
        "label": "CARDINAL"
      },
      {
        "text": "10.1111",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Effects of the P2RX4 antagonist BR11595 in a guinea pig model of chronic asthma.",
    "entities": [
      {
        "text": "P2RX4",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(1)Department of Molecular Pharmacology, University of Groningen, Groningen, the",
    "entities": [
      {
        "text": "Molecular Pharmacology",
        "label": "ORG"
      },
      {
        "text": "University of Groningen",
        "label": "ORG"
      },
      {
        "text": "Groningen",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(2)Groningen Research Institute of Pharmacy, Groningen, the Netherlands.",
    "entities": [
      {
        "text": "2)Groningen Research Institute of Pharmacy",
        "label": "ORG"
      },
      {
        "text": "Groningen",
        "label": "PERSON"
      },
      {
        "text": "Netherlands",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Groningen Research Institute for Asthma and COPD (GRIAC), University Medical",
    "entities": [
      {
        "text": "3)Groningen Research Institute for Asthma and COPD",
        "label": "ORG"
      },
      {
        "text": "University Medical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Center Groningen, University of Groningen, Groningen, the Netherlands.",
    "entities": [
      {
        "text": "Center Groningen",
        "label": "PERSON"
      },
      {
        "text": "University of Groningen",
        "label": "ORG"
      },
      {
        "text": "Groningen",
        "label": "PERSON"
      },
      {
        "text": "Netherlands",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Aquilo BV, Groningen, the Netherlands.",
    "entities": [
      {
        "text": "BV",
        "label": "ORG"
      },
      {
        "text": "Groningen",
        "label": "PERSON"
      },
      {
        "text": "Netherlands",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Department of Pharmaceutical Sciences, Lloyd L. Gregory School of Pharmacy,",
    "entities": [
      {
        "text": "Pharmaceutical Sciences",
        "label": "ORG"
      },
      {
        "text": "Lloyd L. Gregory School of Pharmacy",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Palm Beach Atlantic University, West Palm Beach, Florida, USA.",
    "entities": [
      {
        "text": "Palm Beach Atlantic University",
        "label": "ORG"
      },
      {
        "text": "West Palm Beach",
        "label": "GPE"
      },
      {
        "text": "Florida",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(7)Bayer AG, Wuppertal, Germany.",
    "entities": [
      {
        "text": "AG",
        "label": "ORG"
      },
      {
        "text": "Wuppertal",
        "label": "GPE"
      },
      {
        "text": "Germany",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "BACKGROUND AND PURPOSE: Asthma is characterized by airway hyperresponsiveness",
    "entities": [
      {
        "text": "PURPOSE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(AHR), allergic inflammation, and airway remodelling. Although recent studies",
    "entities": [
      {
        "text": "AHR",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "have shown that asthma pathophysiology involves P2X4 receptor activation, a",
    "entities": []
  },
  {
    "text": "potential link with chronic asthma remains to be explored. We investigated the",
    "entities": []
  },
  {
    "text": "effect of a novel P2X4 receptor antagonist BR11595 on allergen-induced airway",
    "entities": []
  },
  {
    "text": "responses in a guinea pig model of chronic asthma.",
    "entities": []
  },
  {
    "text": "EXPERIMENTAL APPROACH: Sensitized guinea pigs were exposed to saline or",
    "entities": []
  },
  {
    "text": "ovalbumin (OVA) once weekly via aerosolization for 12 weeks. BR11595",
    "entities": [
      {
        "text": "weekly",
        "label": "DATE"
      },
      {
        "text": "12 weeks",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "(10 mg\u00b7kg-1) was injected intraperitoneally five times per week, for four",
    "entities": [
      {
        "text": "10",
        "label": "CARDINAL"
      },
      {
        "text": "five",
        "label": "CARDINAL"
      },
      {
        "text": "four",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "only. Airway responsiveness to histamine was assessed 24 h before and 6 h after",
    "entities": [
      {
        "text": "24",
        "label": "CARDINAL"
      },
      {
        "text": "6",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "OVA exposure in weeks 1, 6, and 12. Lung tissue inflammation and remodelling",
    "entities": [
      {
        "text": "weeks 1",
        "label": "DATE"
      },
      {
        "text": "6",
        "label": "DATE"
      },
      {
        "text": "12",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "were determined 24 h after the last OVA exposure.",
    "entities": [
      {
        "text": "24",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "KEY RESULTS: OVA induced AHR at weeks 1, 6, and 12 compared with",
    "entities": [
      {
        "text": "AHR",
        "label": "ORG"
      },
      {
        "text": "weeks 1",
        "label": "DATE"
      },
      {
        "text": "6",
        "label": "DATE"
      },
      {
        "text": "12",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "saline-challenged animals. The AHR was less pronounced in week 12 compared with",
    "entities": [
      {
        "text": "AHR",
        "label": "ORG"
      },
      {
        "text": "week 12",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "week 1. BR11595 significantly reduced OVA-induced AHR in week 6 in guinea pigs",
    "entities": [
      {
        "text": "week 1",
        "label": "DATE"
      },
      {
        "text": "AHR",
        "label": "ORG"
      },
      {
        "text": "week 6",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "treated with BR11595 for 6 weeks. AHR in week 12 was reduced after BR11595",
    "entities": [
      {
        "text": "6 weeks",
        "label": "DATE"
      },
      {
        "text": "AHR",
        "label": "ORG"
      },
      {
        "text": "week 12",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "treatment in week 12 only, next to OVA-induced eosinophilia and Goblet cell",
    "entities": [
      {
        "text": "week 12",
        "label": "DATE"
      },
      {
        "text": "Goblet",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "hyperplasia, indicating an acute role of P2X4 receptors on chronic inflammation.",
    "entities": [
      {
        "text": "hyperplasia",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "CONCLUSION AND IMPLICATIONS: The P2X4-receptor antagonist BR11595 acutely",
    "entities": []
  },
  {
    "text": "inhibits AHR, eosinophilia, and Goblet cell hyperplasia after 12 weeks,",
    "entities": [
      {
        "text": "AHR",
        "label": "ORG"
      },
      {
        "text": "Goblet",
        "label": "ORG"
      },
      {
        "text": "12 weeks",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "indicating its potential as a therapeutic target for acute intervention of",
    "entities": []
  },
  {
    "text": "chronic asthma attacks or exacerbations.",
    "entities": []
  },
  {
    "text": "\u00a9 2025 The Author(s). British Journal of Pharmacology published by John Wiley &",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "British Journal of Pharmacology",
        "label": "ORG"
      },
      {
        "text": "John Wiley &\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Sons Ltd on behalf of British Pharmacological Society.",
    "entities": [
      {
        "text": "Sons Ltd",
        "label": "ORG"
      },
      {
        "text": "British Pharmacological Society",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Genome-Wide Association Study of COVID-19 Breakthrough Infections and Genetic",
    "entities": [
      {
        "text": "Genome-Wide Association Study",
        "label": "ORG"
      },
      {
        "text": "COVID-19 Breakthrough Infections",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Overlap with Other Diseases: A Study of the UK Biobank.",
    "entities": [
      {
        "text": "the UK Biobank",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(1)School of Medical Technology and Information Engineering, Zhejiang Chinese",
    "entities": [
      {
        "text": "1)School of Medical Technology and Information Engineering",
        "label": "ORG"
      },
      {
        "text": "Zhejiang Chinese",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Medical University, Hangzhou 310053, China.",
    "entities": [
      {
        "text": "Medical University",
        "label": "ORG"
      },
      {
        "text": "Hangzhou",
        "label": "GPE"
      },
      {
        "text": "310053",
        "label": "DATE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong",
    "entities": [
      {
        "text": "Biomedical Sciences",
        "label": "ORG"
      },
      {
        "text": "The Chinese University of Hong Kong",
        "label": "ORG"
      },
      {
        "text": "Hong Kong",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research of Common",
    "entities": [
      {
        "text": "3)KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research of Common\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Diseases, Kunming Institute of Zoology and The Chinese University of Hong Kong,",
    "entities": [
      {
        "text": "Kunming Institute of Zoology",
        "label": "ORG"
      },
      {
        "text": "The Chinese University of Hong Kong",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)Department of Psychiatry, The Chinese University of Hong Kong, Hong Kong SAR,",
    "entities": [
      {
        "text": "Psychiatry",
        "label": "ORG"
      },
      {
        "text": "The Chinese University of Hong Kong",
        "label": "ORG"
      },
      {
        "text": "Hong Kong",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)Margaret K.L. Cheung Research Centre for Management of Parkinsonism, The",
    "entities": [
      {
        "text": "K.L. Cheung Research Centre for Management of Parkinsonism",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Chinese University of Hong Kong, Shatin, Hong Kong SAR, China.",
    "entities": [
      {
        "text": "Chinese University of Hong Kong",
        "label": "ORG"
      },
      {
        "text": "Shatin",
        "label": "ORG"
      },
      {
        "text": "Hong Kong SAR",
        "label": "GPE"
      },
      {
        "text": "China",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(7)Brain and Mind Institute, The Chinese University of Hong Kong, Hong Kong SAR,",
    "entities": [
      {
        "text": "Mind Institute",
        "label": "ORG"
      },
      {
        "text": "The Chinese University of Hong Kong",
        "label": "ORG"
      },
      {
        "text": "Hong Kong",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(8)Hong Kong Branch of the Chinese Academy of Sciences Center for Excellence in",
    "entities": [
      {
        "text": "Kong Branch",
        "label": "PERSON"
      },
      {
        "text": "the Chinese Academy of Sciences Center for Excellence",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Animal Evolution and Genetics, The Chinese University of Hong Kong, Hong Kong",
    "entities": [
      {
        "text": "Animal Evolution and Genetics",
        "label": "ORG"
      },
      {
        "text": "The Chinese University of Hong Kong",
        "label": "ORG"
      },
      {
        "text": "Hong Kong",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "The coronavirus disease 2019 (COVID-19) pandemic has led to substantial health",
    "entities": [
      {
        "text": "2019",
        "label": "DATE"
      },
      {
        "text": "COVID-19",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and financial burdens worldwide, and vaccines provide hope for reducing the",
    "entities": []
  },
  {
    "text": "burden of this pandemic. However, vaccinated people remain at risk for",
    "entities": []
  },
  {
    "text": "SARS-CoV-2 infection. Genome-wide association studies (GWASs) may identify",
    "entities": []
  },
  {
    "text": "potential genetic factors involved in the development of COVID-19 breakthrough",
    "entities": [
      {
        "text": "COVID-19",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "infections (BIs); however, very few or no GWASs have been conducted for COVID-19",
    "entities": [
      {
        "text": "COVID-19",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "BI thus far. We conducted a GWAS and detailed bioinformatics analysis on",
    "entities": [
      {
        "text": "BI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "COVID-19 BIs in a European population via the UK Biobank (UKBB). We conducted a",
    "entities": [
      {
        "text": "European",
        "label": "NORP"
      },
      {
        "text": "the UK Biobank",
        "label": "ORG"
      },
      {
        "text": "UKBB",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "series of analyses at different levels, including SNP-based, gene-based,",
    "entities": [
      {
        "text": "SNP",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "pathway, and transcriptome-wide association analyses, to investigate genetic",
    "entities": []
  },
  {
    "text": "factors associated with COVID-19 BIs and hospitalized infections. The polygenic",
    "entities": [
      {
        "text": "COVID-19",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "risk score (PRS) and Hoeffding's test were performed to reveal the genetic",
    "entities": [
      {
        "text": "Hoeffding",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "relationships between BIs and other medical conditions. Two independent loci",
    "entities": [
      {
        "text": "Two",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "(LD-clumped at r2 = 0.01) reached genome-wide significance (p < 5 \u00d7 10-8),",
    "entities": [
      {
        "text": "0.01",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "including rs36170929, which mapped to LOC102725191/VWDE, and rs28645263, which",
    "entities": [
      {
        "text": "rs36170929",
        "label": "PERSON"
      },
      {
        "text": "LOC102725191/VWDE",
        "label": "ORG"
      },
      {
        "text": "rs28645263",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "mapped to RETREG1. A pathway enrichment analysis highlighted pathways such as",
    "entities": [
      {
        "text": "RETREG1",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "viral myocarditis, Rho-selective guanine exchange factor AKAP13 signaling, and",
    "entities": [
      {
        "text": "AKAP13 signaling",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "lipid metabolism. The PRS analyses revealed significant genetic overlap between",
    "entities": [
      {
        "text": "PRS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "COVID-19 BIs and heart failure and between HbA1c and type 1 diabetes. Genetic",
    "entities": [
      {
        "text": "1",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "dependence was also observed between COVID-19 BIs and asthma, lung",
    "entities": [
      {
        "text": "COVID-19",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "abnormalities, schizophrenia, and type 1 diabetes on the basis of Hoeffding's",
    "entities": [
      {
        "text": "1",
        "label": "CARDINAL"
      },
      {
        "text": "Hoeffding",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "test. This GWAS revealed two significant loci that may be associated with",
    "entities": [
      {
        "text": "two",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "COVID-19 BIs and a number of genes and pathways that may be involved in BIs.",
    "entities": []
  },
  {
    "text": "Genetic overlap with other diseases was identified. Further studies are",
    "entities": []
  },
  {
    "text": "warranted to replicate these findings and elucidate the mechanisms involved.",
    "entities": []
  },
  {
    "text": "PMID: 40650217 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40650217",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Molecular Study from the Signaling Pathways of Four Potential asthma triggers:",
    "entities": [
      {
        "text": "the Signaling Pathways",
        "label": "FAC"
      },
      {
        "text": "Four",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "AKT1, MAPK13, STAT1, and TLR4.",
    "entities": [
      {
        "text": "AKT1",
        "label": "CARDINAL"
      },
      {
        "text": "MAPK13",
        "label": "ORG"
      },
      {
        "text": "STAT1",
        "label": "PERSON"
      },
      {
        "text": "TLR4",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Allergology Service, University Hospital of Navarra, 31008 Pamplona, Spain.",
    "entities": [
      {
        "text": "University Hospital of Navarra",
        "label": "ORG"
      },
      {
        "text": "31008",
        "label": "DATE"
      },
      {
        "text": "Pamplona",
        "label": "GPE"
      },
      {
        "text": "Spain",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Department of Allergy, La Paz University Hospital, IdiPAZ, 28029 Madrid,",
    "entities": [
      {
        "text": "5)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Allergy",
        "label": "GPE"
      },
      {
        "text": "La Paz University Hospital",
        "label": "ORG"
      },
      {
        "text": "28029",
        "label": "DATE"
      },
      {
        "text": "Madrid",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Spain.",
    "entities": [
      {
        "text": "Spain",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Asthma is a chronic and heterogeneous inflammatory airway disease with diverse",
    "entities": []
  },
  {
    "text": "clinical endotypes and limited curative treatment options. Recent systems",
    "entities": []
  },
  {
    "text": "biology analyses identified four potential molecular triggers-AKT1, MAPK13,",
    "entities": [
      {
        "text": "four",
        "label": "CARDINAL"
      },
      {
        "text": "MAPK13",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "STAT1, and TLR4-as candidate regulators of asthma-associated signaling pathways.",
    "entities": [
      {
        "text": "STAT1",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "This study aimed to validate the expression of these four proteins and their",
    "entities": [
      {
        "text": "four",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "downstream signaling elements in peripheral blood mononuclear cells (PBMCs) from",
    "entities": []
  },
  {
    "text": "patients with allergic asthma (AA), nonallergic asthma (NA), and healthy",
    "entities": [
      {
        "text": "NA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "controls (HC), to explore their potential as biomarkers or therapeutic targets.",
    "entities": []
  },
  {
    "text": "For that, PBMC samples were collected from 45 AA patients, 17 NA patients, and",
    "entities": [
      {
        "text": "45",
        "label": "CARDINAL"
      },
      {
        "text": "17",
        "label": "CARDINAL"
      },
      {
        "text": "NA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "15 HC subjects. Gene and protein expression of AKT1, MAPK13, STAT1, and TLR4",
    "entities": [
      {
        "text": "15",
        "label": "CARDINAL"
      },
      {
        "text": "AKT1",
        "label": "CARDINAL"
      },
      {
        "text": "MAPK13",
        "label": "ORG"
      },
      {
        "text": "STAT1",
        "label": "PERSON"
      },
      {
        "text": "TLR4",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "were quantified using RT-qPCR and Western blotting. Expression patterns were",
    "entities": [
      {
        "text": "RT-qPCR",
        "label": "ORG"
      },
      {
        "text": "Western",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "compared across groups and stratified by asthma severity. Correlations with",
    "entities": []
  },
  {
    "text": "clinical parameters (FEV1, FVC, FeNO, IgE, eosinophil counts) and treatment",
    "entities": [
      {
        "text": "FVC",
        "label": "ORG"
      },
      {
        "text": "FeNO",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "regimens were also assessed. All four target genes showed significantly reduced",
    "entities": [
      {
        "text": "four",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "expression in asthma patients compared to controls (p < 0.001), with the most",
    "entities": []
  },
  {
    "text": "marked downregulation in NA patients. At the protein level, MAPK13 and TLR4",
    "entities": [
      {
        "text": "NA",
        "label": "ORG"
      },
      {
        "text": "MAPK13",
        "label": "PERSON"
      },
      {
        "text": "TLR4",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "showed significant differential expression. Stratification by severity revealed",
    "entities": []
  },
  {
    "text": "a stepwise reduction in gene expression in AA patients, correlating with disease",
    "entities": []
  },
  {
    "text": "severity, whereas NA patients showed uniformly low expression regardless of",
    "entities": [
      {
        "text": "NA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "severity. Multiple pathway-related genes, including RELA, SMAD3, NFATC1, and",
    "entities": [
      {
        "text": "RELA",
        "label": "ORG"
      },
      {
        "text": "SMAD3",
        "label": "ORG"
      },
      {
        "text": "NFATC1",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "ALOX5, were also downregulated, particularly in NA patients. Notably,",
    "entities": [
      {
        "text": "ALOX5",
        "label": "ORG"
      },
      {
        "text": "NA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "differential correlations were observed between gene expression and lung",
    "entities": []
  },
  {
    "text": "function parameters in AA vs. NA groups. In conclusion, this study supports the",
    "entities": [
      {
        "text": "AA",
        "label": "GPE"
      },
      {
        "text": "NA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "potential involvement of AKT1, MAPK13, STAT1, and TLR4 in asthma pathogenesis",
    "entities": [
      {
        "text": "AKT1",
        "label": "CARDINAL"
      },
      {
        "text": "MAPK13",
        "label": "ORG"
      },
      {
        "text": "STAT1",
        "label": "PERSON"
      },
      {
        "text": "TLR4",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and highlights differences between allergic and nonallergic asthma at the",
    "entities": []
  },
  {
    "text": "molecular level. These proteins and their associated pathways may serve as",
    "entities": []
  },
  {
    "text": "future targets for biomarker development or endotype-specific therapies. Further",
    "entities": []
  },
  {
    "text": "studies in larger and more diverse cohorts, including functional validation, are",
    "entities": []
  },
  {
    "text": "warranted.",
    "entities": []
  },
  {
    "text": "PMID: 40650018 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40650018",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "A Novel Regulatory Role for RPS4Y1 in Inflammatory and Fibrotic Processes.",
    "entities": [
      {
        "text": "Inflammatory",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(1)School of Life Sciences, Faculty of Science, University of Technology Sydney,",
    "entities": [
      {
        "text": "1)School of Life Sciences, Faculty of Science, University of Technology Sydney",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)Respiratory Cellular and Molecular Biology Group, Woolcock Institute of",
    "entities": [
      {
        "text": "Molecular Biology Group",
        "label": "ORG"
      },
      {
        "text": "Woolcock Institute",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Medical Research, Macquarie University, Macquarie Park, Sydney, NSW 2113,",
    "entities": [
      {
        "text": "Medical Research",
        "label": "ORG"
      },
      {
        "text": "Macquarie University",
        "label": "ORG"
      },
      {
        "text": "Macquarie Park",
        "label": "GPE"
      },
      {
        "text": "Sydney",
        "label": "GPE"
      },
      {
        "text": "NSW 2113",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "(3)Groningen Research Institute for Asthma and COPD, University Medical Centre",
    "entities": [
      {
        "text": "3)Groningen Research Institute for Asthma and COPD,",
        "label": "ORG"
      },
      {
        "text": "University Medical Centre",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Groningen, University of Groningen, 9712 CP Groningen, The Netherlands.",
    "entities": [
      {
        "text": "Groningen, University of Groningen",
        "label": "ORG"
      },
      {
        "text": "9712",
        "label": "CARDINAL"
      },
      {
        "text": "The Netherlands",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Asthma is a chronic inflammatory respiratory disease well-known to demonstrate",
    "entities": []
  },
  {
    "text": "sexual dimorphism in incidence and severity, although the mechanisms causing",
    "entities": []
  },
  {
    "text": "these differences remain incompletely understood. RPS4X and RPS4Y1 are X and",
    "entities": []
  },
  {
    "text": "Y-chromosome-linked genes coding ribosomal subunits previously associated with",
    "entities": []
  },
  {
    "text": "inflammation, airway remodelling and asthma medication efficacy. Particularly,",
    "entities": []
  },
  {
    "text": "RPS4Y1 has been under-investigated within the context of disease, with little",
    "entities": []
  },
  {
    "text": "examination of molecular mechanisms and pathways regulated by this gene. The",
    "entities": []
  },
  {
    "text": "ribosome, a vital cellular machinery, facilitates the translation of mRNA into",
    "entities": []
  },
  {
    "text": "peptides and then proteins. Imbalance or dysfunction in ribosomal components may",
    "entities": []
  },
  {
    "text": "lead to malfunctioning proteins. Using CRISPR-Cas9 knockout cellular models for",
    "entities": []
  },
  {
    "text": "RPS4Y1 and RPS4X, we characterised the function of RPS4Y1 in the context of the",
    "entities": []
  },
  {
    "text": "asthma-relevant processes, inflammation and fibrosis. No viable RPS4X knockouts",
    "entities": []
  },
  {
    "text": "could be generated. We highlight novel molecular mechanisms such as specific",
    "entities": []
  },
  {
    "text": "translation of IL6 and tenascin-C mRNA by RPS4Y1 containing ribosomes.",
    "entities": []
  },
  {
    "text": "Furthermore, an RPS4Y1-centric gene signature correlates with clinical lung",
    "entities": []
  },
  {
    "text": "function measurements, specifically in adult male asthma patients. These",
    "entities": []
  },
  {
    "text": "findings inform the current understanding of sex differences in asthma, as",
    "entities": []
  },
  {
    "text": "females do not produce the RPS4Y1 protein. Therefore, the pathologically",
    "entities": []
  },
  {
    "text": "relevant functions of RPS4Y1 may contribute to the complex sexually dimorphic",
    "entities": []
  },
  {
    "text": "pattern of asthma susceptibility and progression.",
    "entities": []
  },
  {
    "text": "PMID: 40649992 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40649992",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Inhaled Allergy Diagnostics and Treatment in a Polluted Environment.",
    "entities": [
      {
        "text": "Allergy Diagnostics and Treatment",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(1)Department of Clinical and Environmental Allergology, Medical College,",
    "entities": [
      {
        "text": "Clinical and Environmental Allergology",
        "label": "ORG"
      },
      {
        "text": "Medical College",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Allergic diseases have been increasing in prevalence over the last years. In a",
    "entities": [
      {
        "text": "Allergic",
        "label": "ORG"
      },
      {
        "text": "the last years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "polluted environment, this problem can worsen and become more complex. Long-term",
    "entities": []
  },
  {
    "text": "exposure to air pollution can lead to the aggravation of allergic rhinitis (AR)",
    "entities": []
  },
  {
    "text": "and even to the development of seasonal asthma. Climate changes can accelerate",
    "entities": []
  },
  {
    "text": "and extend the pollination season. Research indicates that air pollution may",
    "entities": []
  },
  {
    "text": "modify the properties of pollen, making it more aggressive. Asymptomatic",
    "entities": []
  },
  {
    "text": "allergic people disclose their allergies in a polluted environment. A polluted",
    "entities": []
  },
  {
    "text": "environment complicates the diagnosis of seasonal allergies. The treatment might",
    "entities": [
      {
        "text": "seasonal",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "be more challenging as standard allergy medications may not be enough to control",
    "entities": []
  },
  {
    "text": "symptoms. The causal treatment of allergic rhinitis is specific allergen",
    "entities": []
  },
  {
    "text": "immunotherapy (AIT), which may prove less effective in people living in a",
    "entities": [
      {
        "text": "AIT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "polluted environment. The problem may lie in the proper evaluation for AIT as",
    "entities": [
      {
        "text": "AIT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "well as the assessment of its effectiveness. To date, the best way to confirm an",
    "entities": []
  },
  {
    "text": "allergy and qualify a patient for AIT seems to be molecular diagnostics. The",
    "entities": [
      {
        "text": "AIT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "question arises whether patients exposed to air pollution, which could",
    "entities": []
  },
  {
    "text": "potentially reduce the effectiveness of AIT, are still eligible for AIT. It is",
    "entities": [
      {
        "text": "AIT",
        "label": "ORG"
      },
      {
        "text": "AIT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "also debatable whether molecular diagnostics remain effective in such cases.",
    "entities": []
  },
  {
    "text": "critical pathway toward reducing the growing global burden of allergic diseases.",
    "entities": []
  },
  {
    "text": "PMID: 40649745 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40649745",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "The funders had no role in the design of the study; in the collection, analyses,",
    "entities": []
  },
  {
    "text": "or interpretation of data; in the writing of the manuscript; or in the decision",
    "entities": []
  },
  {
    "text": "to publish the results.",
    "entities": []
  },
  {
    "text": "Biologic Therapy in Severe Asthma: A Phenotype-Driven and Targeted Approach.",
    "entities": [
      {
        "text": "Biologic Therapy",
        "label": "PERSON"
      },
      {
        "text": "Targeted Approach",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "University, 80131 Naples, Italy.",
    "entities": [
      {
        "text": "80131",
        "label": "CARDINAL"
      },
      {
        "text": "Naples",
        "label": "GPE"
      },
      {
        "text": "Italy",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Department of Health Sciences, University \"Magna Gr\u00e6cia\" of Catanzaro, 88100",
    "entities": [
      {
        "text": "Health Sciences",
        "label": "ORG"
      },
      {
        "text": "Catanzaro",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "(3)Department of Biomedicine, Neurosciences and Advanced Diagnostics, University",
    "entities": [
      {
        "text": "Advanced Diagnostics",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of Palermo, 90133 Palermo, Italy.",
    "entities": [
      {
        "text": "Palermo",
        "label": "GPE"
      },
      {
        "text": "Italy",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Department of Experimental and Clinical Medicine, University \"Magna Gr\u00e6cia\"",
    "entities": [
      {
        "text": "Experimental",
        "label": "ORG"
      },
      {
        "text": "Clinical Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(5)Department of Medical and Surgical Sciences, University \"Magna Gr\u00e6cia\" of",
    "entities": [
      {
        "text": "Medical and Surgical Sciences",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(6)Department of Medicine, Surgery and Dentistry, University of Salerno, 84084",
    "entities": [
      {
        "text": "University of Salerno",
        "label": "ORG"
      },
      {
        "text": "84084",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Salerno, Italy.",
    "entities": [
      {
        "text": "Salerno",
        "label": "GPE"
      },
      {
        "text": "Italy",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(7)Department of Respiratory Diseases, Annunziata Hospital, 87100 Cosenza,",
    "entities": [
      {
        "text": "Respiratory Diseases",
        "label": "ORG"
      },
      {
        "text": "Annunziata Hospital",
        "label": "ORG"
      },
      {
        "text": "87100",
        "label": "CARDINAL"
      },
      {
        "text": "Cosenza",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Italy.",
    "entities": [
      {
        "text": "Italy",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Asthma is a highly heterogeneous respiratory disease that, in its severe forms,",
    "entities": []
  },
  {
    "text": "is characterized by persistent symptoms, frequent exacerbations, and a",
    "entities": []
  },
  {
    "text": "significant impact on patients' quality of life. Despite high-dose inhaled",
    "entities": []
  },
  {
    "text": "corticosteroids and long-acting bronchodilators, a subset of patients remains",
    "entities": []
  },
  {
    "text": "uncontrolled, necessitating advanced therapeutic strategies. The advent of",
    "entities": []
  },
  {
    "text": "biologic therapies has revolutionized the management of severe asthma, offering",
    "entities": []
  },
  {
    "text": "targeted interventions based on the underlying inflammatory endotypes, primarily",
    "entities": []
  },
  {
    "text": "T2-high and T2-low. However, selecting the most appropriate biologic remains",
    "entities": [
      {
        "text": "T2",
        "label": "CARDINAL"
      },
      {
        "text": "T2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "challenging due to overlapping phenotypic features and the limited availability",
    "entities": []
  },
  {
    "text": "of validated biomarkers. This narrative review explores the clinical utility of",
    "entities": []
  },
  {
    "text": "key biomarkers, including blood eosinophils, fractional exhaled nitric oxide",
    "entities": []
  },
  {
    "text": "(FeNO), periostin, and total and specific IgE, in guiding biologic therapy. All",
    "entities": [
      {
        "text": "periostin",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "the information provided is based on an extensive literature search conducted on",
    "entities": []
  },
  {
    "text": "PubMed. We also examine the clinical characteristics and comorbidities that",
    "entities": [
      {
        "text": "PubMed",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "influence therapeutic choices. Furthermore, we present a practical",
    "entities": []
  },
  {
    "text": "decision-making platform, including a clinical table matching phenotypes with",
    "entities": []
  },
  {
    "text": "tezepelumab. By integrating biomarker analysis with clinical assessment, based",
    "entities": []
  },
  {
    "text": "on current guidelines and our extensive real-life experience, we aim to offer a",
    "entities": []
  },
  {
    "text": "logical framework to help clinicians select the most suitable biologic treatment",
    "entities": [
      {
        "text": "clinicians",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "for patients with uncontrolled severe asthma. Future research should focus on",
    "entities": []
  },
  {
    "text": "identifying novel biomarkers, refining patient stratification, and evaluating",
    "entities": []
  },
  {
    "text": "long-term outcomes to further advance precision medicine in the management of",
    "entities": []
  },
  {
    "text": "severe asthma.",
    "entities": []
  },
  {
    "text": "Conflict of interest statement: M D\u2019Amato has received speaker and advisory",
    "entities": []
  },
  {
    "text": "board fees from AstraZeneca, GlaxoSmithKline, and Sanofi-Regeneron. A Vatrella",
    "entities": [
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "GlaxoSmithKline",
        "label": "PERSON"
      },
      {
        "text": "Sanofi-Regeneron",
        "label": "ORG"
      },
      {
        "text": "Vatrella",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "has received honoraria for speaking, advisory committees, or research grants",
    "entities": []
  },
  {
    "text": "Lusofarmaco, Menarini, Novartis, Sanofi-Regeneron. G Pelaia has received lecture",
    "entities": [
      {
        "text": "Lusofarmaco",
        "label": "GPE"
      },
      {
        "text": "Menarini",
        "label": "GPE"
      },
      {
        "text": "Novartis",
        "label": "PERSON"
      },
      {
        "text": "G Pelaia",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "fees and advisory board fees from AstraZeneca, Boehringer Ingelheim, Chiesi,",
    "entities": [
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "Boehringer Ingelheim",
        "label": "ORG"
      },
      {
        "text": "Chiesi",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Novartis, Sanofi-Regeneron, Zambon. C Pelaia has received lecture fees and",
    "entities": [
      {
        "text": "Zambon",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "advisory board fees from AstraZeneca, GlaxoSmithKline, and Sanofi-Regeneron. The",
    "entities": [
      {
        "text": "advisory board",
        "label": "ORG"
      },
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "GlaxoSmithKline",
        "label": "PERSON"
      },
      {
        "text": "Sanofi-Regeneron",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "authors have no other relevant affiliations or financial involvements with any",
    "entities": []
  },
  {
    "text": "organization or entity with a financial interest in or financial conflict with",
    "entities": []
  },
  {
    "text": "the subject matter or materials discussed in the manuscript apart from those",
    "entities": []
  },
  {
    "text": "disclosed.",
    "entities": []
  },
  {
    "text": "Evaluating the Impact of Air Quality on Pediatric Asthma-Related Emergency Room",
    "entities": []
  },
  {
    "text": "Visits in the Eastern Province of Saudi Arabia.",
    "entities": [
      {
        "text": "the Eastern Province",
        "label": "GPE"
      },
      {
        "text": "Saudi Arabia",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Yousef AA(1), AlShammari RF(2), AlBugami S(3), AlAbbas BE(2), AlMossally FA(2).",
    "entities": [
      {
        "text": "Yousef AA(1",
        "label": "PERSON"
      },
      {
        "text": "AlShammari",
        "label": "PERSON"
      },
      {
        "text": "AlBugami S(3",
        "label": "PERSON"
      },
      {
        "text": "AlAbbas BE(2",
        "label": "PERSON"
      },
      {
        "text": "AlMossally FA(2",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(1)Department of Pediatrics, College of Medicine, King Fahd Hospital of the",
    "entities": [
      {
        "text": "Pediatrics, College of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)College of Medicine, King Fahd Hospital of the University, Imam Abdulrahman",
    "entities": [
      {
        "text": "2)College",
        "label": "CARDINAL"
      },
      {
        "text": "Imam Abdulrahman",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Bin Faisal University, Dammam 31441, Saudi Arabia.",
    "entities": [
      {
        "text": "Bin Faisal University",
        "label": "ORG"
      },
      {
        "text": "Saudi Arabia",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Department of Physics-GIS Program, College of Science, University of Jeddah,",
    "entities": [
      {
        "text": "Physics-GIS Program",
        "label": "ORG"
      },
      {
        "text": "College of Science, University of Jeddah",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Background/Objectives: Pediatric asthma is a leading cause of emergency",
    "entities": []
  },
  {
    "text": "department visits, and air pollution is a known primary environmental trigger.",
    "entities": []
  },
  {
    "text": "Although worldwide air pollutants have been associated with asthma",
    "entities": []
  },
  {
    "text": "exacerbations, limited data have been reported in the Eastern Province of Saudi",
    "entities": [
      {
        "text": "the Eastern Province",
        "label": "GPE"
      },
      {
        "text": "Saudi",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "Arabia. This study aimed to investigate the relationship between air pollution",
    "entities": []
  },
  {
    "text": "and pediatric asthma admissions among children aged 2 to 14 years old at King",
    "entities": [
      {
        "text": "2 to 14 years old",
        "label": "DATE"
      },
      {
        "text": "King\n",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "Fahd Hospital of the University Hospital (KFHU). Methods: This is a",
    "entities": [
      {
        "text": "Fahd Hospital",
        "label": "ORG"
      },
      {
        "text": "the University Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "retrospective cohort study, over 366 days, including 1750 pediatric",
    "entities": [
      {
        "text": "366 days",
        "label": "DATE"
      },
      {
        "text": "1750",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "asthma-related ER visits and daily concentrations of air pollutants (PM2.5,",
    "entities": [
      {
        "text": "ER",
        "label": "ORG"
      },
      {
        "text": "daily",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "PM10, NO2, SO2, CO, and O3) and meteorological factors (temperature and",
    "entities": [
      {
        "text": "NO2",
        "label": "PERSON"
      },
      {
        "text": "CO",
        "label": "ORG"
      },
      {
        "text": "O3",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "humidity). Various statistical models, such as Poisson regression and ARIMA,",
    "entities": [
      {
        "text": "Poisson",
        "label": "ORG"
      },
      {
        "text": "ARIMA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "were applied to determine the association between pollutants levels and hospital",
    "entities": []
  },
  {
    "text": "ER visits. The data were visit-based in nature, and it was not possible to",
    "entities": [
      {
        "text": "ER",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "follow up with repeat visits or for admission status for individual patients.",
    "entities": []
  },
  {
    "text": "Results: Elevated levels of PM2.5, NO2, and CO were significantly associated",
    "entities": [
      {
        "text": "NO2",
        "label": "NORP"
      },
      {
        "text": "CO",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "with more pediatric asthma ER visits, mainly on the same day and with short",
    "entities": [
      {
        "text": "ER",
        "label": "ORG"
      },
      {
        "text": "the same day",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "lags. PM2.5 displayed the strongest association, consistent with its deeper",
    "entities": []
  },
  {
    "text": "pulmonary penetration and greater toxicity. Also, PM10 levels were inversely",
    "entities": []
  },
  {
    "text": "associated with ER visits, possibly due to particle size and deposition location",
    "entities": [
      {
        "text": "ER",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "differences. Significantly correlated with increased ER visits are lower ambient",
    "entities": [
      {
        "text": "ER",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "temperature and higher humidity. Conclusions: This study offers strong evidence",
    "entities": []
  },
  {
    "text": "on the relationship between air pollution and pediatric asthma events, in turn",
    "entities": []
  },
  {
    "text": "highlighting the vital importance of air quality regulation, public health",
    "entities": []
  },
  {
    "text": "86. J Clin Med. 2025 Jun 26;14(13):4547. doi: 10.3390/jcm14134547.",
    "entities": [
      {
        "text": "86",
        "label": "CARDINAL"
      },
      {
        "text": "Clin Med",
        "label": "PERSON"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "26;14(13):4547",
        "label": "CARDINAL"
      },
      {
        "text": "10.3390",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Impact of Biologic Drugs on Comorbidity Outcomes in Rheumatoid Arthritis: A",
    "entities": [
      {
        "text": "Biologic Drugs",
        "label": "PERSON"
      },
      {
        "text": "Comorbidity Outcomes",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Systematic Review.",
    "entities": [
      {
        "text": "Systematic Review",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Boussaid S(1)(2)(3), Dhahri R(2)(4), Rahmouni S(1)(2)(3), Ceylan H\u0130(5),",
    "entities": [
      {
        "text": "Ceylan H\u0130(5",
        "label": "LOC"
      }
    ]
  },
  {
    "text": "(2)Faculty of Medicine of Tunis, University Tunis El Manar, Tunis 1007, Tunisia.",
    "entities": [
      {
        "text": "Medicine of Tunis, University Tunis El Manar",
        "label": "ORG"
      },
      {
        "text": "Tunis 1007",
        "label": "DATE"
      },
      {
        "text": "Tunisia",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Research Unit LR 05 SP 01, La Rabta Hospital, Tunis 1007, Tunisia.",
    "entities": [
      {
        "text": "LR 05 SP 01",
        "label": "ORG"
      },
      {
        "text": "La Rabta Hospital",
        "label": "ORG"
      },
      {
        "text": "1007",
        "label": "DATE"
      },
      {
        "text": "Tunisia",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Rheumatology Department, Military Hospital of Tunis, Tunis 1006, Tunisia.",
    "entities": [
      {
        "text": "Department, Military Hospital of Tunis, Tunis",
        "label": "ORG"
      },
      {
        "text": "Tunisia",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Department of Physical Education of Sports Teaching, Faculty of Sports",
    "entities": [
      {
        "text": "5)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Physical Education of Sports Teaching, Faculty of Sports",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(6)Higher Institute of Sports and Physical Education of Ksar Said, University of",
    "entities": [
      {
        "text": "6)Higher Institute of Sports and Physical Education",
        "label": "ORG"
      },
      {
        "text": "Ksar Said, University of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(7)English Department, College of arts and humanities of Sousse, University of",
    "entities": [
      {
        "text": "Department, College of arts",
        "label": "ORG"
      },
      {
        "text": "Sousse, University of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Sousse, Sousse 4002, Tunisia.",
    "entities": [
      {
        "text": "Sousse",
        "label": "GPE"
      },
      {
        "text": "4002",
        "label": "DATE"
      },
      {
        "text": "Tunisia",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(8)Department of Physical Education and Sport, Faculty of Law and Social",
    "entities": [
      {
        "text": "Physical Education",
        "label": "ORG"
      },
      {
        "text": "Sport, Faculty of Law and Social\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Sciences, University \"1 Decembrie 1918\" of Alba Iulia, 510009 Alba Iulia,",
    "entities": [
      {
        "text": "University",
        "label": "ORG"
      },
      {
        "text": "Alba Iulia",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Background: The management of rheumatoid arthritis (RA) has advanced",
    "entities": [
      {
        "text": "RA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "significantly with the introduction of biologic disease-modifying antirheumatic",
    "entities": []
  },
  {
    "text": "drugs (bDMARDs). Despite these therapeutic strides, RA prognosis remains",
    "entities": [
      {
        "text": "RA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "profoundly affected by comorbid conditions, particularly cardiovascular and",
    "entities": []
  },
  {
    "text": "metabolic complications, which increase both morbidity and mortality. The role",
    "entities": []
  },
  {
    "text": "of bDMARDs in modulating comorbidities remains underexplored, with limited",
    "entities": []
  },
  {
    "text": "evidence on their effects across various non-RA conditions, such as respiratory,",
    "entities": []
  },
  {
    "text": "diabetic, and hematologic disorders. This systematic review aimed to evaluate",
    "entities": []
  },
  {
    "text": "the impact of bDMARDs on the progression and outcomes of comorbidities in RA",
    "entities": [
      {
        "text": "RA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "patients, providing insights to guide personalized treatment approaches.",
    "entities": []
  },
  {
    "text": "Methods: This systematic review was registered in PROSPERO (CRD42022345903) and",
    "entities": [
      {
        "text": "PROSPERO",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "followed the PRISMA guidelines. Original research articles from PubMed and",
    "entities": [
      {
        "text": "PRISMA",
        "label": "ORG"
      },
      {
        "text": "PubMed",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Scopus, published up to 18 July 2024, were included. Studies assessing the",
    "entities": [
      {
        "text": "18 July 2024",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "impact of bDMARDs on comorbidities in RA patients met the eligibility criteria.",
    "entities": [
      {
        "text": "RA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Results: A total of thirteen studies met the inclusion criteria. They were",
    "entities": [
      {
        "text": "thirteen",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "published from inception until July 2024. The studied comorbidities included",
    "entities": [
      {
        "text": "July 2024",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "pulmonary conditions (asthma, chronic obstructive pulmonary disease, and",
    "entities": []
  },
  {
    "text": "malignancies (n = 3). The bDMARDs studied were tumor necrosis factor inhibitors",
    "entities": [
      {
        "text": "3",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Anakinra (n = 2). The most reported effects of bDMARDs on comorbidities were the",
    "entities": [
      {
        "text": "2",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "following: (i) an exacerbation of pulmonary comorbidities for Abatacept and",
    "entities": [
      {
        "text": "Abatacept",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "TNFis; (ii) patients switched to or initiated on Abatacept as their first",
    "entities": [
      {
        "text": "TNFis",
        "label": "ORG"
      },
      {
        "text": "first",
        "label": "ORDINAL"
      }
    ]
  },
  {
    "text": "targeted disease-modifying antirheumatic drug (tDMARD) showed directionally",
    "entities": []
  },
  {
    "text": "lower rates and costs of T2DM-related complications compared with patients",
    "entities": []
  },
  {
    "text": "switching to or initiating other tDMARDs; (iii) there was no difference between",
    "entities": []
  },
  {
    "text": "Abatacept and TNFis or Rituximab/Tocilizumab regarding diabetes treatment",
    "entities": [
      {
        "text": "TNFis",
        "label": "PERSON"
      },
      {
        "text": "Rituximab/Tocilizumab",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "switching or intensification; (iv) Anakinra significantly reduced the HbA1c%;",
    "entities": []
  },
  {
    "text": "(v) decreased serum hepcidin levels and improvement in anemia were observed in",
    "entities": []
  },
  {
    "text": "patients treated with TNFis or Tocilizumab; and (vi) no decrease in overall",
    "entities": [
      {
        "text": "TNFis",
        "label": "PERSON"
      },
      {
        "text": "Tocilizumab",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "survival time or the significant incident malignancy rate was noted in RA",
    "entities": [
      {
        "text": "RA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "patients. Conclusions: Overall, bDMARDs appear safe for use in RA patients with",
    "entities": [
      {
        "text": "RA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "comorbidities and may even provide specific benefits for conditions such as",
    "entities": []
  },
  {
    "text": "anemia and diabetes. These findings suggest that clinicians could consider",
    "entities": [
      {
        "text": "clinicians",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "tailoring biologic therapy based on each patient's comorbidity profile,",
    "entities": []
  },
  {
    "text": "potentially enhancing both RA management and comorbidity outcomes. For instance,",
    "entities": [
      {
        "text": "RA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "selecting biologics such as Anakinra or Tocilizumab might be advantageous for RA",
    "entities": [
      {
        "text": "Anakinra",
        "label": "PERSON"
      },
      {
        "text": "Tocilizumab",
        "label": "PERSON"
      },
      {
        "text": "RA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "patients with concurrent diabetes or anemia, given their observed metabolic and",
    "entities": []
  },
  {
    "text": "hematologic benefits. This personalized approach could improve the quality of",
    "entities": []
  },
  {
    "text": "life and reduce healthcare costs by addressing RA and associated comorbidities",
    "entities": [
      {
        "text": "RA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "more effectively.",
    "entities": []
  },
  {
    "text": "Conflict of interest statement: The authors declare no conflict of interest.",
    "entities": []
  },
  {
    "text": "87. J Clin Med. 2025 Jun 26;14(13):4525. doi: 10.3390/jcm14134525.",
    "entities": [
      {
        "text": "87",
        "label": "CARDINAL"
      },
      {
        "text": "Clin Med",
        "label": "PERSON"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "10.3390",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Effect of COVID-19 Disease on Serum Vitamin D Status in Children with Asthma-A",
    "entities": [
      {
        "text": "Serum Vitamin D Status",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Retrospective Study.",
    "entities": [
      {
        "text": "Retrospective Study",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)Doctoral School, University of Medicine and Pharmacy of Craiova, 200349",
    "entities": [
      {
        "text": "School, University of Medicine and Pharmacy of Craiova",
        "label": "ORG"
      },
      {
        "text": "200349",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "(2)Department of Pediatrics \"Mother and Child\", Faculty of Medicine, University",
    "entities": [
      {
        "text": "Mother and Child",
        "label": "WORK_OF_ART"
      },
      {
        "text": "Faculty of Medicine, University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.",
    "entities": [
      {
        "text": "Medicine and Pharmacy of Craiova",
        "label": "ORG"
      },
      {
        "text": "200349",
        "label": "DATE"
      },
      {
        "text": "Craiova",
        "label": "GPE"
      },
      {
        "text": "Romania",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Department of Medical Informatics, Faculty of Dental Medicine, University of",
    "entities": [
      {
        "text": "Medical Informatics, Faculty of Dental Medicine, University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.",
    "entities": [
      {
        "text": "200349",
        "label": "DATE"
      },
      {
        "text": "Craiova",
        "label": "GPE"
      },
      {
        "text": "Romania",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Department of Endodontics, Faculty of Dental Medicine, University of Medicine",
    "entities": [
      {
        "text": "Endodontics, Faculty of Dental Medicine, University of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and Pharmacy of Craiova, 200349 Craiova, Romania.",
    "entities": [
      {
        "text": "Pharmacy of Craiova",
        "label": "ORG"
      },
      {
        "text": "200349",
        "label": "DATE"
      },
      {
        "text": "Craiova",
        "label": "GPE"
      },
      {
        "text": "Romania",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Department of Hygiene, Faculty of Medicine, University of Medicine and",
    "entities": [
      {
        "text": "5)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Hygiene, Faculty of Medicine, University of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Pharmacy of Craiova, 200349 Craiova, Romania.",
    "entities": [
      {
        "text": "200349",
        "label": "DATE"
      },
      {
        "text": "Craiova",
        "label": "GPE"
      },
      {
        "text": "Romania",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Background/Objectives: Vitamin D is known to decrease the risk of contracting",
    "entities": [
      {
        "text": "Vitamin D",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "respiratory infections and developing exacerbations for children with asthma.",
    "entities": []
  },
  {
    "text": "This research evaluates the alterations in serum vitamin D concentrations and",
    "entities": []
  },
  {
    "text": "examines lung function in children with asthma, as indicated by clinical",
    "entities": []
  },
  {
    "text": "symptoms and paraclinical results, after experiencing SARS-CoV-2 infection or",
    "entities": []
  },
  {
    "text": "other acute respiratory infections. Material and Method: This retrospective",
    "entities": []
  },
  {
    "text": "study included 145 children with asthma. For each patient, the following",
    "entities": [
      {
        "text": "145",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "variables were acquired: demographic data, serum vitamin D levels, GINA asthma",
    "entities": []
  },
  {
    "text": "control levels, the fraction of exhaled nitric oxide (FeNO), pulmonary function",
    "entities": []
  },
  {
    "text": "tests parameters, data related to allergies, and the presence of exacerbations.",
    "entities": []
  },
  {
    "text": "Children were divided into two groups, according to the presence or absence of",
    "entities": [
      {
        "text": "two",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "SARS-CoV-2 infection or other acute respiratory infections. Variables were",
    "entities": []
  },
  {
    "text": "statistically processed in SPSS. Results: In total, 93 children with asthma with",
    "entities": [
      {
        "text": "SPSS",
        "label": "ORG"
      },
      {
        "text": "93",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "SARS-CoV-2 infection or other acute respiratory infections and 52 children with",
    "entities": [
      {
        "text": "52",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "asthma without SARS-CoV-2 infection or other acute respiratory infections were",
    "entities": []
  },
  {
    "text": "included in the study. Median serum vitamin D values were statistically",
    "entities": []
  },
  {
    "text": "significantly lower in children with a variable airflow limitation, compared to",
    "entities": []
  },
  {
    "text": "children with normal values (p = 0.004), as well as for children with partially",
    "entities": [
      {
        "text": "0.004",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "controlled asthma, relative to children with well controlled asthma (p <",
    "entities": []
  },
  {
    "text": "0.0005). Similarly, children with acute respiratory infections/COVID-19 disease",
    "entities": [
      {
        "text": "0.0005",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "had lower median values of serum vitamin D, compared to children without acute",
    "entities": []
  },
  {
    "text": "respiratory infections/COVID-19 disease (p < 0.0005). A decrease in serum",
    "entities": []
  },
  {
    "text": "vitamin D value was statistically significantly associated with an increase in",
    "entities": []
  },
  {
    "text": "FeNO value for children with asthma with COVID-19 disease (p = 0.027), as well",
    "entities": [
      {
        "text": "COVID-19",
        "label": "ORG"
      },
      {
        "text": "0.027",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "as for the entire study group (p < 0.0005). Conclusions: Children with asthma",
    "entities": []
  },
  {
    "text": "who had acute respiratory infections, including COVID-19 disease, showed",
    "entities": [
      {
        "text": "COVID-19",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "considerably reduced serum vitamin D levels and were linked to more significant",
    "entities": []
  },
  {
    "text": "airflow limitation, reduced asthma control and elevated airway inflammation,",
    "entities": []
  },
  {
    "text": "suggesting its potential role in influencing asthma severity and infection",
    "entities": []
  },
  {
    "text": "Optimizing Airway Function Through Craniofacial and Cervical Manipulations and",
    "entities": [
      {
        "text": "Optimizing Airway Function Through Craniofacial and Cervical Manipulations",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Emergency-Anesthesia Maneuvers: Applications in Airway Function Enhancement,",
    "entities": [
      {
        "text": "Emergency-Anesthesia Maneuvers: Applications in Airway Function Enhancement",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Pneumonia, and Asthma-Narrative Review.",
    "entities": [
      {
        "text": "Pneumonia",
        "label": "GPE"
      },
      {
        "text": "Asthma-Narrative Review",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(1)College of Osteopathic Medicine, Sam Houston State University, Conroe, TX",
    "entities": [
      {
        "text": "Osteopathic Medicine",
        "label": "ORG"
      },
      {
        "text": "Sam Houston State University",
        "label": "PERSON"
      },
      {
        "text": "Conroe",
        "label": "ORG"
      },
      {
        "text": "TX",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)Faculty of Medicine, Ala-Too International University, Bishkek 720048,",
    "entities": [
      {
        "text": "Medicine, Ala-Too International University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(3)Department of Medicine, Mass General Brigham, Boston, MA 02114, USA.",
    "entities": [
      {
        "text": "Boston",
        "label": "GPE"
      },
      {
        "text": "MA 02114",
        "label": "ORG"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Independent Scholar of Anesthesiology & Pain Medicine, Houston, TX 77004,",
    "entities": [
      {
        "text": "Scholar of Anesthesiology & Pain Medicine",
        "label": "ORG"
      },
      {
        "text": "Houston",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Department of Surgery, Bielefeld University-Campus Detmold, Klinikum Lippe,",
    "entities": [
      {
        "text": "Surgery",
        "label": "GPE"
      },
      {
        "text": "Klinikum Lippe",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "32756 Detmold, Germany.",
    "entities": [
      {
        "text": "32756",
        "label": "CARDINAL"
      },
      {
        "text": "Germany",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)Department of Intensive Care Medicine, Elisabeth-Tweesteden Hospital, 5022 GC",
    "entities": [
      {
        "text": "Intensive Care Medicine",
        "label": "ORG"
      },
      {
        "text": "Elisabeth-Tweesteden Hospital",
        "label": "ORG"
      },
      {
        "text": "5022",
        "label": "DATE"
      },
      {
        "text": "GC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Tilburg, The Netherlands.",
    "entities": [
      {
        "text": "Tilburg",
        "label": "GPE"
      },
      {
        "text": "The Netherlands",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Background: Even with advanced management involving pharmacologic and",
    "entities": []
  },
  {
    "text": "ventilatory strategies, respiratory dysfunction increases morbidity and reduces",
    "entities": []
  },
  {
    "text": "the quality of life. This narrative review examines how craniofacial and",
    "entities": []
  },
  {
    "text": "cervical manipulative interventions-including nasomaxillary skeletal expansion,",
    "entities": []
  },
  {
    "text": "breathing re-education, and structural techniques-may holistically optimize",
    "entities": []
  },
  {
    "text": "airway function by enhancing neurological and lymphatic dynamics, modulating",
    "entities": []
  },
  {
    "text": "vagal tone, reducing pharyngeal collapsibility, and supporting immune regulation",
    "entities": []
  },
  {
    "text": "across diverse clinical settings. Objectives: To explore manual techniques that",
    "entities": []
  },
  {
    "text": "influence respiratory and autonomic function and to evaluate their reported",
    "entities": []
  },
  {
    "text": "clinical efficacy and supporting evidence, particularly in the context of airway",
    "entities": []
  },
  {
    "text": "disorders such as asthma and pneumonia. Methods: A narrative review of the",
    "entities": []
  },
  {
    "text": "literature from PubMed and Google Scholar was conducted using search terms",
    "entities": [
      {
        "text": "PubMed",
        "label": "ORG"
      },
      {
        "text": "Google Scholar",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "related to airway function and osteopathic manipulative techniques (OMTs). The",
    "entities": []
  },
  {
    "text": "inclusion criteria spanned 2010-2025 English-language peer-reviewed full-text",
    "entities": [
      {
        "text": "2010-2025",
        "label": "DATE"
      },
      {
        "text": "English",
        "label": "LANGUAGE"
      }
    ]
  },
  {
    "text": "articles on airway function, OMT, and emergency airway maneuvers. Clinical",
    "entities": [
      {
        "text": "OMT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "trials, observational studies, and reviews were included; non-peer-reviewed",
    "entities": []
  },
  {
    "text": "content and animal studies (unless mechanistically relevant) were excluded.",
    "entities": []
  },
  {
    "text": "Chapman's reflexes related to respiratory function were incorporated to",
    "entities": [
      {
        "text": "Chapman",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "highlight somatic-visceral correlations. Key Findings: The techniques reviewed",
    "entities": []
  },
  {
    "text": "included frontal lift, vomer manipulation, maxillary and zygomatic balancing,",
    "entities": []
  },
  {
    "text": "and cervical adjustments. Thoracic OMT methods, such as diaphragm doming and",
    "entities": [
      {
        "text": "Thoracic",
        "label": "ORG"
      },
      {
        "text": "OMT",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "lymphatic pump techniques, were also addressed. Emergency techniques, such as",
    "entities": []
  },
  {
    "text": "the BURP and Larson maneuvers, prone positioning, and high-frequency chest wall",
    "entities": [
      {
        "text": "BURP",
        "label": "ORG"
      },
      {
        "text": "Larson",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "oscillation, were presented as comparative strategies to OMTs for acute airway",
    "entities": []
  },
  {
    "text": "management. Conclusions: Craniofacial and cervical manipulations can be a",
    "entities": []
  },
  {
    "text": "promising adjunct for enhancing airway function. However, the current literature",
    "entities": []
  },
  {
    "text": "displays heterogeneity and lack of large-scale randomized trials, which",
    "entities": []
  },
  {
    "text": "emphasize the necessity for standardized research and the establishment of",
    "entities": []
  },
  {
    "text": "clinical guidelines with the collected evidence.",
    "entities": []
  },
  {
    "text": "89. Healthcare (Basel). 2025 Jul 5;13(13):1613. doi: 10.3390/healthcare13131613.",
    "entities": [
      {
        "text": "89",
        "label": "CARDINAL"
      },
      {
        "text": "Healthcare",
        "label": "ORG"
      },
      {
        "text": "Basel",
        "label": "GPE"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      },
      {
        "text": "10.3390",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Factors Associated with Asthma Medication Adherence in Parents with Asthmatic",
    "entities": [
      {
        "text": "Asthma Medication Adherence",
        "label": "PRODUCT"
      },
      {
        "text": "Parents",
        "label": "GPE"
      },
      {
        "text": "Asthmatic",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "Children: Theory of Planned Behaviour.",
    "entities": []
  },
  {
    "text": "(1)Clinical Pharmacy Department, College of Pharmacy, Prince Sattam Bin",
    "entities": [
      {
        "text": "1)Clinical Pharmacy Department, College of Pharmacy",
        "label": "ORG"
      },
      {
        "text": "Sattam Bin\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(2)Department of Pharmacy Practice, College of Pharmacy, Qassim University,",
    "entities": [
      {
        "text": "Pharmacy Practice",
        "label": "ORG"
      },
      {
        "text": "College of Pharmacy",
        "label": "ORG"
      },
      {
        "text": "Qassim University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(3)Maternity and Children Hospital, Qassim Health Cluster, Ministry of Health,",
    "entities": [
      {
        "text": "Children Hospital",
        "label": "ORG"
      },
      {
        "text": "Ministry of Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)Department of Pharmacology and Toxicology, College of Pharmacy, King Saud",
    "entities": [
      {
        "text": "Pharmacology and Toxicology, College of Pharmacy",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(5)Department of Pharmacy, King Fahd Specialist Hospital, Buraydah 52719, Saudi",
    "entities": [
      {
        "text": "King Fahd Specialist Hospital",
        "label": "ORG"
      },
      {
        "text": "52719",
        "label": "DATE"
      },
      {
        "text": "Saudi",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "BACKGROUND/OBJECTIVES: Asthma is a prevalent chronic condition affecting",
    "entities": []
  },
  {
    "text": "approximately 300 million people globally. Despite advancements in treatment",
    "entities": [
      {
        "text": "approximately 300 million",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "protocols, poor adherence to asthma medication remains a significant issue,",
    "entities": []
  },
  {
    "text": "often leading to severe complications, especially in children. This study aimed",
    "entities": []
  },
  {
    "text": "to identify factors influencing medication adherence among parents of children",
    "entities": []
  },
  {
    "text": "with asthma, using constructs from the theory of planned behaviour to better",
    "entities": []
  },
  {
    "text": "understand and improve adherence.",
    "entities": []
  },
  {
    "text": "METHODS: This cross-sectional study employed a survey incorporating constructs",
    "entities": []
  },
  {
    "text": "from the theory of planned behaviour, demographic variables, and other",
    "entities": []
  },
  {
    "text": "adherence-related factors. Descriptive statistics and logistic regression",
    "entities": []
  },
  {
    "text": "analyses were applied to explore the relationship between these factors and",
    "entities": []
  },
  {
    "text": "adherence to asthma medications.",
    "entities": []
  },
  {
    "text": "RESULTS: Out of 152 parents who visited the survey link, 150 were eligible. The",
    "entities": [
      {
        "text": "152",
        "label": "CARDINAL"
      },
      {
        "text": "150",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "average age was 35.58 \u00b1 9.913 years; most participants were married (82%) and",
    "entities": [
      {
        "text": "35.58",
        "label": "DATE"
      },
      {
        "text": "9.913 years",
        "label": "DATE"
      },
      {
        "text": "82%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "female (62.6%). Multivariate linear regression analysis of the parents' factor",
    "entities": [
      {
        "text": "62.6%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "showed parental attitude (\u03b2 = 0.38, p < 0.001) and subjective norms (\u03b2 = 0.34, p",
    "entities": [
      {
        "text": "0.38",
        "label": "CARDINAL"
      },
      {
        "text": "p < 0.001",
        "label": "ORG"
      },
      {
        "text": "0.34",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "< 0.002) were significantly associated with parents' intention to adhere to",
    "entities": [
      {
        "text": "0.002",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "asthma medications.",
    "entities": []
  },
  {
    "text": "CONCLUSION: The study found that parental attitudes and subjective norms",
    "entities": []
  },
  {
    "text": "significantly impact the intention to adhere to asthma medication. Improving",
    "entities": []
  },
  {
    "text": "adherence is crucial for effective disease management, reducing healthcare",
    "entities": []
  },
  {
    "text": "costs, and enhancing the quality of life for children and their families.",
    "entities": []
  },
  {
    "text": "Interventions should focus on educating parents about the importance of",
    "entities": []
  },
  {
    "text": "adherence and engaging more family members to positively influence adherence",
    "entities": []
  },
  {
    "text": "through strengthened subjective norms.",
    "entities": []
  },
  {
    "text": "DOI: 10.3390/healthcare13131613",
    "entities": [
      {
        "text": "10.3390",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Intestinal Microbiota in Early Life: Latest Findings Regarding the Role of",
    "entities": []
  },
  {
    "text": "Probiotics as a Treatment Approach for Dysbiosis.",
    "entities": []
  },
  {
    "text": "(1)Department of Surgery, University of Medicine and Pharmacy of Craiova, 200349",
    "entities": [
      {
        "text": "Surgery, University of Medicine and Pharmacy of Craiova",
        "label": "ORG"
      },
      {
        "text": "200349",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "(2)Department of Morphological Sciences, Cell and Molecular Biology and",
    "entities": [
      {
        "text": "Morphological Sciences",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Histology, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest,",
    "entities": [
      {
        "text": "Carol Davila University of Medicine and Pharmacy",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(3)Department of Oncology, Elias University Emergency Hospital, 011461",
    "entities": [
      {
        "text": "Elias University Emergency Hospital",
        "label": "ORG"
      },
      {
        "text": "011461",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "(4)Department of Radiology and Medical Imaging, Fundeni Clinical Institute,",
    "entities": [
      {
        "text": "Radiology and Medical Imaging",
        "label": "ORG"
      },
      {
        "text": "Fundeni Clinical Institute",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(5)Department of Psychiatry, Faculty of Medicine, University of Medicine and",
    "entities": [
      {
        "text": "5)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Psychiatry, Faculty of Medicine, University of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(6)Psychiatry Clinic, Craiova Clinical Hospital for Neuropsychiatry, 200615",
    "entities": [
      {
        "text": "Clinic",
        "label": "ORG"
      },
      {
        "text": "200615",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "The gut microbiota plays a crucial role in early-life development, influencing",
    "entities": []
  },
  {
    "text": "various aspects of health and disease. Dysbiosis, an imbalance in the gut",
    "entities": []
  },
  {
    "text": "microbiota, has been linked to multiple health conditions, including allergies,",
    "entities": []
  },
  {
    "text": "asthma, and obesity. In early life, the gut microbiota plays a key role in the",
    "entities": []
  },
  {
    "text": "development and maturation of the immune system. Probiotics, live microorganisms",
    "entities": []
  },
  {
    "text": "that confer health benefits when administered in adequate amounts, have emerged",
    "entities": []
  },
  {
    "text": "as a potential treatment approach for dysbiosis in early life. Dysbiosis can",
    "entities": []
  },
  {
    "text": "alter the resistance to pathogens, promoting atopic diseases, food",
    "entities": []
  },
  {
    "text": "sensitization, and infections such as necrotizing enterocolitis (NEC).",
    "entities": [
      {
        "text": "NEC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Probiotics have been shown to modulate the composition and function of the gut",
    "entities": []
  },
  {
    "text": "microbiota in the perinatal and infant periods. They can increase the abundance",
    "entities": []
  },
  {
    "text": "of beneficial bacteria, such as Bifidobacteria and Lactobacilli, and reduce the",
    "entities": [
      {
        "text": "Bifidobacteria",
        "label": "GPE"
      },
      {
        "text": "Lactobacilli",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "levels of potentially harmful bacteria. Not all probiotics are created equal.",
    "entities": []
  },
  {
    "text": "The effects of probiotics can vary depending on the specific strain used.",
    "entities": []
  },
  {
    "text": "Probiotics have also been investigated for their potential benefits in other",
    "entities": []
  },
  {
    "text": "areas of infant health, such as reducing the risk of respiratory infections and",
    "entities": []
  },
  {
    "text": "improving growth and development. This review aims to analyze the current data",
    "entities": []
  },
  {
    "text": "in the literature and to evaluate the health benefits of probiotic",
    "entities": []
  },
  {
    "text": "administration in early life. Several studies have investigated the use of",
    "entities": []
  },
  {
    "text": "probiotics in preventing or treating allergic diseases, such as eczema and food",
    "entities": []
  },
  {
    "text": "allergies. While some studies have shown promising results, more research is",
    "entities": []
  },
  {
    "text": "needed to fully understand the benefits and risks of probiotics in early life.",
    "entities": []
  },
  {
    "text": "In conclusion, using probiotics to prevent dysbiosis-related conditions may be",
    "entities": []
  },
  {
    "text": "considered a method of 'programming' the individual for optimal health",
    "entities": []
  },
  {
    "text": "PMID: 40647176 [Indexed for MEDLINE]",
    "entities": []
  },
  {
    "text": "Obesity-Associated Metabolomic and Functional Reprogramming in Neutrophils from",
    "entities": [
      {
        "text": "Neutrophils",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Horses with Asthma.",
    "entities": [
      {
        "text": "Asthma",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(1)Institute of Pharmacology and Morphophysiology, Faculty of Veterinary",
    "entities": [
      {
        "text": "Pharmacology and Morphophysiology, Faculty of Veterinary\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(2)Graduate School, Faculty of Veterinary Sciences, Universidad Austral de",
    "entities": [
      {
        "text": "2)Graduate School, Faculty of Veterinary Sciences",
        "label": "ORG"
      },
      {
        "text": "Universidad Austral de\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Equine asthma is a chronic respiratory disease characterised by neutrophilic",
    "entities": [
      {
        "text": "Equine",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "inflammation, airway hyperresponsiveness, and impaired pulmonary function.",
    "entities": []
  },
  {
    "text": "Obesity, increasingly prevalent among domestic horses, has been identified as a",
    "entities": []
  },
  {
    "text": "potential risk factor for exacerbating inflammatory conditions. This study aimed",
    "entities": []
  },
  {
    "text": "to explore whether obesity modifies neutrophil metabolism and inflammatory",
    "entities": []
  },
  {
    "text": "responses in horses affected by asthma. Six asthmatic horses in clinical",
    "entities": [
      {
        "text": "Six",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "remission were categorised into two groups: obese and non-obese, based on body",
    "entities": [
      {
        "text": "two",
        "label": "CARDINAL"
      },
      {
        "text": "obese",
        "label": "NORP"
      },
      {
        "text": "non-obese",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "condition score. Serum levels of interleukin-1\u03b2 (IL-1\u03b2) and peripheral blood",
    "entities": [
      {
        "text": "IL-1\u03b2",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "neutrophil counts were significantly higher in obese horses, indicating a",
    "entities": [
      {
        "text": "obese",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "heightened systemic inflammatory state. Neutrophils from obese horses displayed",
    "entities": [
      {
        "text": "obese",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "a stronger oxidative burst following zymosan stimulation and elevated IL-1\u03b2 gene",
    "entities": [
      {
        "text": "IL-1\u03b2",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "expression in response to lipopolysaccharide, suggesting a hyperinflammatory",
    "entities": []
  },
  {
    "text": "phenotype. Metabolomic profiling of neutrophils identified 139 metabolites, with",
    "entities": [
      {
        "text": "139",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "notable differences in fatty acids, branched-chain amino acids, and",
    "entities": []
  },
  {
    "text": "tricarboxylic acid (TCA) cycle intermediates. Pathway enrichment analysis",
    "entities": []
  },
  {
    "text": "revealed significant alterations in fatty acid biosynthesis, amino acid",
    "entities": []
  },
  {
    "text": "metabolism, and glutathione-related pathways. Elevated levels of itaconate,",
    "entities": []
  },
  {
    "text": "citraconic acid, and citrate in obese horses indicate profound metabolic",
    "entities": [
      {
        "text": "obese",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "reprogramming within neutrophils. These results suggest that obesity promotes a",
    "entities": []
  },
  {
    "text": "distinct neutrophil phenotype marked by increased metabolic activity and",
    "entities": []
  },
  {
    "text": "heightened responsiveness to inflammatory stimuli. This altered profile may",
    "entities": []
  },
  {
    "text": "contribute to the persistence or worsening of airway inflammation in asthmatic",
    "entities": []
  },
  {
    "text": "horses. The findings underscore the importance of addressing obesity in the",
    "entities": []
  },
  {
    "text": "clinical management of equine asthma and open avenues for further research into",
    "entities": []
  },
  {
    "text": "metabolic-targeted therapies in veterinary medicine.",
    "entities": []
  },
  {
    "text": "Conflict of interest statement: All authors declare that they have no conflicts",
    "entities": []
  },
  {
    "text": "of interest.",
    "entities": []
  },
  {
    "text": "92. Intern Emerg Med. 2025 Jul 12. doi: 10.1007/s11739-025-04045-8. Online ahead",
    "entities": [
      {
        "text": "92",
        "label": "CARDINAL"
      },
      {
        "text": "Intern Emerg Med",
        "label": "ORG"
      },
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "12",
        "label": "CARDINAL"
      },
      {
        "text": "10.1007",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Predictors of e-cigarette use among individuals with asthma: findings from a",
    "entities": []
  },
  {
    "text": "cross-sectional population-based study.",
    "entities": []
  },
  {
    "text": "(1)College of Social Sciences, University of Glasgow, 40 Bute Gardens, Glasgow,",
    "entities": [
      {
        "text": "Social Sciences",
        "label": "ORG"
      },
      {
        "text": "University of Glasgow",
        "label": "ORG"
      },
      {
        "text": "40",
        "label": "CARDINAL"
      },
      {
        "text": "Bute Gardens",
        "label": "LOC"
      },
      {
        "text": "Glasgow",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(2)Department of Family and Community Medicine, Faculty of Medicine, University",
    "entities": [
      {
        "text": "Family and Community Medicine, Faculty of Medicine, University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "The use of electronic cigarettes (e-cigarettes) among individuals with asthma is",
    "entities": []
  },
  {
    "text": "rising, yet limited evidence exists on predictors of use in this clinical",
    "entities": []
  },
  {
    "text": "population. Understanding factors associated with e-cigarette use may help",
    "entities": []
  },
  {
    "text": "inform public health interventions. In this study, we analysed data from 2671",
    "entities": [
      {
        "text": "2671",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "individuals aged 16 years and older with doctor-diagnosed asthma, drawn from the",
    "entities": [
      {
        "text": "16 years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "2017, 2018, 2019, and 2021 waves of the Scottish Health Survey. Current",
    "entities": [
      {
        "text": "2017, 2018",
        "label": "DATE"
      },
      {
        "text": "2019",
        "label": "DATE"
      },
      {
        "text": "2021",
        "label": "DATE"
      },
      {
        "text": "the Scottish Health Survey",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "e-cigarette use was defined as self-reported use at the time of the survey. We",
    "entities": []
  },
  {
    "text": "used multivariable logistic regression to examine factors associated with",
    "entities": []
  },
  {
    "text": "current e-cigarette use among individuals with asthma, estimating adjusted odds",
    "entities": []
  },
  {
    "text": "ratios (aORs), 95% confidence intervals (CIs), and p values for age, sex,",
    "entities": [
      {
        "text": "95%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "self-rated health. Overall, 193 participants (7.2%) reported current e-cigarette",
    "entities": [
      {
        "text": "193",
        "label": "CARDINAL"
      },
      {
        "text": "7.2%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "use. Current smokers had significantly higher odds of using e-cigarettes",
    "entities": []
  },
  {
    "text": "compared to never smokers (aOR: 38.9; 95% CI: 18.5-82.0; p < 0.001). Former",
    "entities": [
      {
        "text": "38.9",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "18.5-82.0",
        "label": "CARDINAL"
      },
      {
        "text": "p < 0.001",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "smokers also had increased odds of e-cigarette use relative to never smokers",
    "entities": []
  },
  {
    "text": "(aOR: 32.0; 95% CI: 15.2-67.2; p < 0.001). Each one-category increase in age",
    "entities": [
      {
        "text": "32.0",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "15.2",
        "label": "CARDINAL"
      },
      {
        "text": "p < 0.001",
        "label": "ORG"
      },
      {
        "text": "one",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "group (spanning approximately 10 years) was associated with a 23% reduction in",
    "entities": [
      {
        "text": "approximately 10 years",
        "label": "DATE"
      },
      {
        "text": "23%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "the odds of current e-cigarette use (aOR: 0.77; 95% CI: 0.69-0.86; p < 0.001).",
    "entities": [
      {
        "text": "0.77",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "0.69-0.86",
        "label": "CARDINAL"
      },
      {
        "text": "p < 0.001",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Participants living in less deprived areas had 15% lower odds of current",
    "entities": [
      {
        "text": "15%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "e-cigarette use for each one-quintile increase in the Scottish Index of Multiple",
    "entities": [
      {
        "text": "one",
        "label": "CARDINAL"
      },
      {
        "text": "Scottish",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "Deprivation (aOR: 0.85; 95% CI: 0.74-0.97; p = 0.016). E-cigarette use was not",
    "entities": [
      {
        "text": "0.85",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "PERSON"
      },
      {
        "text": "0.74",
        "label": "CARDINAL"
      },
      {
        "text": "0.016",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "significantly associated with sex, educational level, alcohol consumption, or",
    "entities": []
  },
  {
    "text": "self-rated health. These findings indicate that e-cigarette use among",
    "entities": []
  },
  {
    "text": "individuals with asthma is more prevalent among younger participants, those",
    "entities": []
  },
  {
    "text": "living in socioeconomically deprived areas, and those with a current or former",
    "entities": []
  },
  {
    "text": "smoking history. Further longitudinal research is needed to explore usage",
    "entities": []
  },
  {
    "text": "trajectories and respiratory health impacts in this clinical population.",
    "entities": []
  },
  {
    "text": "Conflict of interest statement: Declarations. Conflict of interest: Yusuff",
    "entities": [
      {
        "text": "Yusuff",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Adebayo Adebisi and Najim Z Alshahrani declare no conflicts of interest.",
    "entities": [
      {
        "text": "Adebayo Adebisi",
        "label": "PERSON"
      },
      {
        "text": "Najim Z",
        "label": "PERSON"
      },
      {
        "text": "Alshahrani",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "However, Yusuff Adebayo Adebisi has previously received funding through the",
    "entities": [
      {
        "text": "Yusuff Adebayo Adebisi",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Tobacco Harm Reduction Scholarship and the Kevin Molloy Fellowship, both awarded",
    "entities": [
      {
        "text": "Harm Reduction Scholarship",
        "label": "PERSON"
      },
      {
        "text": "the Kevin Molloy Fellowship",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "by Knowledge-Action-Change (KAC), an independent public health organisation",
    "entities": [
      {
        "text": "Knowledge-Action-Change",
        "label": "ORG"
      },
      {
        "text": "KAC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "based in the UK. KAC is funded by Global Action to End Smoking (GA), an",
    "entities": [
      {
        "text": "UK",
        "label": "GPE"
      },
      {
        "text": "KAC",
        "label": "ORG"
      },
      {
        "text": "Global Action to End Smoking",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "independent U.S. nonprofit 501(c)(3) grant-making organisation that supports",
    "entities": [
      {
        "text": "U.S.",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "health and science research, cessation education, and agricultural",
    "entities": []
  },
  {
    "text": "transformation initiatives. The authors have never received funding from, nor",
    "entities": []
  },
  {
    "text": "held any affiliations with, tobacco or e-cigarette companies. This research was",
    "entities": []
  },
  {
    "text": "conducted independently, and no funding was received for the present study.",
    "entities": []
  },
  {
    "text": "Ethics approval: This was a secondary analysis of publicly available, anonymised",
    "entities": []
  },
  {
    "text": "data. No ethical approval was sought. Human and animal rights and informed",
    "entities": []
  },
  {
    "text": "consent: As this study involved secondary data analysis, no ethical approval or",
    "entities": []
  },
  {
    "text": "informed consent was required by the authors for this research, as it qualifies",
    "entities": []
  },
  {
    "text": "for exemption from human subjects research. Patient and public involvement:",
    "entities": []
  },
  {
    "text": "Patients and/or the public were not involved in the design, or conduct, or",
    "entities": []
  },
  {
    "text": "reporting, or dissemination plans of this research.",
    "entities": []
  },
  {
    "text": "European, multicentre, prospective observational phase IV clinical study to",
    "entities": [
      {
        "text": "European",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "assess the impact of lebrikizumab on health-related well-being and control of",
    "entities": []
  },
  {
    "text": "skin manifestations in patients with moderate-to-severe atopic dermatitis",
    "entities": []
  },
  {
    "text": "(ADTrust): study protocol.",
    "entities": []
  },
  {
    "text": "(1)Institute for Health Services Research in Dermatology and Nursing, University",
    "entities": [
      {
        "text": "Health Services Research in Dermatology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Medical Center Hamburg-Eppendorf, Hamburg, Germany m.augustin@uke.de.",
    "entities": [
      {
        "text": "Hamburg",
        "label": "GPE"
      },
      {
        "text": "Germany",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Whipps Cross University Hospital, Whitechapel, London, UK.",
    "entities": [
      {
        "text": "2)Whipps Cross University Hospital",
        "label": "ORG"
      },
      {
        "text": "Whitechapel",
        "label": "GPE"
      },
      {
        "text": "London",
        "label": "GPE"
      },
      {
        "text": "UK",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Royal London Hospital, Whitechapel, London, UK.",
    "entities": [
      {
        "text": "3)Royal",
        "label": "CARDINAL"
      },
      {
        "text": "London Hospital",
        "label": "ORG"
      },
      {
        "text": "Whitechapel",
        "label": "GPE"
      },
      {
        "text": "London",
        "label": "GPE"
      },
      {
        "text": "UK",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Department of Dermatology, University Hospital Zurich, Z\u00fcrich, Switzerland.",
    "entities": [
      {
        "text": "Dermatology, University Hospital Zurich",
        "label": "ORG"
      },
      {
        "text": "Z\u00fcrich",
        "label": "GPE"
      },
      {
        "text": "Switzerland",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)Christine K\u00fchne-Center for Allergy Research and Education, Davos,",
    "entities": [
      {
        "text": "6)Christine",
        "label": "CARDINAL"
      },
      {
        "text": "K\u00fchne-Center for Allergy Research and Education",
        "label": "ORG"
      },
      {
        "text": "Davos",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(7)Department of Dermatology and Allergology, National Expertise Center for",
    "entities": [
      {
        "text": "Dermatology and Allergology",
        "label": "ORG"
      },
      {
        "text": "National Expertise Center",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Atopic Dermatitis, University Medical Center Utrecht, Utrecht, Netherlands.",
    "entities": [
      {
        "text": "Atopic Dermatitis",
        "label": "ORG"
      },
      {
        "text": "University Medical Center Utrecht",
        "label": "ORG"
      },
      {
        "text": "Utrecht",
        "label": "GPE"
      },
      {
        "text": "Netherlands",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(8)Department of Dermatology, EpiDermE, Henri Mondor Hospital, Universit\u00e9",
    "entities": [
      {
        "text": "Universit\u00e9\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(11)Department of Dermatovenereology, Third Faculty of Medicine, Charles",
    "entities": [
      {
        "text": "11)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Third Faculty of Medicine",
        "label": "ORG"
      },
      {
        "text": "Charles\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "University and Kralovske Vinohrady University Hospital, Prague, Czech Republic.",
    "entities": [
      {
        "text": "University",
        "label": "ORG"
      },
      {
        "text": "Kralovske Vinohrady University Hospital",
        "label": "ORG"
      },
      {
        "text": "Prague",
        "label": "GPE"
      },
      {
        "text": "Czech Republic",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(12)Dermatology Department, Hospital Universitario La Paz, Madrid, Spain.",
    "entities": [
      {
        "text": "Hospital Universitario La",
        "label": "FAC"
      },
      {
        "text": "Madrid",
        "label": "GPE"
      },
      {
        "text": "Spain",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(13)Division of Dermatology and Venereology, Department of Medicine Solna,",
    "entities": [
      {
        "text": "Dermatology and Venereology",
        "label": "ORG"
      },
      {
        "text": "Department of Medicine Solna",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(14)Department of Dermatology and Venereology, Karolinska University Hospital,",
    "entities": [
      {
        "text": "14)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Karolinska University Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(15)Department of Dermatovenerology, University Hospital Luis Pasteur, Ko\u0161ice,",
    "entities": [
      {
        "text": "15)Department",
        "label": "CARDINAL"
      },
      {
        "text": "University Hospital Luis Pasteur",
        "label": "ORG"
      },
      {
        "text": "Ko\u0161ice",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(16)Department of Dermatology, Ghent University Hospital, Ghent, Belgium.",
    "entities": [
      {
        "text": "16)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Belgium",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(18)Department of Dermatology, Oslo University Hospital, Oslo, Norway.",
    "entities": [
      {
        "text": "18)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Oslo University Hospital",
        "label": "ORG"
      },
      {
        "text": "Oslo",
        "label": "GPE"
      },
      {
        "text": "Norway",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(19)Faculty of Medicine, Institute of Clinical Medicine, University of Oslo,",
    "entities": [
      {
        "text": "Medicine, Institute of Clinical Medicine",
        "label": "ORG"
      },
      {
        "text": "University of Oslo",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(20)Department of Dermato-Venereology, 4th Military Hospital, Faculty of",
    "entities": [
      {
        "text": "20)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Dermato-Venereology",
        "label": "ORG"
      },
      {
        "text": "4th Military Hospital, Faculty",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Medicine, University of Science and Technology, Wroclaw, Poland.",
    "entities": [
      {
        "text": "Medicine, University of Science and Technology, Wroclaw",
        "label": "ORG"
      },
      {
        "text": "Poland",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(21)Department of Dermatology, CAC ICBAS-CHP, Porto, Portugal.",
    "entities": [
      {
        "text": "21)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Porto",
        "label": "GPE"
      },
      {
        "text": "Portugal",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(22)Unit for Multidisciplinary Research in Biomedicine, Instituto de Ci\u00eancias",
    "entities": [
      {
        "text": "22)Unit",
        "label": "CARDINAL"
      },
      {
        "text": "Multidisciplinary Research",
        "label": "ORG"
      },
      {
        "text": "Instituto de Ci\u00eancias",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(23)Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.",
    "entities": [
      {
        "text": "23)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Aarhus University Hospital",
        "label": "ORG"
      },
      {
        "text": "Aarhus",
        "label": "GPE"
      },
      {
        "text": "Denmark",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(24)Department of Dermatology and Allergy, Hannover Medical School, Hannover,",
    "entities": [
      {
        "text": "24)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Hannover Medical School",
        "label": "ORG"
      },
      {
        "text": "Hannover",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(25)Almirall S.A, Barcelona, Spain.",
    "entities": [
      {
        "text": "25)Almirall",
        "label": "CARDINAL"
      },
      {
        "text": "Barcelona",
        "label": "GPE"
      },
      {
        "text": "Spain",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(26)Avant Health LLC, Bethesda, Maryland, USA.",
    "entities": [
      {
        "text": "26)Avant Health LLC",
        "label": "ORG"
      },
      {
        "text": "Bethesda",
        "label": "GPE"
      },
      {
        "text": "Maryland",
        "label": "GPE"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(27)Department of Dermatology, Vrije Universiteit Brussel, Universitair",
    "entities": [
      {
        "text": "27)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Vrije Universiteit Brussel",
        "label": "PERSON"
      },
      {
        "text": "Universitair",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "INTRODUCTION: Atopic dermatitis (AD) is a chronic, relapsing, heterogeneous skin",
    "entities": []
  },
  {
    "text": "disease affecting 2%-7% of adults, with roughly 30% having moderate-to-severe",
    "entities": [
      {
        "text": "2%-7%",
        "label": "PERCENT"
      },
      {
        "text": "roughly 30%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "disease. AD symptoms, like intense itching and skin pain, carry a substantial",
    "entities": [
      {
        "text": "AD",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "disease burden that negatively impacts patients' quality of life (QoL) and",
    "entities": [
      {
        "text": "QoL",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "psychosocial well-being. Lebrikizumab is a novel, high-affinity monoclonal",
    "entities": [
      {
        "text": "Lebrikizumab",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "antibody that selectively binds to and neutralises interleukin-13 with high",
    "entities": [
      {
        "text": "interleukin-13",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "potency. Three clinical trials with lebrikizumab (ADvocate 1 and 2; ADhere)",
    "entities": [
      {
        "text": "Three",
        "label": "CARDINAL"
      },
      {
        "text": "1",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "demonstrated significant clinical benefit in patients with AD, while the 3-year",
    "entities": [
      {
        "text": "3-year",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "long-term extension study of lebrikizumab (ADjoin) further demonstrated",
    "entities": []
  },
  {
    "text": "long-term efficacy and safety in patients with AD. The ADTrust study will",
    "entities": []
  },
  {
    "text": "evaluate patient well-being, their relationship with their skin, long-term",
    "entities": []
  },
  {
    "text": "effectiveness, and safety of lebrikizumab, treatment satisfaction, and long-term",
    "entities": []
  },
  {
    "text": "effect of lebrikizumab treatment on different aspects of patients' lives,",
    "entities": []
  },
  {
    "text": "including itch, pain, sleep, fatigue, work impairment and overall QoL among",
    "entities": [
      {
        "text": "QoL",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "adult patients with moderate-to-severe AD in a real-world setting.",
    "entities": []
  },
  {
    "text": "METHODS AND ANALYSIS: This non-interventional, prospective, observational,",
    "entities": []
  },
  {
    "text": "real-world evidence study will involve approximately 150 sites across Europe and",
    "entities": [
      {
        "text": "approximately 150",
        "label": "CARDINAL"
      },
      {
        "text": "Europe",
        "label": "LOC"
      }
    ]
  },
  {
    "text": "approximately 1200 adults with moderate-to-severe AD treated with lebrikizumab",
    "entities": [
      {
        "text": "1200",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "for 2 years. The primary endpoint is patient well-being assessed by the 5-item",
    "entities": [
      {
        "text": "2 years",
        "label": "DATE"
      },
      {
        "text": "5",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "WHO Well-Being Index (WHO-5) questionnaire. Key secondary endpoints include",
    "entities": [
      {
        "text": "WHO-5",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "clinical effectiveness (Eczema Area and Severity Index and Investigator's Global",
    "entities": []
  },
  {
    "text": "Assessment Scale), disease symptomatology and control (Patient-Oriented Eczema",
    "entities": [
      {
        "text": "Assessment Scale",
        "label": "PERSON"
      },
      {
        "text": "Patient-Oriented Eczema",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Measure, 24-hour peak pruritus, skin pain, fatigue and sleep quality Numerical",
    "entities": [
      {
        "text": "Measure",
        "label": "WORK_OF_ART"
      },
      {
        "text": "24-hour",
        "label": "TIME"
      },
      {
        "text": "Numerical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Rating Scale, and safety and tolerability. Other validated endpoints will",
    "entities": []
  },
  {
    "text": "evaluate physician-reported and patient-reported QoL and treatment satisfaction",
    "entities": [
      {
        "text": "QoL",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(Dermatology Life Quality Index, Treatment Satisfaction Questionnaire-9),",
    "entities": []
  },
  {
    "text": "patients' work productivity and impairment (Work Productivity and Activity",
    "entities": [
      {
        "text": "Work Productivity",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Impairment (WPAI)-AD) and disease control (AD Control Tool). Novel experimental",
    "entities": [
      {
        "text": "WPAI)-AD",
        "label": "GPE"
      },
      {
        "text": "AD Control Tool",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "endpoints will also be evaluated with the aim to assess patients' relationship",
    "entities": []
  },
  {
    "text": "with their skin (SkinLove questionnaire), disease control (intensity and",
    "entities": []
  },
  {
    "text": "frequency of flares) and an Effectiveness Diary+\u00a9 (a brief monthly survey on a",
    "entities": [
      {
        "text": "an Effectiveness Diary+",
        "label": "ORG"
      },
      {
        "text": "monthly",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "voluntary basis with the aim to assess the long-term impact of lebrikizumab on",
    "entities": []
  },
  {
    "text": "three fundamental aspects of the patients' life: the well-being (WHO-5), the",
    "entities": [
      {
        "text": "three",
        "label": "CARDINAL"
      },
      {
        "text": "WHO-5",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "itch intensity (24 hours peak pruritus) and the frequency and intensity of",
    "entities": [
      {
        "text": "24 hours",
        "label": "TIME"
      }
    ]
  },
  {
    "text": "flares). Statistical analyses will be descriptive and explorative and based on",
    "entities": []
  },
  {
    "text": "observed cases. Missing data imputation may be used to handle missing data for",
    "entities": []
  },
  {
    "text": "primary endpoints and secondary effectiveness endpoints.",
    "entities": []
  },
  {
    "text": "ETHICS AND DISSEMINATION: This study will be conducted according to the",
    "entities": [
      {
        "text": "ETHICS",
        "label": "ORG"
      },
      {
        "text": "DISSEMINATION",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "protocol, which has ethics committee approval (Hamburg Ethic Committee in",
    "entities": [
      {
        "text": "Hamburg Ethic Committee",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Germany: 2024-101358-BO-ff), and all applicable laws and regulatory requirements",
    "entities": [
      {
        "text": "Germany",
        "label": "GPE"
      },
      {
        "text": "2024-101358-BO-ff",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "for each participating country. The results will be disseminated through",
    "entities": []
  },
  {
    "text": "scientific publications and congress presentations.",
    "entities": [
      {
        "text": "congress",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "PMID: 40645621 [Indexed for MEDLINE]",
    "entities": [
      {
        "text": "40645621",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Competing interests: Matthias Augustin has",
    "entities": [
      {
        "text": "Matthias Augustin",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "served as a consultant and paid speaker. Moreover, he has received research",
    "entities": []
  },
  {
    "text": "grants and honoraries for consulting. In addition, he has held scientific",
    "entities": []
  },
  {
    "text": "lectures, got travel expenses reimbursed, participated in clinical trials",
    "entities": []
  },
  {
    "text": "Ingelheim, Bristol Myers Squibb, Celgene, Centocor, Dermira, Eli Lilly,",
    "entities": [
      {
        "text": "Ingelheim",
        "label": "ORG"
      },
      {
        "text": "Bristol Myers Squibb",
        "label": "ORG"
      },
      {
        "text": "Celgene",
        "label": "PERSON"
      },
      {
        "text": "Centocor",
        "label": "ORG"
      },
      {
        "text": "Dermira",
        "label": "PERSON"
      },
      {
        "text": "Eli Lilly",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Trevi and UCB; Anthony Bewley has had ad hoc consultancy/trave/lecturing fees",
    "entities": [
      {
        "text": "UCB",
        "label": "ORG"
      },
      {
        "text": "Anthony Bewley",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "from Abbvie, Almirall, BMS, Galderma, Janssen, Lilly, Leo-Pharma, Novartis,",
    "entities": [
      {
        "text": "Almirall",
        "label": "PERSON"
      },
      {
        "text": "BMS",
        "label": "ORG"
      },
      {
        "text": "Galderma",
        "label": "NORP"
      },
      {
        "text": "Lilly",
        "label": "ORG"
      },
      {
        "text": "Leo-Pharma",
        "label": "ORG"
      },
      {
        "text": "Novartis",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Pfizer, Sanofi, UCB; Charlotte Br\u00fcggen has received grants from the Swiss",
    "entities": [
      {
        "text": "Pfizer",
        "label": "ORG"
      },
      {
        "text": "Sanofi",
        "label": "ORG"
      },
      {
        "text": "UCB",
        "label": "ORG"
      },
      {
        "text": "Charlotte Br\u00fcggen",
        "label": "PERSON"
      },
      {
        "text": "Swiss",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "National Science Foundation, Christine K\u00fchneCenter for Allergy Research and",
    "entities": [
      {
        "text": "National Science Foundation",
        "label": "ORG"
      },
      {
        "text": "Christine K\u00fchneCenter",
        "label": "PERSON"
      },
      {
        "text": "Allergy Research",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Education, Leo Foundation, LEO Pharmacy, and Freenovation, advisory board fees",
    "entities": [
      {
        "text": "Leo Foundation",
        "label": "ORG"
      },
      {
        "text": "LEO Pharmacy",
        "label": "ORG"
      },
      {
        "text": "Freenovation",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "from AstraZeneca, Almirall, LEO Pharma, lecture honorarium from Almirall and",
    "entities": [
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "Almirall",
        "label": "PERSON"
      },
      {
        "text": "LEO Pharma",
        "label": "ORG"
      },
      {
        "text": "Almirall",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "AstraZeneca, and patient education grant from AstraZeneca and GSK; Marjolein S",
    "entities": [
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "Marjolein S",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "de Bruin-Weller has been a consultant, advisory board member, and/or speaker",
    "entities": [
      {
        "text": "de Bruin-Weller",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "forAbbVie, Almirall, Amgen, Aslan, Eli Lilly, Galderma, Janssen, LeoPharma,",
    "entities": [
      {
        "text": "Almirall",
        "label": "PERSON"
      },
      {
        "text": "Amgen",
        "label": "ORG"
      },
      {
        "text": "Aslan",
        "label": "ORG"
      },
      {
        "text": "Eli Lilly",
        "label": "ORG"
      },
      {
        "text": "Galderma",
        "label": "NORP"
      },
      {
        "text": "Janssen",
        "label": "DATE"
      },
      {
        "text": "LeoPharma",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Pfizer, Regeneron, and Sanofi; Khaled Ezzedine is a consultant for AbbVie,",
    "entities": [
      {
        "text": "Pfizer",
        "label": "ORG"
      },
      {
        "text": "Regeneron",
        "label": "GPE"
      },
      {
        "text": "Sanofi",
        "label": "ORG"
      },
      {
        "text": "Khaled Ezzedine",
        "label": "PERSON"
      },
      {
        "text": "AbbVie",
        "label": "LAW"
      }
    ]
  },
  {
    "text": "Incyte, LaRoche-Posay, Pfizer, Pierre Fabre, Sanofi, Almirall, and Merck Sharp &",
    "entities": [
      {
        "text": "Incyte",
        "label": "ORG"
      },
      {
        "text": "LaRoche-Posay",
        "label": "ORG"
      },
      {
        "text": "Pfizer",
        "label": "PERSON"
      },
      {
        "text": "Pierre Fabre",
        "label": "PERSON"
      },
      {
        "text": "Almirall",
        "label": "PERSON"
      },
      {
        "text": "Merck Sharp &",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Dohme; Silvia M Ferrucci reports consultancy/advisory boards disease-relevant",
    "entities": [
      {
        "text": "Silvia M Ferrucci",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "honoraria from Amgen, Sanofi, Novartis, Lilly, Leo Pharma, Abbvie, Novartis and",
    "entities": [
      {
        "text": "Amgen",
        "label": "ORG"
      },
      {
        "text": "Sanofi",
        "label": "GPE"
      },
      {
        "text": "Novartis",
        "label": "ORG"
      },
      {
        "text": "Lilly",
        "label": "ORG"
      },
      {
        "text": "Leo Pharma",
        "label": "PERSON"
      },
      {
        "text": "Novartis",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Menarini; Spyridon Gkalpakiotis has served as a consultant, speaker, or",
    "entities": [
      {
        "text": "Menarini",
        "label": "GPE"
      },
      {
        "text": "Spyridon Gkalpakiotis",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Pharma, Nektar, Novartis, Pfizer, Sanofi and UCB; Pedro Herranz has received",
    "entities": [
      {
        "text": "Pharma",
        "label": "PERSON"
      },
      {
        "text": "Nektar",
        "label": "PERSON"
      },
      {
        "text": "Novartis",
        "label": "ORG"
      },
      {
        "text": "Pfizer",
        "label": "ORG"
      },
      {
        "text": "Sanofi",
        "label": "ORG"
      },
      {
        "text": "UCB",
        "label": "ORG"
      },
      {
        "text": "Pedro Herranz",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "grants and speaker's honoraria and/or has participated in advisory meetings and",
    "entities": [
      {
        "text": "honoraria and/or",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Roche, Sandoz, Sanofi Genzyme, Takeda and UCB; Emma K Johansson has served as",
    "entities": [
      {
        "text": "Roche",
        "label": "ORG"
      },
      {
        "text": "Sandoz",
        "label": "ORG"
      },
      {
        "text": "Sanofi Genzyme",
        "label": "ORG"
      },
      {
        "text": "UCB",
        "label": "ORG"
      },
      {
        "text": "Emma K Johansson",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "consultant and/or received speaker honoraria and/or been a been co-investigator",
    "entities": [
      {
        "text": "honoraria and/or",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "in clinical trials for AbbVie, ACO, Almirall, Amgen, the Swedish Asthma and",
    "entities": [
      {
        "text": "AbbVie",
        "label": "LAW"
      },
      {
        "text": "ACO",
        "label": "ORG"
      },
      {
        "text": "Almirall",
        "label": "PERSON"
      },
      {
        "text": "Amgen",
        "label": "ORG"
      },
      {
        "text": "Swedish",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "Allergy Foundation, Galenica, LEO Pharma, Lakartidningen, Novartis, Pfizer,",
    "entities": [
      {
        "text": "Allergy Foundation",
        "label": "ORG"
      },
      {
        "text": "Galenica",
        "label": "ORG"
      },
      {
        "text": "LEO Pharma, Lakartidningen",
        "label": "ORG"
      },
      {
        "text": "Novartis",
        "label": "PERSON"
      },
      {
        "text": "Pfizer",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Sanofi-Genzyme, Swedish National Board of Health and Welfare, and the Swedish",
    "entities": [
      {
        "text": "Sanofi-Genzyme",
        "label": "ORG"
      },
      {
        "text": "Swedish National Board of Health and Welfare",
        "label": "ORG"
      },
      {
        "text": "Swedish",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "Society for Dermatology and Venereology; Tom\u00e1\u0161 Kampe has served as consultant",
    "entities": [
      {
        "text": "Society for Dermatology and Venereology",
        "label": "ORG"
      },
      {
        "text": "Tom\u00e1\u0161 Kampe",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "and/or received speaker honoraria and/or been a been co-investigator in clinical",
    "entities": [
      {
        "text": "honoraria and/or",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "trials for Novartis, Lilly Slovakia, Amgen, Celgene, Pfizer, Sanofi Aventis, LEO",
    "entities": [
      {
        "text": "Novartis",
        "label": "ORG"
      },
      {
        "text": "Lilly Slovakia",
        "label": "ORG"
      },
      {
        "text": "Amgen",
        "label": "ORG"
      },
      {
        "text": "Celgene",
        "label": "PERSON"
      },
      {
        "text": "Pfizer",
        "label": "PERSON"
      },
      {
        "text": "Sanofi Aventis",
        "label": "PERSON"
      },
      {
        "text": "LEO",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Pharma, Merck, MSD, Johnson& Johnson and Almirall; Hilde Lapeere has served as",
    "entities": [
      {
        "text": "Pharma, Merck",
        "label": "ORG"
      },
      {
        "text": "MSD",
        "label": "ORG"
      },
      {
        "text": "Johnson& Johnson",
        "label": "ORG"
      },
      {
        "text": "Almirall",
        "label": "PERSON"
      },
      {
        "text": "Hilde Lapeere",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "consultant and/or lecturer for Sanofi, Eli Lilly, Celltrion, LEO Pharma,",
    "entities": [
      {
        "text": "Sanofi",
        "label": "ORG"
      },
      {
        "text": "Eli Lilly",
        "label": "ORG"
      },
      {
        "text": "Celltrion",
        "label": "ORG"
      },
      {
        "text": "LEO Pharma",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Galderma, Almirall, Pfizer and/or has participated in clinical trials for",
    "entities": [
      {
        "text": "Galderma",
        "label": "NORP"
      },
      {
        "text": "Almirall",
        "label": "PERSON"
      },
      {
        "text": "Pfizer and/or",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "honoraria as a consultant and/or advisory board member and/or speaker from",
    "entities": []
  },
  {
    "text": "AbbVie, Almirall, Celgene, Eli Lilly, Galderma, Menlo Therapeutics, Novartis,",
    "entities": [
      {
        "text": "AbbVie",
        "label": "ORG"
      },
      {
        "text": "Almirall",
        "label": "PERSON"
      },
      {
        "text": "Celgene, Eli Lilly",
        "label": "ORG"
      },
      {
        "text": "Galderma",
        "label": "NORP"
      },
      {
        "text": "Menlo Therapeutics",
        "label": "GPE"
      },
      {
        "text": "Novartis",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Pelpharma, Pfizer, Regeneron, Sanofi, Trevi Therapeutics, Vifor Pharma; has",
    "entities": [
      {
        "text": "Pelpharma",
        "label": "GPE"
      },
      {
        "text": "Pfizer",
        "label": "GPE"
      },
      {
        "text": "Regeneron",
        "label": "GPE"
      },
      {
        "text": "Sanofi",
        "label": "GPE"
      },
      {
        "text": "Vifor Pharma",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "received support for participating in scientific meetings from AbbVie, Almirall,",
    "entities": [
      {
        "text": "AbbVie",
        "label": "ORG"
      },
      {
        "text": "Almirall",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Pelpharma, Pfizer, Sanofi; and has served as Principal investigator in clinical",
    "entities": [
      {
        "text": "Pelpharma",
        "label": "GPE"
      },
      {
        "text": "Pfizer",
        "label": "PERSON"
      },
      {
        "text": "Sanofi",
        "label": "ORG"
      },
      {
        "text": "Principal",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "studies for Almirall, Amgen, DS Biopharma, Eli Lilly, Galderma, Incyte, Kiniksa,",
    "entities": [
      {
        "text": "Almirall",
        "label": "ORG"
      },
      {
        "text": "Amgen",
        "label": "ORG"
      },
      {
        "text": "Biopharma",
        "label": "PERSON"
      },
      {
        "text": "Eli Lilly",
        "label": "ORG"
      },
      {
        "text": "Galderma",
        "label": "NORP"
      },
      {
        "text": "Incyte",
        "label": "PERSON"
      },
      {
        "text": "Kiniksa",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Menlo Therapeutics, Leo Pharma, Pfizer, Trevi Therapeutics; Eva Maria Rehbinder",
    "entities": [
      {
        "text": "Menlo Therapeutics",
        "label": "PERSON"
      },
      {
        "text": "Leo Pharma",
        "label": "PERSON"
      },
      {
        "text": "Pfizer",
        "label": "PERSON"
      },
      {
        "text": "Eva Maria Rehbinder",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "has received support for participating in scientific meetings from Almirall, and",
    "entities": [
      {
        "text": "Almirall",
        "label": "WORK_OF_ART"
      }
    ]
  },
  {
    "text": "received honoraria for lectures from Sanofi Genzyme, The Norwegian psoriasis and",
    "entities": [
      {
        "text": "Sanofi Genzyme",
        "label": "ORG"
      },
      {
        "text": "Norwegian",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "eczema association and Abbvie; Jacek C Szepietowski has received consulting fees",
    "entities": [
      {
        "text": "Jacek C Szepietowski",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "or honoraria from Galderma, AbbVie, Almirall, Eli Lilly, Janssen, LEO Pharma,",
    "entities": [
      {
        "text": "Galderma",
        "label": "NORP"
      },
      {
        "text": "Almirall",
        "label": "PERSON"
      },
      {
        "text": "Eli Lilly",
        "label": "ORG"
      },
      {
        "text": "Janssen",
        "label": "GPE"
      },
      {
        "text": "LEO Pharma",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Novartis, PierreFabre, Pfzer, Sanof Genzyme, Trevi, and UCB; and has served as",
    "entities": [
      {
        "text": "Novartis",
        "label": "ORG"
      },
      {
        "text": "PierreFabre",
        "label": "ORG"
      },
      {
        "text": "Pfzer",
        "label": "PERSON"
      },
      {
        "text": "Sanof Genzyme",
        "label": "ORG"
      },
      {
        "text": "Trevi",
        "label": "PERSON"
      },
      {
        "text": "UCB",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Incyte, InfaRx, Janssen, Kliniksa, Kymab, Menlo Therapeutics, Merck, Novartis,",
    "entities": [
      {
        "text": "Incyte",
        "label": "ORG"
      },
      {
        "text": "InfaRx",
        "label": "LANGUAGE"
      },
      {
        "text": "Kliniksa",
        "label": "GPE"
      },
      {
        "text": "Kymab",
        "label": "GPE"
      },
      {
        "text": "Menlo Therapeutics",
        "label": "PERSON"
      },
      {
        "text": "Merck",
        "label": "ORG"
      },
      {
        "text": "Novartis",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Pfzer, Regeneron Pharmaceuti- cals, Trevi Therapeutics, and UCB Pharma; Tiago",
    "entities": [
      {
        "text": "Pfzer",
        "label": "PERSON"
      },
      {
        "text": "Regeneron",
        "label": "GPE"
      },
      {
        "text": "Trevi Therapeutics",
        "label": "WORK_OF_ART"
      },
      {
        "text": "UCB Pharma",
        "label": "NORP"
      },
      {
        "text": "Tiago",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Torres has received consultancy and/or speaker\u2019s honoraria from and/or",
    "entities": []
  },
  {
    "text": "participated in clinical trials sponsored by AbbVie, Almirall, Amgen, Arena",
    "entities": [
      {
        "text": "AbbVie",
        "label": "LAW"
      },
      {
        "text": "Almirall",
        "label": "PERSON"
      },
      {
        "text": "Amgen",
        "label": "ORG"
      },
      {
        "text": "Arena",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Celgene, Fresenius Kabi, Janssen, LEO Pharma, Eli Lilly, MSD, Mylan, Novartis,",
    "entities": [
      {
        "text": "Fresenius Kabi",
        "label": "PERSON"
      },
      {
        "text": "Janssen",
        "label": "GPE"
      },
      {
        "text": "LEO Pharma",
        "label": "ORG"
      },
      {
        "text": "Eli Lilly",
        "label": "ORG"
      },
      {
        "text": "MSD",
        "label": "ORG"
      },
      {
        "text": "Mylan",
        "label": "ORG"
      },
      {
        "text": "Novartis",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "has received honoraria from Novartis, AbbVie, Leo Pharma, Sanofi, GSK, Pierre",
    "entities": [
      {
        "text": "Novartis",
        "label": "ORG"
      },
      {
        "text": "AbbVie",
        "label": "ORG"
      },
      {
        "text": "Leo Pharma",
        "label": "PERSON"
      },
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "Pierre\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Fabre and Almirall, received research grants from Novartis, Sanofi and LEO",
    "entities": [
      {
        "text": "Almirall",
        "label": "PERSON"
      },
      {
        "text": "Novartis",
        "label": "GPE"
      },
      {
        "text": "Sanofi",
        "label": "GPE"
      },
      {
        "text": "LEO",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Pharma and worked as investigator for Novartis, AbbVie, Sanofi and Almirall;",
    "entities": [
      {
        "text": "Pharma",
        "label": "PERSON"
      },
      {
        "text": "Novartis",
        "label": "ORG"
      },
      {
        "text": "AbbVie",
        "label": "ORG"
      },
      {
        "text": "Sanofi",
        "label": "PRODUCT"
      },
      {
        "text": "Almirall",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Thomas Werfel has received support for consultancy, lectures, and other",
    "entities": [
      {
        "text": "Thomas Werfel",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "scientific activities from AbbVie, ALK Abello, Almirall, Astellas, Bencard,",
    "entities": [
      {
        "text": "AbbVie",
        "label": "ORG"
      },
      {
        "text": "ALK Abello",
        "label": "PERSON"
      },
      {
        "text": "Almirall",
        "label": "PERSON"
      },
      {
        "text": "Astellas",
        "label": "PERSON"
      },
      {
        "text": "Bencard",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Galderma, Janssen/JNJ, Leo Pharma, Leti, Lilly, Novartis, Pfizer,",
    "entities": [
      {
        "text": "Galderma",
        "label": "NORP"
      },
      {
        "text": "Leo Pharma",
        "label": "PERSON"
      },
      {
        "text": "Leti",
        "label": "PERSON"
      },
      {
        "text": "Lilly",
        "label": "ORG"
      },
      {
        "text": "Novartis",
        "label": "ORG"
      },
      {
        "text": "Pfizer",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Regeneron/Sanofi, Stallergen; Arnau Domenech is an employee of Almirall, Spain;",
    "entities": [
      {
        "text": "Regeneron/Sanofi",
        "label": "ORG"
      },
      {
        "text": "Stallergen",
        "label": "PERSON"
      },
      {
        "text": "Arnau Domenech",
        "label": "PERSON"
      },
      {
        "text": "Almirall",
        "label": "GPE"
      },
      {
        "text": "Spain",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Eric Massana is an employee of Almirall, Spain; Volker Koscielny is an employee",
    "entities": [
      {
        "text": "Eric Massana",
        "label": "PERSON"
      },
      {
        "text": "Almirall",
        "label": "GPE"
      },
      {
        "text": "Spain",
        "label": "GPE"
      },
      {
        "text": "Volker Koscielny",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of Almirall, Spain; Siva Narayanan is an employee of Avant Health LLC, and has",
    "entities": [
      {
        "text": "Almirall",
        "label": "GPE"
      },
      {
        "text": "Spain",
        "label": "GPE"
      },
      {
        "text": "Siva Narayanan",
        "label": "PERSON"
      },
      {
        "text": "Avant Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "served as a consultant for Almirall, Biogen, Johnson & Johnson, Progentech",
    "entities": [
      {
        "text": "Almirall",
        "label": "PERSON"
      },
      {
        "text": "Biogen",
        "label": "ORG"
      },
      {
        "text": "Johnson & Johnson",
        "label": "ORG"
      },
      {
        "text": "Progentech",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "diagnostics, Sarepta Therapeutics, SeaGen, and Takeda; Ismail Kasujee is an",
    "entities": [
      {
        "text": "Sarepta Therapeutics",
        "label": "ORG"
      },
      {
        "text": "SeaGen",
        "label": "PRODUCT"
      },
      {
        "text": "Takeda",
        "label": "PRODUCT"
      },
      {
        "text": "Ismail Kasujee",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "employee of Almirall, Spain; Jan Gutermuth has conducted clinical trials and/or",
    "entities": [
      {
        "text": "Almirall",
        "label": "GPE"
      },
      {
        "text": "Spain",
        "label": "GPE"
      },
      {
        "text": "Jan Gutermuth",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "has been an advisory board member and/or speaker for: AbbVie, Almirall, Eli",
    "entities": [
      {
        "text": "AbbVie",
        "label": "PERSON"
      },
      {
        "text": "Almirall",
        "label": "PERSON"
      },
      {
        "text": "Eli",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Lilly and Company, Galderma, Janssen, LEO Pharma, Pfizer, Regeneron, and Sanofi",
    "entities": [
      {
        "text": "Lilly",
        "label": "ORG"
      },
      {
        "text": "Galderma",
        "label": "NORP"
      },
      {
        "text": "Janssen",
        "label": "GPE"
      },
      {
        "text": "LEO Pharma",
        "label": "ORG"
      },
      {
        "text": "Pfizer",
        "label": "GPE"
      },
      {
        "text": "Regeneron",
        "label": "GPE"
      },
      {
        "text": "Sanofi",
        "label": "PRODUCT"
      }
    ]
  },
  {
    "text": "Disparities in Caregiver-reported Knowledge, Attitudes, Behaviors, and Clinical",
    "entities": [
      {
        "text": "Caregiver",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Guidance regarding Primary Prevention of Peanut Allergy.",
    "entities": []
  },
  {
    "text": "(1)Center for Food Allergy and Asthma Research, Institute for Public Health and",
    "entities": [
      {
        "text": "Food Allergy and Asthma Research",
        "label": "ORG"
      },
      {
        "text": "Institute for Public Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Medicine, Northwestern University Feinberg School of Medicine, 750 N Lake Shore",
    "entities": [
      {
        "text": "Northwestern University Feinberg School of Medicine",
        "label": "ORG"
      },
      {
        "text": "750",
        "label": "CARDINAL"
      },
      {
        "text": "N Lake Shore",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "Dr, 6th floor, #633, Chicago, IL 60611, USA. Electronic address:",
    "entities": [
      {
        "text": "Dr",
        "label": "GPE"
      },
      {
        "text": "6th",
        "label": "ORDINAL"
      },
      {
        "text": "633",
        "label": "MONEY"
      },
      {
        "text": "Chicago",
        "label": "GPE"
      },
      {
        "text": "IL 60611",
        "label": "ORG"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Northwestern University Feinberg School of Medicine, 420 E Superior St,",
    "entities": [
      {
        "text": "2)Northwestern University Feinberg School of Medicine",
        "label": "ORG"
      },
      {
        "text": "420",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Chicago, IL 60611, USA. Electronic address: alanna.stinson@nm.org.",
    "entities": [
      {
        "text": "Chicago",
        "label": "GPE"
      },
      {
        "text": "IL 60611",
        "label": "ORG"
      },
      {
        "text": "USA",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Center for Food Allergy and Asthma Research, Institute for Public Health and",
    "entities": [
      {
        "text": "Food Allergy and Asthma Research",
        "label": "ORG"
      },
      {
        "text": "Institute for Public Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(4)Center for Food Allergy and Asthma Research, Institute for Public Health and",
    "entities": [
      {
        "text": "Food Allergy and Asthma Research",
        "label": "ORG"
      },
      {
        "text": "Institute for Public Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(5)Center for Food Allergy and Asthma Research, Institute for Public Health and",
    "entities": [
      {
        "text": "Food Allergy and Asthma Research",
        "label": "ORG"
      },
      {
        "text": "Institute for Public Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(6)Center for Food Allergy and Asthma Research, Institute for Public Health and",
    "entities": [
      {
        "text": "6)Center",
        "label": "CARDINAL"
      },
      {
        "text": "Food Allergy and Asthma Research",
        "label": "ORG"
      },
      {
        "text": "Institute for Public Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "OBJECTIVE: Significant differences have been observed in the prevalence of",
    "entities": []
  },
  {
    "text": "peanut allergy across different US racial and ethnic groups. We aimed to",
    "entities": [
      {
        "text": "US",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "characterize current patterns of infant peanut introduction across racial,",
    "entities": []
  },
  {
    "text": "ethnic, and socioeconomic strata, and their clinical, behavioral and attitudinal",
    "entities": []
  },
  {
    "text": "METHODS: Surveys assessing parental knowledge, attitudes and infant feeding",
    "entities": []
  },
  {
    "text": "behavior were administered to a US population-based sample of 3062",
    "entities": [
      {
        "text": "US",
        "label": "GPE"
      },
      {
        "text": "3062",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "parents/caregivers of children aged 7-42 months. Complex survey-weighted test",
    "entities": [
      {
        "text": "7-42 months",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "statistics estimated differences across relevant racial/ethnic, household",
    "entities": []
  },
  {
    "text": "income, and caregiver educational attainment strata.",
    "entities": []
  },
  {
    "text": "RESULTS: Cumulative rates of peanut introduction in the first 11 months of age",
    "entities": [
      {
        "text": "the first 11 months of age\n",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "were significantly higher among White, non-Hispanic caregivers (F=7.7; p<.001),",
    "entities": [
      {
        "text": "non-Hispanic",
        "label": "NORP"
      },
      {
        "text": "F=7.7",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "caregivers with higher annual household incomes (F=5.6; p<0.001) and caregivers",
    "entities": []
  },
  {
    "text": "reporting higher educational attainment (F=2.5; p=0.002). Similar racial,",
    "entities": []
  },
  {
    "text": "ethnic, and socioeconomic differences emerged regarding perceived safety of",
    "entities": []
  },
  {
    "text": "peanut introduction during the first year, as well as the perceived",
    "entities": [
      {
        "text": "the first year",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "effectiveness of early dietary introduction for peanut allergy prevention.",
    "entities": []
  },
  {
    "text": "Caregivers reporting lower household incomes and educational attainment were",
    "entities": []
  },
  {
    "text": "less likely to think peanut introduction during the first year was safe or",
    "entities": [
      {
        "text": "the first year",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "effective in peanut allergy prevention than those reporting higher socioeconomic",
    "entities": []
  },
  {
    "text": "status. Similarly, caregivers of non-Hispanic Black children, those with lower",
    "entities": [
      {
        "text": "non-Hispanic",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "incomes, and those with lower educational attainment were less likely to report",
    "entities": []
  },
  {
    "text": "receiving timely guidance from their child's primary care provider regarding",
    "entities": []
  },
  {
    "text": "peanut allergy prevention.",
    "entities": []
  },
  {
    "text": "CONCLUSIONS: Differences in the timing of peanut introduction may contribute to",
    "entities": []
  },
  {
    "text": "observed racial, ethnic, and socioeconomic disparities in peanut allergy",
    "entities": []
  },
  {
    "text": "Copyright \u00a9 2025 Academic Pediatric Association. Published by Elsevier Inc. All",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "Academic Pediatric Association",
        "label": "ORG"
      },
      {
        "text": "Elsevier Inc.",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "rights reserved.",
    "entities": []
  },
  {
    "text": "declare no conflicts of interest. Dr. Warren reports research funding from",
    "entities": [
      {
        "text": "Warren",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "NIH/NIAID, FARE, and Genentech Inc. Ruchi Gupta received research grant support",
    "entities": [
      {
        "text": "NIH",
        "label": "ORG"
      },
      {
        "text": "NIAID",
        "label": "ORG"
      },
      {
        "text": "FARE",
        "label": "ORG"
      },
      {
        "text": "Genentech Inc.",
        "label": "ORG"
      },
      {
        "text": "Ruchi Gupta",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "from Allergy & Asthma Network, FARE, Genentech, Inc., Melchiorre Family",
    "entities": [
      {
        "text": "Allergy & Asthma Network",
        "label": "ORG"
      },
      {
        "text": "FARE",
        "label": "ORG"
      },
      {
        "text": "Genentech, Inc.",
        "label": "ORG"
      },
      {
        "text": "Melchiorre Family",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Foundation, National Confectioners Association, the National Institutes of",
    "entities": [
      {
        "text": "National Confectioners Association",
        "label": "ORG"
      },
      {
        "text": "the National Institutes of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Health, Stanford Sean N. Parker Center for Allergy Research, Sunshine Charitable",
    "entities": [
      {
        "text": "Stanford",
        "label": "ORG"
      },
      {
        "text": "Sunshine Charitable",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Foundation, Thermo Fisher Scientific, UnitedHealth Group, and the Walder",
    "entities": [
      {
        "text": "Thermo Fisher Scientific",
        "label": "PERSON"
      },
      {
        "text": "UnitedHealth Group",
        "label": "ORG"
      },
      {
        "text": "the Walder\n",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "Foundation; acted as medical consultant/adviser for FARE, Genentech, Inc., and",
    "entities": [
      {
        "text": "FARE",
        "label": "PERSON"
      },
      {
        "text": "Genentech, Inc.",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Novartis; and has ownership interest in YoBee Care, Inc.",
    "entities": [
      {
        "text": "YoBee Care, Inc.",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "95. J Allergy Clin Immunol Pract. 2025 Jul 9:S2213-2198(25)00629-4. doi:",
    "entities": [
      {
        "text": "95",
        "label": "CARDINAL"
      },
      {
        "text": "Allergy Clin Immunol Pract",
        "label": "PERSON"
      },
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "9",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Socioeconomic Disparities Explain Increased Exacerbations Among Black Patients",
    "entities": []
  },
  {
    "text": "with Severe Asthma.",
    "entities": []
  },
  {
    "text": "Baptist AP(1), Zhou W(2), Chipps BE(3), Carstens DD(4), Ambrose CS(5).",
    "entities": [
      {
        "text": "Baptist AP(1",
        "label": "PERSON"
      },
      {
        "text": "Zhou W(2",
        "label": "PERSON"
      },
      {
        "text": "Chipps BE(3",
        "label": "PERSON"
      },
      {
        "text": "Carstens DD(4",
        "label": "PERSON"
      },
      {
        "text": "Ambrose",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)Division of Allergy and Clinical Immunology, Henry Ford Health and Michigan",
    "entities": [
      {
        "text": "Allergy and Clinical Immunology",
        "label": "ORG"
      },
      {
        "text": "Henry Ford Health",
        "label": "PERSON"
      },
      {
        "text": "Michigan",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "State University, Detroit, MI, United States. Electronic address:",
    "entities": [
      {
        "text": "State University",
        "label": "ORG"
      },
      {
        "text": "Detroit",
        "label": "GPE"
      },
      {
        "text": "MI",
        "label": "GPE"
      },
      {
        "text": "United States",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)ClinChoice Inc., Fort Washington, PA, United States. Electronic address:",
    "entities": [
      {
        "text": "2)ClinChoice Inc.",
        "label": "MONEY"
      },
      {
        "text": "Fort Washington",
        "label": "GPE"
      },
      {
        "text": "PA",
        "label": "GPE"
      },
      {
        "text": "United States",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Capital Allergy & Respiratory Disease Center, Sacramento, CA, United States.",
    "entities": [
      {
        "text": "Allergy & Respiratory Disease Center",
        "label": "ORG"
      },
      {
        "text": "Sacramento",
        "label": "GPE"
      },
      {
        "text": "CA",
        "label": "GPE"
      },
      {
        "text": "United States",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, United States.",
    "entities": [
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "Wilmington",
        "label": "GPE"
      },
      {
        "text": "DE",
        "label": "GPE"
      },
      {
        "text": "United States",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, United States.",
    "entities": [
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "Gaithersburg",
        "label": "GPE"
      },
      {
        "text": "MD",
        "label": "GPE"
      },
      {
        "text": "United States",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "BACKGROUND: In the United States, Black patients with asthma experience higher",
    "entities": [
      {
        "text": "the United States",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "exacerbation rates compared with non-Black patients.",
    "entities": [
      {
        "text": "non-Black",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "OBJECTIVE: To identify factors that might explain the exacerbation rate",
    "entities": []
  },
  {
    "text": "association with race in a cohort of patients with severe asthma (SA).",
    "entities": [
      {
        "text": "SA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "METHODS: CHRONICLE was an observational study of US adults with SA treated by",
    "entities": [
      {
        "text": "US",
        "label": "GPE"
      },
      {
        "text": "SA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "allergists/immunologists or pulmonologists. The analysis population was patients",
    "entities": []
  },
  {
    "text": "not receiving biologic treatment. Propensity score (PS) methods were used to",
    "entities": [
      {
        "text": "PS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "identify factors associated with Black race. Non-Black-non-Hispanic or Latino",
    "entities": [
      {
        "text": "Non-Black-non-Hispanic",
        "label": "ORG"
      },
      {
        "text": "Latino",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "patients (non-Black) were the control group. A generalized linear model (GLM)",
    "entities": [
      {
        "text": "GLM",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "assessed the association between Black race and exacerbation rate, adjusted for",
    "entities": []
  },
  {
    "text": "the PS.",
    "entities": [
      {
        "text": "PS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "RESULTS: Between February 2018 and July 2022, 180 Black and 574 non-Black",
    "entities": [
      {
        "text": "Between February 2018",
        "label": "DATE"
      },
      {
        "text": "July 2022",
        "label": "DATE"
      },
      {
        "text": "180",
        "label": "CARDINAL"
      },
      {
        "text": "574",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "patients were eligible for PS analysis. Socioeconomic status was the strongest",
    "entities": [
      {
        "text": "PS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "discriminator of race (C statistic of 0.75), followed by environment (0.65),",
    "entities": [
      {
        "text": "0.75",
        "label": "CARDINAL"
      },
      {
        "text": "0.65",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "demographics (0.64), smoking status (0.55), and comorbidities (0.55). Before",
    "entities": [
      {
        "text": "0.64",
        "label": "CARDINAL"
      },
      {
        "text": "0.55",
        "label": "CARDINAL"
      },
      {
        "text": "0.55",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "adjusting for PS, the GLM showed a 1.28-fold higher exacerbation rate among",
    "entities": [
      {
        "text": "PS",
        "label": "ORG"
      },
      {
        "text": "GLM",
        "label": "ORG"
      },
      {
        "text": "1.28-fold",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Black patients compared with non-Black patients (RR [rate ratio] 1.28, 95% CI",
    "entities": [
      {
        "text": "non-Black",
        "label": "ORG"
      },
      {
        "text": "1.28",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "1.01, 1.62; P=0.039). In the PS-adjusted GLM, Black race was no longer",
    "entities": [
      {
        "text": "1.01",
        "label": "CARDINAL"
      },
      {
        "text": "1.62",
        "label": "CARDINAL"
      },
      {
        "text": "PS",
        "label": "ORG"
      },
      {
        "text": "GLM",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "associated with exacerbation rate (RR: 0.87, 95% CI 0.56, 1.35; P=0.522).",
    "entities": [
      {
        "text": "0.87",
        "label": "CARDINAL"
      },
      {
        "text": "95%",
        "label": "PERCENT"
      },
      {
        "text": "CI",
        "label": "ORG"
      },
      {
        "text": "0.56",
        "label": "MONEY"
      },
      {
        "text": "1.35",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Results were similar for asthma-related emergency department and hospitalization",
    "entities": []
  },
  {
    "text": "CONCLUSION: Higher exacerbation rates in Black patients with SA may be explained",
    "entities": [
      {
        "text": "Black",
        "label": "LOC"
      },
      {
        "text": "SA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "by factors associated with Black race, such as socioeconomic status. Addressing",
    "entities": []
  },
  {
    "text": "socioeconomic disparities and social determinants of health may help reduce the",
    "entities": []
  },
  {
    "text": "exacerbation risk difference observed between Black and non-Black patients with",
    "entities": []
  },
  {
    "text": "GOV IDENTIFIER: NCT03373045.",
    "entities": [
      {
        "text": "GOV",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "96. Respir Med. 2025 Jul 9:108224. doi: 10.1016/j.rmed.2025.108224. Online ahead",
    "entities": [
      {
        "text": "96",
        "label": "CARDINAL"
      },
      {
        "text": "Respir Med",
        "label": "PERSON"
      },
      {
        "text": "10.1016",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Real-world use of beclometasone dipropionate and formoterol fumarate NEXThaler\u00ae",
    "entities": [
      {
        "text": "NEXThaler",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "and asthma control among adult asthmatic patients in Europe: The results of the",
    "entities": [
      {
        "text": "Europe",
        "label": "LOC"
      }
    ]
  },
  {
    "text": "NEWTON Study.",
    "entities": [
      {
        "text": "NEWTON Study",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "A(6), Ingrassia E(7), Piraino A(8), Caruso C(9); NEWTON study group.",
    "entities": [
      {
        "text": "Ingrassia",
        "label": "PERSON"
      },
      {
        "text": "Piraino A(8",
        "label": "PERSON"
      },
      {
        "text": "Caruso C(9",
        "label": "PERSON"
      },
      {
        "text": "NEWTON",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Collaborators: Mucsi J, J\u00e4ger AG, La\u00dfmann H, Ricci A, Xanthopoulos A, Maurer C,",
    "entities": [
      {
        "text": "J\u00e4ger AG",
        "label": "ORG"
      },
      {
        "text": "La\u00dfmann H",
        "label": "ORG"
      },
      {
        "text": "Ricci A",
        "label": "PERSON"
      },
      {
        "text": "Xanthopoulos A",
        "label": "PERSON"
      },
      {
        "text": "Maurer C",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Italy. Electronic address: fulvio.braido@unige.it.",
    "entities": [
      {
        "text": "Italy",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Insaf Respiratory Research Institute, Taunusstein, Germany.",
    "entities": [
      {
        "text": "Respiratory Research Institute",
        "label": "ORG"
      },
      {
        "text": "Taunusstein",
        "label": "GPE"
      },
      {
        "text": "Germany",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Department of Neumology, University Hospital La Princesa, Madrid, Spain.",
    "entities": [
      {
        "text": "Neumology, University Hospital La Princesa",
        "label": "ORG"
      },
      {
        "text": "Madrid",
        "label": "GPE"
      },
      {
        "text": "Spain",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Department of Respiratory and Sleep Medicine, Cochin Hospital, Universit\u00e9",
    "entities": [
      {
        "text": "Respiratory and Sleep Medicine",
        "label": "ORG"
      },
      {
        "text": "Cochin Hospital",
        "label": "ORG"
      },
      {
        "text": "Universit\u00e9\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(5)Department of Pulmonology, Semmelweis University, Budapest, Hungary.",
    "entities": [
      {
        "text": "5)Department",
        "label": "CARDINAL"
      },
      {
        "text": "Pulmonology, Semmelweis University",
        "label": "ORG"
      },
      {
        "text": "Budapest",
        "label": "GPE"
      },
      {
        "text": "Hungary",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)\"Grigore T. Popa\" University of Medicine and Pharmacy, Iasi, Romania; Clinic",
    "entities": [
      {
        "text": "6)\"Grigore",
        "label": "CARDINAL"
      },
      {
        "text": "University of Medicine and Pharmacy",
        "label": "ORG"
      },
      {
        "text": "Iasi",
        "label": "GPE"
      },
      {
        "text": "Romania",
        "label": "GPE"
      },
      {
        "text": "Clinic\n",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "Hospital of Pulmonary Diseases, Iasi, Romania.",
    "entities": [
      {
        "text": "Iasi",
        "label": "GPE"
      },
      {
        "text": "Romania",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(7)Chiesi Italia S.p.A., Parma, Italy.",
    "entities": [
      {
        "text": "Italia S.p.A.",
        "label": "ORG"
      },
      {
        "text": "Parma",
        "label": "GPE"
      },
      {
        "text": "Italy",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(8)Chiesi Farmaceutici S.p.A., Global Medical Affairs - AIR Parma, Italy.",
    "entities": [
      {
        "text": "Farmaceutici S.p.A.",
        "label": "ORG"
      },
      {
        "text": "Global Medical Affairs - AIR Parma",
        "label": "ORG"
      },
      {
        "text": "Italy",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "IRCCS, Catholic University of Sacre Heart, Rome, Italy.",
    "entities": [
      {
        "text": "Catholic University of Sacre Heart",
        "label": "ORG"
      },
      {
        "text": "Rome",
        "label": "GPE"
      },
      {
        "text": "Italy",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "PURPOSE: The NEWTON study aims to describe clinical characteristics and",
    "entities": [
      {
        "text": "PURPOSE",
        "label": "ORG"
      },
      {
        "text": "NEWTON",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "evolution of asthma control of adult asthmatic patients treated with extrafine",
    "entities": []
  },
  {
    "text": "beclometasone dipropionate and formoterol fumarate (BDP/FF) NEXThaler\u00ae 100/6 \u03bcg.",
    "entities": [
      {
        "text": "BDP/FF",
        "label": "ORG"
      },
      {
        "text": "NEXThaler",
        "label": "PERSON"
      },
      {
        "text": "100/6",
        "label": "TIME"
      }
    ]
  },
  {
    "text": "SUBJECTS AND METHODS: NEWTON (NCT05168995) is a European multinational,",
    "entities": [
      {
        "text": "NEWTON",
        "label": "ORG"
      },
      {
        "text": "European",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "multicentre, observational, prospective cohort study that included adults with",
    "entities": []
  },
  {
    "text": "uncontrolled or poorly controlled asthma, starting BDP/FF NEXThaler\u00ae 100/6 \u03bcg",
    "entities": [
      {
        "text": "BDP",
        "label": "ORG"
      },
      {
        "text": "NEXThaler",
        "label": "PERSON"
      },
      {
        "text": "100/6",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "treatment within 14 days of enrolment and with no use of extrafine formulations",
    "entities": [
      {
        "text": "14 days",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "in the previous 6 months. Improvement of asthma control, lung function, quality",
    "entities": [
      {
        "text": "the previous 6 months",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "of life (QoL), treatment adherence, and satisfaction with the device were",
    "entities": [
      {
        "text": "QoL",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "assessed after 3 and 6 months from the enrolment visit. In addition, safety",
    "entities": [
      {
        "text": "3 and 6 months",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "events were monitored.",
    "entities": []
  },
  {
    "text": "RESULTS: 620 subjects were enrolled in the study. 423 completed the ACQ-5",
    "entities": [
      {
        "text": "620",
        "label": "CARDINAL"
      },
      {
        "text": "423",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "questionnaire at enrolment and at least once during the following 6 months.",
    "entities": [
      {
        "text": "6 months",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "69.3% of patients were initiated on maintenance and reliever treatment. At",
    "entities": [
      {
        "text": "69.3%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "baseline, the median ACQ-5 score was 2.0. After 6 months the median ACQ-5 score",
    "entities": [
      {
        "text": "2.0",
        "label": "CARDINAL"
      },
      {
        "text": "6 months",
        "label": "DATE"
      },
      {
        "text": "ACQ-5",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "had decreased significantly to 0.6 (p<0.0001). Similarly, after 6 months 66.1%",
    "entities": [
      {
        "text": "0.6",
        "label": "CARDINAL"
      },
      {
        "text": "6 months",
        "label": "DATE"
      },
      {
        "text": "66.1%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "of patients showed improved asthma control. The proportion of subjects with",
    "entities": []
  },
  {
    "text": "poorly controlled asthma fell from 65.1% to 17.5%. These improvements were",
    "entities": [
      {
        "text": "65.1%",
        "label": "PERCENT"
      },
      {
        "text": "17.5%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "consistent with the 3-month follow-up results and improved lung function, QoL,",
    "entities": [
      {
        "text": "3-month",
        "label": "DATE"
      },
      {
        "text": "QoL",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "treatment adherence and device satisfaction. No new safety concerns were",
    "entities": []
  },
  {
    "text": "reported.",
    "entities": []
  },
  {
    "text": "CONCLUSION: Results of the NEWTON study confirm the effectiveness and safety of",
    "entities": [
      {
        "text": "NEWTON",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "the extrafine fixed combination of BDP/FF NEXThaler\u00ae 100/6 \u03bcg in adults with",
    "entities": [
      {
        "text": "BDP",
        "label": "ORG"
      },
      {
        "text": "NEXThaler",
        "label": "PERSON"
      },
      {
        "text": "100/6",
        "label": "TIME"
      }
    ]
  },
  {
    "text": "uncontrolled asthma in a real-world setting.",
    "entities": []
  },
  {
    "text": "considered as potential competing interests:Alessio Piraino reports article",
    "entities": [
      {
        "text": "Alessio Piraino",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "publishing charges and writing assistance were provided by Chiesi Italia S.p.A.",
    "entities": [
      {
        "text": "Chiesi Italia S.p.A.\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Fulvio Braido reports financial support was provided by Chiesi Farmaceutici SpA.",
    "entities": [
      {
        "text": "Fulvio Braido",
        "label": "PERSON"
      },
      {
        "text": "Chiesi Farmaceutici SpA.\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Carolina Cisneros Serrano reports financial support was provided by Chiesi",
    "entities": [
      {
        "text": "Carolina Cisneros Serrano",
        "label": "PERSON"
      },
      {
        "text": "Chiesi",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Espa\u00f1a SA. Fulvio Braido reports a relationship with GSK that includes: board",
    "entities": [
      {
        "text": "Espa\u00f1a SA",
        "label": "PERSON"
      },
      {
        "text": "Fulvio Braido",
        "label": "PERSON"
      },
      {
        "text": "GSK",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "membership and speaking and lecture fees. Fulvio Braido reports a relationship",
    "entities": [
      {
        "text": "Fulvio Braido",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "with Chiesi that includes: board membership and speaking and lecture fees.",
    "entities": [
      {
        "text": "Chiesi",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Fulvio Braido reports a relationship with Menarini group that includes: board",
    "entities": [
      {
        "text": "Fulvio Braido",
        "label": "PERSON"
      },
      {
        "text": "Menarini",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "with Astra Zeneca that includes: board membership and speaking and lecture fees.",
    "entities": [
      {
        "text": "Astra Zeneca",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Fulvio Braido reports a relationship with Sanofi that includes: board membership",
    "entities": [
      {
        "text": "Fulvio Braido",
        "label": "PERSON"
      },
      {
        "text": "Sanofi",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and speaking and lecture fees. Fulvio Braido reports a relationship with",
    "entities": [
      {
        "text": "Fulvio Braido",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Regeneron that includes: board membership and speaking and lecture fees.",
    "entities": [
      {
        "text": "Regeneron",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Kai-Michael Beeh reports a relationship with Astra Zeneca that includes:",
    "entities": [
      {
        "text": "Kai-Michael Beeh",
        "label": "PERSON"
      },
      {
        "text": "Astra Zeneca",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "consulting or advisory, speaking and lecture fees, and travel reimbursement.",
    "entities": []
  },
  {
    "text": "Kai-Michael Beeh reports a relationship with Chiesi Farmaceutici SpA that",
    "entities": [
      {
        "text": "Kai-Michael Beeh",
        "label": "PERSON"
      },
      {
        "text": "Chiesi Farmaceutici",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "includes: consulting or advisory, speaking and lecture fees, and travel",
    "entities": []
  },
  {
    "text": "reimbursement. Kai-Michael Beeh reports a relationship with Bosch Healthcare",
    "entities": [
      {
        "text": "Kai-Michael Beeh",
        "label": "PERSON"
      },
      {
        "text": "Bosch Healthcare",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Solutions GmbH that includes: consulting or advisory, speaking and lecture fees,",
    "entities": []
  },
  {
    "text": "and travel reimbursement. Kai-Michael Beeh reports a relationship with",
    "entities": [
      {
        "text": "Kai-Michael Beeh",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Berlin-Chemie AG that includes: consulting or advisory, speaking and lecture",
    "entities": [
      {
        "text": "Berlin-Chemie AG",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "fees, and travel reimbursement. Kai-Michael Beeh reports a relationship with",
    "entities": [
      {
        "text": "Kai-Michael Beeh",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Sanofi-Aventis Deutschland GmbH that includes: consulting or advisory, speaking",
    "entities": [
      {
        "text": "Sanofi-Aventis Deutschland GmbH",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and lecture fees, and travel reimbursement. Kai-Michael Beeh reports a",
    "entities": [
      {
        "text": "Kai-Michael Beeh",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "relationship with GlaxoSmithKline Inc that includes: consulting or advisory,",
    "entities": [
      {
        "text": "GlaxoSmithKline Inc",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "speaking and lecture fees, and travel reimbursement. Carolina Cisneros Serrano",
    "entities": [
      {
        "text": "Carolina Cisneros Serrano",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "reports a relationship with Sanofi SA that includes: consulting or advisory,",
    "entities": [
      {
        "text": "Sanofi SA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "funding grants, non-financial support, speaking and lecture fees, and travel",
    "entities": []
  },
  {
    "text": "reimbursement. Carolina Cisneros Serrano reports a relationship with",
    "entities": [
      {
        "text": "Carolina Cisneros Serrano",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "GlaxoSmithKline SpA that includes: consulting or advisory and speaking and",
    "entities": [
      {
        "text": "GlaxoSmithKline",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "lecture fees. Carolina Cisneros Serrano reports a relationship with AstraZeneca",
    "entities": [
      {
        "text": "Carolina Cisneros Serrano",
        "label": "PERSON"
      },
      {
        "text": "AstraZeneca",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "that includes: consulting or advisory, funding grants, speaking and lecture",
    "entities": []
  },
  {
    "text": "fees, and travel reimbursement. Anh Tuan Dinh-Xuan reports a relationship with",
    "entities": [
      {
        "text": "Anh Tuan Dinh-Xuan",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Boehringer Ingelheim that includes: speaking and lecture fees. Anh Tuan",
    "entities": [
      {
        "text": "Boehringer Ingelheim",
        "label": "ORG"
      },
      {
        "text": "Anh Tuan",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Dinh-Xuan reports a relationship with GSK that includes: speaking and lecture",
    "entities": [
      {
        "text": "Dinh-Xuan",
        "label": "ORG"
      },
      {
        "text": "GSK",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "fees. Anh Tuan Dinh-Xuan reports a relationship with Menarini that includes:",
    "entities": [
      {
        "text": "Anh Tuan Dinh-Xuan",
        "label": "ORG"
      },
      {
        "text": "Menarini",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "speaking and lecture fees. Anh Tuan Dinh-Xuan reports a relationship with Sanofi",
    "entities": [
      {
        "text": "Anh Tuan Dinh-Xuan",
        "label": "ORG"
      },
      {
        "text": "Sanofi",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "that includes: speaking and lecture fees. Eleonora Ingrassia reports a",
    "entities": [
      {
        "text": "Eleonora Ingrassia",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "relationship with Chiesi Italia that includes: employment. Alessio Piraino",
    "entities": [
      {
        "text": "Chiesi Italia",
        "label": "ORG"
      },
      {
        "text": "Alessio Piraino",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "reports a relationship with Chiesi Farmaceutici SpA that includes: employment.",
    "entities": [
      {
        "text": "Chiesi Farmaceutici",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Kai-Michael Beeh declares that, in the past five years, the institution has",
    "entities": [
      {
        "text": "Kai-Michael Beeh",
        "label": "PERSON"
      },
      {
        "text": "the past five years",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "received compensation for the conduct of clinical trials by the following",
    "entities": []
  },
  {
    "text": "corporations: AstraZeneca, Bosch Healthcare Solutions GmbH, Chiesi, GSK,",
    "entities": [
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "Bosch Healthcare Solutions GmbH",
        "label": "ORG"
      },
      {
        "text": "Chiesi",
        "label": "GPE"
      },
      {
        "text": "GSK",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Novartis, Sterna. If there are other authors, they declare that they have no",
    "entities": [
      {
        "text": "Novartis",
        "label": "ORG"
      },
      {
        "text": "Sterna",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "known competing financial interests or personal relationships that could have",
    "entities": []
  },
  {
    "text": "appeared to influence the work reported in this paper.",
    "entities": []
  },
  {
    "text": "10.1016/S2213-2600(25)00135-3. Online ahead of print.",
    "entities": [
      {
        "text": "10.1016",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Evaluation of the effect of multimorbidity on difficult-to-treat asthma using a",
    "entities": []
  },
  {
    "text": "novel score (MiDAS): a multinational study of asthma cohorts.",
    "entities": []
  },
  {
    "text": "Clark V(6), Gibson PG(7), Varkonyi-Sepp J(8), Ainsworth B(9), Hudson-Colby",
    "entities": [
      {
        "text": "Clark",
        "label": "PERSON"
      },
      {
        "text": "Gibson PG(7",
        "label": "PERSON"
      },
      {
        "text": "Varkonyi",
        "label": "NORP"
      },
      {
        "text": "Ainsworth",
        "label": "PERSON"
      },
      {
        "text": "Hudson-Colby",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "JJ(10), Lewis A(11), Eames C(12), Wei L(13), Fong WCG(14), Djukanovic R(2),",
    "entities": [
      {
        "text": "Lewis A(11",
        "label": "PERSON"
      },
      {
        "text": "Eames C(12",
        "label": "PERSON"
      },
      {
        "text": "Wei",
        "label": "PERSON"
      },
      {
        "text": "Fong",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Hromis S(15), Tay TR(16), Lugogo N(17), McDonald VM(6), Hew M(5), Haitchi",
    "entities": [
      {
        "text": "Hromis S(15",
        "label": "ORG"
      },
      {
        "text": "Tay TR(16",
        "label": "PERSON"
      },
      {
        "text": "Lugogo N(17",
        "label": "PERSON"
      },
      {
        "text": "McDonald VM(6",
        "label": "ORG"
      },
      {
        "text": "Hew",
        "label": "PERSON"
      },
      {
        "text": "Haitchi",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(1)School of Clinical and Experimental Sciences, Faculty of Medicine, University",
    "entities": [
      {
        "text": "Experimental Sciences",
        "label": "ORG"
      },
      {
        "text": "Faculty of Medicine, University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of Southampton, Southampton, UK; National Institute for Health and Care Research",
    "entities": [
      {
        "text": "Southampton",
        "label": "GPE"
      },
      {
        "text": "Southampton",
        "label": "GPE"
      },
      {
        "text": "UK",
        "label": "GPE"
      },
      {
        "text": "National Institute for Health and Care Research",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Southampton Biomedical Research Centre, University Hospital Southampton NHS",
    "entities": [
      {
        "text": "Southampton Biomedical Research Centre",
        "label": "ORG"
      },
      {
        "text": "University Hospital Southampton NHS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Foundation Trust, Southampton, UK; David Hide Asthma & Allergy Research Centre,",
    "entities": [
      {
        "text": "Foundation Trust",
        "label": "ORG"
      },
      {
        "text": "Southampton",
        "label": "GPE"
      },
      {
        "text": "UK",
        "label": "GPE"
      },
      {
        "text": "David Hide Asthma & Allergy Research Centre",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "St Mary's Hospital, Newport, Isle of Wight, UK; Respiratory Medicine Department,",
    "entities": [
      {
        "text": "St Mary's",
        "label": "PERSON"
      },
      {
        "text": "Newport",
        "label": "GPE"
      },
      {
        "text": "Isle of Wight",
        "label": "GPE"
      },
      {
        "text": "UK",
        "label": "GPE"
      },
      {
        "text": "Respiratory Medicine Department",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University Hospital Southampton NHS Foundation Trust, Southampton, UK.",
    "entities": [
      {
        "text": "University Hospital Southampton NHS Foundation Trust",
        "label": "ORG"
      },
      {
        "text": "Southampton",
        "label": "GPE"
      },
      {
        "text": "UK",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)School of Clinical and Experimental Sciences, Faculty of Medicine, University",
    "entities": [
      {
        "text": "Experimental Sciences",
        "label": "ORG"
      },
      {
        "text": "Faculty of Medicine, University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Foundation Trust, Southampton, UK; Respiratory Medicine Department, University",
    "entities": [
      {
        "text": "Foundation Trust",
        "label": "ORG"
      },
      {
        "text": "Southampton",
        "label": "GPE"
      },
      {
        "text": "UK",
        "label": "GPE"
      },
      {
        "text": "Respiratory Medicine Department",
        "label": "ORG"
      },
      {
        "text": "University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Hospital Southampton NHS Foundation Trust, Southampton, UK.",
    "entities": [
      {
        "text": "Hospital Southampton NHS Foundation Trust",
        "label": "ORG"
      },
      {
        "text": "Southampton",
        "label": "GPE"
      },
      {
        "text": "UK",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Acclarogen, St John's Innovation Centre, Cambridge, UK.",
    "entities": [
      {
        "text": "St John's",
        "label": "PERSON"
      },
      {
        "text": "Cambridge",
        "label": "GPE"
      },
      {
        "text": "UK",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)School of Clinical and Experimental Sciences, Faculty of Medicine, University",
    "entities": [
      {
        "text": "Clinical",
        "label": "GPE"
      },
      {
        "text": "Experimental Sciences",
        "label": "ORG"
      },
      {
        "text": "Faculty of Medicine, University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "of Southampton, Southampton, UK; School of Chemistry and Chemical Engineering,",
    "entities": [
      {
        "text": "Southampton",
        "label": "GPE"
      },
      {
        "text": "Southampton",
        "label": "GPE"
      },
      {
        "text": "UK",
        "label": "GPE"
      },
      {
        "text": "School of Chemistry",
        "label": "ORG"
      },
      {
        "text": "Chemical Engineering",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Faculty of Engineering and Physical Sciences, University of Southampton,",
    "entities": [
      {
        "text": "Faculty of Engineering and Physical Sciences",
        "label": "ORG"
      },
      {
        "text": "University of Southampton",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Southampton, UK.",
    "entities": [
      {
        "text": "Southampton",
        "label": "GPE"
      },
      {
        "text": "UK",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)Allergy, Asthma & Clinical Immunology, Alfred Hospital, Melbourne, VIC,",
    "entities": [
      {
        "text": "Asthma & Clinical Immunology",
        "label": "ORG"
      },
      {
        "text": "Alfred Hospital",
        "label": "ORG"
      },
      {
        "text": "Melbourne",
        "label": "GPE"
      },
      {
        "text": "VIC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Australia; Public Health and Preventive Medicine, Monash University, Melbourne,",
    "entities": [
      {
        "text": "Australia",
        "label": "GPE"
      },
      {
        "text": "Public Health and Preventive Medicine",
        "label": "ORG"
      },
      {
        "text": "Monash University",
        "label": "ORG"
      },
      {
        "text": "Melbourne",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)National Health and Medical Research Council Centre for Research Excellence",
    "entities": [
      {
        "text": "Health and Medical Research Council Centre for Research Excellence",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "in Severe Asthma, University of Newcastle, Newcastle, NSW, Australia; National",
    "entities": [
      {
        "text": "Severe Asthma, University of Newcastle",
        "label": "ORG"
      },
      {
        "text": "Newcastle",
        "label": "GPE"
      },
      {
        "text": "NSW",
        "label": "ORG"
      },
      {
        "text": "Australia",
        "label": "GPE"
      },
      {
        "text": "National",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Health and Medical Research Council Centre for Research Excellence in Treatable",
    "entities": [
      {
        "text": "Health and Medical Research Council Centre for Research Excellence",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Traits, Hunter Medical Research Institute Asthma and Breathing Research Program,",
    "entities": [
      {
        "text": "Hunter Medical Research Institute Asthma and Breathing Research Program",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Newcastle, NSW, Australia; School of Nursing and Midwifery, University of",
    "entities": [
      {
        "text": "Newcastle",
        "label": "GPE"
      },
      {
        "text": "NSW",
        "label": "ORG"
      },
      {
        "text": "Australia",
        "label": "GPE"
      },
      {
        "text": "School of Nursing and Midwifery, University of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Newcastle, Newcastle, NSW, Australia.",
    "entities": [
      {
        "text": "Newcastle",
        "label": "GPE"
      },
      {
        "text": "Newcastle",
        "label": "GPE"
      },
      {
        "text": "NSW",
        "label": "GPE"
      },
      {
        "text": "Australia",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(7)National Health and Medical Research Council Centre for Research Excellence",
    "entities": [
      {
        "text": "Health and Medical Research Council Centre for Research Excellence",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Newcastle, NSW, Australia; Department of Respiratory and Sleep Medicine, John",
    "entities": [
      {
        "text": "Newcastle",
        "label": "GPE"
      },
      {
        "text": "NSW",
        "label": "ORG"
      },
      {
        "text": "Australia",
        "label": "GPE"
      },
      {
        "text": "Department of Respiratory",
        "label": "ORG"
      },
      {
        "text": "Sleep Medicine",
        "label": "PERSON"
      },
      {
        "text": "John\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Hunter Hospital, Hunter Medical Research Institute, Newcastle, NSW, Australia.",
    "entities": [
      {
        "text": "Hunter Hospital",
        "label": "ORG"
      },
      {
        "text": "Hunter Medical Research Institute",
        "label": "ORG"
      },
      {
        "text": "Newcastle",
        "label": "GPE"
      },
      {
        "text": "NSW",
        "label": "GPE"
      },
      {
        "text": "Australia",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(8)National Institute for Health and Care Research Southampton Biomedical",
    "entities": [
      {
        "text": "Institute for Health and Care Research Southampton Biomedical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Research Centre, University Hospital Southampton NHS Foundation Trust,",
    "entities": [
      {
        "text": "Research Centre",
        "label": "ORG"
      },
      {
        "text": "University Hospital Southampton NHS Foundation Trust",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Southampton, UK; Clinical Health Psychology Department, University Hospital",
    "entities": [
      {
        "text": "Southampton",
        "label": "GPE"
      },
      {
        "text": "UK",
        "label": "GPE"
      },
      {
        "text": "Clinical Health Psychology Department",
        "label": "ORG"
      },
      {
        "text": "University Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Southampton NHS Foundation Trust, Southampton, UK.",
    "entities": [
      {
        "text": "Southampton NHS Foundation Trust",
        "label": "ORG"
      },
      {
        "text": "Southampton",
        "label": "GPE"
      },
      {
        "text": "UK",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(9)National Institute for Health and Care Research Southampton Biomedical",
    "entities": [
      {
        "text": "Institute for Health and Care Research Southampton Biomedical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Southampton, UK; School of Psychology, Faculty of Environmental and Life",
    "entities": [
      {
        "text": "Southampton",
        "label": "GPE"
      },
      {
        "text": "UK",
        "label": "GPE"
      },
      {
        "text": "School of Psychology, Faculty of Environmental and Life",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Sciences, University of Southampton, Southampton, UK.",
    "entities": [
      {
        "text": "University of Southampton",
        "label": "ORG"
      },
      {
        "text": "Southampton",
        "label": "GPE"
      },
      {
        "text": "UK",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(10)Physiotherapy Department, University Hospital Southampton NHS Foundation",
    "entities": [
      {
        "text": "University Hospital Southampton NHS Foundation",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Trust, Southampton, UK; School of Health Sciences, University of Southampton,",
    "entities": [
      {
        "text": "Southampton",
        "label": "GPE"
      },
      {
        "text": "UK",
        "label": "GPE"
      },
      {
        "text": "School of Health Sciences",
        "label": "ORG"
      },
      {
        "text": "University of Southampton",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(11)School of Health Sciences, University of Southampton, Southampton, UK.",
    "entities": [
      {
        "text": "Health Sciences",
        "label": "ORG"
      },
      {
        "text": "University of Southampton",
        "label": "ORG"
      },
      {
        "text": "Southampton",
        "label": "GPE"
      },
      {
        "text": "UK",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(12)Respiratory Medicine Department, University Hospital Southampton NHS",
    "entities": [
      {
        "text": "12)Respiratory Medicine Department",
        "label": "ORG"
      },
      {
        "text": "University Hospital Southampton NHS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Foundation Trust, Southampton, UK.",
    "entities": [
      {
        "text": "Foundation Trust",
        "label": "ORG"
      },
      {
        "text": "Southampton",
        "label": "GPE"
      },
      {
        "text": "UK",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(13)National Institute for Health and Care Research Southampton Biomedical",
    "entities": [
      {
        "text": "13)National Institute for Health and Care Research Southampton Biomedical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(14)School of Clinical and Experimental Sciences, Faculty of Medicine,",
    "entities": [
      {
        "text": "14)School",
        "label": "CARDINAL"
      },
      {
        "text": "Experimental Sciences",
        "label": "ORG"
      },
      {
        "text": "Faculty of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University of Southampton, Southampton, UK; School of Psychology, Faculty of",
    "entities": [
      {
        "text": "University of Southampton",
        "label": "ORG"
      },
      {
        "text": "Southampton",
        "label": "GPE"
      },
      {
        "text": "UK",
        "label": "GPE"
      },
      {
        "text": "School of Psychology, Faculty of\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Environmental and Life Sciences, University of Southampton, Southampton, UK.",
    "entities": [
      {
        "text": "Environmental and Life Sciences",
        "label": "ORG"
      },
      {
        "text": "University of Southampton",
        "label": "ORG"
      },
      {
        "text": "Southampton",
        "label": "GPE"
      },
      {
        "text": "UK",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(15)Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia;",
    "entities": [
      {
        "text": "15)Institute",
        "label": "CARDINAL"
      },
      {
        "text": "Vojvodina",
        "label": "GPE"
      },
      {
        "text": "Sremska Kamenica",
        "label": "GPE"
      },
      {
        "text": "Serbia",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.",
    "entities": [
      {
        "text": "Faculty of Medicine, University of Novi Sad",
        "label": "ORG"
      },
      {
        "text": "Serbia",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(16)Duke-NUS Medical School, Singapore; Department of Respiratory and Critical",
    "entities": [
      {
        "text": "Singapore",
        "label": "GPE"
      },
      {
        "text": "Department of Respiratory and Critical",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(17)Michigan Medicine Asthma Program, University of Michigan, Ann Arbor, MI,",
    "entities": [
      {
        "text": "17)Michigan",
        "label": "CARDINAL"
      },
      {
        "text": "Medicine Asthma Program",
        "label": "ORG"
      },
      {
        "text": "University of Michigan",
        "label": "ORG"
      },
      {
        "text": "Ann Arbor",
        "label": "GPE"
      },
      {
        "text": "MI",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(18)School of Clinical and Experimental Sciences, Faculty of Medicine,",
    "entities": [
      {
        "text": "18)School",
        "label": "CARDINAL"
      },
      {
        "text": "Experimental Sciences",
        "label": "ORG"
      },
      {
        "text": "Faculty of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University of Southampton, Southampton, UK; National Institute for Health and",
    "entities": [
      {
        "text": "University of Southampton",
        "label": "ORG"
      },
      {
        "text": "Southampton",
        "label": "GPE"
      },
      {
        "text": "UK",
        "label": "GPE"
      },
      {
        "text": "National Institute for Health",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Care Research Southampton Biomedical Research Centre, University Hospital",
    "entities": [
      {
        "text": "Care Research Southampton Biomedical Research Centre",
        "label": "ORG"
      },
      {
        "text": "University Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Southampton NHS Foundation Trust, Southampton, UK; Respiratory Medicine",
    "entities": [
      {
        "text": "Southampton NHS Foundation Trust",
        "label": "ORG"
      },
      {
        "text": "Southampton",
        "label": "GPE"
      },
      {
        "text": "UK",
        "label": "GPE"
      },
      {
        "text": "Respiratory Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Department, University Hospital Southampton NHS Foundation Trust, Southampton,",
    "entities": [
      {
        "text": "University Hospital Southampton NHS Foundation Trust",
        "label": "ORG"
      },
      {
        "text": "Southampton",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "UK; Institute for Life Sciences, University of Southampton, Southampton, UK.",
    "entities": [
      {
        "text": "UK",
        "label": "GPE"
      },
      {
        "text": "Institute for Life Sciences",
        "label": "ORG"
      },
      {
        "text": "University of Southampton",
        "label": "ORG"
      },
      {
        "text": "Southampton",
        "label": "GPE"
      },
      {
        "text": "UK",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "BACKGROUND: Multimorbidity (ie, co-existence of two or more health conditions)",
    "entities": [
      {
        "text": "two",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "is highly prevalent in patients with difficult-to-treat asthma. However, it",
    "entities": []
  },
  {
    "text": "remains unclear how multimorbidity correlates with disease severity and adverse",
    "entities": []
  },
  {
    "text": "health outcomes in these patients and which comorbidities are most important. We",
    "entities": []
  },
  {
    "text": "aimed to address this knowledge gap by developing a patient-centred, clinically",
    "entities": []
  },
  {
    "text": "descriptive multimorbidity score for difficult-to-treat asthma.",
    "entities": []
  },
  {
    "text": "METHODS: We used data from the UK-based Wessex Asthma Cohort of Difficult Asthma",
    "entities": [
      {
        "text": "UK",
        "label": "GPE"
      },
      {
        "text": "Wessex Asthma Cohort of Difficult Asthma",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(WATCH; n=500, data collected between April 22, 2015, and April 1, 2020) to",
    "entities": [
      {
        "text": "April 22, 2015",
        "label": "DATE"
      },
      {
        "text": "April 1, 2020",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "develop the Multimorbidity in Difficult Asthma Score (MiDAS). Initially, we",
    "entities": []
  },
  {
    "text": "created a modified Asthma Severity Scoring System (m-ASSESS) in WATCH. We then",
    "entities": [
      {
        "text": "Asthma Severity Scoring System",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "conducted univariate association analysis to test the association between the 13",
    "entities": [
      {
        "text": "13",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "commonest comorbidities and m-ASSESS in WATCH and used a branch-and-bound",
    "entities": [
      {
        "text": "WATCH",
        "label": "WORK_OF_ART"
      }
    ]
  },
  {
    "text": "approach to select the most relevant comorbidities for inclusion in MiDAS. We",
    "entities": [
      {
        "text": "MiDAS",
        "label": "LOC"
      }
    ]
  },
  {
    "text": "calculated MiDAS values for all patients with complete information in WATCH",
    "entities": [
      {
        "text": "WATCH",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(n=319) and assessed them for correlation with components of m-ASSESS,",
    "entities": []
  },
  {
    "text": "proinflammatory biomarkers, and St George's Respiratory Questionnaire (SGRQ)",
    "entities": [
      {
        "text": "St George's",
        "label": "PERSON"
      },
      {
        "text": "Respiratory Questionnaire",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "score, a quality-of-life measure. We also assessed the association of MiDAS with",
    "entities": [
      {
        "text": "MiDAS",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "multiple clinical outcomes in four international cohorts: two from Australia",
    "entities": [
      {
        "text": "four",
        "label": "CARDINAL"
      },
      {
        "text": "two",
        "label": "CARDINAL"
      },
      {
        "text": "Australia",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(n=236, data collected between June 14, 2014, and April 1, 2022; and n=140, Aug",
    "entities": [
      {
        "text": "June 14, 2014",
        "label": "DATE"
      },
      {
        "text": "April 1, 2022",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "6, 2012, to Oct 18, 2016), one from southeast Asia (n=151, March 21, 2017, to",
    "entities": [
      {
        "text": "6, 2012",
        "label": "DATE"
      },
      {
        "text": "Oct 18, 2016",
        "label": "DATE"
      },
      {
        "text": "one",
        "label": "CARDINAL"
      },
      {
        "text": "Asia",
        "label": "LOC"
      },
      {
        "text": "March 21, 2017",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "Jan 16, 2024), and one from the USA (n=100, July 9, 2021, to Dec 14, 2023).",
    "entities": [
      {
        "text": "Jan 16, 2024",
        "label": "DATE"
      },
      {
        "text": "USA",
        "label": "GPE"
      },
      {
        "text": "July 9, 2021",
        "label": "DATE"
      },
      {
        "text": "Dec 14, 2023",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "FINDINGS: We selected seven common comorbidities (ie, rhinitis,",
    "entities": [
      {
        "text": "seven",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "gastro-oesophageal reflux disease, breathing pattern disorder, obesity,",
    "entities": [
      {
        "text": "gastro",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "bronchiectasis, non-steroidal anti-inflammatory drug-exacerbated respiratory",
    "entities": []
  },
  {
    "text": "disease, and obstructive sleep apnoea) for inclusion in MiDAS on the basis of",
    "entities": [
      {
        "text": "MiDAS",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "the branch-and-bound analysis and combined them using multivariate linear",
    "entities": []
  },
  {
    "text": "regression to derive a MiDAS model associated with m-ASSESS in WATCH. The range",
    "entities": [
      {
        "text": "MiDAS",
        "label": "NORP"
      },
      {
        "text": "WATCH",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "of MiDAS scores was 9\u00b76-16\u00b72. In WATCH members, mean MiDAS value was 11\u00b797 (SD",
    "entities": [
      {
        "text": "MiDAS",
        "label": "ORG"
      },
      {
        "text": "9\u00b76-16\u00b72",
        "label": "DATE"
      },
      {
        "text": "MiDAS",
        "label": "PERSON"
      },
      {
        "text": "11\u00b797",
        "label": "DATE"
      }
    ]
  },
  {
    "text": "1\u00b721) and MiDAS was nominally correlated with m-ASSESS components of poor asthma",
    "entities": [
      {
        "text": "1\u00b721",
        "label": "CARDINAL"
      },
      {
        "text": "MiDAS",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "MiDAS was also correlated with worse total SGRQ score (r=0\u00b739 [95% 0\u00b728-0\u00b749],",
    "entities": [
      {
        "text": "95%",
        "label": "PERCENT"
      }
    ]
  },
  {
    "text": "p<0\u00b70001) and with the proinflammatory plasma cytokines interleukin (IL)-4",
    "entities": []
  },
  {
    "text": "leptin (r=0\u00b729 [0\u00b717-0\u00b740], p<0\u00b70001) in WATCH. MiDAS values across the four",
    "entities": [
      {
        "text": "leptin",
        "label": "PERSON"
      },
      {
        "text": "four",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "international cohorts were similar to those of WATCH (UK cohort), with mean",
    "entities": [
      {
        "text": "WATCH",
        "label": "ORG"
      },
      {
        "text": "UK",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "values of 12\u00b733 (SD 1\u00b747) and 12\u00b731 (1\u00b737) in the Australian cohorts, 11\u00b780",
    "entities": [
      {
        "text": "12\u00b733",
        "label": "CARDINAL"
      },
      {
        "text": "12\u00b731",
        "label": "CARDINAL"
      },
      {
        "text": "Australian",
        "label": "NORP"
      },
      {
        "text": "11\u00b780",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "(1\u00b720) in the USA cohort, and 11\u00b755 (1\u00b723) in the Singapore cohort. In these",
    "entities": [
      {
        "text": "USA",
        "label": "GPE"
      },
      {
        "text": "11\u00b755",
        "label": "DATE"
      },
      {
        "text": "1\u00b723",
        "label": "CARDINAL"
      },
      {
        "text": "Singapore",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "cohorts, MiDAS correlated with worse asthma control, worse quality of life,",
    "entities": [
      {
        "text": "MiDAS",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "anxiety, depression, and increased inflammation.",
    "entities": []
  },
  {
    "text": "INTERPRETATION: MiDAS highlights the co-occurrence of multimorbidity with the",
    "entities": []
  },
  {
    "text": "worst outcomes in difficult-to-treat asthma. These findings strongly indicate",
    "entities": []
  },
  {
    "text": "that an airway-centric approach is inadequate and that holistic and",
    "entities": []
  },
  {
    "text": "multidisciplinary care is imperative. This clinical score could help clinicians",
    "entities": []
  },
  {
    "text": "to identify patients most at risk from their multimorbidity.",
    "entities": []
  },
  {
    "text": "FUNDING: UK National Institute for Health and Care Research, Australian National",
    "entities": [
      {
        "text": "UK National Institute for Health and Care Research",
        "label": "ORG"
      },
      {
        "text": "Australian National",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Health and Medical Research Council, Hunter Medical Research Institute,",
    "entities": [
      {
        "text": "Health and Medical Research Council",
        "label": "ORG"
      },
      {
        "text": "Hunter Medical Research Institute",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "University of Newcastle (Australia), and John Hunter Hospital Charitable Trust.",
    "entities": [
      {
        "text": "University of Newcastle",
        "label": "ORG"
      },
      {
        "text": "Australia",
        "label": "GPE"
      },
      {
        "text": "John Hunter Hospital Charitable Trust",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All",
    "entities": [
      {
        "text": "CC",
        "label": "ORG"
      },
      {
        "text": "4.0",
        "label": "CARDINAL"
      },
      {
        "text": "Elsevier Ltd",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: Declaration of interests RJK co-holds a methods",
    "entities": [
      {
        "text": "RJK",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "patent outside the submitted work on the cellular profiles of tissue resident",
    "entities": []
  },
  {
    "text": "memory T-cells and their use in asthma. BA is a member of the UK Taskforce for",
    "entities": [
      {
        "text": "BA",
        "label": "ORG"
      },
      {
        "text": "the UK Taskforce",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Lung Health, has received honoraria for educational talks from AstraZeneca, and",
    "entities": [
      {
        "text": "Lung Health",
        "label": "PERSON"
      },
      {
        "text": "AstraZeneca",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "sits on advisory boards for the Medito Foundation and earGym (all unrelated to",
    "entities": [
      {
        "text": "the Medito Foundation",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "this work). PGG reports personal fees from AstraZeneca, GSK, and Novartis and",
    "entities": [
      {
        "text": "PGG",
        "label": "ORG"
      },
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "Novartis",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "grants from AstraZeneca and GSK, outside the submitted work. VMM reports grants",
    "entities": [
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "VMM",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "from GSK outside the submitted work, and advisory board and speaker fees from",
    "entities": [
      {
        "text": "GSK",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "GSK, Menarini, and Boehringer-Ingelheim outside the submitted work. VC reports",
    "entities": [
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "Menarini",
        "label": "PERSON"
      },
      {
        "text": "Boehringer-Ingelheim",
        "label": "ORG"
      },
      {
        "text": "VC",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "speakers fees from AstraZeneca, unrelated to the conduct of this study. MH has",
    "entities": [
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "MH",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "received grants and personal fees outside the submitted work from GSK,",
    "entities": [
      {
        "text": "GSK",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "AstraZeneca, Sanofi, Novartis, Teva, and Chiesi, all paid to his employer Alfred",
    "entities": [
      {
        "text": "AstraZeneca, Sanofi",
        "label": "ORG"
      },
      {
        "text": "Novartis",
        "label": "PERSON"
      },
      {
        "text": "Teva",
        "label": "GPE"
      },
      {
        "text": "Chiesi",
        "label": "GPE"
      },
      {
        "text": "Alfred\n",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Health. CE reports travel support from Chiesi and speaker fees from AstraZeneca",
    "entities": [
      {
        "text": "CE",
        "label": "ORG"
      },
      {
        "text": "Chiesi",
        "label": "GPE"
      },
      {
        "text": "AstraZeneca",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "outside the submitted work. RD is a co-founder of and consultant to Synairgen,",
    "entities": [
      {
        "text": "RD",
        "label": "ORG"
      },
      {
        "text": "Synairgen",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "has received funding for lectures from GSK, and has been on advisory boards of",
    "entities": [
      {
        "text": "GSK",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "GSK, Celltrion, ALK Abello, and ZenasBio, all unrelated to this work. Unrelated",
    "entities": [
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "Celltrion",
        "label": "ORG"
      },
      {
        "text": "ALK Abello",
        "label": "PERSON"
      },
      {
        "text": "ZenasBio",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "to this work, NL has received consulting fees from Amgen, AstraZeneca, Avillion,",
    "entities": [
      {
        "text": "NL",
        "label": "ORG"
      },
      {
        "text": "Amgen",
        "label": "ORG"
      },
      {
        "text": "AstraZeneca, Avillion",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Genentech, GSK, Niox, Novartis, Regeneron, Sanofi, and Teva; honoraria for",
    "entities": [
      {
        "text": "Genentech",
        "label": "ORG"
      },
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "Niox",
        "label": "ORG"
      },
      {
        "text": "Novartis",
        "label": "GPE"
      },
      {
        "text": "Regeneron",
        "label": "GPE"
      },
      {
        "text": "Sanofi",
        "label": "GPE"
      },
      {
        "text": "Teva",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "non-speakers bureau presentations from GSK, Teva, and AstraZeneca; and travel",
    "entities": [
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "Teva",
        "label": "ORG"
      },
      {
        "text": "AstraZeneca",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "support from AstraZeneca, Sanofi, Teva, Regeneron, and GSK; her institution",
    "entities": [
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "Teva",
        "label": "GPE"
      },
      {
        "text": "Regeneron",
        "label": "GPE"
      },
      {
        "text": "GSK",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "received research support from Amgen, AstraZeneca, Avillion, Bellus, Evidera,",
    "entities": [
      {
        "text": "Amgen",
        "label": "ORG"
      },
      {
        "text": "AstraZeneca, Avillion, Bellus",
        "label": "ORG"
      },
      {
        "text": "Evidera",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Teva. NL is an honorary faculty member of the Observational and Pragmatic",
    "entities": [
      {
        "text": "NL",
        "label": "ORG"
      },
      {
        "text": "the Observational and Pragmatic\n",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Research Institute but does not receive compensation for this role. SH reports",
    "entities": [
      {
        "text": "Research Institute",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "speakers fees from AstraZeneca, Berlin-Chemie Menarini, Takeda, Providens, and",
    "entities": [
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "Berlin-Chemie Menarini",
        "label": "ORG"
      },
      {
        "text": "Providens",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Amicus Therapeutics; support for attending meetings from AstraZeneca, Chiesi",
    "entities": [
      {
        "text": "Amicus Therapeutics",
        "label": "ORG"
      },
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "Chiesi",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(Providens), and Hemofarm; and payment for advisory boards from AstraZeneca,",
    "entities": [
      {
        "text": "Providens",
        "label": "PERSON"
      },
      {
        "text": "Hemofarm",
        "label": "NORP"
      },
      {
        "text": "AstraZeneca",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Berlin-Chemie Menarini, and Providens, all unrelated to this work. WCGF declares",
    "entities": [
      {
        "text": "Berlin-Chemie Menarini",
        "label": "ORG"
      },
      {
        "text": "Providens",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "stock ownership in relation to Sanofi, GSK, and AstraZeneca, unrelated to this",
    "entities": [
      {
        "text": "Sanofi",
        "label": "ORG"
      },
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "AstraZeneca",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "work. HMH co-holds a method patent on anti-ADAM33 oligonucleotides and related",
    "entities": [
      {
        "text": "anti-ADAM33",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "methods, which is unrelated to the current work. All other authors declare no",
    "entities": []
  },
  {
    "text": "10.1016/S2213-2600(25)00170-5. Online ahead of print.",
    "entities": [
      {
        "text": "10.1016",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Beyond the airways in difficult-to-treat asthma: multimorbidity as the rule, not",
    "entities": []
  },
  {
    "text": "the exception.",
    "entities": []
  },
  {
    "text": "(1)Krefting Research Centre, Institute of Medicine, Sahlgrenska Academy,",
    "entities": [
      {
        "text": "Research Centre",
        "label": "ORG"
      },
      {
        "text": "Institute of Medicine",
        "label": "ORG"
      },
      {
        "text": "Sahlgrenska Academy",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "University of Gothenburg, 41390 Gothenburg, Sweden; Department of Respiratory",
    "entities": [
      {
        "text": "University of Gothenburg",
        "label": "ORG"
      },
      {
        "text": "41390",
        "label": "DATE"
      },
      {
        "text": "Gothenburg",
        "label": "GPE"
      },
      {
        "text": "Sweden",
        "label": "GPE"
      },
      {
        "text": "Department of Respiratory",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Medicine, Sein\u00e4joki Central Hospital, Sein\u00e4joki, Finland; Faculty of Medicine",
    "entities": [
      {
        "text": "Sein\u00e4joki",
        "label": "GPE"
      },
      {
        "text": "Finland",
        "label": "GPE"
      },
      {
        "text": "Faculty of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and Health Technology, Tampere University, Tampere, Finland. Electronic address:",
    "entities": [
      {
        "text": "Health Technology",
        "label": "ORG"
      },
      {
        "text": "Tampere University",
        "label": "ORG"
      },
      {
        "text": "Tampere",
        "label": "GPE"
      },
      {
        "text": "Finland",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Krefting Research Centre, Institute of Medicine, Sahlgrenska Academy,",
    "entities": [
      {
        "text": "Research Centre",
        "label": "ORG"
      },
      {
        "text": "Institute of Medicine",
        "label": "ORG"
      },
      {
        "text": "Sahlgrenska Academy",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "University of Gothenburg, 41390 Gothenburg, Sweden.",
    "entities": [
      {
        "text": "University of Gothenburg",
        "label": "ORG"
      },
      {
        "text": "41390",
        "label": "DATE"
      },
      {
        "text": "Gothenburg",
        "label": "GPE"
      },
      {
        "text": "Sweden",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Conflict of interest statement: HK reports personal fees for lectures and",
    "entities": []
  },
  {
    "text": "consulting from AstraZeneca, Boehringer-Ingelheim, Chiesi Pharma, Covis Pharma,",
    "entities": [
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "Boehringer-Ingelheim",
        "label": "ORG"
      },
      {
        "text": "Chiesi Pharma",
        "label": "PERSON"
      },
      {
        "text": "Covis Pharma",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "GSK, MSD, Orion Pharma, and Sanofi, outside the submitted work. BIN declares no",
    "entities": [
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "MSD",
        "label": "ORG"
      },
      {
        "text": "Sanofi",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "99. Lancet Respir Med. 2025 Jul 8:S2213-2600(25)00174-2. doi:",
    "entities": [
      {
        "text": "99",
        "label": "CARDINAL"
      },
      {
        "text": "Lancet Respir Med",
        "label": "PERSON"
      },
      {
        "text": "2025",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "10.1016/S2213-2600(25)00174-2. Online ahead of print.",
    "entities": [
      {
        "text": "10.1016",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Eosinophils in asthma phenotypes: perpetrators or guilty by association?",
    "entities": []
  },
  {
    "text": "Jackson DJ(6), Heaney LG(7), Nair P(8), Virchow JC(9).",
    "entities": [
      {
        "text": "Jackson DJ(6",
        "label": "PERSON"
      },
      {
        "text": "Heaney LG(7",
        "label": "PERSON"
      },
      {
        "text": "Virchow JC(9",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "(1)Department of Pneumology, University of Rostock, Rostock, Germany; Intensive",
    "entities": [
      {
        "text": "Pneumology, University of Rostock, Rostock",
        "label": "ORG"
      },
      {
        "text": "Germany",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Care Medicine, University of Rostock, Rostock, Germany. Electronic address:",
    "entities": [
      {
        "text": "Care Medicine, University of Rostock",
        "label": "ORG"
      },
      {
        "text": "Germany",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)Pulmonary Department, Mainz University Hospital, Mainz, Germany.",
    "entities": [
      {
        "text": "2)Pulmonary",
        "label": "CARDINAL"
      },
      {
        "text": "Mainz University Hospital",
        "label": "ORG"
      },
      {
        "text": "Mainz",
        "label": "GPE"
      },
      {
        "text": "Germany",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Germany; Fraunhofer Institute for Translational Medicine, Pharmacology,",
    "entities": [
      {
        "text": "Germany",
        "label": "GPE"
      },
      {
        "text": "Fraunhofer Institute for Translational Medicine, Pharmacology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Immunology, and Allergology, Charite\u00e9 - Universit\u00e4tsmedizin Berlin, Berlin,",
    "entities": [
      {
        "text": "Berlin",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Department of Respiratory Medicine, Ghent University Hospital, Ghent,",
    "entities": [
      {
        "text": "Respiratory Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(5)Department of Biomedical Sciences, Humanitas University, Milan, Italy;",
    "entities": [
      {
        "text": "Biomedical Sciences",
        "label": "ORG"
      },
      {
        "text": "Humanitas University",
        "label": "ORG"
      },
      {
        "text": "Milan",
        "label": "GPE"
      },
      {
        "text": "Italy",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Personalized Medicine Asthma & Allergy, IRCCS Humanitas Research Hospital,",
    "entities": [
      {
        "text": "Personalized Medicine Asthma & Allergy",
        "label": "ORG"
      },
      {
        "text": "IRCCS Humanitas Research Hospital",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(6)Guy's Severe Asthma Centre, School of Immunology and Microbial Sciences,",
    "entities": [
      {
        "text": "6)Guy",
        "label": "DATE"
      },
      {
        "text": "Severe Asthma Centre, School of Immunology and Microbial Sciences",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "King's College London, London, UK.",
    "entities": [
      {
        "text": "King's College London",
        "label": "ORG"
      },
      {
        "text": "London",
        "label": "GPE"
      },
      {
        "text": "UK",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(7)Wellcome-Wolfson Centre for Experimental Medicine, Queen's University,",
    "entities": [
      {
        "text": "7)Wellcome-Wolfson Centre for Experimental Medicine",
        "label": "ORG"
      },
      {
        "text": "Queen's University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Belfast, Northern Ireland, UK.",
    "entities": [
      {
        "text": "Belfast",
        "label": "GPE"
      },
      {
        "text": "Northern Ireland",
        "label": "GPE"
      },
      {
        "text": "UK",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(8)McMaster University, Hamilton, ON, Canada.",
    "entities": [
      {
        "text": "Hamilton",
        "label": "PERSON"
      },
      {
        "text": "ON",
        "label": "GPE"
      },
      {
        "text": "Canada",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(9)Department of Pneumology, University of Rostock, Rostock, Germany; Intensive",
    "entities": [
      {
        "text": "Pneumology, University of Rostock, Rostock",
        "label": "ORG"
      },
      {
        "text": "Germany",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Care Medicine, University of Rostock, Rostock, Germany.",
    "entities": [
      {
        "text": "Care Medicine, University of Rostock",
        "label": "ORG"
      },
      {
        "text": "Germany",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "25 years after publication of a clinical trial in The Lancet on the anti-IL-5",
    "entities": [
      {
        "text": "25 years",
        "label": "DATE"
      },
      {
        "text": "Lancet",
        "label": "ORG"
      },
      {
        "text": "anti-IL-5",
        "label": "NORP"
      }
    ]
  },
  {
    "text": "antibody mepolizumab in individuals with allergic asthma, evidence has",
    "entities": []
  },
  {
    "text": "accumulated that the pathogenetic role of eosinophils is fundamentally different",
    "entities": []
  },
  {
    "text": "between asthma phenotypes. In the allergen-driven form of asthma, often starting",
    "entities": []
  },
  {
    "text": "in childhood or during adolescence (ie, early onset asthma), blood eosinophil",
    "entities": []
  },
  {
    "text": "counts are variable, mainly dependent on allergen exposure, and play only a",
    "entities": []
  },
  {
    "text": "minor role (as a so-called sidekick) in allergen-induced asthma symptoms. By",
    "entities": []
  },
  {
    "text": "contrast, eosinophils are persistently elevated and are crucial drivers of the",
    "entities": []
  },
  {
    "text": "disease in the intrinsic (eosinophilic) form of asthma, which typically starts",
    "entities": []
  },
  {
    "text": "in adulthood (ie, adult-onset asthma). These data suggest that eosinophilia",
    "entities": []
  },
  {
    "text": "should not be considered a treatable trait in people with chronic airway",
    "entities": []
  },
  {
    "text": "diseases, but only a complement to an accurate clinical diagnosis. This evidence",
    "entities": []
  },
  {
    "text": "has major implications for the diagnosis of asthma phenotypes and the treatment",
    "entities": []
  },
  {
    "text": "of asthma (eg, choice of the right biologic).",
    "entities": []
  },
  {
    "text": "Conflict of interest statement: Declaration of interests ML has received",
    "entities": [
      {
        "text": "ML",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "consulting fees or honoraria for lectures from ALK, Allergopharma, Apontis,",
    "entities": [
      {
        "text": "ALK",
        "label": "ORG"
      },
      {
        "text": "Allergopharma",
        "label": "PERSON"
      },
      {
        "text": "Apontis",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "meetings or travel from AstraZeneca and Novartis; and grants for research or",
    "entities": [
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "Novartis",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "has received consulting fees or honoraria for lectures from ALK, Allergopharma,",
    "entities": [
      {
        "text": "ALK",
        "label": "ORG"
      },
      {
        "text": "Allergopharma",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "Allergy, Leti, Novartis, Roche, Sanofi, and TEVA; has received grants for",
    "entities": [
      {
        "text": "Leti",
        "label": "GPE"
      },
      {
        "text": "Roche",
        "label": "ORG"
      },
      {
        "text": "Sanofi",
        "label": "ORG"
      },
      {
        "text": "TEVA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "research or clinical trials from Boehringer Ingelheim, GSK, Novartis, and Roche;",
    "entities": [
      {
        "text": "Boehringer Ingelheim",
        "label": "ORG"
      },
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "Novartis",
        "label": "ORG"
      },
      {
        "text": "Roche",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "and has participated in advisory boards for AstraZeneca, Berlin-Chemie,",
    "entities": [
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "Berlin-Chemie",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "received consulting fees or honoraria for lectures from ALK, AstraZeneca,",
    "entities": [
      {
        "text": "ALK",
        "label": "ORG"
      },
      {
        "text": "AstraZeneca",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Novartis, and Sanofi. GGB has received honoraria for lectures from AstraZeneca,",
    "entities": [
      {
        "text": "Sanofi",
        "label": "ORG"
      },
      {
        "text": "GGB",
        "label": "ORG"
      },
      {
        "text": "AstraZeneca",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "GSK, Boehringer-Ingelheim, Novartis, Chiesi, and Sanofi. GWC has received",
    "entities": [
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "Boehringer-Ingelheim",
        "label": "ORG"
      },
      {
        "text": "Novartis",
        "label": "GPE"
      },
      {
        "text": "Chiesi",
        "label": "GPE"
      },
      {
        "text": "Sanofi",
        "label": "ORG"
      },
      {
        "text": "GWC",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "consulting fees or honoraria for lectures from AstraZeneca, Chiesi, Novartis,",
    "entities": [
      {
        "text": "AstraZeneca",
        "label": "NORP"
      },
      {
        "text": "Chiesi",
        "label": "GPE"
      },
      {
        "text": "Novartis",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "received consulting fees or honoraria for lectures from AstraZeneca, GSK, and",
    "entities": [
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "GSK",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Sanofi and grants for research from AstraZeneca. LGH has received honoraria for",
    "entities": [
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "LGH",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "lectures from Astra Zeneca, Sanofi, Circassia, GSK, and TEVA; honoraria for",
    "entities": [
      {
        "text": "Astra Zeneca",
        "label": "PERSON"
      },
      {
        "text": "Sanofi",
        "label": "GPE"
      },
      {
        "text": "Circassia",
        "label": "GPE"
      },
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "TEVA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "participation on a data safety monitoring or advisory boards from GSK,",
    "entities": [
      {
        "text": "GSK",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "AstraZeneca, and Celltrion; support for attending meetings or travel from",
    "entities": [
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "Celltrion",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "AstraZeneca, Sanofi, and GSK; and grants for research from AstraZeneca, GSK, and",
    "entities": [
      {
        "text": "AstraZeneca, Sanofi",
        "label": "ORG"
      },
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "GSK",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Roche\u2013Genentech. PN has received honoraria for lectures from AstraZeneca, TEVA,",
    "entities": [
      {
        "text": "Roche",
        "label": "ORG"
      },
      {
        "text": "Genentech",
        "label": "ORG"
      },
      {
        "text": "PN",
        "label": "ORG"
      },
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "TEVA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Roche, Sanofi, Cyclomedica, and GSK; support for attending meetings or travel",
    "entities": [
      {
        "text": "Roche",
        "label": "ORG"
      },
      {
        "text": "Sanofi",
        "label": "GPE"
      },
      {
        "text": "Cyclomedica",
        "label": "PERSON"
      },
      {
        "text": "GSK",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "from AstraZeneca and TEVA; consulting fees from Equillium and Arrowhead Pharma;",
    "entities": [
      {
        "text": "AstraZeneca",
        "label": "ORG"
      },
      {
        "text": "TEVA",
        "label": "ORG"
      },
      {
        "text": "Equillium",
        "label": "ORG"
      },
      {
        "text": "Arrowhead Pharma",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "and grants for research from Astra Zeneca, TEVA, and Foresee. JCV has received",
    "entities": [
      {
        "text": "Astra Zeneca",
        "label": "PERSON"
      },
      {
        "text": "TEVA",
        "label": "ORG"
      },
      {
        "text": "Foresee",
        "label": "GPE"
      },
      {
        "text": "JCV",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "consulting fees or honoraria for lectures or participations in advisory boards",
    "entities": []
  },
  {
    "text": "from AstraZeneca, Avontec, Bayer, Bencard, Bionorica, Boehringer Ingelheim,",
    "entities": [
      {
        "text": "AstraZeneca, Avontec,",
        "label": "ORG"
      },
      {
        "text": "Bayer",
        "label": "GPE"
      },
      {
        "text": "Bencard",
        "label": "GPE"
      },
      {
        "text": "Bionorica",
        "label": "ORG"
      },
      {
        "text": "Boehringer Ingelheim",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Merck, MSD, Mundipharma, Novartis, Nycomed\u2013Altana, Pfizer, Regeneron, Revotar,",
    "entities": [
      {
        "text": "Merck",
        "label": "ORG"
      },
      {
        "text": "MSD",
        "label": "ORG"
      },
      {
        "text": "Mundipharma",
        "label": "GPE"
      },
      {
        "text": "Nycomed",
        "label": "GPE"
      },
      {
        "text": "Altana",
        "label": "PERSON"
      },
      {
        "text": "Pfizer",
        "label": "GPE"
      },
      {
        "text": "Regeneron",
        "label": "GPE"
      },
      {
        "text": "Revotar",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "Sanofi, Sandoz-Hexal, Stallergens, TEVA, UCB\u2013Schwarz-Pharma, and Zydus\u2013Cadila;",
    "entities": [
      {
        "text": "Sandoz-Hexal",
        "label": "ORG"
      },
      {
        "text": "Stallergens",
        "label": "GPE"
      },
      {
        "text": "Schwarz-Pharma",
        "label": "EVENT"
      },
      {
        "text": "Zydus",
        "label": "GPE"
      },
      {
        "text": "Cadila",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "GSK, and MSD.",
    "entities": [
      {
        "text": "GSK",
        "label": "ORG"
      },
      {
        "text": "MSD",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "100. Int Forum Allergy Rhinol. 2025 Jul 11:e23623. doi: 10.1002/alr.23623. Online",
    "entities": [
      {
        "text": "100",
        "label": "CARDINAL"
      },
      {
        "text": "Int Forum Allergy Rhinol",
        "label": "ORG"
      },
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "11",
        "label": "CARDINAL"
      },
      {
        "text": "10.1002",
        "label": "CARDINAL"
      }
    ]
  },
  {
    "text": "Selective PAR2 Inhibition Attenuates HDM-Induced Th1/Th2 Responses in Human",
    "entities": []
  },
  {
    "text": "Epithelial and Murine Models of Allergic Rhinitis and Asthma.",
    "entities": [
      {
        "text": "Murine Models",
        "label": "PERSON"
      },
      {
        "text": "Asthma",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "(1)Department of Otorhinolaryngology, Yonsei University College of Medicine,",
    "entities": [
      {
        "text": "Otorhinolaryngology, Yonsei University College of Medicine",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Seoul, South Korea.",
    "entities": [
      {
        "text": "Seoul",
        "label": "GPE"
      },
      {
        "text": "South Korea",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(2)College of Pharmacy, Yonsei Institute of Pharmaceutical Science, Yonsei",
    "entities": [
      {
        "text": "2)College",
        "label": "CARDINAL"
      },
      {
        "text": "Yonsei Institute of Pharmaceutical Science",
        "label": "ORG"
      },
      {
        "text": "Yonsei",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "University, Incheon, South Korea.",
    "entities": [
      {
        "text": "Incheon",
        "label": "GPE"
      },
      {
        "text": "South Korea",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(3)Department of Bio-Nanomaterials, Bio Campus of Korea Polytechnics, Nonsan,",
    "entities": [
      {
        "text": "Bio-Nanomaterials",
        "label": "ORG"
      },
      {
        "text": "Nonsan",
        "label": "PERSON"
      }
    ]
  },
  {
    "text": "South Korea.",
    "entities": [
      {
        "text": "South Korea",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(4)Department of Otorhinolaryngology-Head and Neck Surgery, Chung-Ang University",
    "entities": [
      {
        "text": "Otorhinolaryngology-Head and Neck Surgery",
        "label": "ORG"
      },
      {
        "text": "Chung-Ang University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "College of Medicine, Seoul, South Korea.",
    "entities": [
      {
        "text": "College of Medicine",
        "label": "ORG"
      },
      {
        "text": "Seoul",
        "label": "GPE"
      },
      {
        "text": "South Korea",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(5)The Airway Mucus Institute, Yonsei University College of Medicine, Seoul,",
    "entities": [
      {
        "text": "Airway Mucus Institute",
        "label": "ORG"
      },
      {
        "text": "Yonsei University College of Medicine",
        "label": "ORG"
      },
      {
        "text": "Seoul",
        "label": "GPE"
      }
    ]
  },
  {
    "text": "(6)Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University",
    "entities": [
      {
        "text": "6)Graduate School of Medical Science",
        "label": "ORG"
      },
      {
        "text": "21 Project",
        "label": "PERCENT"
      },
      {
        "text": "Yonsei University",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "BACKGROUND: Allergic rhinitis (AR) and asthma are involved in complex",
    "entities": []
  },
  {
    "text": "interactions between Th1 and Th2 inflammatory pathways. House dust mite (HDM)",
    "entities": [
      {
        "text": "Th1",
        "label": "ORG"
      },
      {
        "text": "House",
        "label": "ORG"
      },
      {
        "text": "HDM",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "activates protease-activated receptor 2 (PAR2) to trigger inflammatory",
    "entities": [
      {
        "text": "2",
        "label": "CARDINAL"
      },
      {
        "text": "PAR2",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "responses, but current treatments often provide inadequate control.",
    "entities": []
  },
  {
    "text": "OBJECTIVE: This study aimed to investigate the effects of selective PAR2",
    "entities": []
  },
  {
    "text": "inhibition on Th1 and Th2 responses in human nasal epithelial (HNE) cells and",
    "entities": [
      {
        "text": "Th2",
        "label": "GPE"
      },
      {
        "text": "HNE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "murine models of AR and asthma.",
    "entities": [
      {
        "text": "AR",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "METHODS: We examined the effects of selective PAR2 inhibition using primary HNE",
    "entities": [
      {
        "text": "HNE",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "cells and HDM-induced mouse models (PAR2-wild-type [PAR2-wt] and knockout",
    "entities": [
      {
        "text": "HDM",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "[PAR2-ko]). Analyses included inflammatory signaling pathways, cytokine",
    "entities": []
  },
  {
    "text": "profiles, airway responses, histopathology, and transcriptomics.",
    "entities": []
  },
  {
    "text": "RESULTS: In HNE cells, PAR2 inhibition suppressed Th2 (interleukin [IL]-33,",
    "entities": [
      {
        "text": "HNE",
        "label": "ORG"
      },
      {
        "text": "PAR2",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "TSLP) and Th1 (TNF-\u03b1, IL-6) inflammatory cytokines while inhibiting calcium",
    "entities": [
      {
        "text": "IL-6",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "mobilization and ERK/NF-\u03baB signaling cascades. In PAR2-wt mice, treatment with",
    "entities": [
      {
        "text": "ERK/NF-\u03baB",
        "label": "ORG"
      },
      {
        "text": "PAR2",
        "label": "FAC"
      }
    ]
  },
  {
    "text": "the PAR2 inhibitor reduced HDM-specific Immunoglobulin E (IgE), airway",
    "entities": [
      {
        "text": "PAR2",
        "label": "ORG"
      },
      {
        "text": "HDM",
        "label": "ORG"
      },
      {
        "text": "Immunoglobulin",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "hyperresponsiveness, and allergic inflammation in both nasal and bronchial",
    "entities": []
  },
  {
    "text": "tissues, matching the anti-inflammatory profile of PAR2-ko mice. Bulk RNA",
    "entities": [
      {
        "text": "PAR2-ko",
        "label": "PRODUCT"
      },
      {
        "text": "RNA",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "sequencing confirmed comprehensive suppression of inflammatory gene expression.",
    "entities": []
  },
  {
    "text": "CONCLUSIONS: Selective PAR2 inhibition effectively attenuates HDM-induced",
    "entities": [
      {
        "text": "HDM",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "allergic inflammation by modulation of Th1 and Th2 pathways in human airway",
    "entities": []
  },
  {
    "text": "epithelium and murine models. We suggest that PAR2 can be a possible target for",
    "entities": [
      {
        "text": "PAR2",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "AR and asthma.",
    "entities": []
  },
  {
    "text": "\u00a9 2025 The Author(s). International Forum of Allergy & Rhinology published by",
    "entities": [
      {
        "text": "2025",
        "label": "DATE"
      },
      {
        "text": "International Forum of Allergy & Rhinology",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "Wiley Periodicals LLC on behalf of American Academy of Otolaryngic Allergy and",
    "entities": [
      {
        "text": "Wiley Periodicals",
        "label": "ORG"
      },
      {
        "text": "American Academy of Otolaryngic Allergy",
        "label": "ORG"
      }
    ]
  },
  {
    "text": "American Rhinologic Society.",
    "entities": [
      {
        "text": "American Rhinologic Society",
        "label": "ORG"
      }
    ]
  }
]